0001492298-23-000025.txt : 20231106 0001492298-23-000025.hdr.sgml : 20231106 20231106160721 ACCESSION NUMBER: 0001492298-23-000025 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 86 CONFORMED PERIOD OF REPORT: 20230930 FILED AS OF DATE: 20231106 DATE AS OF CHANGE: 20231106 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sabra Health Care REIT, Inc. CENTRAL INDEX KEY: 0001492298 STANDARD INDUSTRIAL CLASSIFICATION: REAL ESTATE INVESTMENT TRUSTS [6798] IRS NUMBER: 272560479 STATE OF INCORPORATION: MD FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-34950 FILM NUMBER: 231380011 BUSINESS ADDRESS: STREET 1: 18500 VON KARMAN STREET 2: SUITE 550 CITY: IRVINE STATE: CA ZIP: 92612 BUSINESS PHONE: 888-393-8248 MAIL ADDRESS: STREET 1: 18500 VON KARMAN STREET 2: SUITE 550 CITY: IRVINE STATE: CA ZIP: 92612 10-Q 1 sbra-20230930.htm 10-Q sbra-20230930
000149229812/312023Q3falsehttp://fasb.org/us-gaap/2023#HealthCareResidentServiceMemberhttp://fasb.org/us-gaap/2023#HealthCareResidentServiceMemberhttp://fasb.org/us-gaap/2023#HealthCareResidentServiceMemberhttp://fasb.org/us-gaap/2023#HealthCareResidentServiceMemberhttp://www.sabrahealth.com/20230930#AccountsReceivablePrepaidExpensesDeferredFinancingCostsAndOtherAssetsNethttp://fasb.org/us-gaap/2023#AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent http://fasb.org/us-gaap/2023#LineOfCredit http://fasb.org/us-gaap/2023#LoansPayableToBankhttp://fasb.org/us-gaap/2023#AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent http://fasb.org/us-gaap/2023#LineOfCredit http://fasb.org/us-gaap/2023#LoansPayableToBankhttp://www.sabrahealth.com/20230930#AccountsReceivablePrepaidExpensesDeferredFinancingCostsAndOtherAssetsNet00014922982023-01-012023-09-3000014922982023-11-01xbrli:shares00014922982023-09-30iso4217:USD00014922982022-12-31iso4217:USDxbrli:shares00014922982023-07-012023-09-3000014922982022-07-012022-09-3000014922982022-01-012022-09-300001492298sbra:TripleNetPortfolioMember2023-07-012023-09-300001492298sbra:TripleNetPortfolioMember2022-07-012022-09-300001492298sbra:TripleNetPortfolioMember2023-01-012023-09-300001492298sbra:TripleNetPortfolioMember2022-01-012022-09-300001492298sbra:SeniorHousingFacilitiesManagedPortfolioMember2023-07-012023-09-300001492298sbra:SeniorHousingFacilitiesManagedPortfolioMember2022-07-012022-09-300001492298sbra:SeniorHousingFacilitiesManagedPortfolioMember2023-01-012023-09-300001492298sbra:SeniorHousingFacilitiesManagedPortfolioMember2022-01-012022-09-300001492298us-gaap:CommonStockMember2022-06-300001492298us-gaap:AdditionalPaidInCapitalMember2022-06-300001492298us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2022-06-300001492298us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-3000014922982022-06-300001492298us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2022-07-012022-09-300001492298us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300001492298us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001492298us-gaap:CommonStockMember2022-07-012022-09-300001492298us-gaap:CommonStockMember2022-09-300001492298us-gaap:AdditionalPaidInCapitalMember2022-09-300001492298us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2022-09-300001492298us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-3000014922982022-09-300001492298us-gaap:CommonStockMember2023-06-300001492298us-gaap:AdditionalPaidInCapitalMember2023-06-300001492298us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2023-06-300001492298us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-3000014922982023-06-300001492298us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2023-07-012023-09-300001492298us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001492298us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001492298us-gaap:CommonStockMember2023-07-012023-09-300001492298us-gaap:CommonStockMember2023-09-300001492298us-gaap:AdditionalPaidInCapitalMember2023-09-300001492298us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2023-09-300001492298us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001492298us-gaap:CommonStockMember2021-12-310001492298us-gaap:AdditionalPaidInCapitalMember2021-12-310001492298us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2021-12-310001492298us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-3100014922982021-12-310001492298us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2022-01-012022-09-300001492298us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-09-300001492298us-gaap:AdditionalPaidInCapitalMember2022-01-012022-09-300001492298us-gaap:CommonStockMember2022-01-012022-09-300001492298us-gaap:CommonStockMember2022-12-310001492298us-gaap:AdditionalPaidInCapitalMember2022-12-310001492298us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2022-12-310001492298us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001492298us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2023-01-012023-09-300001492298us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300001492298us-gaap:AdditionalPaidInCapitalMember2023-01-012023-09-300001492298us-gaap:CommonStockMember2023-01-012023-09-300001492298us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2023-09-30sbra:variableInterestEntitysbra:investment0001492298sbra:VandalismAndTheftMember2023-07-012023-09-300001492298sbra:VandalismAndTheftMember2023-01-012023-09-300001492298us-gaap:FireMember2023-07-012023-09-300001492298us-gaap:FireMember2023-01-012023-09-300001492298us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMembersbra:SeniorHousingFacilitiesLeasedMember2023-01-012023-09-30sbra:property0001492298us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMembersbra:SeniorHousingFacilitiesManagedPortfolioMember2023-01-012023-09-300001492298us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMembersbra:SeniorHousingFacilitiesManagedPortfolioMember2022-01-012022-09-300001492298sbra:SeniorHousingFacilitiesManagedCommunitiesProprietaryDevelopmentPipelineMemberus-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2022-01-012022-09-300001492298us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2023-09-300001492298us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2022-09-300001492298us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMembersbra:TenantOriginationAndAbsorptionCostsMember2023-09-300001492298us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMembersbra:TenantOriginationAndAbsorptionCostsMember2022-09-300001492298sbra:TenantRelationshipMemberus-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2023-09-300001492298sbra:TenantRelationshipMemberus-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2022-09-300001492298us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMembersbra:TenantOriginationAndAbsorptionCostsMember2023-01-012023-09-300001492298sbra:TenantRelationshipMemberus-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2023-01-012023-09-300001492298us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMembersbra:TenantOriginationAndAbsorptionCostsMember2022-01-012022-09-300001492298us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2023-07-012023-09-300001492298us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2023-01-012023-09-300001492298us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2022-07-012022-09-300001492298us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2022-01-012022-09-300001492298us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMembersbra:SeniorHousingFacilitiesManagedPortfolioMember2023-04-012023-06-300001492298us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMembersbra:SeniorHousingFacilitiesManagedPortfolioMember2023-06-300001492298us-gaap:OperatingSegmentsMembersbra:SkilledNursingTransitionalCareFacilitiesMember2023-09-30sbra:facilitysbra:bed0001492298us-gaap:OperatingSegmentsMembersbra:SeniorHousingFacilitiesLeasedMember2023-09-300001492298us-gaap:OperatingSegmentsMembersbra:SeniorHousingFacilitiesManagedPortfolioMember2023-09-300001492298us-gaap:OperatingSegmentsMembersbra:BehavioralHealthMember2023-09-300001492298us-gaap:OperatingSegmentsMembersbra:SpecialtyHospitalsAndOtherMember2023-09-300001492298us-gaap:OperatingSegmentsMember2023-09-300001492298us-gaap:CorporateMember2023-09-300001492298us-gaap:OperatingSegmentsMembersbra:SkilledNursingTransitionalCareFacilitiesMember2022-12-310001492298us-gaap:OperatingSegmentsMembersbra:SeniorHousingFacilitiesLeasedMember2022-12-310001492298us-gaap:OperatingSegmentsMembersbra:SeniorHousingFacilitiesManagedPortfolioMember2022-12-310001492298us-gaap:OperatingSegmentsMembersbra:BehavioralHealthMember2022-12-310001492298us-gaap:OperatingSegmentsMembersbra:SpecialtyHospitalsAndOtherMember2022-12-310001492298us-gaap:OperatingSegmentsMember2022-12-310001492298us-gaap:CorporateMember2022-12-310001492298srt:MinimumMember2023-09-300001492298srt:MaximumMember2023-09-300001492298sbra:NorthAmericanHealthCareIncMember2022-07-012022-09-300001492298sbra:HealthCareResidentServiceAncillaryServiceMember2023-07-012023-09-300001492298sbra:HealthCareResidentServiceAncillaryServiceMember2023-01-012023-09-300001492298sbra:HealthCareResidentServiceAncillaryServiceMember2022-07-012022-09-300001492298sbra:HealthCareResidentServiceAncillaryServiceMember2022-01-012022-09-300001492298sbra:SeniorHousingFacilitiesMembersbra:SiennaJointVentureMember2023-09-300001492298sbra:SiennaJointVentureMember2023-09-30xbrli:pure0001492298sbra:SiennaJointVentureMember2022-12-310001492298sbra:SeniorHousingFacilitiesMembersbra:MarlinSpringJointVentureMember2023-09-300001492298sbra:MarlinSpringJointVentureMember2023-09-300001492298sbra:MarlinSpringJointVentureMember2022-12-310001492298sbra:SeniorHousingFacilitiesMembersbra:MarlinSpringJointVentureMember2023-09-300001492298sbra:SeniorHousingFacilitiesMembersbra:MarlinSpringJointVentureMember2023-01-012023-09-30iso4217:CAD0001492298sbra:SeniorHousingFacilitiesMembersbra:MarlinSpringJointVentureMembersbra:MarlinSpringJointVentureMember2023-09-300001492298sbra:EnlivantJointVentureMember2022-10-012022-12-310001492298sbra:EnlivantJointVentureMember2023-01-010001492298sbra:EnlivantJointVentureMember2022-01-012022-09-300001492298sbra:SkilledNursingTransitionalCareFacilitiesMember2022-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMember2023-01-012023-03-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember2023-09-300001492298sbra:SkilledNursingTransitionalCareFacilitiesMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember2022-09-300001492298sbra:MortgageLoansReceivableMember2023-09-30sbra:loan0001492298sbra:MortgageLoansReceivableMember2022-12-310001492298sbra:OtherMember2023-09-300001492298sbra:OtherMember2022-12-31sbra:preferredEquityInvestment0001492298us-gaap:FinancialAssetAcquiredWithCreditDeteriorationMember2023-09-300001492298us-gaap:FinancialAssetAcquiredWithCreditDeteriorationMember2022-12-310001492298us-gaap:NonperformingFinancingReceivableMember2023-09-300001492298us-gaap:NonperformingFinancingReceivableMember2022-12-310001492298sbra:FixedRateMortgagesMemberus-gaap:SecuredDebtMember2023-09-300001492298sbra:FixedRateMortgagesMemberus-gaap:SecuredDebtMember2022-12-310001492298us-gaap:SecuredDebtMember2023-09-300001492298us-gaap:SecuredDebtMember2022-12-310001492298sbra:A5.125SeniorUnsecuredNotesDue2026Memberus-gaap:SeniorNotesMember2023-09-300001492298sbra:A5.125SeniorUnsecuredNotesDue2026Memberus-gaap:SeniorNotesMember2022-12-310001492298sbra:A5.88SeniorUnsecuredNotesDue2027Memberus-gaap:SeniorNotesMember2023-09-300001492298sbra:A5.88SeniorUnsecuredNotesDue2027Memberus-gaap:SeniorNotesMember2022-12-310001492298sbra:A3.90SeniorUnsecuredNotesDue2029Memberus-gaap:SeniorNotesMember2023-09-300001492298sbra:A3.90SeniorUnsecuredNotesDue2029Memberus-gaap:SeniorNotesMember2022-12-310001492298sbra:A320SeniorUnsecuredNotesDue2031Memberus-gaap:SeniorNotesMember2023-09-300001492298sbra:A320SeniorUnsecuredNotesDue2031Memberus-gaap:SeniorNotesMember2022-12-310001492298us-gaap:SeniorNotesMember2023-09-300001492298us-gaap:SeniorNotesMember2022-12-310001492298sbra:A5375SeniorUnsecuredNotesDue2023Memberus-gaap:SeniorNotesMember2023-09-300001492298sbra:CreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2019-09-090001492298sbra:CreditAgreementMembersbra:U.S.DollarTermLoanMember2019-09-090001492298sbra:CreditAgreementMembersbra:CanadianDollarTermLoanMember2019-09-090001492298sbra:CreditAgreementMemberus-gaap:LineOfCreditMember2019-09-090001492298sbra:CreditAgreementMembersbra:U.S.DollarTermLoanMember2022-07-012022-09-300001492298sbra:CreditAgreementMembersbra:U.S.DollarTermLoanMember2022-01-012022-09-300001492298sbra:CreditAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:PrimeRateMember2023-01-012023-09-300001492298sbra:CreditAgreementMemberus-gaap:BaseRateMemberus-gaap:RevolvingCreditFacilityMember2023-01-012023-09-300001492298sbra:CreditAgreementMemberus-gaap:RevolvingCreditFacilityMembersrt:MinimumMembersbra:LondonInterbankOfferedRateLIBOR1Member2023-01-012023-09-300001492298sbra:CreditAgreementMemberus-gaap:RevolvingCreditFacilityMembersrt:MaximumMembersbra:LondonInterbankOfferedRateLIBOR1Member2023-01-012023-09-300001492298sbra:CreditAgreementMemberus-gaap:BaseRateMemberus-gaap:RevolvingCreditFacilityMembersrt:MinimumMember2023-01-012023-09-300001492298sbra:CreditAgreementMemberus-gaap:BaseRateMemberus-gaap:RevolvingCreditFacilityMembersrt:MaximumMember2023-01-012023-09-300001492298sbra:CreditAgreementMemberus-gaap:RevolvingCreditFacilityMembersrt:MinimumMember2023-01-012023-09-300001492298sbra:CreditAgreementMemberus-gaap:RevolvingCreditFacilityMembersrt:MaximumMember2023-01-012023-09-300001492298sbra:CreditAgreementMembersbra:U.S.DollarTermLoanMembersrt:MinimumMembersbra:LondonInterbankOfferedRateLIBOR1Member2023-01-012023-09-300001492298sbra:CreditAgreementMembersbra:U.S.DollarTermLoanMembersrt:MaximumMembersbra:LondonInterbankOfferedRateLIBOR1Member2023-01-012023-09-300001492298sbra:CreditAgreementMembersbra:U.S.DollarTermLoanMemberus-gaap:BaseRateMembersrt:MinimumMember2023-01-012023-09-300001492298sbra:CreditAgreementMembersbra:U.S.DollarTermLoanMemberus-gaap:BaseRateMembersrt:MaximumMember2023-01-012023-09-300001492298sbra:CreditAgreementMembersbra:CanadianDollarTermLoanMembersbra:CanadianDollarOfferRateCDORMembersrt:MinimumMember2023-01-012023-09-300001492298sbra:CreditAgreementMembersbra:CanadianDollarTermLoanMembersbra:CanadianDollarOfferRateCDORMembersrt:MaximumMember2023-01-012023-09-300001492298sbra:CreditAgreementMember2023-09-300001492298sbra:U.S.DollarTermLoanMembersbra:FifthAmendedandRestatedCreditAgreementMember2023-01-012023-09-300001492298sbra:CreditAgreementMember2023-07-012023-09-300001492298sbra:CreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2023-01-040001492298sbra:CreditAgreementMembersbra:U.S.DollarTermLoanMember2023-01-040001492298sbra:CreditAgreementMembersbra:CanadianDollarTermLoanMember2023-01-040001492298sbra:CreditAgreementMemberus-gaap:LineOfCreditMember2023-01-04sbra:extensionOption0001492298sbra:CreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2023-01-042023-01-040001492298sbra:CreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2023-09-300001492298sbra:CreditAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:PrimeRateMember2023-01-042023-01-040001492298sbra:CreditAgreementMemberus-gaap:BaseRateMemberus-gaap:RevolvingCreditFacilityMember2023-01-042023-01-040001492298sbra:CreditAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMembersrt:MinimumMember2023-01-042023-01-040001492298sbra:CreditAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMembersrt:MaximumMember2023-01-042023-01-040001492298sbra:CreditAgreementMemberus-gaap:BaseRateMemberus-gaap:RevolvingCreditFacilityMembersrt:MinimumMember2023-01-042023-01-040001492298sbra:CreditAgreementMemberus-gaap:BaseRateMemberus-gaap:RevolvingCreditFacilityMembersrt:MaximumMember2023-01-042023-01-040001492298sbra:CreditAgreementMemberus-gaap:RevolvingCreditFacilityMembersrt:MinimumMember2023-01-042023-01-040001492298sbra:CreditAgreementMemberus-gaap:RevolvingCreditFacilityMembersrt:MaximumMember2023-01-042023-01-040001492298sbra:CreditAgreementMembersbra:U.S.DollarTermLoanMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMembersrt:MinimumMember2023-01-042023-01-040001492298sbra:CreditAgreementMembersbra:U.S.DollarTermLoanMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMembersrt:MaximumMember2023-01-042023-01-040001492298sbra:CreditAgreementMembersbra:U.S.DollarTermLoanMemberus-gaap:BaseRateMembersrt:MinimumMember2023-01-042023-01-040001492298sbra:CreditAgreementMembersbra:U.S.DollarTermLoanMemberus-gaap:BaseRateMembersrt:MaximumMember2023-01-042023-01-040001492298sbra:CreditAgreementMembersbra:U.S.DollarTermLoanMember2023-09-300001492298sbra:CreditAgreementMembersbra:CanadianDollarTermLoanMembersbra:CanadianDollarOfferRateCDORMembersrt:MinimumMember2023-01-042023-01-040001492298sbra:CreditAgreementMembersbra:CanadianDollarTermLoanMembersbra:CanadianDollarOfferRateCDORMembersrt:MaximumMember2023-01-042023-01-040001492298sbra:CreditAgreementMembersbra:CanadianDollarTermLoanMember2023-09-300001492298sbra:CreditAgreementMembersbra:U.S.DollarTermLoanMemberus-gaap:InterestRateSwapMember2023-09-300001492298sbra:CreditAgreementMembersbra:CanadianDollarTermLoanMemberus-gaap:InterestRateSwapMember2023-09-300001492298us-gaap:LineOfCreditMember2023-09-300001492298us-gaap:LoansPayableMember2023-09-300001492298us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-01-012023-09-300001492298us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-09-300001492298us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-12-310001492298us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CrossCurrencyInterestRateContractMember2023-09-300001492298us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CrossCurrencyInterestRateContractMember2022-12-310001492298us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CrossCurrencyInterestRateContractMember2023-09-300001492298us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CrossCurrencyInterestRateContractMember2022-12-310001492298us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-09-300001492298us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-12-310001492298us-gaap:NondesignatedMemberus-gaap:NetInvestmentHedgingMemberus-gaap:CrossCurrencyInterestRateContractMember2023-09-300001492298us-gaap:NondesignatedMemberus-gaap:NetInvestmentHedgingMemberus-gaap:CrossCurrencyInterestRateContractMember2022-12-310001492298us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2023-09-30sbra:derivative0001492298us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMembersbra:InterestRateSwapOneMember2023-09-300001492298us-gaap:CashFlowHedgingMembersbra:InterestRateSwapTwoMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-09-30sbra:instrument0001492298us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2022-12-310001492298us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMembersbra:InterestRateCollarMember2023-09-300001492298us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMembersbra:InterestRateCollarMember2022-12-310001492298us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMembersbra:ForwardStartingInterestRateSwapsMember2023-09-300001492298us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMembersbra:ForwardStartingInterestRateSwapsMember2022-12-310001492298us-gaap:DesignatedAsHedgingInstrumentMember2023-09-300001492298us-gaap:DesignatedAsHedgingInstrumentMember2022-12-310001492298us-gaap:CurrencySwapMembersbra:LongTermLineOfCreditMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-09-300001492298us-gaap:CurrencySwapMembersbra:LongTermLineOfCreditMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-12-310001492298us-gaap:CurrencySwapMembersbra:LoansPayableToBankMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-09-300001492298us-gaap:CurrencySwapMembersbra:LoansPayableToBankMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-12-310001492298us-gaap:InterestRateContractMember2023-07-012023-09-300001492298us-gaap:InterestRateContractMember2022-07-012022-09-300001492298us-gaap:InterestRateContractMember2023-01-012023-09-300001492298us-gaap:InterestRateContractMember2022-01-012022-09-300001492298us-gaap:ForeignExchangeContractMember2023-07-012023-09-300001492298us-gaap:ForeignExchangeContractMember2022-07-012022-09-300001492298us-gaap:ForeignExchangeContractMember2023-01-012023-09-300001492298us-gaap:ForeignExchangeContractMember2022-01-012022-09-300001492298us-gaap:CurrencySwapMemberus-gaap:RevolvingCreditFacilityMember2023-07-012023-09-300001492298us-gaap:CurrencySwapMemberus-gaap:RevolvingCreditFacilityMember2022-07-012022-09-300001492298us-gaap:CurrencySwapMemberus-gaap:RevolvingCreditFacilityMember2023-01-012023-09-300001492298us-gaap:CurrencySwapMemberus-gaap:RevolvingCreditFacilityMember2022-01-012022-09-300001492298us-gaap:CurrencySwapMember2023-07-012023-09-300001492298us-gaap:CurrencySwapMember2022-07-012022-09-300001492298us-gaap:CurrencySwapMember2023-01-012023-09-300001492298us-gaap:CurrencySwapMember2022-01-012022-09-300001492298us-gaap:InterestRateContractMemberus-gaap:InterestExpenseMember2023-07-012023-09-300001492298us-gaap:InterestRateContractMemberus-gaap:InterestExpenseMember2022-07-012022-09-300001492298us-gaap:InterestRateContractMemberus-gaap:InterestExpenseMember2023-01-012023-09-300001492298us-gaap:InterestRateContractMemberus-gaap:InterestExpenseMember2022-01-012022-09-300001492298us-gaap:CashFlowHedgingMemberus-gaap:InterestRateSwapMember2022-01-012022-09-300001492298us-gaap:CashFlowHedgingMemberus-gaap:InterestRateSwapMember2022-07-012022-09-300001492298us-gaap:CashFlowHedgingMemberus-gaap:InterestRateSwapMember2023-01-012023-09-300001492298us-gaap:CashFlowHedgingMemberus-gaap:InterestRateSwapMember2023-07-012023-09-300001492298us-gaap:NondesignatedMemberus-gaap:CrossCurrencyInterestRateContractMember2022-01-012022-09-300001492298us-gaap:NondesignatedMemberus-gaap:CrossCurrencyInterestRateContractMember2023-07-012023-09-300001492298us-gaap:NondesignatedMemberus-gaap:CrossCurrencyInterestRateContractMember2022-07-012022-09-300001492298us-gaap:NondesignatedMemberus-gaap:CrossCurrencyInterestRateContractMember2023-01-012023-09-300001492298us-gaap:CreditRiskContractMember2023-09-300001492298srt:MinimumMemberus-gaap:MeasurementInputDiscountRateMember2023-09-300001492298us-gaap:MeasurementInputDiscountRateMembersrt:MaximumMember2023-09-300001492298srt:WeightedAverageMemberus-gaap:MeasurementInputDiscountRateMember2023-09-300001492298srt:WeightedAverageMemberus-gaap:SecuredDebtMemberus-gaap:MeasurementInputDiscountRateMember2023-09-300001492298us-gaap:CarryingReportedAmountFairValueDisclosureMember2023-09-300001492298us-gaap:EstimateOfFairValueFairValueDisclosureMember2023-09-300001492298us-gaap:CarryingReportedAmountFairValueDisclosureMember2022-12-310001492298us-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001492298us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:SeniorNotesMember2023-09-300001492298us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:SeniorNotesMember2023-09-300001492298us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:SeniorNotesMember2022-12-310001492298us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:SeniorNotesMember2022-12-310001492298us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:SecuredDebtMember2023-09-300001492298us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:SecuredDebtMember2023-09-300001492298us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:SecuredDebtMember2022-12-310001492298us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:SecuredDebtMember2022-12-310001492298us-gaap:FairValueMeasurementsRecurringMember2023-09-300001492298us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001492298us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001492298us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001492298us-gaap:SeniorNotesMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001492298us-gaap:FairValueInputsLevel1Memberus-gaap:SeniorNotesMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001492298us-gaap:FairValueInputsLevel2Memberus-gaap:SeniorNotesMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001492298us-gaap:FairValueInputsLevel3Memberus-gaap:SeniorNotesMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001492298us-gaap:SecuredDebtMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001492298us-gaap:FairValueInputsLevel1Memberus-gaap:SecuredDebtMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001492298us-gaap:FairValueInputsLevel2Memberus-gaap:SecuredDebtMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001492298us-gaap:FairValueInputsLevel3Memberus-gaap:SecuredDebtMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001492298us-gaap:InterestRateSwapMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001492298us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001492298us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001492298us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001492298sbra:InterestRateCollarMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001492298us-gaap:FairValueInputsLevel1Membersbra:InterestRateCollarMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001492298us-gaap:FairValueInputsLevel2Membersbra:InterestRateCollarMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001492298us-gaap:FairValueInputsLevel3Membersbra:InterestRateCollarMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001492298sbra:ForwardStartingInterestRateSwapsMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001492298sbra:ForwardStartingInterestRateSwapsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001492298sbra:ForwardStartingInterestRateSwapsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001492298sbra:ForwardStartingInterestRateSwapsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001492298us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001492298us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001492298us-gaap:FairValueInputsLevel2Memberus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001492298us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001492298sbra:EquityDistributionAgreementATMProgramMember2023-02-232023-02-230001492298sbra:EquityDistributionAgreementATMProgramMember2023-01-012023-09-300001492298sbra:EquityDistributionAgreementATMProgramMember2023-07-012023-09-300001492298sbra:EquityDistributionAgreementATMProgramMember2023-09-3000014922982023-02-012023-02-0100014922982023-05-032023-05-0300014922982023-08-072023-08-070001492298us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300001492298us-gaap:AccumulatedTranslationAdjustmentMember2023-09-300001492298us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310001492298us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-09-300001492298us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-12-310001492298us-gaap:RestrictedStockUnitsRSUMember2023-07-012023-09-300001492298us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300001492298us-gaap:RestrictedStockUnitsRSUMember2022-07-012022-09-300001492298us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-09-300001492298us-gaap:SubsequentEventMember2023-11-062023-11-06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 FORM 10-Q  
(Mark One)
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2023
OR 
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission file number 001-34950
SABRA HEALTH CARE REIT, INC.
(Exact Name of Registrant as Specified in Its Charter) 
Maryland 27-2560479
(State of Incorporation) (I.R.S. Employer Identification No.)
18500 Von Karman Avenue, Suite 550
Irvine, CA 92612
(888) 393-8248
(Address, zip code and telephone number of Registrant)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbol(s)Name of each exchange on which registered
Common stock, $.01 par valueSBRAThe Nasdaq Stock Market LLC
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer☒Accelerated filer☐
Non-accelerated filer☐Smaller reporting company☐
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ☐    No  ☒
As of November 1, 2023, there were 231,219,523 shares of the registrant’s $0.01 par value Common Stock outstanding.

SABRA HEALTH CARE REIT, INC. AND SUBSIDIARIES
Index
 
1
References throughout this document to “Sabra,” “we,” “our,” “ours” and “us” refer to Sabra Health Care REIT, Inc. and its direct and indirect consolidated subsidiaries and not any other person.
STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
Certain statements in this Quarterly Report on Form 10-Q (this “10-Q”) contain “forward-looking” information as that term is defined by the Private Securities Litigation Reform Act of 1995. Any statements that do not relate to historical or current facts or matters are forward-looking statements. Examples of forward-looking statements include all statements regarding our expected future financial position, results of operations, cash flows, liquidity, financing plans, business strategy, tenants, borrowers and Senior Housing - Managed communities (as defined below), the expected amounts and timing of dividends and other distributions, projected expenses and capital expenditures, competitive position, growth opportunities, potential investments, potential dispositions, plans and objectives for future operations, and compliance with and changes in governmental regulations. You can identify some of the forward-looking statements by the use of forward-looking words such as “anticipate,” “believe,” “plan,” “estimate,” “expect,” “intend,” “should,” “may” and other similar expressions, although not all forward-looking statements contain these identifying words.
Our actual results may differ materially from those projected or contemplated by our forward-looking statements as a result of various factors, including, among others, the following:
•pandemics or epidemics, including COVID-19, and the related impact on our tenants, borrowers and Senior Housing - Managed communities;
•increased labor costs and historically low unemployment;
•increases in market interest rates and inflation;
•operational risks with respect to our Senior Housing - Managed communities;
•competitive conditions in our industry;
•the loss of key management personnel;
•uninsured or underinsured losses affecting our properties;
•potential impairment charges and adjustments related to the accounting of our assets;
•the potential variability of our reported rental and related revenues as a result of Accounting Standards Update (“ASU”) 2016-02, Leases, as amended by subsequent ASUs;
•risks associated with our investment in our unconsolidated joint ventures;
•catastrophic weather and other natural or man-made disasters, the effects of climate change on our properties and a failure to implement sustainable and energy-efficient measures;
•increased operating costs and competition for our tenants, borrowers and Senior Housing - Managed communities;
•increased healthcare regulation and enforcement;
•our tenants’ dependency on reimbursement from governmental and other third-party payor programs;
•the effect of our tenants, operators or borrowers declaring bankruptcy or becoming insolvent;
•our ability to find replacement tenants and the impact of unforeseen costs in acquiring new properties;
•the impact of litigation and rising insurance costs on the business of our tenants;
•the impact of required regulatory approvals of transfers of healthcare properties;
•environmental compliance costs and liabilities associated with real estate properties we own;
•our tenants’, borrowers’ or operators’ failure to adhere to applicable privacy and data security laws, or a material breach of our or our tenants’, borrowers’ or operators’ information technology;
•our concentration in the healthcare property sector, particularly in skilled nursing/transitional care facilities and senior housing communities, which makes our profitability more vulnerable to a downturn in a specific sector than if we were investing in multiple industries;
•the significant amount of and our ability to service our indebtedness;
•covenants in our debt agreements that may restrict our ability to pay dividends, make investments, incur additional indebtedness and refinance indebtedness on favorable terms;
•adverse changes in our credit ratings;
•our ability to make dividend distributions at expected levels;
•our ability to raise capital through equity and debt financings;
•changes and uncertainty in macroeconomic conditions and disruptions in the financial markets;
•risks associated with our ownership of property outside the U.S., including currency fluctuations;
•the relatively illiquid nature of real estate investments;
•our ability to maintain our status as a real estate investment trust (“REIT”) under the federal tax laws;
•compliance with REIT requirements and certain tax and tax regulatory matters related to our status as a REIT;
•changes in tax laws and regulations affecting REITs;
2
•the ownership limits and takeover defenses in our governing documents and under Maryland law, which may restrict change of control or business combination opportunities; and
•the exclusive forum provisions in our bylaws.
We urge you to carefully consider these risks and review the additional disclosures we make concerning risks and other factors that may materially affect the outcome of our forward-looking statements and our future business and operating results, including those made in Part I, Item 1A, “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2022 (our “2022 Annual Report on Form 10-K”), as such risk factors may be amended, supplemented or superseded from time to time by other reports we file with the Securities and Exchange Commission (the “SEC”), including subsequent Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. We caution you that any forward-looking statements made in this 10-Q are not guarantees of future performance, events or results, and you should not place undue reliance on these forward-looking statements, which speak only as of the date of this report. We do not intend, and we undertake no obligation, to update any forward-looking information to reflect events or circumstances after the date of this 10-Q or to reflect the occurrence of unanticipated events, unless required by law to do so.

3
PART I. FINANCIAL INFORMATION
 
ITEM 1.FINANCIAL STATEMENTS
SABRA HEALTH CARE REIT, INC.
CONSOLIDATED BALANCE SHEETS
(dollars in thousands, except per share data)
 
September 30, 2023December 31, 2022
 (unaudited) 
Assets
Real estate investments, net of accumulated depreciation of $1,002,484 and $913,345 as of September 30, 2023 and December 31, 2022, respectively
$4,603,014 $4,959,343 
Loans receivable and other investments, net417,947 411,396 
Investment in unconsolidated joint ventures135,755 134,962 
Cash and cash equivalents33,256 49,308 
Restricted cash5,602 4,624 
Lease intangible assets, net32,749 40,131 
Accounts receivable, prepaid expenses and other assets, net152,239 147,908 
Total assets$5,380,562 $5,747,672 
Liabilities
Secured debt, net$47,789 $49,232 
Revolving credit facility32,623 196,982 
Term loans, net534,011 526,129 
Senior unsecured notes, net1,735,055 1,734,431 
Accounts payable and accrued liabilities128,039 142,259 
Lease intangible liabilities, net34,192 42,244 
Total liabilities2,511,709 2,691,277 
Commitments and contingencies (Note 12)
Equity
Preferred stock, $0.01 par value; 10,000,000 shares authorized, zero shares issued and outstanding as of September 30, 2023 and December 31, 2022
— — 
Common stock, $0.01 par value; 500,000,000 shares authorized, 231,219,523 and 231,009,295 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively
2,312 2,310 
Additional paid-in capital4,491,917 4,486,967 
Cumulative distributions in excess of net income(1,665,045)(1,451,945)
Accumulated other comprehensive income39,669 19,063 
Total equity2,868,853 3,056,395 
Total liabilities and equity$5,380,562 $5,747,672 

See accompanying notes to consolidated financial statements.
4
SABRA HEALTH CARE REIT, INC.
CONSOLIDATED STATEMENTS OF (LOSS) INCOME
(dollars in thousands, except per share data)
(unaudited)
 
Three Months Ended September 30,Nine Months Ended September 30,
 2023202220232022
Revenues:
Rental and related revenues (Note 4)$93,085 $84,214 $283,229 $297,268 
Resident fees and services59,748 47,610 174,897 133,973 
Interest and other income8,794 8,940 25,991 28,585 
   
Total revenues161,627 140,764 484,117 459,826 
  
Expenses:
Depreciation and amortization43,242 47,427 140,211 137,855 
Interest28,156 27,071 85,024 77,573 
Triple-net portfolio operating expenses4,304 5,120 13,243 14,983 
Senior housing - managed portfolio operating expenses44,523 36,705 132,124 103,835 
General and administrative10,759 9,676 30,793 28,721 
Provision for (recovery of) loan losses and other reserves328 (217)549 (12)
Impairment of real estate— 60,857 7,064 72,602 
   
Total expenses131,312 186,639 409,008 435,557 
  
Other (expense) income:
Loss on extinguishment of debt— (140)(1,541)(411)
Other income (expense)2,229 994 2,570 (1,101)
Net loss on sales of real estate(46,545)(80)(75,893)(4,581)
Total other (expense) income(44,316)774 (74,864)(6,093)
(Loss) income before loss from unconsolidated joint ventures and income tax expense(14,001)(45,101)245 18,176 
Loss from unconsolidated joint ventures(645)(4,384)(2,136)(9,715)
Income tax expense(455)(579)(1,509)(1,118)
Net (loss) income$(15,101)$(50,064)$(3,400)$7,343 
  
Net (loss) income, per:
Basic common share$(0.07)$(0.22)$(0.01)$0.03 
    
Diluted common share$(0.07)$(0.22)$(0.01)$0.03 
    
Weighted average number of common shares outstanding, basic231,224,692 230,982,227 231,197,375 230,936,032 
 
Weighted average number of common shares outstanding, diluted231,224,692 230,982,227 231,197,375 231,779,750 

See accompanying notes to consolidated financial statements.
5
SABRA HEALTH CARE REIT, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME
(in thousands)
(unaudited)
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Net (loss) income$(15,101)$(50,064)$(3,400)$7,343 
Other comprehensive income:
Unrealized gain (loss), net of tax:
Foreign currency translation (loss) gain(1,347)1,068 (1,948)3,505 
Unrealized gain on cash flow hedges8,777 7,309 22,554 25,038 
Total other comprehensive income7,430 8,377 20,606 28,543 
Comprehensive (loss) income$(7,671)$(41,687)$17,206 $35,886 

See accompanying notes to consolidated financial statements.

6

SABRA HEALTH CARE REIT, INC.
CONSOLIDATED STATEMENTS OF EQUITY
(dollars in thousands, except per share data)
(unaudited)
 
Three Months Ended September 30, 2022
 Common StockAdditional
Paid-in Capital		Cumulative Distributions in Excess of Net IncomeAccumulated Other Comprehensive IncomeTotal Equity
 SharesAmounts
Balance, June 30, 2022230,968,872 $2,310 $4,482,239 $(1,176,968)$10,145 $3,317,726 
Net loss— — — (50,064)— (50,064)
Other comprehensive income— — — — 8,377 8,377 
Amortization of stock-based compensation— — 2,657 — — 2,657 
Common stock issuance, net7,734 — (127)— — (127)
Common dividends ($0.30 per share)
— — — (69,836)— (69,836)
Balance, September 30, 2022230,976,606 $2,310 $4,484,769 $(1,296,868)$18,522 $3,208,733 
Three Months Ended September 30, 2023
 Common StockAdditional
Paid-in Capital		Cumulative Distributions in Excess of Net IncomeAccumulated Other Comprehensive IncomeTotal Equity
SharesAmounts
Balance, June 30, 2023231,218,658 $2,312 $4,489,107 $(1,579,914)$32,239 $2,943,744 
Net loss— — — (15,101)— (15,101)
Other comprehensive income— — — — 7,430 7,430 
Amortization of stock-based compensation— — 2,900 — — 2,900 
Common stock issuance, net865 — (90)— — (90)
Common dividends ($0.30 per share)
— — — (70,030)— (70,030)
Balance, September 30, 2023231,219,523 $2,312 $4,491,917 $(1,665,045)$39,669 $2,868,853 

See accompanying notes to consolidated financial statements.

7

SABRA HEALTH CARE REIT, INC.
CONSOLIDATED STATEMENTS OF EQUITY (CONTINUED)
(dollars in thousands, except per share data)
(unaudited)
 
Nine Months Ended September 30, 2022
 Common StockAdditional
Paid-in Capital		Cumulative Distributions in Excess of Net IncomeAccumulated Other Comprehensive (Loss) IncomeTotal Equity
 SharesAmounts
Balance, December 31, 2021230,398,655 $2,304 $4,482,451 $(1,095,204)$(10,021)$3,379,530 
Net income— — — 7,343 — 7,343 
Other comprehensive income— — — — 28,543 28,543 
Amortization of stock-based compensation— — 6,513 — — 6,513 
Common stock issuance, net577,951 6 (4,195)— — (4,189)
Common dividends ($0.90 per share)
— — — (209,007)— (209,007)
Balance, September 30, 2022230,976,606 $2,310 $4,484,769 $(1,296,868)$18,522 $3,208,733 
Nine Months Ended September 30, 2023
 Common StockAdditional
Paid-in Capital		Cumulative Distributions in Excess of Net IncomeAccumulated Other Comprehensive IncomeTotal Equity
SharesAmounts
Balance, December 31, 2022231,009,295 $2,310 $4,486,967 $(1,451,945)$19,063 $3,056,395 
Net loss— — — (3,400)— (3,400)
Other comprehensive income— — — — 20,606 20,606 
Amortization of stock-based compensation— — 7,090 — — 7,090 
Common stock issuance, net210,228 2 (2,140)— — (2,138)
Common dividends ($0.90 per share)
— — — (209,700)— (209,700)
Balance, September 30, 2023231,219,523 $2,312 $4,491,917 $(1,665,045)$39,669 $2,868,853 

See accompanying notes to consolidated financial statements.
8
SABRA HEALTH CARE REIT, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)
 Nine Months Ended September 30,
20232022
Cash flows from operating activities:
Net (loss) income$(3,400)$7,343 
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization140,211 137,855 
Non-cash rental and related revenues(6,781)4,970 
Non-cash interest income(380)(1,683)
Non-cash interest expense9,179 8,300 
Stock-based compensation expense5,468 5,367 
Loss on extinguishment of debt1,541 411 
Provision for (recovery of) loan losses and other reserves549 (12)
Net loss on sales of real estate75,893 4,581 
Impairment of real estate7,064 72,602 
Loss from unconsolidated joint ventures2,136 9,715 
Distributions of earnings from unconsolidated joint ventures1,705 — 
Other non-cash items(3,704)2,167 
Changes in operating assets and liabilities:
Accounts receivable, prepaid expenses and other assets, net(10,660)(5,631)
Accounts payable and accrued liabilities3,013 2,161 
Net cash provided by operating activities221,834 248,146 
Cash flows from investing activities:
Acquisition of real estate(39,630)(83,985)
Origination and fundings of loans receivable(9,614)(4,500)
Origination and fundings of preferred equity investments(11,015)(5,813)
Additions to real estate(63,794)(33,809)
Escrow deposits for potential investments— (836)
Repayments of loans receivable8,674 4,885 
Repayments of preferred equity investments4,828 4,173 
Investment in unconsolidated joint ventures(4,797)(128,019)
Net proceeds from the sales of real estate248,222 62,816 
Net proceeds from sales-type lease25,490 — 
Insurance proceeds6,001 — 
Distributions in excess of earnings from unconsolidated joint ventures544 — 
Net cash provided by (used in) investing activities164,909 (185,088)
Cash flows from financing activities:
Net (repayments of) borrowings from revolving credit facility(165,338)147,353 
Proceeds from term loans12,188 — 
Principal payments on term loans— (63,750)
Principal payments on secured debt(1,479)(17,030)
Payments of deferred financing costs(18,135)(6)
Payment of contingent consideration(17,900)(2,500)
Issuance of common stock, net(2,194)(4,394)
Dividends paid on common stock(208,079)(207,861)
Net cash used in financing activities(400,937)(148,188)
Net decrease in cash, cash equivalents and restricted cash(14,194)(85,130)
Effect of foreign currency translation on cash, cash equivalents and restricted cash(880)392 
Cash, cash equivalents and restricted cash, beginning of period53,932 115,886 
Cash, cash equivalents and restricted cash, end of period$38,858 $31,148 
Supplemental disclosure of cash flow information:
Interest paid$72,911 $68,778 
Supplemental disclosure of non-cash investing activities:
Decrease in loans receivable and other investments due to acquisition of real estate$4,644 $14,311 
See accompanying notes to consolidated financial statements.
9
SABRA HEALTH CARE REIT, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
 
1.     BUSINESS
Overview
Sabra Health Care REIT, Inc. (“Sabra” or the “Company”) was incorporated on May 10, 2010 as a wholly owned subsidiary of Sun Healthcare Group, Inc. (“Sun”) and commenced operations on November 15, 2010 following Sabra’s separation from Sun. Sabra elected to be treated as a real estate investment trust (“REIT”) with the filing of its United States (“U.S.”) federal income tax return for the taxable year beginning January 1, 2011. Sabra believes that it has been organized and operated, and it intends to continue to operate, in a manner to qualify as a REIT. Sabra’s primary business consists of acquiring, financing and owning real estate property to be leased to third-party tenants in the healthcare sector. Sabra primarily generates revenues by leasing properties to tenants throughout the U.S. and Canada. Sabra owns substantially all of its assets and properties and conducts its operations through Sabra Health Care Limited Partnership, a Delaware limited partnership (the “Operating Partnership”), of which Sabra is the sole general partner and a wholly owned subsidiary of Sabra is currently the only limited partner, or by subsidiaries of the Operating Partnership. The Company’s investment portfolio is primarily comprised of skilled nursing/transitional care facilities, senior housing communities (“Senior Housing - Leased”), behavioral health facilities and specialty hospitals and other facilities, in each case leased to tenants who are responsible for the operations of these facilities; senior housing communities operated by third-party property managers pursuant to property management agreements (“Senior Housing - Managed”); investments in joint ventures; investments in loans receivable; and preferred equity investments.

2.     SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Principles of Consolidation and Basis of Presentation
The accompanying consolidated financial statements include the accounts of Sabra and its wholly owned subsidiaries as of September 30, 2023 and December 31, 2022 and for the three and nine month periods ended September 30, 2023 and 2022. All significant intercompany transactions and balances have been eliminated in consolidation.
The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information as contained within the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification and the rules and regulations of the SEC, including the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the unaudited consolidated financial statements do not include all of the information and footnotes required by GAAP for financial statements. In the opinion of management, the financial statements for the unaudited interim periods presented include all adjustments, which are of a normal and recurring nature, necessary for a fair statement of the results for such periods. Operating results for the three and nine months ended September 30, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023. For further information, refer to the Company’s consolidated financial statements and notes thereto for the year ended December 31, 2022 included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC.
GAAP requires the Company to identify entities for which control is achieved through voting rights or other means and to determine which business enterprise is the primary beneficiary of variable interest entities (“VIEs”). A VIE is broadly defined as an entity with one or more of the following characteristics: (a) the total equity investment at risk is insufficient to finance the entity’s activities without additional subordinated financial support; (b) as a group, the holders of the equity investment at risk lack (i) the ability to make decisions about the entity’s activities through voting or similar rights, (ii) the obligation to absorb the expected losses of the entity, or (iii) the right to receive the expected residual returns of the entity; or (c) the equity investors have voting rights that are not proportional to their economic interests, and substantially all of the entity’s activities either involve, or are conducted on behalf of, an investor that has disproportionately few voting rights. If the Company were determined to be the primary beneficiary of the VIE, the Company would consolidate investments in the VIE. The Company may change its original assessment of a VIE due to events such as modifications of contractual arrangements that affect the characteristics or adequacy of the entity’s equity investments at risk and the disposal of all or a portion of an interest held by the primary beneficiary.
10
The Company identifies the primary beneficiary of a VIE as the enterprise that has both: (i) the power to direct the activities of the VIE that most significantly impact the entity’s economic performance; and (ii) the obligation to absorb losses or the right to receive benefits of the VIE that could be significant to the entity. The Company performs this analysis on an ongoing basis. As of September 30, 2023, the Company determined that it was not the primary beneficiary of any VIEs.
As it relates to investments in loans, in addition to the Company’s assessment of VIEs and whether the Company is the primary beneficiary of those VIEs, the Company evaluates the loan terms and other pertinent facts to determine whether the loan investment should be accounted for as a loan or as a real estate joint venture. If an investment has the characteristics of a real estate joint venture, including if the Company participates in the majority of the borrower’s expected residual profit, the Company would account for the investment as an investment in a real estate joint venture and not as a loan investment. Expected residual profit is defined as the amount of profit, whether called interest or another name, such as an equity kicker, above a reasonable amount of interest and fees expected to be earned by a lender. At September 30, 2023, none of the Company’s investments in loans were accounted for as real estate joint ventures.
As it relates to investments in joint ventures, the Company assesses any partners’ rights and their impact on the presumption of control of the partnership by any single partner. The Company also applies this guidance to managing member interests in limited liability companies. The Company reassesses its determination of which entity controls the joint venture if: there is a change to the terms or in the exercisability of the rights of any partners or members, the general partner or managing member increases or decreases its ownership interests, or there is an increase or decrease in the number of outstanding ownership interests. As of September 30, 2023, the Company’s determination of which entity controls its investments in joint ventures has not changed as a result of any reassessment.
Use of Estimates
The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates.
Casualty Gains and Losses
Income resulting from insurance recoveries of property damage or business interruption losses is recognized when proceeds are received or contingencies related to the insurance recoveries are resolved.
A vacant facility owned by the Company suffered damages as a result of vandalism and theft. The Company received $6.0 million of net insurance proceeds and recorded a $3.7 million gain related to the property damage during the three and nine months ended September 30, 2023 which is included in other income (expense) on the accompanying consolidated statements of (loss) income.
A fire occurred at one of the Company’s Senior Housing - Managed communities. The Company received $1.1 million of insurance proceeds and recorded $0.5 million of business interruption insurance income during the three and nine months ended September 30, 2023 which is included in other income (expense) on the accompanying consolidated statements of (loss) income. The remaining proceeds were recorded as expense reimbursements in Senior Housing - Managed portfolio operating expenses on the accompanying consolidated statements of (loss) income.

11
3.     RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED)
During the nine months ended September 30, 2023, the Company acquired one Senior Housing - Leased community and one Senior Housing - Managed community. During the nine months ended September 30, 2022, the Company acquired three Senior Housing - Managed communities. The Senior Housing - Managed community acquired during the nine months ended September 30, 2023 and two of the Senior Housing - Managed communities acquired during the nine months ended September 30, 2022 were part of the Company’s proprietary development pipeline and were previously reflected as preferred equity investments which had a book value of $4.6 million and $14.3 million, respectively, at the time of acquisition. The consideration was allocated as follows (in thousands):
Nine Months Ended September 30,
20232022
Land$3,415 $10,292 
Building and improvements45,333 83,118 
Tenant origination and absorption costs intangible assets2,706 4,887 
Tenant relationship intangible assets20 — 
Total consideration$51,474 $98,297 
The tenant origination and absorption costs intangible assets and tenant relationship intangible assets had weighted average amortization periods as of the respective dates of acquisition of one year and 22 years, respectively, for the acquisitions completed during the nine months ended September 30, 2023. The tenant origination and absorption costs intangible assets had an amortization period as of the date of acquisition of one year for the acquisitions completed during the nine months ended September 30, 2022.
For the three and nine months ended September 30, 2023, the Company recognized $2.6 million and $6.8 million of total revenues, respectively, and $46,000 of net loss and less than $1,000 of net income, respectively, from the facilities acquired during the nine months ended September 30, 2023. For the three and nine months ended September 30, 2022, the Company recognized $3.9 million and $6.0 million of total revenues, respectively, and $0.3 million and $0.9 million of net loss, respectively, from the facilities acquired during the nine months ended September 30, 2022.
During the three months ended June 30, 2023, the Company, in accordance with the terms of the agreements pursuant to which it purchased the facilities, paid $17.9 million in additional consideration related to two Senior Housing - Managed communities that achieved certain performance metrics. This amount is included in real estate investments, net of accumulated depreciation on the accompanying consolidated balance sheets.

4.    INVESTMENT IN REAL ESTATE PROPERTIES
The Company’s real estate properties held for investment consisted of the following (dollars in thousands):
As of September 30, 2023
Property TypeNumber of
Properties		Number of
Beds/Units		Total
Real Estate
at Cost		Accumulated
Depreciation		Total
Real Estate
Investments, Net
Skilled Nursing/Transitional Care240 26,623 $3,035,231 $(530,290)$2,504,941 
Senior Housing - Leased43 3,473 572,633 (106,063)466,570 
Senior Housing - Managed61 6,041 1,278,352 (250,772)1,027,580 
Behavioral Health18 1,077 492,236 (68,654)423,582 
Specialty Hospitals and Other15 392 225,443 (46,100)179,343 
377 37,606 5,603,895 (1,001,879)4,602,016 
Corporate Level1,603 (605)998 
$5,605,498 $(1,002,484)$4,603,014 
12
As of December 31, 2022
Property TypeNumber of
Properties		Number of
Beds/Units		Total
Real Estate
at Cost		Accumulated
Depreciation		Total
Real Estate
Investments, Net
Skilled Nursing/Transitional Care264 29,136 $3,385,221 $(492,495)$2,892,726 
Senior Housing - Leased47 3,550 590,694 (97,716)492,978 
Senior Housing - Managed59 5,942 1,205,283 (222,089)983,194 
Behavioral Health17 965 465,143 (58,481)406,662 
Specialty Hospitals and Other15 392 225,443 (42,038)183,405 
402 39,985 5,871,784 (912,819)4,958,965 
Corporate Level904 (526)378 
$5,872,688 $(913,345)$4,959,343 
September 30, 2023December 31, 2022
Building and improvements$4,815,199 $5,034,470 
Furniture and equipment234,882 262,644 
Land improvements10,241 7,085 
Land545,176 568,489 
Total real estate at cost5,605,498 5,872,688 
Accumulated depreciation(1,002,484)(913,345)
Total real estate investments, net$4,603,014 $4,959,343 
Operating Leases
As of September 30, 2023, the substantial majority of the Company’s real estate properties (excluding 61 Senior Housing - Managed communities) were leased under triple-net operating leases with expirations ranging from less than one year to 19 years. As of September 30, 2023, the leases had a weighted average remaining term of eight years. The leases generally include provisions to extend the lease terms and other negotiated terms and conditions. The Company, through its subsidiaries, retains substantially all of the risks and benefits of ownership of the real estate assets leased to the tenants. The Company may receive additional security under these operating leases in the form of letters of credit and security deposits from the lessee or guarantees from the parent of the lessee. Security deposits received in cash related to tenant leases are included in accounts payable and accrued liabilities on the accompanying consolidated balance sheets and totaled $17.0 million and $13.0 million as of September 30, 2023 and December 31, 2022, respectively, and letters of credit deposited with the Company totaled approximately $57 million as of each of September 30, 2023 and December 31, 2022. In addition, the Company’s tenants have deposited with the Company $11.6 million and $13.3 million as of September 30, 2023 and December 31, 2022, respectively, for future real estate taxes, insurance expenditures and tenant improvements related to the Company’s properties and their operations, and these amounts are included in accounts payable and accrued liabilities on the accompanying consolidated balance sheets.
Lessor costs that are paid by the lessor and reimbursed by the lessee are included in the measurement of variable lease revenue and the associated expense. As a result, the Company recognized variable lease revenue and the associated expense of $3.8 million and $11.4 million during the three and nine months ended September 30, 2023, respectively, and $4.3 million and $13.7 million during the three and nine months ended September 30, 2022, respectively.
The Company monitors the creditworthiness of its tenants by evaluating the ability of the tenants to meet their lease obligations to the Company based on the tenants’ financial performance, including, as applicable and appropriate, the evaluation of any parent guarantees (or the guarantees of other related parties) of such lease obligations. The primary basis for the Company’s evaluation of the credit quality of its tenants (and more specifically the tenant’s ability to pay their rent obligations to the Company) is the tenant’s lease coverage ratio as supplemented by the parent’s fixed charge coverage ratio for those entities with a parent guarantee. These coverage ratios include earnings before interest, taxes, depreciation, amortization and rent (“EBITDAR”) to rent and earnings before interest, taxes, depreciation, amortization, rent and management fees (“EBITDARM”) to rent at the lease level and consolidated EBITDAR to total fixed charges at the parent guarantor level when such a guarantee exists. The Company obtains various financial and operational information from the majority of its tenants each month and reviews this information in conjunction with the above-described coverage metrics to identify financial and operational trends, evaluate the impact of the industry’s operational and financial environment (including the impact of
13
government reimbursement), and evaluate the management of the tenant’s operations. These metrics help the Company identify potential areas of concern relative to its tenants’ credit quality and ultimately the tenant’s ability to generate sufficient liquidity to meet its obligations, including its obligation to continue to pay the rent due to the Company.
During the third quarter of 2022, the Company concluded that its leases with North American Health Care, Inc. should no longer be accounted for on an accrual basis and wrote off $15.6 million of straight-line rent receivable balances related to these leases. The facilities were transitioned to the Ensign Group or Avamere, as applicable, effective February 1, 2023.
For the three and nine months ended September 30, 2023, no tenant relationship represented 10% or more of the Company’s total revenues.
As of September 30, 2023, the future minimum rental payments from the Company’s properties held for investment under non-cancelable operating leases were as follows and may materially differ from actual future rental payments received (in thousands):
October 1 through December 31, 2023$91,919 
2024371,661 
2025366,190 
2026350,583 
2027327,530 
Thereafter1,508,364 
$3,016,247 
Senior Housing - Managed Communities
The Company’s Senior Housing - Managed communities offer residents certain ancillary services that are not contemplated in the lease with each resident (i.e., housekeeping, laundry, guest meals, etc.). These services are provided and paid for in addition to the standard services included in each resident lease (i.e., room and board, standard meals, etc.). The Company bills residents for ancillary services one month in arrears and recognizes revenue as the services are provided, as the Company has no continuing performance obligation related to those services. Resident fees and services include ancillary service revenue of $0.4 million and $1.4 million for the three and nine months ended September 30, 2023, respectively, and $0.4 million and $1.0 million for the three and nine months ended September 30, 2022, respectively.
Capital and Other Expenditures
As of September 30, 2023, the Company’s aggregate commitment for future capital and other expenditures associated with facilities leased under triple-net operating leases was approximately $44 million. These commitments are principally for improvements to its facilities.
Investment in Unconsolidated Joint Ventures
The following is a summary of the Company’s investment in unconsolidated joint ventures (dollars in thousands):
Property Type
Number of
Properties as of
September 30, 2023
Ownership as of
September 30, 2023 (1)
Book Value
September 30, 2023December 31, 2022
Sienna Joint VentureSenior Housing - Managed12 50 %$118,150 $120,269 
Marlin Spring Joint VentureSenior Housing - Managed4 85 %17,605 14,693 
$135,755 $134,962 
(1)    These investments are not consolidated because the Company does not control, through voting rights or other means, the joint ventures.
During the nine months ended September 30, 2023, the Company’s joint venture with Marlin Spring (the “Marlin Spring Joint Venture”) completed the acquisition of one additional senior housing community that is being managed by a third-party property manager. The gross investment in the additional acquisition was CAD $30.0 million, excluding acquisition costs. In addition, the Marlin Spring Joint Venture assumed and financed an aggregate CAD $23.6 million of debt associated with the additional acquisition. The Company’s equity investment in the additional acquisition was CAD $6.1 million.
During the fourth quarter of 2022, due to the confluence of labor shortages, increased labor costs, elevated interest rates and a slower than anticipated recovery in the operating performance of the underlying facilities, the Company concluded that
14
the estimated fair value of its investment in its joint venture with affiliates of TPG Real Estate, the real estate platform of TPG (the “Enlivant Joint Venture”) had declined to zero based on updated future cash flow analyses. This decline was deemed to be other-than-temporary, and the Company recorded an impairment charge totaling $57.8 million during the three months ended December 31, 2022.
Effective January 1, 2023, the Company discontinued applying the equity method of accounting to the Enlivant Joint Venture, in which it had a 49% equity interest. Effective May 1, 2023, the Company withdrew and resigned its membership in the Enlivant Joint Venture and accordingly, no longer has an equity interest in the Enlivant Joint Venture as of such date.
During the nine months ended September 30, 2022, the Enlivant Joint Venture was a significant equity method investee of the Company. The following table presents summarized financial information for the Enlivant Joint Venture and, except for basis adjustments and loss from unconsolidated joint venture, reflects the historical cost basis of the assets which pre-dated the Company’s investment in the Enlivant Joint Venture (in thousands):
Nine Months Ended September 30, 2022
Total revenues$237,144 
Operating expenses215,293 
Net loss(7,177)
Company’s share of net loss$(3,525)
Basis adjustments5,755 
Loss from unconsolidated joint venture$(9,280)
Certain amounts in the financial information for the Enlivant Joint Venture have been reclassified to conform to Sabra’s presentation. The Company’s share of net loss in the Enlivant Joint Venture reflects its 49% equity interest and excludes certain equity-like compensation expense and the related income tax impact as such expense is not the responsibility of the Company under the terms of the joint venture agreement.
Net Investment in Sales-Type Lease
As of December 31, 2022, the Company had a $25.5 million net investment in one skilled nursing/transitional care facility leased to a tenant under a sales-type lease, as the tenant is obligated to purchase the property at the end of the lease term. During the three months ended March 31, 2023, the tenant purchased the skilled nursing/transitional care facility for net proceeds of $25.5 million as obligated under the terms of the lease.

5.    IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS
Impairment of Real Estate
During the nine months ended September 30, 2023, the Company recognized $7.1 million of real estate impairment related to one skilled nursing/transitional care facility that has sold.
During the nine months ended September 30, 2022, the Company recognized $72.6 million of real estate impairment related to ten skilled nursing/transitional care facilities that have sold.
To estimate the fair value of the impaired facilities, the Company utilized a market approach which considered binding sale agreements, non-binding offers from unrelated third parties or model-derived valuations with significant unobservable inputs (Level 3 measurements), as applicable.
The Company continues to evaluate additional assets for sale as part of its initiative to recycle capital and further improve its portfolio quality. This could lead to a shorter hold period and could result in the determination that the full amount of the Company’s investment is not recoverable, resulting in an impairment charge or loss on sale which could be material.
15
Dispositions
The following table summarizes the Company’s dispositions for the periods presented (dollars in millions):
Nine Months Ended September 30,
20232022
Number of facilities27 11 
Consideration, net of closing costs$256.2 $62.8 
Net carrying value332.1 67.4 
Net loss on sale$(75.9)$(4.6)
Net loss (1)
$(80.3)$(63.1)
(1)    In addition to net loss on sale, net loss includes impairment of real estate of $7.1 million and $65.8 million for the nine months ended September 30, 2023 and 2022, respectively.
The sale of the disposition facilities does not represent a strategic shift that has or will have a major effect on the Company’s operations and financial results, and therefore the results of operations attributable to these facilities have remained in continuing operations.

6.    LOANS RECEIVABLE AND OTHER INVESTMENTS
As of September 30, 2023 and December 31, 2022, the Company’s loans receivable and other investments consisted of the following (dollars in thousands):
As of September 30, 2023
Investment
Quantity
as of
September 30, 2023
Property Type
Principal Balance
as of
September 30, 2023 (1)
Book Value
as of
September 30, 2023
Book Value
as of December 31, 2022
Weighted Average Contractual Interest Rate / Rate of ReturnWeighted Average Annualized Effective Interest Rate / Rate of Return
Maturity Date
as of
September 30, 2023
Loans Receivable:
Mortgage2 Behavioral Health$319,000 $319,000 $319,000 7.6 %7.6 %11/01/26 - 01/31/27
Other10 Multiple52,133 48,703 47,936 7.5 %7.0 %08/31/23 - 05/01/29
12 371,133 367,703 366,936 7.6 %7.6 %
Allowance for loan losses— (6,677)(6,611)
$371,133 $361,026 $360,325 
Other Investments:
Preferred Equity5 Skilled Nursing / Senior Housing56,760 56,921 51,071 11.0 %11.0 %N/A
Total 17 $427,893 $417,947 $411,396 8.1 %8.0 %
(1)    Principal balance includes amounts funded and accrued but unpaid interest / preferred return and excludes capitalizable fees.
16
Additional information regarding the Company’s loans receivable is as follows (dollars in thousands):
Nine Months Ended September 30,
20232022
Allowance for loan losses:
Balance at beginning of the period$6,611 $6,344 
Provision for loan losses549 83 
Write-off of uncollectible balances(483)— 
Balance at end of the period$6,677 $6,427 
September 30, 2023December 31, 2022
Deteriorated credit quality:
Number of loans receivable investments1 1 
Principal balance$1,214 $1,214 
Book value— — 
Nonaccrual status:
Number of loans receivable investments3 3 
Book value$— $— 
As of September 30, 2023 and December 31, 2022, the Company did not consider any preferred equity investments to be impaired, and no preferred equity investments were on nonaccrual status.

7.    DEBT
Secured Indebtedness
The Company’s secured debt consists of the following (dollars in thousands):
As of September 30, 2023
Interest Rate Type
Principal Balance as of
September 30, 2023 (1)
Principal Balance as of
December 31, 2022 (1)
Weighted Average
Interest Rate
Weighted Average
Effective Interest Rate (2)
Maturity
Date
Fixed Rate$48,643 $50,123 2.85 %3.34 %May 2031 - 
August 2051
(1)     Principal balance does not include deferred financing costs, net of $0.9 million as of each of September 30, 2023 and December 31, 2022.
(2)     Weighted average effective interest rate includes private mortgage insurance.
Senior Unsecured Notes
The Company’s senior unsecured notes consist of the following (dollars in thousands):
Principal Balance as of
TitleMaturity Date
September 30, 2023 (1)
December 31, 2022 (1)
5.125% senior unsecured notes due 2026 (“2026 Notes”)
August 15, 2026$500,000 $500,000 
5.88% senior unsecured notes due 2027 (“2027 Notes”)
May 17, 2027100,000 100,000 
3.90% senior unsecured notes due 2029 (“2029 Notes”)
October 15, 2029350,000 350,000 
3.20% senior unsecured notes due 2031 (“2031 Notes”)
December 1, 2031800,000 800,000 
$1,750,000 $1,750,000 
(1)    Principal balance does not include discount, net of $4.1 million and deferred financing costs, net of $10.9 million as of September 30, 2023 and does not include discount, net of $3.5 million and deferred financing costs, net of $12.0 million as of December 31, 2022. In addition, the weighted average effective interest rate as of September 30, 2023 was 4.01%.
The 2026 Notes and the 2027 Notes were assumed as a result of the Company’s merger with Care Capital Properties, Inc. in 2017 and accrue interest at a rate of 5.125% and 5.88%, respectively, per annum. Interest is payable semiannually on February 15 and August 15 of each year for the 2026 Notes and on May 17 and November 17 of each year for the 2027 Notes.
17
The 2029 Notes were issued by the Operating Partnership and, until redemption of the Company’s previously outstanding 5.375% senior notes due 2023 in October 2019, Sabra Capital Corporation, wholly owned subsidiaries of the Company, and accrue interest at a rate of 3.90% per annum. Interest is payable semiannually on April 15 and October 15 of each year.
The 2031 Notes were issued by the Operating Partnership, a wholly owned subsidiary of the Company, and accrue interest at a rate of 3.20% per annum. Interest is payable semiannually on June 1 and December 1 of each year, commencing on June 1, 2022.
The obligations under the 2027 Notes are fully and unconditionally guaranteed, jointly and severally, on an unsecured basis, by Sabra and one of its non-operating subsidiaries, subject to release under certain customary circumstances. The obligations under the 2026 Notes, 2029 Notes and 2031 Notes are fully and unconditionally guaranteed, on an unsecured basis, by Sabra; provided, however, that such guarantee is subject to release under certain customary circumstances.
The indentures and agreements (the “Senior Notes Indentures”) governing the 2026 Notes, 2027 Notes, 2029 Notes and 2031 Notes (collectively, the “Senior Notes”) include customary events of default and require the Company to comply with specified restrictive covenants. As of September 30, 2023, the Company was in compliance with all applicable financial covenants under the Senior Notes Indentures.
Credit Agreement
On September 9, 2019, the Operating Partnership and Sabra Canadian Holdings, LLC (together, the “Borrowers”), Sabra and the other parties thereto entered into a fifth amended and restated unsecured credit agreement (the “Prior Credit Agreement”).
The Prior Credit Agreement included a $1.0 billion revolving credit facility (the “Prior Revolving Credit Facility”), a $436.3 million U.S. dollar term loan and a CAD $125.0 million Canadian dollar term loan (collectively, the “Prior Term Loans”). Further, up to $175.0 million of the Prior Revolving Credit Facility could be used for borrowings in certain foreign currencies. The Prior Credit Agreement also contained an accordion feature that allowed for an increase in the total available borrowings to $2.75 billion, subject to terms and conditions.
During the three and nine months ended September 30, 2022, the Company recognized $0.1 million and $0.4 million, respectively, of loss on extinguishment of debt related to write-offs of deferred financing costs in connection with the partial pay downs of the U.S. dollar Prior Term Loan.
Borrowings under the Prior Revolving Credit Facility bore interest on the outstanding principal amount at a rate equal to a ratings-based applicable interest margin plus, Canadian Dollar Offered Rate (“CDOR”) for Canadian dollar borrowings, or at the Operating Partnership’s option for U.S. dollar borrowings, either (a) LIBOR or (b) a base rate determined as the greater of (i) the federal funds rate plus 0.5%, (ii) the prime rate, and (iii) one-month LIBOR plus 1.0% (the “Prior Base Rate”). The ratings-based applicable interest margin for borrowings varied based on the Debt Ratings, as defined in the Prior Credit Agreement, and ranged from 0.775% to 1.45% per annum for CDOR or LIBOR based borrowings and 0.00% to 0.45% per annum for borrowings at the Prior Base Rate. In addition, the Operating Partnership paid a facility fee ranging between 0.125% and 0.300% per annum based on the aggregate amount of commitments under the Prior Revolving Credit Facility regardless of amounts outstanding thereunder.
The U.S. dollar Prior Term Loan bore interest on the outstanding principal amount at a rate equal to a ratings-based applicable interest margin plus, at the Operating Partnership’s option, either (a) LIBOR or (b) the Prior Base Rate. The ratings-based applicable interest margin for borrowings varied based on the Debt Ratings and ranged from 0.85% to 1.65% per annum for LIBOR based borrowings and 0.00% to 0.65% per annum for borrowings at the Prior Base Rate. The Canadian dollar Prior Term Loan bore interest on the outstanding principal amount at a rate equal to CDOR plus an interest margin that ranged from 0.85% to 1.65% depending on the Debt Ratings.
On January 4, 2023, the Borrowers, and the other parties thereto entered into a sixth amended and restated unsecured credit agreement (the “Credit Agreement”). During the nine months ended September 30, 2023, the Company recorded $18.1 million of deferred financing costs related to the Credit Agreement and recognized $1.5 million of loss on extinguishment of debt related to write-offs of deferred financing costs in connection with amending and restating the Prior Credit Agreement. No loss on extinguishment of debt was recognized during the three months ended September 30, 2023.
The Credit Agreement includes a $1.0 billion revolving credit facility (the “Revolving Credit Facility”), a $430.0 million U.S. dollar term loan and a CAD $150.0 million Canadian dollar term loan (collectively, the “Term Loans”). Further, up to $350.0 million of the Revolving Credit Facility may be used for borrowings in certain foreign currencies. The Credit
18
Agreement also contains an accordion feature that can increase the total available borrowings to $2.75 billion, subject to terms and conditions.
The Revolving Credit Facility has a maturity date of January 4, 2027, and includes two six-month extension options. The Term Loans have a maturity date of January 4, 2028.
As of September 30, 2023, there was $32.6 million (CAD $44.3 million) outstanding under the Revolving Credit Facility and $967.4 million available for borrowing.
Borrowings under the Revolving Credit Facility bear interest on the outstanding principal amount at a rate equal to a ratings-based applicable interest margin plus, CDOR for Canadian dollar borrowings, or at the Operating Partnership’s option for U.S. dollar borrowings, either (a) Daily Simple SOFR, as defined in the Credit Agreement, or (b) a base rate determined as the greater of (i) the federal funds rate plus 0.5%, (ii) the prime rate, (iii) Term SOFR, as defined in the Credit Agreement, plus 1.0% (the “Base Rate”), and (iv) 1.00%. The ratings-based applicable interest margin for borrowings will vary based on the Debt Ratings, as defined in the Credit Agreement, and will range from 0.775% to 1.450% per annum for Daily Simple SOFR-based borrowings and 0.00% to 0.450% per annum for borrowings at the Base Rate. As of September 30, 2023, the weighted average interest rate on the Revolving Credit Facility was 6.49%. In addition, the Operating Partnership pays a facility fee ranging between 0.125% and 0.300% per annum based on the aggregate amount of commitments under the Revolving Credit Facility regardless of amounts outstanding thereunder.
The U.S. dollar Term Loan bears interest on the outstanding principal amount at a ratings-based applicable interest margin plus, at the Operating Partnership’s option, either (a) Term SOFR or (b) the Base Rate. The ratings-based applicable interest margin for borrowings will vary based on the Debt Ratings and will range from 0.850% to 1.650% per annum for Term SOFR-based borrowings and 0.00% to 0.650% per annum for borrowings at the Base Rate. As of September 30, 2023, the interest rate on the U.S. dollar Term Loan was 6.66%. The Canadian dollar Term Loan bears interest on the outstanding principal amount at a rate equal CDOR plus an interest margin that will range from 0.850% to 1.650% depending on the Debt Ratings. As of September 30, 2023, the interest rate on the Canadian dollar Term Loan was 6.64%.
The Company has interest rate swaps and interest rate collars that fix and set a cap and floor, respectively, for the SOFR portion of the interest rate for $430.0 million of SOFR-based borrowings under its U.S. dollar Term Loan at a weighted average rate of 2.69% and interest rate swaps that fix the CDOR portion of the interest rate for CAD $150.0 million of CDOR-based borrowings under its Canadian dollar Term Loan at a rate of 1.63%. As of September 30, 2023, the effective interest rate on the U.S. dollar and Canadian dollar Term Loans was 3.94% and 2.88%, respectively. In addition, the Canadian dollar Term Loan and the CAD $44.3 million outstanding as of September 30, 2023 under the Revolving Credit Facility are designated as net investment hedges. See Note 8, “Derivative and Hedging Instruments,” for further information.
The obligations of the Borrowers under the Credit Agreement are guaranteed by the Company and certain of its subsidiaries.
The Credit Agreement contains customary covenants that include restrictions or limitations on the ability to pay dividends, incur additional indebtedness, engage in non-healthcare related business activities, enter into transactions with affiliates and sell or otherwise transfer certain assets as well as customary events of default. The Credit Agreement also requires Sabra, through the Operating Partnership, to comply with specified financial covenants, which include a maximum total leverage ratio, a maximum secured debt leverage ratio, a minimum fixed charge coverage ratio, a maximum unsecured leverage ratio, a minimum tangible net worth requirement and a minimum unsecured interest coverage ratio. As of September 30, 2023, the Company was in compliance with all applicable financial covenants under the Credit Agreement.
Interest Expense
The Company incurred interest expense of $28.2 million and $85.0 million during the three and nine months ended September 30, 2023, respectively, and $27.1 million and $77.6 million during the three and nine months ended September 30, 2022, respectively. Interest expense includes non-cash interest expense of $3.1 million and $9.2 million for the three and nine months ended September 30, 2023, respectively, and $2.8 million and $8.3 million for the three and nine months ended September 30, 2022, respectively. As of September 30, 2023 and December 31, 2022, the Company had $21.1 million and $18.2 million, respectively, of accrued interest included in accounts payable and accrued liabilities on the accompanying consolidated balance sheets.
19
Maturities
The following is a schedule of maturities for the Company’s outstanding debt as of September 30, 2023 (in thousands): 
Secured
Indebtedness
Revolving Credit
    Facility (1)
Term LoansSenior NotesTotal
October 1 through December 31, 2023$499 $— $— $— $499 
20242,034 — — — 2,034 
20252,089 — — — 2,089 
20262,147 — — 500,000 502,147 
20272,206 32,623 — 100,000 134,829 
Thereafter39,668 — 540,460 1,150,000 1,730,128 
Total Debt48,643 32,623 540,460 1,750,000 2,371,726 
Discount, net— — — (4,075)(4,075)
Deferred financing costs, net(854)— (6,449)(10,870)(18,173)
Total Debt, Net$47,789 $32,623 $534,011 $1,735,055 $2,349,478 
(1)    Revolving Credit Facility is subject to two six-month extension options.
    
8.    DERIVATIVE AND HEDGING INSTRUMENTS
The Company is exposed to various market risks, including the potential loss arising from adverse changes in interest rates and foreign exchange rates. The Company enters into derivative financial instruments to manage exposures that arise from business activities that result in the receipt or payment of future known and uncertain cash amounts, the value of which are determined by interest rates and foreign exchange rates. The Company’s derivative financial instruments are used to manage differences in the amount of the Company’s known or expected cash receipts and its known or expected cash payments principally related to the Company’s investments and borrowings.
Certain of the Company’s foreign operations expose the Company to fluctuations of foreign interest rates and exchange rates. These fluctuations may impact the value in the Company’s functional currency, the U.S. dollar, of the Company’s investment in foreign operations, the cash receipts and payments related to these foreign operations and payments of interest and principal under Canadian dollar denominated debt. The Company enters into derivative financial instruments to protect the value of its foreign investments and fix a portion of the interest payments for certain debt obligations. The Company does not enter into derivatives for speculative purposes.
Cash Flow Hedges
The Company’s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish these objectives, the Company primarily uses interest rate swaps and collars as part of its interest rate risk management strategy. As of September 30, 2023, approximately $9.6 million of gains, which are included in accumulated other comprehensive income, are expected to be reclassified into earnings in the next 12 months.
Net Investment Hedges
The Company is exposed to fluctuations in foreign exchange rates on investments it holds in Canada. The Company uses cross currency interest rate swaps to hedge its exposure to changes in foreign exchange rates on these foreign investments.
20
The following presents the notional amount of derivative instruments as of the dates indicated (in thousands):
September 30, 2023December 31, 2022
Derivatives designated as cash flow hedges:
Denominated in U.S. Dollars (1)
$753,750 $436,250 
Denominated in Canadian Dollars (2)
$300,000 $125,000 
Derivatives designated as net investment hedges:
Denominated in Canadian Dollars$56,300 $55,991 
Financial instruments designated as net investment hedges:
Denominated in Canadian Dollars$194,300 $329,500 
Derivatives not designated as net investment hedges:
Denominated in Canadian Dollars$— $309 
(1) Balance as of September 30, 2023 includes two forward starting interest rate swaps with an effective date of August 2024 and an aggregate notional amount of $323.8 million.
(2)    Balance as of September 30, 2023 includes two forward starting interest rate swaps with an effective date of September 2024 and an aggregate notional amount of CAD $150.0 million.
Derivative and Financial Instruments Designated as Hedging Instruments
The following is a summary of the derivative and financial instruments designated as hedging instruments held by the Company at September 30, 2023 and December 31, 2022 (dollars in thousands):    
Count as of September 30, 2023
Fair Value as ofMaturity Dates
TypeDesignationSeptember 30, 2023December 31, 2022Balance Sheet Location
Assets:
Interest rate swapsCash flow5 $11,986 $11,004 2024 - 2028Accounts receivable, prepaid expenses and other assets, net
Interest rate collarsCash flow2 5,133 6,622 2024Accounts receivable, prepaid expenses and other assets, net
Forward starting interest rate swapsCash flow4 18,164 — 2028Accounts receivable, prepaid expenses and other assets, net
Cross currency interest rate swapsNet investment2 4,048 3,851 2025Accounts receivable, prepaid expenses and other assets, net
$39,331 $21,477 
Liabilities:
CAD borrowings under Revolving Credit FacilityNet investment1 32,623 150,982 2027Revolving credit facility
CAD Term LoanNet investment1 110,460 92,288 2028Term loans, net
$143,083 $243,270 
21
The following presents the effect of the Company’s derivative and financial instruments designated as hedging instruments on the consolidated statements of (loss) income and the consolidated statements of equity for the three and nine months ended September 30, 2023 and 2022 (in thousands):
Gain (Loss) Recognized in Other Comprehensive Income
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Cash Flow Hedges:
Interest rate products$11,373 $6,817 $28,462 $20,146 
Net Investment Hedges:
Foreign currency products1,140 2,253 349 2,840 
CAD borrowings under Revolving Credit Facility42 8,790 (2,650)11,157 
CAD term loan2,760 5,988 265 7,463 
$15,315 $23,848 $26,426 $41,606 
Gain (Loss) Reclassified from Accumulated Other Comprehensive Income into Income
Three Months Ended September 30,Nine Months Ended September 30,
Income Statement Location2023202220232022
Cash Flow Hedges:
Interest rate productsInterest expense$2,369 $(602)$5,848 $(5,264)
During the three and nine months ended September 30, 2023 and 2022, no cash flow hedges were determined to be ineffective.
Derivatives Not Designated as Hedging Instruments
As of September 30, 2023, the Company’s derivatives were all designated as hedging instruments. During the nine months ended September 30, 2022, the Company recorded $0.1 million of other expense related to the portion of derivatives not designated as hedging instruments and no such expense was recorded during each of the three months ended September 30, 2022 and the three and nine months ended September 30, 2023.
Offsetting Derivatives
The Company enters into master netting arrangements, which reduce credit risk by permitting net settlement of transactions with the same counterparty. The table below presents a gross presentation, the effects of offsetting, and a net presentation of the Company’s derivatives as of September 30, 2023 and December 31, 2022 (in thousands):
As of September 30, 2023
Gross Amounts of Recognized Assets / LiabilitiesGross Amounts Offset in the Balance SheetNet Amounts of Assets / Liabilities presented in the Balance SheetGross Amounts Not Offset in the Balance Sheet
Financial InstrumentsCash Collateral ReceivedNet Amount
Offsetting Assets:
Derivatives$39,331 $— $39,331 $— $— $39,331 
Offsetting Liabilities:
Derivatives$— $— $— $— $— $— 
22
As of December 31, 2022
Gross Amounts of Recognized Assets / LiabilitiesGross Amounts Offset in the Balance SheetNet Amounts of Assets / Liabilities presented in the Balance SheetGross Amounts Not Offset in the Balance Sheet
Financial InstrumentsCash Collateral ReceivedNet Amount
Offsetting Assets:
Derivatives$21,477 $— $21,477 $— $— $21,477 
Offsetting Liabilities:
Derivatives$— $— $— $— $— $— 
Credit Risk-related Contingent Features
The Company has agreements with each of its derivative counterparties that contain a provision pursuant to which the Company could be declared in default on the derivative obligation if the Company defaults on any of its indebtedness, including a default where repayment of the indebtedness has not been accelerated by the lender. As of September 30, 2023, the Company had no derivatives in a net liability position related to these agreements.

9.    FAIR VALUE DISCLOSURES
Under GAAP, the Company is required to measure certain financial instruments at fair value on a recurring basis. In addition, the Company is required to measure other financial instruments and balances at fair value on a non-recurring basis (e.g., carrying value of impaired loans receivable and long-lived assets). Fair value is defined as the price that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The GAAP fair value framework uses a three-tiered approach. Fair value measurements are classified and disclosed in one of the following three categories:
•Level 1: unadjusted quoted prices in active markets that are accessible at the measurement date for identical assets or liabilities;
•Level 2: quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-derived valuations in which significant inputs and significant value drivers are observable in active markets; and
•Level 3: prices or valuation techniques where little or no market data is available that requires inputs that are both significant to the fair value measurement and unobservable.
Financial Instruments
The fair value for certain financial instruments is derived using a combination of market quotes, pricing models and other valuation techniques that involve significant management judgment. The price transparency of financial instruments is a key determinant of the degree of judgment involved in determining the fair value of the Company’s financial instruments.
Financial instruments for which actively quoted prices or pricing parameters are available and whose markets contain orderly transactions will generally have a higher degree of price transparency than financial instruments whose markets are inactive or consist of non-orderly trades. The Company evaluates several factors when determining if a market is inactive or when market transactions are not orderly. The carrying values of cash and cash equivalents, restricted cash, accounts payable, accrued liabilities and the Credit Agreement are reasonable estimates of fair value because of the short-term maturities of these instruments. Fair values for other financial instruments are derived as follows:
Loans receivable: These instruments are presented on the accompanying consolidated balance sheets at their amortized cost and not at fair value. The fair values of the loans receivable were estimated using an internal valuation model that considered the expected cash flows for the loans receivable, as well as the underlying collateral value and other credit enhancements as applicable. The Company utilized discount rates ranging from 8% to 15% with a weighted average rate of 8% in its fair value calculation. As such, the Company classifies these instruments as Level 3.
Preferred equity investments: These instruments are presented on the accompanying consolidated balance sheets at their cost and not at fair value. The fair values of the preferred equity investments were estimated using an internal valuation model that considered the expected future cash flows for the preferred equity investments, the underlying collateral value and other credit enhancements. The Company utilized discount rates ranging from 10% to 15% with a weighted average rate of 11% in its fair value calculation. As such, the Company classifies these instruments as Level 3.
23
Derivative instruments: The Company’s derivative instruments are presented at fair value on the accompanying consolidated balance sheets. The Company estimates the fair value of derivative instruments, including its interest rate swaps, interest rate collars and cross currency swaps, using the assistance of a third party using inputs that are observable in the market, which include forward yield curves and other relevant information. Although the Company has determined that the majority of the inputs used to value its derivative financial instruments fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with its derivative financial instruments utilize Level 3 inputs, such as estimates of current credit spreads, to evaluate the likelihood of default by itself and its counterparties. The Company has assessed the significance of the impact of the credit valuation adjustments on the overall valuation of its derivative positions and has determined that the credit valuation adjustments are not significant to the overall valuation of its derivative financial instruments. As a result, the Company has determined that its derivative financial instruments valuations in their entirety are classified in Level 2 of the fair value hierarchy.
Senior Notes: These instruments are presented on the accompanying consolidated balance sheets at their outstanding principal balance, net of unamortized deferred financing costs and premiums/discounts and not at fair value. The fair values of the Senior Notes were determined using third-party market quotes derived from orderly trades. As such, the Company classifies these instruments as Level 2.
Secured indebtedness: These instruments are presented on the accompanying consolidated balance sheets at their outstanding principal balance, net of unamortized deferred financing costs and premiums/discounts and not at fair value. The fair values of the Company’s secured debt were estimated using a discounted cash flow analysis based on management’s estimates of current market interest rates for instruments with similar characteristics, including remaining loan term, loan-to-value ratio, type of collateral and other credit enhancements. The Company utilized a rate of 7% in its fair value calculation. As such, the Company classifies these instruments as Level 3.
The following are the face values, carrying amounts and fair values of the Company’s financial instruments as of September 30, 2023 and December 31, 2022 whose carrying amounts do not approximate their fair value (in thousands):
 As of September 30, 2023As of December 31, 2022
 
Face
Value (1)
Carrying
Amount (2)
Fair
Value
Face
Value (1)
Carrying
Amount (2)
Fair
Value
Financial assets:
Loans receivable$371,133 $361,026 $368,437 $370,364 $360,325 $370,188 
Preferred equity investments56,760 56,921 58,697 50,902 51,071 51,995 
Financial liabilities:
Senior Notes1,750,000 1,735,055 1,468,812 1,750,000 1,734,431 1,463,041 
Secured indebtedness48,643 47,789 34,164 50,123 49,232 38,149 
(1)    Face value represents amounts contractually due under the terms of the respective agreements.
(2)    Carrying amount represents the book value of financial instruments, including unamortized premiums/discounts and deferred financing costs.
The Company determined the fair value of financial instruments as of September 30, 2023 whose carrying amounts do not approximate their fair value with valuation methods utilizing the following types of inputs (in thousands):
Fair Value Measurements Using
TotalQuoted Prices in
Active Markets for
Identical Assets
(Level 1)		Significant Other
Observable Inputs
(Level 2)		Significant
Unobservable Inputs
(Level 3)
Financial assets:
Loans receivable$368,437 $— $— $368,437 
Preferred equity investments58,697 — — 58,697 
Financial liabilities:
Senior Notes1,468,812 — 1,468,812 — 
Secured indebtedness34,164 — — 34,164 
Disclosure of the fair value of financial instruments is based on pertinent information available to the Company at the applicable dates and requires a significant amount of judgment. Transaction volume for certain of the Company’s financial instruments remains relatively low, which has made the estimation of fair values difficult. Therefore, both the actual results and the Company’s estimate of fair value at a future date could be materially different.
24
Items Measured at Fair Value on a Recurring Basis
During the nine months ended September 30, 2023, the Company recorded the following amounts measured at fair value (in thousands):
Fair Value Measurements Using
TotalQuoted Prices in
Active Markets for
Identical Assets
(Level 1)		Significant Other
Observable Inputs
(Level 2)		Significant
Unobservable Inputs
(Level 3)
Recurring Basis:
Financial assets:
Interest rate swaps$11,986 $— $11,986 $— 
Interest rate collars5,133 — 5,133 — 
Forward starting interest rate swaps18,164 — 18,164 — 
Cross currency interest rate swaps4,048 — 4,048 — 

10.    EQUITY
Common Stock
On February 23, 2023, the Company established an at-the-market equity offering program (the “ATM Program”) pursuant to which shares of its common stock having an aggregate gross sales price of up to $500.0 million may be sold from time to time (i) by the Company through a consortium of banks acting as sales agents or directly to the banks acting as principals or (ii) by a consortium of banks acting as forward sellers on behalf of any forward purchasers pursuant to a forward sale agreement. The use of a forward sale agreement would allow the Company to lock in a share price on the sale of shares at the time the agreement is effective, but defer receiving the proceeds from the sale of the shares until a later date. The Company may also elect to cash settle or net share settle all or a portion of its obligations under any forward sale agreement. The forward sale agreements have a one year term during which time the Company may settle the forward sales by delivery of physical shares of common stock to the forward purchasers or, at the Company’s election, in cash or net shares. The forward sale price that the Company expects to receive upon settlement will be the initial forward price established upon the effective date, subject to adjustments for (i) the forward purchasers’ stock borrowing costs and (ii) certain fixed price reductions during the term of the agreement.
During the three and nine months ended September 30, 2023, no shares were sold under the ATM Program and the Company did not utilize the forward feature of the ATM Program. As of September 30, 2023, the Company had $500.0 million available under the ATM Program.
The following table lists the cash dividends on common stock declared and paid by the Company during the nine months ended September 30, 2023:
Declaration Date Record Date Amount Per Share Dividend Payable Date
February 1, 2023 February 13, 2023 $0.30  February 28, 2023
May 3, 2023May 16, 2023$0.30 May 31, 2023
August 7, 2023August 17, 2023$0.30 August 31, 2023
During the nine months ended September 30, 2023, the Company issued 0.2 million shares of common stock as a result of restricted stock unit vestings.
Upon any payment of shares to team members as a result of restricted stock unit vestings, the team members’ related tax withholding obligation will generally be satisfied by the Company reducing the number of shares to be delivered by a number of shares necessary to satisfy the related applicable tax withholding obligation. During the nine months ended September 30, 2023 and 2022, the Company incurred $1.4 million and $3.3 million, respectively, in tax withholding obligations on behalf of its team members that were satisfied through a reduction in the number of shares delivered to those participants.
25
Accumulated Other Comprehensive Income
The following is a summary of the Company’s accumulated other comprehensive income (in thousands):
September 30, 2023December 31, 2022
Foreign currency translation (loss) gain$(780)$1,168 
Unrealized gain on cash flow hedges40,449 17,895 
Total accumulated other comprehensive income$39,669 $19,063 

11.    EARNINGS PER COMMON SHARE
The following table illustrates the computation of basic and diluted earnings per share for the three and nine months ended September 30, 2023 and 2022 (in thousands, except share and per share amounts):
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Numerator
Net (loss) income$(15,101)$(50,064)$(3,400)$7,343 
Denominator
Basic weighted average common shares and common equivalents231,224,692 230,982,227 231,197,375 230,936,032 
Dilutive restricted stock units— — — 843,718 
Diluted weighted average common shares231,224,692 230,982,227 231,197,375 231,779,750 
Net (loss) income, per:
Basic common share$(0.07)$(0.22)$(0.01)$0.03 
Diluted common share$(0.07)$(0.22)$(0.01)$0.03 
During the three and nine months ended September 30, 2023, approximately 1.6 million and 1.4 million restricted stock units, respectively, were not included in computing diluted earnings per share because they were considered anti-dilutive. During the three and nine months ended September 30, 2022, approximately 1.0 million and 10,500 restricted stock units, respectively, were not included in computing diluted earnings per share because they were considered anti-dilutive.

12.    COMMITMENTS AND CONTINGENCIES
Environmental
As an owner of real estate, the Company is subject to various environmental laws of federal, state and local governments. The Company is not aware of any environmental liability that could have a material adverse effect on its financial condition or results of operations. However, changes in applicable environmental laws and regulations, the uses and conditions of properties in the vicinity of the Company’s properties, the activities of its tenants and other environmental conditions of which the Company is unaware with respect to the properties could result in future environmental liabilities. As of September 30, 2023, the Company does not expect that compliance with existing environmental laws will have a material adverse effect on the Company’s financial condition and results of operations.
Legal Matters
From time to time, the Company and its subsidiaries are party to legal proceedings that arise in the ordinary course of its business. Management is not aware of any legal proceedings where the likelihood of a loss contingency is reasonably possible and the amount or range of reasonably possible losses is material to the Company’s results of operations, financial condition or cash flows.

26
13.    SUBSEQUENT EVENTS
The Company evaluates subsequent events up until the date the consolidated financial statements are issued.
Dividend Declaration
On November 6, 2023, the Company’s board of directors declared a quarterly cash dividend of $0.30 per share of common stock. The dividend will be paid on November 30, 2023 to common stockholders of record as of the close of business on November 17, 2023.
27
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The discussion below contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those which are discussed in the “Risk Factors” section in Part I, Item 1A of our 2022 Annual Report on Form 10-K. Also see “Statement Regarding Forward-Looking Statements” preceding Part I.
The following discussion and analysis should be read in conjunction with our accompanying consolidated financial statements and the notes thereto.
Our Management’s Discussion and Analysis of Financial Condition and Results of Operations is organized as follows:
•Overview
•Critical Accounting Policies and Estimates
•Recently Issued Accounting Standards Update
•Results of Operations
•Liquidity and Capital Resources
•Concentration of Credit Risk
•Skilled Nursing Facility Reimbursement Rates
Overview
We operate as a self-administered, self-managed REIT that, through our subsidiaries, owns and invests in real estate serving the healthcare industry.
Our primary business consists of acquiring, financing and owning real estate property to be leased to third party tenants in the healthcare sector. We primarily generate revenues by leasing properties to tenants and owning properties operated by third-party property managers throughout the United States (“U.S.”) and Canada.
Our investment portfolio is primarily comprised of skilled nursing/transitional care facilities, senior housing communities (“Senior Housing - Leased”), behavioral health facilities, and specialty hospitals and other facilities, in each case leased to third-party operators; senior housing communities operated by third-party property managers pursuant to property management agreements (“Senior Housing - Managed”); investments in joint ventures; loans receivable; and preferred equity investments.
We expect to grow our investment portfolio while diversifying our portfolio by tenant, facility type and geography within the healthcare sector. We plan to achieve these objectives primarily through making investments directly or indirectly in healthcare real estate, including the development of purpose-built healthcare facilities with select developers. We also intend to achieve our objective of diversifying our portfolio by tenant and facility type through select asset sales and other arrangements with our tenants.
We employ a disciplined approach in our healthcare real estate investment strategy by investing in assets that provide attractive opportunities for dividend growth and appreciation of asset values, while maintaining balance sheet strength and liquidity, thereby creating long-term stockholder value.
We elected to be treated as a REIT with the filing of our U.S. federal income tax return for the taxable year beginning January 1, 2011. We believe that we have been organized and have operated, and we intend to continue to operate, in a manner to qualify as a REIT. We operate through an umbrella partnership, commonly referred to as an UPREIT structure, in which substantially all of our properties and assets are held by Sabra Health Care Limited Partnership, a Delaware limited partnership (the “Operating Partnership”), of which we are the sole general partner and a wholly owned subsidiary of ours is currently the only limited partner, or by subsidiaries of the Operating Partnership.
Market Trends and Uncertainties
Our operations have been and are expected to continue to be impacted by economic and market conditions. Increases in interest rates, labor shortages, supply chain disruptions, high inflation and increased volatility in public equity and fixed income markets have led to increased costs and limited the availability of capital. If our tenants, borrowers and Senior Housing -
28
Managed communities experience increased costs or financing difficulties due to these macroeconomic conditions, our tenants and borrowers may be unable to meet their financial obligations to us and our results of operations may be adversely affected.
The above factors, together with the impact of COVID-19, have resulted in decreased occupancy and increased operating costs for our tenants and borrowers, which have negatively impacted their operating results and may adversely impact their ability to make full and timely rental payments and debt service payments, respectively, to us. Our Senior Housing - Managed portfolio has been similarly impacted, and we expect that decreased occupancy and increased operating costs will continue to negatively impact the operating results of these investments. While our tenants, borrowers and Senior Housing - Managed portfolio have experienced increases in occupancy, certain of those occupancy rates are still below pre-pandemic levels. Similarly, while our tenants, borrowers and Senior Housing - Managed portfolio have more recently experienced small, incremental improvements in both labor availability and overall labor costs, labor supply remains lower and costs remain higher than pre-pandemic levels. In some cases, we may have to restructure or temporarily defer tenants’ long-term rent obligations and may not be able to do so on terms that are as favorable to us as those currently in place. Reduced or modified rental and debt service amounts could result in the determination that the full amounts of our investments are not recoverable, which could result in an impairment charge. If our tenants and borrowers default on these obligations, such defaults could materially and adversely affect our results of operations and liquidity, in addition to resulting in potential impairment charges. Further, prolonged deterioration in the operating results for our investments in our Senior Housing - Managed portfolio could result in the determination that the full amounts of our investments are not recoverable, which could result in an impairment charge.
We regularly monitor the effects of economic and market conditions on our operations and financial position, as well as on the operations and financial position of our tenants and borrowers, in order to respond and adapt to the ongoing changes in our operating environment.
Investment in Unconsolidated Joint Venture
During the nine months ended September 30, 2023, our joint venture with Marlin Spring (the “Marlin Spring Joint Venture”) completed the acquisition of one additional senior housing community with a gross investment of CAD $30.0 million, excluding acquisition costs. In addition, the Marlin Spring Joint Venture assumed and financed an aggregate CAD $23.6 million of debt associated with the additional acquisition. Our equity investment in the additional acquisition was CAD $6.1 million. See Note 4, “Investment in Real Estate Properties—Investment in Unconsolidated Joint Ventures,” in the Notes to Consolidated Financial Statements for additional information regarding this investment.
Acquisitions
During the nine months ended September 30, 2023, we acquired one Senior Housing - Leased community and one Senior Housing - Managed community for aggregate consideration of $51.5 million, including acquisition costs. See Note 3, “Recent Real Estate Acquisitions,” in the Notes to Consolidated Financial Statements for additional information regarding these acquisitions.
Dispositions
During the nine months ended September 30, 2023, we completed the sale of 24 skilled nursing/transitional care facilities (including one leased to a tenant under a sales-type lease) and four senior housing communities for aggregate consideration, net of closing costs, of $281.8 million. The net carrying value of the assets and liabilities of these facilities was $357.7 million, which resulted in an aggregate $75.9 million net loss on sale. We continue to evaluate additional assets for sale as part of our initiative to recycle capital and further improve our portfolio quality.
Credit Agreement
Effective on January 4, 2023, we and certain of our subsidiaries entered into the Credit Agreement. See “—Liquidity and Capital Resources—Material Cash Requirements—Credit Agreement.”
At-The-Market Common Stock Offering Program
On February 23, 2023, we established the ATM Program (as defined below) pursuant to which shares of our common stock having an aggregate gross sales price of up to $500.0 million may be sold from time to time. See “—Liquidity and Capital Resources.”
Critical Accounting Policies and Estimates
Our consolidated interim financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and in conjunction with the rules and regulations of the SEC. The preparation of our financial statements
29
requires significant management judgments, assumptions and estimates about matters that are inherently uncertain. These judgments affect the reported amounts of assets and liabilities and our disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. With different estimates or assumptions, materially different amounts could be reported in our financial statements. Additionally, other companies may utilize different estimates that may impact the comparability of our results of operations to those of companies in similar businesses. A discussion of the accounting policies that management considers critical in that they involve significant management judgments and assumptions, require estimates about matters that are inherently uncertain and because they are important for understanding and evaluating our reported financial results is included in Part II, Item 7 of our 2022 Annual Report on Form 10-K filed with the SEC. There have been no significant changes to our critical accounting policies during the nine months ended September 30, 2023.
Recently Issued Accounting Standards Update
See Note 2, “Summary of Significant Accounting Policies,” in the Notes to Consolidated Financial Statements for information concerning recently issued accounting standards updates.
Results of Operations
As of September 30, 2023, our investment portfolio consisted of 377 real estate properties held for investment, 12 investments in loans receivable, five preferred equity investments and two investments in unconsolidated joint ventures. As of September 30, 2022, our investment portfolio consisted of 407 real estate properties held for investment, one asset held for sale, one investment in a sales-type lease, 15 investments in loans receivable, seven preferred equity investments and two investments in unconsolidated joint ventures. In general, we expect that income and expenses related to our portfolio will fluctuate in future periods in comparison to the corresponding prior periods as a result of investment and disposition activity and anticipated future changes in our portfolio. The results of operations presented are not directly comparable due to ongoing acquisition and disposition activity, including our capital recycling initiative.
30
Comparison of results of operations for the three months ended September 30, 2023 versus the three months ended September 30, 2022 (dollars in thousands):
Three Months Ended September 30,Increase / (Decrease)Percentage
Difference
Variance due to Acquisitions, Originations and Dispositions (1)
Remaining Variance (2)
20232022
Revenues:
Rental and related revenues$93,085 $84,214 $8,871 11 %$(4,115)$12,986 
Resident fees and services59,748 47,610 12,138 25 %3,940 8,198 
Interest and other income8,794 8,940 (146)(2)%(644)498 
Expenses:
Depreciation and amortization43,242 47,427 (4,185)(9)%(1,706)(2,479)
Interest28,156 27,071 1,085 4 %— 1,085 
Triple-net portfolio operating expenses4,304 5,120 (816)(16)%(352)(464)
Senior housing - managed portfolio operating expenses44,523 36,705 7,818 21 %2,264 5,554 
General and administrative10,759 9,676 1,083 11 %— 1,083 
Provision for (recovery of) loan losses and other reserves328 (217)545 (251)%432 113 
Impairment of real estate— 60,857 (60,857)(100)%(60,857)— 
Other expense:
Loss on extinguishment of debt— (140)140 (100)%— 140 
Other income2,229 994 1,235 124 %— 1,235 
Net loss on sales of real estate(46,545)(80)(46,465)NM(46,465)— 
Loss from unconsolidated joint ventures(645)(4,384)3,739 (85)%3,450 289 
Income tax expense(455)(579)124 (21)%— 124 
(1)    Represents the dollar amount increase (decrease) for the three months ended September 30, 2023 compared to the three months ended September 30, 2022 as a result of investments/dispositions made after July 1, 2022.
(2)    Represents the dollar amount increase (decrease) for the three months ended September 30, 2023 compared to the three months ended September 30, 2022 that is not a direct result of investments/dispositions made after July 1, 2022.
Rental and Related Revenues
During the three months ended September 30, 2023, we recognized $93.1 million of rental income compared to $84.2 million for the three months ended September 30, 2022. The $8.9 million net increase in rental income is related to (i) a $15.6 million decrease in straight-line rental income receivable write-offs primarily due to the termination of the North American leases in 2022, (ii) a $1.2 million increase in earned cash rents and operating expense recoveries related to leases that are no longer accounted for on an accrual basis, (iii) a $0.7 million increase due to lease amendments and annual rental increases based on changes in the Consumer Price Index and (iv) a $0.5 million increase from properties acquired after July 1, 2022. These increases are partially offset by (i) a $4.6 million decrease from properties disposed of after July 1, 2022, (ii) a $2.5 million decrease from properties that were transitioned to new operators and (iii) a $2.2 million decrease in Genesis excess rents in accordance with the terms of the memorandum of understanding entered into in 2017.
Our reported rental and related revenues may be subject to increased variability in the future as a result of lease accounting standards. If at any time we cannot determine that it is probable that substantially all rents over the life of a lease are collectible, rental revenue will be recognized only to the extent of payments received and all receivables associated with the lease will be written off, irrespective of amounts expected to be collectible. However, there can be no assurances regarding the timing and amount of these revenues. Amounts due under the terms of all of our lease agreements are subject to contractual increases, and contingent rental income may be derived from certain lease agreements. No material contingent rental income was derived during the three months ended September 30, 2023 and 2022.
Resident Fees and Services
During the three months ended September 30, 2023, we recognized $59.7 million of resident fees and services compared to $47.6 million for the three months ended September 30, 2022. The $12.1 million increase is due to (i) a $6.9 million increase
31
related to nine facilities that were transitioned to Senior Housing - Managed communities after July 1, 2022, (ii) a $4.4 million increase from three Senior Housing - Managed communities acquired after July 1, 2022 and (iii) a $2.3 million increase related to increased occupancy and an increase in rates. These increases are partially offset by a $1.0 million decrease related to one community that is closed due to a fire and a $0.5 million decrease related to one Senior Housing - Managed community disposed of after July 1, 2022.
Interest and Other Income
Interest and other income primarily consists of income earned on our loans receivable investments and preferred returns earned on our preferred equity investments. During the three months ended September 30, 2023, we recognized $8.8 million of interest and other income compared to $8.9 million for the three months ended September 30, 2022. The net decrease of $0.1 million is due to a $1.1 million decrease in income from investments repaid after July 1, 2022, partially offset by a $0.6 million increase due to increased fundings for existing investments and a $0.4 million increase from investments made after July 1, 2022.
Depreciation and Amortization
During the three months ended September 30, 2023, we incurred $43.2 million of depreciation and amortization expense compared to $47.4 million for the three months ended September 30, 2022. The net decrease of $4.2 million is due to a $3.4 million decrease from properties disposed of after July 1, 2022 and a $3.4 million decrease due to assets that have been fully amortized. These decreases are partially offset by a $1.7 million increase from properties acquired after July 1, 2022 and a $1.1 million increase from additions to real estate.
Interest Expense
We incur interest expense comprised of costs of borrowings plus the amortization of deferred financing costs related to our indebtedness. During the three months ended September 30, 2023, we incurred $28.2 million of interest expense compared to $27.1 million for the three months ended September 30, 2022. The $1.1 million net increase is primarily related to an increase in the borrowings outstanding under the Credit Agreement (as defined below) and an increase in interest rates.
Triple-Net Portfolio Operating Expenses
During the three months ended September 30, 2023, we recognized $4.3 million of triple-net portfolio operating expenses compared to $5.1 million during the three months ended September 30, 2022. The $0.8 million net decrease is related to a $0.4 million decrease due to properties disposed of after July 1, 2022 and a $0.4 million decrease due to facilities that have since been transitioned to new operators who are now paying the property taxes directly.
Senior Housing - Managed Portfolio Operating Expenses
During the three months ended September 30, 2023, we recognized $44.5 million of Senior Housing - Managed portfolio operating expenses compared to $36.7 million for the three months ended September 30, 2022. The $7.8 million net increase is due to a $6.3 million increase related to nine facilities that were transitioned to Senior Housing - Managed communities after July 1, 2022 and a $2.8 million increase related to three Senior Housing - Managed communities acquired after July 1, 2022. The increases are partially offset by a $0.5 million decrease related to one Senior Housing - Managed community disposed of after July 1, 2022 and a $0.6 million decrease due to one community that is closed due to a fire.
General and Administrative Expenses
General and administrative expenses include compensation-related expenses as well as professional services, office costs, other costs associated with asset management, and merger and acquisition costs. During the three months ended September 30, 2023, general and administrative expenses were $10.8 million compared to $9.7 million during the three months ended September 30, 2022. The $1.1 million net increase is related to (i) a $0.7 million increase in compensation for our team members as a result of increased staffing and annual salary adjustments, (ii) a $0.2 million increase in insurance premiums and (iii) a $0.2 million increase in conference and travel expenses primarily related to the 2023 Sabra operator conference.
Provision for (Recovery of) Loan Losses and Other Reserves
During the three months ended September 30, 2023 and 2022, we recognized a $0.3 million provision for and a $0.2 million recovery of loan losses and other reserves, respectively, primarily associated with our loans receivable investments.
32
Impairment of Real Estate
No impairment of real estate was recognized during the three months ended September 30, 2023. During the three months ended September 30, 2022, we recognized a $60.9 million impairment related to six skilled nursing/transitional care facilities that have sold. See Note 5, “Impairment of Real Estate and Dispositions,” in the Notes to Consolidated Financial Statements for additional information regarding these impairments.
Loss on Extinguishment of Debt
No loss on extinguishment of debt was recognized during the three months ended September 30, 2023. During the three months ended September 30, 2022, we recognized $0.1 million of loss on extinguishment of debt related to write-offs of deferred financing costs in connection with the partial pay downs of the U.S. dollar term loan (˝Prior Term Loan”) under our Prior Credit Agreement (as defined below).
Other Income
During the three months ended September 30, 2023, we recognized $2.2 million of other income related to a $3.7 million gain on insurance proceeds received related to property damage incurred by a vacant facility and $0.5 million of business interruption insurance income related to one Senior Housing - Managed community that is closed due to a fire. This income is partially offset by $1.4 million of transition-related expenses related to the transition of 14 Senior Housing - Managed communities to new operators in 2023. During the three months ended September 30, 2022, we recognized $1.0 million of other income primarily related to settlement payments related to legacy Care Capital Properties investments.
Net Loss on Sales of Real Estate
During the three months ended September 30, 2023, we recognized an aggregate net loss of $46.5 million related to the disposition of 13 skilled nursing/transitional care facilities and two Senior Housing - Leased communities. During the three months ended September 30, 2022, we recognized an aggregate net loss of $0.1 million related to the disposition of three skilled nursing/transitional care facilities.
Loss from Unconsolidated Joint Ventures
During the three months ended September 30, 2023, we recognized $0.6 million of loss from our unconsolidated joint ventures compared to $4.4 million of loss for the three months ended September 30, 2022. The $3.7 million net decrease in loss is primarily related a $4.2 million decrease in loss from our joint venture with affiliates of TPG Real Estate, the real estate platform of TPG (the “Enlivant Joint Venture”). Effective January 1, 2023, we discontinued applying the equity method of accounting to the Enlivant Joint Venture and no loss was recognized during the three months ended September 30, 2023. Effective May 1, 2023, we withdrew and resigned our membership in the Enlivant Joint Venture and accordingly, no longer have an equity interest in the Enlivant Joint Venture as of such date. We have not guaranteed any obligations of and are not required to provide any support to the Enlivant Joint Venture. The decrease in loss is partially offset by $0.7 million of net loss, including $0.8 million of depreciation expense and $0.9 million of interest expense, related to four senior housing communities acquired by one joint venture after July 1, 2022.
Income Tax Expense
During the three months ended September 30, 2023, we recognized $0.5 million of income tax expense compared to $0.6 million during the three months ended September 30, 2022. The $0.1 million decrease is due to adjusting our foreign income tax estimates.
33
Comparison of results of operations for the nine months ended September 30, 2023 versus the nine months ended September 30, 2022 (dollars in thousands):
Nine Months Ended September 30,Increase / (Decrease)Percentage
Difference
Variance due to Acquisitions, Originations and Dispositions (1)
Remaining Variance (2)
20232022
Revenues:
Rental and related revenues$283,229 $297,268 $(14,039)(5)%$(13,782)$(257)
Resident fees and services174,897 133,973 40,924 31 %16,397 24,527 
Interest and other income25,991 28,585 (2,594)(9)%(3,293)699 
Expenses:
Depreciation and amortization140,211 137,855 2,356 2 %(3,941)6,297 
Interest85,024 77,573 7,451 10 %— 7,451 
Triple-net portfolio operating expenses13,243 14,983 (1,740)(12)%(873)(867)
Senior housing - managed portfolio operating expenses132,124 103,835 28,289 27 %10,078 18,211 
General and administrative30,793 28,721 2,072 7 %— 2,072 
Provision for (recovery of) loan losses and other reserves549 (12)561 NM530 31 
Impairment of real estate7,064 72,602 (65,538)(90)%(65,538)— 
Other (expense) income:
Loss on extinguishment of debt(1,541)(411)(1,130)275 %— (1,130)
Other income (expense)2,570 (1,101)3,671 (333)%— 3,671 
Net loss on sales of real estate(75,893)(4,581)(71,312)NM(71,312)— 
Loss from unconsolidated joint ventures(2,136)(9,715)7,579 (78)%7,579 — 
Income tax expense(1,509)(1,118)(391)35 %— (391)
(1)    Represents the dollar amount increase (decrease) for the nine months ended September 30, 2023 compared to the nine months ended September 30, 2022 as a result of investments/dispositions made after January 1, 2022.
(2)    Represents the dollar amount increase (decrease) for the nine months ended September 30, 2023 compared to the nine months ended September 30, 2022 that is not a direct result of investments/dispositions made after January 1, 2022.
Rental and Related Revenues
During the nine months ended September 30, 2023, we recognized $283.2 million of rental income compared to $297.3 million for the nine months ended September 30, 2022. The $14.0 million net decrease in rental income is related to (i) a $14.8 million decrease from properties disposed of after January 1, 2022, (ii) a $6.5 million decrease from properties that were transitioned to new operators, (iii) a $6.2 million decrease in Genesis excess rents in accordance with the terms of the memorandum of understanding entered into in 2017, (iv) a $4.1 million decrease in earned cash rents and operating expense recoveries related to leases that are no longer accounted for on an accrual basis, of which $1.5 million is due to the Avamere lease amendment effective February 1, 2022, and (v) a $1.1 million decrease from facilities transitioned from triple-net lease to Senior Housing - Managed communities. These decreases are partially offset by (i) a $15.6 million decrease in straight-line rental income receivable write-offs primarily due to the termination of the North American leases in 2022, (ii) a $1.6 million increase due to lease amendments and annual rental increases based on changes in the Consumer Price Index, (iii) a $0.9 million increase due to incremental revenue related to capital expenditures and (iv) a $1.0 million increase from properties acquired after January 1, 2022.
Our reported rental and related revenues may be subject to increased variability in the future as a result of lease accounting standards. If at any time we cannot determine that it is probable that substantially all rents over the life of a lease are collectible, rental revenue will be recognized only to the extent of payments received and all receivables associated with the lease will be written off, irrespective of amounts expected to be collectible. However, there can be no assurances regarding the timing and amount of these revenues. Amounts due under the terms of all of our lease agreements are subject to contractual increases, and contingent rental income may be derived from certain lease agreements. No material contingent rental income was derived during the nine months ended September 30, 2023 and 2022.
34
Resident Fees and Services
During the nine months ended September 30, 2023, we recognized $174.9 million of resident fees and services compared to $134.0 million for the nine months ended September 30, 2022. The $40.9 million increase is due to (i) a $19.2 million increase related to nine facilities that were transitioned to Senior Housing - Managed communities after January 1, 2022, (ii) a $17.5 million increase from four Senior Housing - Managed communities acquired after January 1, 2022 and (iii) an $8.2 million increase related to increased occupancy and an increase in rates. These increases are partially offset by a $2.9 million decrease related to one community that is closed due to a fire and a $1.1 million decrease related to one Senior Housing - Managed community disposed of after January 1, 2022.
Interest and Other Income
Interest and other income primarily consists of income earned on our loans receivable investments and preferred returns earned on our preferred equity investments. During the nine months ended September 30, 2023, we recognized $26.0 million of interest and other income compared to $28.6 million for the nine months ended September 30, 2022. The net decrease of $2.6 million is due to a $3.1 million decrease in income from investments repaid after January 1, 2022 and a $2.3 million lease termination payment related to one skilled nursing/transitional care facility that sold in 2022, partially offset by a $2.1 million increase from investments made after January 1, 2022 and a $0.6 million increase due to increased fundings for existing investments.
Depreciation and Amortization
During the nine months ended September 30, 2023, we incurred $140.2 million of depreciation and amortization expense compared to $137.9 million for the nine months ended September 30, 2022. The net increase of $2.4 million is due to (i) a $7.8 million increase due to accelerating the remaining useful life of a facility that is being demolished, (ii) a $5.5 million increase from properties acquired after January 1, 2022 and (iii) a $2.1 million increase from additions to real estate. The increases are partially offset by a $9.4 million decrease from properties disposed of after January 1, 2022 and a $3.1 million decrease due to assets that have been fully amortized.
Interest Expense
We incur interest expense comprised of costs of borrowings plus the amortization of deferred financing costs related to our indebtedness. During the nine months ended September 30, 2023, we incurred $85.0 million of interest expense compared to $77.6 million for the nine months ended September 30, 2022. The $7.5 million net increase is primarily related to an increase in the borrowings outstanding under the Credit Agreement and an increase in interest rates.
Triple-Net Portfolio Operating Expenses
During the nine months ended September 30, 2023, we recognized $13.2 million of triple-net portfolio operating expenses compared to $15.0 million for the nine months ended September 30, 2022. The $1.7 million net decrease is related to a $1.3 million decrease due to facilities that have since transitioned to new operators who are now paying the property taxes directly and a $0.9 million decrease due to properties disposed of after January 1, 2022. These decreases are partially offset by an increase in our estimates related to property taxes.
Senior Housing - Managed Portfolio Operating Expenses
During the nine months ended September 30, 2023, we recognized $132.1 million of Senior Housing - Managed portfolio operating expenses compared to $103.8 million for the nine months ended September 30, 2022. The $28.3 million net increase is due to (i) an $18.2 million increase related to nine facilities that were transitioned to Senior Housing - Managed communities after January 1, 2022, (ii) an $11.3 million increase related to four Senior Housing - Managed communities acquired after January 1, 2022, (iii) a $0.8 million increase in employee compensation primarily due to increased labor rates and staffing and (iv) a $0.6 million increase in insurance premiums. These increases are partially offset by a $1.6 million decrease in operating expenses related to one community that is closed due to a fire and a $1.2 million decrease related to one Senior Housing - Managed community disposed of after January 1, 2022.
General and Administrative Expenses
General and administrative expenses include compensation-related expenses as well as professional services, office costs, other costs associated with asset management, and merger and acquisition costs. During the nine months ended September 30, 2023, general and administrative expenses were $30.8 million compared to $28.7 million during the nine months ended September 30, 2022. The $2.1 million net increase is related to (i) a $1.0 million increase in compensation for our team
35
members as a result of increased staffing and annual salary adjustments, (ii) a $0.5 million increase in insurance premiums and (iii) a $0.3 million increase in conference and travel expenses primarily related to the 2023 Sabra operator conference.
Provision for (Recovery of) Loan Losses and Other Reserves
During the nine months ended September 30, 2023 and 2022, we recognized a $0.5 million provision for and a $12,000 recovery of loan losses and other reserves, respectively, associated with our loans receivable investments and sales-type lease that was terminated in March 2023.
Impairment of Real Estate
During the nine months ended September 30, 2023, we recognized a $7.1 million impairment related to one skilled nursing/transitional care facility that was sold. During the nine months ended September 30, 2022, we recognized a $72.6 million impairment related to ten skilled nursing/transitional care facilities that have sold.
Loss on Extinguishment of Debt
During the nine months ended September 30, 2023, we recognized a $1.5 million loss on extinguishment of debt related to write-offs of deferred financing costs in connection with amending and restating the fifth amended and restated unsecured credit agreement entered into by the Operating Partnership and Sabra Canadian Holdings, LLC and the other parties thereto on September 9, 2019 (“Prior Credit Agreement”). During the nine months ended September 30, 2022, we recognized a $0.4 million loss on extinguishment of debt related to write-offs of deferred financing costs in connection with the partial pay downs of the U.S. dollar Prior Term Loan.
Other Income (Expense)
During the nine months ended September 30, 2023, we recognized $2.6 million of other income related to (i) a $3.7 million gain on insurance proceeds received related to property damage incurred by a vacant facility, (ii) $0.5 million of business interruption insurance income related to one Senior Housing - Managed community that is closed due to a fire and (iii) $0.3 million of income related to the sale of licensed beds. This income is partially offset by $1.5 million of transition-related expenses related to the transition of 14 Senior Housing - Managed communities to new operators in 2023. During the nine months ended September 30, 2022, we recognized $1.1 million of other expense primarily related to foreign currency transaction loss related to our Canadian borrowings.
Net Loss on Sales of Real Estate
During the nine months ended September 30, 2023, we recognized an aggregate net loss of $75.9 million related to the disposition of 23 skilled nursing/transitional care facilities, three Senior Housing - Leased communities and one Senior Housing - Managed community. During the nine months ended September 30, 2022, we recognized an aggregate net loss of $4.6 million related to the disposition of six skilled nursing/transitional care facilities and five Senior Housing - Leased communities.
Loss from Unconsolidated Joint Ventures
During the nine months ended September 30, 2023, we recognized $2.1 million of loss, including $6.5 million of depreciation expense and $2.9 million of interest expense, related to 16 senior housing communities acquired by two joint ventures after January 1, 2022.
During the nine months ended September 30, 2022, we recognized $9.7 million of loss primarily from the Enlivant Joint Venture. Effective January 1, 2023, we discontinued applying the equity method of accounting to the Enlivant Joint Venture and no loss was recognized during the nine months ended September 30, 2023. Effective May 1, 2023, we withdrew and resigned our membership in the Enlivant Joint Venture and accordingly, no longer have an equity interest in the Enlivant Joint Venture as of such date. We have not guaranteed any obligations of and are not required to provide any support to the Enlivant Joint Venture.
Income Tax Expense
During the nine months ended September 30, 2023, we recognized $1.5 million of income tax expense compared to $1.1 million for the nine months ended September 30, 2022. The $0.4 million increase is due to adjusting our estimates related to state and foreign income taxes.

36
Funds from Operations and Adjusted Funds from Operations
We believe that net income as defined by GAAP is the most appropriate earnings measure. We also believe that funds from operations (“FFO”), as defined in accordance with the definition used by the National Association of Real Estate Investment Trusts (“Nareit”), and adjusted funds from operations (“AFFO”) (and related per share amounts) are important non-GAAP supplemental measures of our operating performance. Because the historical cost accounting convention used for real estate assets requires straight-line depreciation (except on land), such accounting presentation implies that the value of real estate assets diminishes predictably over time. However, since real estate values have historically risen or fallen with market and other conditions, presentations of operating results for a REIT that use historical cost accounting for depreciation could be less informative. Thus, Nareit created FFO as a supplemental measure of operating performance for REITs that excludes historical cost depreciation and amortization, among other items, from net income, as defined by GAAP. FFO is defined as net income, computed in accordance with GAAP, excluding gains or losses from real estate dispositions and our share of gains or losses from real estate dispositions related to our unconsolidated joint ventures, plus real estate depreciation and amortization, net of amounts related to noncontrolling interests, plus our share of depreciation and amortization related to our unconsolidated joint ventures, and real estate impairment charges of both consolidated and unconsolidated entities when the impairment is directly attributable to decreases in the value of the depreciable real estate held by the entity. AFFO is defined as FFO excluding merger and acquisition costs, stock-based compensation expense, non-cash rental and related revenues, non-cash interest income, non-cash interest expense, non-cash portion of loss on extinguishment of debt, provision for loan losses and other reserves, non-cash lease termination income and deferred income taxes, as well as other non-cash revenue and expense items (including ineffectiveness gain/loss on derivative instruments, and non-cash revenue and expense amounts related to noncontrolling interests) and our share of non-cash adjustments related to our unconsolidated joint ventures. We believe that the use of FFO and AFFO (and the related per share amounts), combined with the required GAAP presentations, improves the understanding of our operating results among investors and makes comparisons of operating results among REITs more meaningful. We consider FFO and AFFO to be useful measures for reviewing comparative operating and financial performance because, by excluding the applicable items listed above, FFO and AFFO can help investors compare our operating performance between periods or as compared to other companies. While FFO and AFFO are relevant and widely used measures of operating performance of REITs, they do not represent cash flows from operations or net income as defined by GAAP and should not be considered an alternative to those measures in evaluating our liquidity or operating performance. FFO and AFFO also do not consider the costs associated with capital expenditures related to our real estate assets nor do they purport to be indicative of cash available to fund our future cash requirements. Further, our computation of FFO and AFFO may not be comparable to FFO and AFFO reported by other REITs that do not define FFO in accordance with the current Nareit definition or that interpret the current Nareit definition or define AFFO differently than we do.
37
The following table reconciles our calculations of FFO and AFFO for the three and nine months ended September 30, 2023 and 2022, to net income, the most directly comparable GAAP financial measure, for the same periods (in thousands, except share and per share amounts):
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Net (loss) income$(15,101)$(50,064)$(3,400)$7,343 
Depreciation and amortization of real estate assets43,242 47,427 140,211 137,855 
Depreciation, amortization and impairment of real estate assets related to unconsolidated joint ventures2,255 6,090 6,505 15,856 
Net loss on sales of real estate46,545 80 75,893 4,581 
Net gain on sales of real estate related to unconsolidated joint ventures— — — (220)
Impairment of real estate— 60,857 7,064 72,602 
 
FFO76,941 64,390 226,273 238,017 
Stock-based compensation expense2,235 2,117 5,468 5,367 
Non-cash rental and related revenues(1,312)13,031 (6,781)4,970 
Non-cash interest income8 (589)(380)(1,683)
Non-cash interest expense3,088 2,798 9,179 8,300 
Non-cash portion of loss on extinguishment of debt— 140 1,541 411 
Provision for (recovery of) loan losses and other reserves328 (217)549 (12)
Other adjustments related to unconsolidated joint ventures133 (2,378)371 (4,056)
Other adjustments (1)
61 36 224 2,430 
 
AFFO$81,482 $79,328 $236,444 $253,744 
 
FFO per diluted common share
$0.33 $0.28 $0.97 $1.03 
  
AFFO per diluted common share$0.35 $0.34 $1.01 $1.09 
 
Weighted average number of common shares outstanding, diluted:
FFO232,835,849 231,993,295 232,566,392 231,779,750 
 
AFFO233,988,463 232,858,600 233,878,874 232,810,528 
 
(1) Other adjustments for the nine months ended September 30, 2022 includes $2.2 million of foreign currency transaction loss related to our Canadian borrowings.
38
The following table sets forth additional information related to certain other items included in net income above, and the portions of each that are included in FFO and AFFO, which may be helpful in assessing our operating results. Please refer to “—Results of Operations” above for additional information regarding these items (in millions):
Three Months Ended September 30,Nine Months Ended September 30,
202320222023202220232022202320222023202220232022
Net IncomeFFOAFFONet IncomeFFOAFFO
Rental and related revenues:
Non-cash rental and related revenue write-offs$1.0 $16.6 $1.0 $16.6 $— $— $1.5 $16.7 $1.5 $16.7 $— $— 
Interest and other income:
Lease termination income— — — — — — — 2.3 — 2.3 — 2.3 
Provision for (recovery of) loan losses and other reserves0.3 (0.2)0.3 (0.2)— — 0.5 — 0.5 — — — 
Loss on extinguishment of debt— 0.1 — 0.1 — — 1.5 0.4 1.5 0.4 — — 
Other income (expense):
Insurance income4.2 — 4.2 — 4.2 — 4.2 — 4.2 — 4.2 — 
Other (expense) income(2.0)1.0 (2.0)1.0 (2.0)1.0 (1.6)(1.1)(1.6)(1.1)(1.6)1.2 
Loss from unconsolidated joint ventures:
Grant income under government programs (1)
— 0.1 — 0.1 — 0.1 — 3.5 — 3.5 — 3.5 
Deferred income tax benefit— 0.8 — 0.8 — — — 1.2 — 1.2 — — 
Support payment paid to joint venture manager (2)
— 2.3 — 2.3 — 2.3 — 5.9 — 5.9 — 5.9 
(1)    Consists of funds specifically paid to communities in our Senior Housing - Managed portfolio from state or federal governments related to the pandemic and were incremental to the amounts that would have otherwise been received for providing care to residents.
(2)    Funding for support payments did not require capital contributions from Sabra but rather were funded with proceeds received by the Enlivant Joint Venture from TPG for the issuance of senior preferred interests.
Liquidity and Capital Resources
As of September 30, 2023, we had approximately $1.0 billion in liquidity, consisting of unrestricted cash and cash equivalents of $33.3 million and available borrowings under our Revolving Credit Facility (as defined below) of $967.4 million. The Credit Agreement also contains an accordion feature that can increase the total available borrowings to $2.75 billion (from U.S. $1.4 billion plus CAD $150.0 million), subject to terms and conditions.
We have filed a shelf registration statement with the SEC that expires in November 2025, which allows us to offer and sell shares of common stock, preferred stock, warrants, rights, units, and certain of our subsidiaries to offer and sell debt securities, through underwriters, dealers or agents or directly to purchasers, on a continuous or delayed basis, in amounts, at prices and on terms we determine at the time of the offering, subject to market conditions.
On February 23, 2023, we established an at-the-market equity offering program (the “ATM Program”) pursuant to which shares of our common stock having an aggregate gross sales price of up to $500.0 million may be sold from time to time (i) by us through a consortium of banks acting as sales agents or directly to the banks acting as principals or (ii) by a consortium of banks acting as forward sellers on behalf of any forward purchasers pursuant to a forward sale agreement.
During the three and nine months ended September 30, 2023, no shares were sold under the ATM Program and we did not utilize the forward feature of the ATM Program. As of September 30, 2023, we had $500.0 million available under the ATM Program.
Our short-term liquidity requirements consist primarily of operating expenses, including our planned capital expenditures and funding commitments, interest expense, scheduled debt service payments under our loan agreements, dividend requirements, general and administrative expenses and other requirements described under “Material Cash Requirements” below. Based on our current assessment, we believe that our available cash, operating cash flows and borrowings available to us under our Revolving Credit Facility provide sufficient funds for such requirements for the next twelve months. In addition, we do not believe that the restrictions under our Senior Notes Indentures (as defined below) or Credit Agreement significantly limit our ability to use our available liquidity for these purposes.
Our long-term liquidity requirements consist primarily of future investments in properties, including any improvements or renovations of current or newly-acquired properties, as well as scheduled debt maturities. We expect to meet these liquidity
39
needs using the sources above as well as the proceeds from issuances of common stock, preferred stock, debt or other securities, additional borrowings, including mortgage debt or a new or refinanced credit facility, and proceeds from the sale of properties. In addition, we may seek financing from U.S. government agencies, including through Fannie Mae, Freddie Mac and the U.S. Department of Housing and Urban Development, in appropriate circumstances in connection with acquisitions.
Cash Flows from Operating Activities
Net cash provided by operating activities was $221.8 million for the nine months ended September 30, 2023. Operating cash inflows were derived primarily from the rental payments received under our lease agreements, resident fees and services net of the corresponding operating expenses, and interest payments from borrowers under our loan and preferred equity investments. Operating cash outflows consisted primarily of interest payments on borrowings and payment of general and administrative expenses, including corporate overhead. Increases to operating cash flows primarily relate to completed investment activity, and decreases to operating cash flows primarily relate to disposition activity and interest expense from increased borrowing activity and higher interest rates. In addition, the change in operating cash flows was impacted by the timing of collections from our tenants and borrowers and fluctuations in the operating results of our Senior Housing - Managed communities. We expect our annualized cash flows provided by operating activities to fluctuate as a result of such activity.
Cash Flows from Investing Activities
During the nine months ended September 30, 2023, net cash provided by investing activities was $164.9 million and included $248.2 million of net proceeds from the sales of real estate, $25.5 million of net proceeds from the sale of a facility under a sales-type lease, $8.7 million in repayments of loans receivable, $6.0 million in insurance proceeds, $4.8 million in repayments of preferred equity investments and $0.5 million of distributions in excess of earnings from an unconsolidated joint venture, partially offset by $63.8 million used for additions to real estate, $39.6 million used for the acquisition of two facilities, $11.0 million used to provide funding for preferred equity investments, $9.6 million used to provide funding for loans receivable and $4.8 million used for the investment in an unconsolidated joint venture.
Cash Flows from Financing Activities
During the nine months ended September 30, 2023, net cash used in financing activities was $400.9 million and included $208.1 million of dividends paid to stockholders, $165.3 million of net repayments of our Revolving Credit Facility, $18.1 million of payments of deferred financing costs related to the Credit Agreement, $17.9 million of payments of contingent consideration, $2.2 million of net costs related to payroll tax payments related to the issuance of common stock pursuant to equity compensation arrangements and our ATM Program and $1.5 million of principal repayments on secured debt, partially offset by $12.2 million of proceeds from Term Loans (as defined below).
Please see the accompanying consolidated statements of cash flows for details of our operating, investing and financing cash activities.
Material Cash Requirements
Our material cash requirements include the following contractual and other obligations.
Senior Unsecured Notes. Our senior unsecured notes consisted of the following (collectively, the “Senior Notes”) as of September 30, 2023 (dollars in thousands):
TitleMaturity Date
Principal Balance (1)
5.125% senior unsecured notes due 2026 (the “2026 Notes”)
August 15, 2026$500,000 
5.88% senior unsecured notes due 2027 (the “2027 Notes”)
May 17, 2027100,000 
3.90% senior unsecured notes due 2029 (the “2029 Notes”)
October 15, 2029350,000 
3.20% senior unsecured notes due 2031 (the “2031 Notes”)
December 1, 2031800,000 
$1,750,000 
(1)    Principal balance does not include discount, net of $4.1 million and deferred financing costs, net of $10.9 million as of September 30, 2023.
See Note 7, “Debt,” in the Notes to Consolidated Financial Statements and “Subsidiary Issuer and Guarantor Financial Information” below for additional information concerning the Senior Notes, including information regarding the indentures and agreements governing the Senior Notes (the “Senior Notes Indentures”). As of September 30, 2023, we were in compliance with all applicable covenants under the Senior Notes Indentures.
40
Credit Agreement. Effective January 4, 2023, the Operating Partnership and Sabra Canadian Holdings, LLC (together, the “Borrowers”), and the other parties thereto entered into a sixth amended and restated unsecured credit agreement (the “Credit Agreement”). The Credit Agreement includes a $1.0 billion revolving credit facility (the “Revolving Credit Facility”), a $430.0 million U.S. dollar term loan and a CAD $150.0 million Canadian dollar term loan (collectively, the “Term Loans”). Further, up to $350.0 million of the Revolving Credit Facility may be used for borrowings in certain foreign currencies. The Credit Agreement also contains an accordion feature that can increase the total available borrowings to $2.75 billion, subject to terms and conditions.
The Revolving Credit Facility has a maturity date of January 4, 2027, and includes two six-month extension options. The Term Loans have a maturity date of January 4, 2028.
The obligations of the Borrowers under the Credit Agreement are fully and unconditionally guaranteed, jointly and severally, on an unsecured basis, by us and one of our non-operating subsidiaries, subject to release under certain customary circumstances.
See Note 7, “Debt,” in the Notes to Consolidated Financial Statements for additional information concerning the Credit Agreement, including information regarding covenants contained in the Credit Agreement. As of September 30, 2023, we were in compliance with all applicable covenants under the Credit Agreement.
Secured Indebtedness. As of September 30, 2023, eight of our properties held for investment were subject to secured indebtedness to third parties, and our secured debt consisted of the following (dollars in thousands):
Interest Rate Type
Principal Balance (1)
Weighted Average Interest RateMaturity Date
Fixed Rate$48,643 2.85 %May 2031 - 
August 2051
(1)    Principal balance does not include deferred financing costs, net of $0.9 million as of September 30, 2023.
Interest. Our estimated interest and facility fee payments based on principal amounts of debt outstanding as of September 30, 2023, applicable interest rates in effect as of September 30, 2023, and including the impact of interest rate swaps and collars are $29.2 million for the remainder of 2023, $97.9 million in 2024, $99.3 million in 2025, $99.2 million in 2026, $66.0 million in 2027 and $141.5 million thereafter.
Capital and Other Expenditures and Funding Commitments. For the nine months ended September 30, 2023 and 2022, our aggregate capital expenditures were $63.8 million and $33.8 million, respectively. As of September 30, 2023, our aggregate commitment for future capital and other expenditures related to facilities leased under triple-net operating leases was approximately $44 million, of which $36 million will directly result in incremental rental income, and approximately $26 million will be spent over the next 12 months. Additionally, as of September 30, 2023, anticipated capital expenditures related to our Senior Housing - Managed communities were approximately $41 million, of which we expect to spend approximately $34 million over the next 12 months.
Dividends. To maintain REIT status, we are required each year to distribute to stockholders at least 90% of our annual REIT taxable income after certain adjustments. All distributions will be made by us at the discretion of our board of directors and will depend on our financial position, results of operations, cash flows, capital requirements, debt covenants (which include limits on distributions by us), applicable law, and other factors as our board of directors deems relevant.
We paid dividends of $208.1 million on our common stock during the nine months ended September 30, 2023. On November 6, 2023, our board of directors declared a quarterly cash dividend of $0.30 per share of common stock. The dividend will be paid on November 30, 2023 to common stockholders of record as of November 17, 2023.
Subsidiary Issuer and Guarantor Financial Information. In connection with the Operating Partnership’s assumption of the 2026 Notes, we have fully and unconditionally guaranteed the 2026 Notes. The 2029 Notes and 2031 Notes are issued by the Operating Partnership and guaranteed, fully and unconditionally, by us.
These guarantees are subordinated to all existing and future senior debt and senior guarantees of us, as guarantor, and are unsecured. We conduct all of our business through and derive virtually all of our income from our subsidiaries. Therefore, our ability to make required payments with respect to our indebtedness (including the Senior Notes) and other obligations depends on the financial results and condition of our subsidiaries and our ability to receive funds from our subsidiaries.
41
In accordance with Regulation S-X, the following aggregate summarized financial information is provided for Sabra and the Operating Partnership. This aggregate summarized financial information has been prepared from the books and records maintained by us and the Operating Partnership. The aggregate summarized financial information does not include the investments in, nor the earnings from, subsidiaries other than the Operating Partnership and therefore is not necessarily indicative of the results of operations or financial position had the Operating Partnership operated as an independent entity. Intercompany transactions have been eliminated. The aggregate summarized balance sheet information as of September 30, 2023 and December 31, 2022 and aggregate summarized statement of loss information for the nine months ended September 30, 2023 is as follows (in thousands):
September 30, 2023December 31, 2022
Total assets$86,975 $74,063 
Total liabilities2,206,623 2,275,511 
Nine Months Ended September 30, 2023
Total revenues$431 
Total expenses98,213 
Net loss(100,307)
Concentration of Credit Risk
Concentrations of credit risk arise when a number of tenants or obligors related to our investments are engaged in similar business activities, or activities in the same geographic region, or have similar economic features that would cause their ability to meet contractual obligations, including those to us, to be similarly affected by changes in economic conditions. We regularly monitor our portfolio to assess potential concentrations of risks.
Management believes our current portfolio is reasonably diversified across healthcare related real estate and geographical location and does not contain any other significant concentration of credit risks. Our portfolio of 377 real estate properties held for investment as of September 30, 2023 is diversified by location across the U.S. and Canada.
For the three and nine months ended September 30, 2023, no tenant relationship represented 10% or more of our total revenues.
Skilled Nursing Facility Reimbursement Rates
For the nine months ended September 30, 2023, 42.5% of our revenues was derived directly or indirectly from skilled nursing/transitional care facilities. Medicare reimburses skilled nursing facilities for Medicare Part A services under the Prospective Payment System (“PPS”), as implemented pursuant to the Balanced Budget Act of 1997 and modified pursuant to subsequent laws, most recently the Patient Protection and Affordable Care Act of 2010. PPS regulations predetermine a payment amount per patient, per day, based on a market basket index calculated for all covered costs.
On October 1, 2019, a case-mix classification system called the skilled nursing facility Patient-Driven Payment Model (“PDPM”) became effective pursuant to a Centers for Medicare & Medicaid Services (“CMS”) final rule. PDPM focuses on clinically relevant factors, rather than volume-based service, for determining Medicare payment. PDPM adjusts Medicare payments based on each aspect of a resident’s care, most notably for non-therapy ancillaries, which are items and services not related to the provision of therapy such as drugs and medical supplies, thereby more accurately addressing costs associated with medically complex patients. It further adjusts the skilled nursing facility per diem payments to reflect varying costs throughout the stay and incorporates safeguards against potential financial incentives to ensure that beneficiaries receive care consistent with their unique needs and goals.
On July 29, 2022, CMS issued a final rule regarding fiscal year 2023 Medicare rates for skilled nursing facilities providing an estimated net increase of 2.7% compared to fiscal year 2022 comprised of an increase as a result of an update to the payment rates of 5.1% (which is based on (i) a market basket increase of 3.9% plus (ii) a market basket forecast error adjustment of 1.5% and less (iii) a productivity adjustment of 0.3%), partially offset by the recalibrated PDPM parity adjustment of 2.3% (the total PDPM parity adjustment is 4.6%, and it is being phased in over a two-year period). These figures do not incorporate any of the estimated value-based purchasing reductions for skilled nursing facilities. The new payment rates became effective on October 1, 2022.
On July 31, 2023, CMS issued a final rule regarding fiscal year 2024 Medicare rates for skilled nursing facilities providing an estimated net increase of 4.0% compared to fiscal year 2023 comprised of an increase as a result of an update to
42
the payment rates of 6.4% (which is based on (i) a market basket increase of 3.0% plus (ii) a market basket forecast error adjustment of 3.6% and less (iii) a productivity adjustment of 0.2%), partially offset by the second phase of the recalibrated PDPM parity adjustment of 2.3%. These figures do not incorporate any of the estimated value-based purchasing reductions for skilled nursing facilities. The new payment rates became effective on October 1, 2023.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
There have been no material changes to the quantitative and qualitative disclosures about market risk set forth in our 2022 Annual Report on Form 10-K.

ITEM 4. CONTROLS AND PROCEDURES
Disclosure Controls and Procedures
As of the end of the period covered by this report, management, including our chief executive officer and chief financial officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures. Based upon, and as of the date of, the evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were effective as of September 30, 2023 to ensure that information required to be disclosed in the reports we file or submit under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our chief executive officer and our chief financial officer, as appropriate to allow timely decisions regarding required disclosure.
Changes in Internal Control Over Financial Reporting
There were no changes in our internal control over financial reporting during the quarter ended September 30, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
43
PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
None of the Company or any of its subsidiaries is a party to, and none of their respective property is the subject of, any material legal proceeding, although we are from time to time party to legal proceedings that arise in the ordinary course of our business.

ITEM 1A. RISK FACTORS
There have been no material changes in our assessment of our risk factors from those set forth in Part I, Item 1A of our 2022 Annual Report on Form 10-K.

ITEM 5. OTHER INFORMATION
None.

ITEM 6. EXHIBITS
Ex.Description
3.1
3.1.1
3.1.2
3.1.3
3.2
22.1
31.1*
31.2*
32.1**
32.2**
101.INS*XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH*XBRL Taxonomy Extension Schema Document.
101.CAL*XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF*XBRL Taxonomy Extension Definition Linkbase Document.
44
Ex.Description
101.LAB*XBRL Taxonomy Extension Label Linkbase Document.
101.PRE*XBRL Taxonomy Extension Presentation Linkbase Document.
104*Cover Page Interactive Data File - the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
 
*Filed herewith.
**Furnished herewith.
45
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
SABRA HEALTH CARE REIT, INC.
Date: November 6, 2023By:/S/    RICHARD K. MATROS
Richard K. Matros
Chief Executive Officer, President and Chair
(Principal Executive Officer)
Date: November 6, 2023By:/S/    MICHAEL COSTA
Michael Costa
Chief Financial Officer, Secretary and Executive Vice President
(Principal Financial Officer)
46
 EX-31.1 2 sbraex3112023q3.htm SECTION 302 CEO CERTIFICATION Document

Exhibit 31.1
Certification of Chief Executive Officer pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002
I, Richard K. Matros, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Sabra Health Care REIT, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 6, 2023
 
/S/    RICHARD K. MATROS
Richard K. Matros
Chief Executive Officer, President and Chair



 EX-31.2 3 sbraex3122023q3.htm SECTION 302 CFO CERTIFICATION Document

Exhibit 31.2
Certification of Chief Financial Officer pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002
I, Michael Costa, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Sabra Health Care REIT, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: 
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 6, 2023
 
/S/    MICHAEL COSTA
Michael Costa
Chief Financial Officer, Secretary and Executive Vice President


 EX-32.1 4 sbraex3212023q3.htm SECTION 906 CEO CERTIFICATION Document

Exhibit 32.1
Certification pursuant to 18 U.S.C. Section 1350,
as Adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002
In connection with the Quarterly Report on Form 10-Q of Sabra Health Care REIT, Inc. (the “Registrant”) for the three months ended September 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Richard K. Matros, as Chief Executive Officer, President and Chair of the Registrant, hereby certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge:

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

Date: November 6, 2023
 
/S/    RICHARD K. MATROS
Richard K. Matros
Chief Executive Officer, President and Chair


 EX-32.2 5 sbraex3222023q3.htm SECTION 906 CFO CERTIFICATION Document

Exhibit 32.2
Certification pursuant to 18 U.S.C. Section 1350,
as Adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002
In connection with the Quarterly Report on Form 10-Q of Sabra Health Care REIT, Inc. (the “Registrant”) for the three months ended September 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Michael Costa, as Chief Financial Officer, Secretary and Executive Vice President of the Registrant, hereby certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge:

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.
 

Date: November 6, 2023
 
/S/    MICHAEL COSTA
Michael Costa
Chief Financial Officer, Secretary and Executive Vice President



 EX-101.SCH 6 sbra-20230930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - CONSOLIDATED STATEMENTS OF (LOSS) INCOME link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - CONSOLIDATED STATEMENTS OF EQUITY link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - CONSOLIDATED STATEMENTS OF EQUITY (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - BUSINESS link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED) link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - LOANS RECEIVABLE AND OTHER INVESTMENTS link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - DEBT link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - DERIVATIVE AND HEDGING INSTRUMENTS link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - FAIR VALUE DISCLOSURES link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - EQUITY link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - EARNINGS PER COMMON SHARE link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED) (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - LOANS RECEIVABLE AND OTHER INVESTMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - DEBT (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - DERIVATIVE AND HEDGING INSTRUMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - FAIR VALUE DISCLOSURES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - EARNINGS PER COMMON SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED) - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED) - Purchase Price Allocation for Recent Real Estate Acquisitions (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES - Real Estate Properties Held for Investment (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES - Operating Leases Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES - Future Minimum Rental Payments Receivable for Properties Held for Investment Under Non-Cancelable Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES - Senior Housing - Managed Communities Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES - Capital and Other Expenditures Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES - Schedule of Investment in Joint Ventures (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES - Investment in Unconsolidated Joint Venture Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES - Summarized Financial Data of Unconsolidated Joint Venture (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES - Net Investment in Sales-Type Lease Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS - Dispositions (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - LOANS RECEIVABLE AND OTHER INVESTMENTS - Composition of Loans Receivable and Other Investments (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - LOANS RECEIVABLE AND OTHER INVESTMENTS - Schedule of Additional Information Regarding the Company's Loans Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - DEBT - Secured Indebtedness (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - DEBT - Senior Unsecured Notes (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - DEBT - Senior Unsecured Notes Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - DEBT - Credit Agreement Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - DEBT - Interest Expense Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - DEBT - Schedule of Maturities for Outstanding Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - DERIVATIVE AND HEDGING INSTRUMENTS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - DERIVATIVE AND HEDGING INSTRUMENTS - Notional Amount of Derivatives Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - DERIVATIVE AND HEDGING INSTRUMENTS - Derivative and Financial Instruments Designated as Hedging Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - DERIVATIVE AND HEDGING INSTRUMENTS - Effect of Derivative Financial Instruments on the Condensed Consolidated Statements of (Loss) Income and Condensed Consolidated Statements of Equity (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - DERIVATIVE AND HEDGING INSTRUMENTS - Gross Presentation, Effects of Offsetting, and Net Presentation of Derivatives (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - FAIR VALUE DISCLOSURES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - FAIR VALUE DISCLOSURES - Face Values, Carrying Amounts and Fair Values of Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9954510 - Disclosure - FAIR VALUE DISCLOSURES - Fair Value of Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9954511 - Disclosure - FAIR VALUE DISCLOSURES - Items Measured at Fair Value on a Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 9954512 - Disclosure - EQUITY - Common Stock (Details) link:presentationLink link:calculationLink link:definitionLink 9954513 - Disclosure - EQUITY - Cash Dividends on Common Stock Declared and Paid (Details) link:presentationLink link:calculationLink link:definitionLink 9954514 - Disclosure - EQUITY - Accumulated Other Comprehensive Income (Details) link:presentationLink link:calculationLink link:definitionLink 9954515 - Disclosure - EARNINGS PER COMMON SHARE - Computation of Basic and Diluted Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954516 - Disclosure - EARNINGS PER COMMON SHARE - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954517 - Disclosure - SUBSEQUENT EVENTS (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 sbra-20230930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 sbra-20230930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 sbra-20230930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Net (loss) income, per: Net Income (Loss) Attributable To Common Stockholders [Abstract] Net income (loss) attributable to common stockholders Consolidated Entities [Axis] Consolidated Entities [Axis] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Variable Rate [Domain] Variable Rate [Domain] Pay vs Performance Disclosure [Line Items] Financing Receivable, Allowance for Credit Loss [Roll Forward] Financing Receivable, Allowance for Credit Loss [Roll Forward] Statistical Measurement [Domain] Statistical Measurement [Domain] Borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Underlying Security Market Price Change Underlying Security Market Price Change, Percent Award Type [Domain] Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Investment, Name [Domain] Investment, Name [Domain] Interest rate Line of Credit Facility, Interest Rate at Period End DEBT Debt Disclosure [Text Block] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Schedule of Purchase Price Allocation Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Interest rate Debt Instrument, Interest Rate At Period End Debt Instrument, Interest Rate At Period End Cross currency interest rate swaps Cross currency interest rate swaps Cross Currency Interest Rate Contract [Member] Revolving Credit Facility Revolving Credit Facility [Member] Primary beneficiary Variable Interest Entity, Primary Beneficiary [Member] Effect of foreign currency translation on cash, cash equivalents and restricted cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Credit Loss Status [Domain] Credit Loss Status [Domain] Sienna Joint Venture Sienna Joint Venture [Member] Sienna Joint Venture MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Discontinued Operations and Disposal Groups [Abstract] Discontinued Operations and Disposal Groups [Abstract] Impairment upon disposal Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down Net (loss) income (less than in nine months ended 2023) Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual Restatement Determination Date: Restatement Determination Date [Axis] Investment, Name [Axis] Investment, Name [Axis] Number of Beds/Units Number of Units in Real Estate Property Letters of credit deposited Letters Of Credit Deposits Letters Of Credit Deposits Commitments and contingencies (Note 12) Commitments and Contingencies Insider Trading Policies and Procedures [Line Items] Notional amount Derivative, Amount of Hedged Item Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Thereafter Lessor, Operating Lease, Payment To Be Received, After Year Four Lessor, Operating Lease, Payment To Be Received, After Year Four Weighted Average Contractual Interest Rate / Rate of Return Preferred Equity Investment, Weighted Average Contractual Rate Preferred Equity Investment, Weighted Average Contractual Rate Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Behavioral Health Behavioral Health [Member] Behavioral Health EQUITY Equity [Text Block] Total Real Estate at Cost Real Estate Investment Property, at Cost Financial assets: Financial Assets [Abstract] Financial Assets [Abstract] Total quantity Number Of Investments Number Of Investments Net (repayments of) borrowings from revolving credit facility Proceeds from (Repayments of) Lines of Credit Origination and fundings of preferred equity investments Payments For Preferred Equity Investments Payments For Preferred Equity Investments Mortgage Mortgage Loans Receivable [Member] Mortgage Loans Receivable [Member] Par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, $0.01 par value; 10,000,000 shares authorized, zero shares issued and outstanding as of September 30, 2023 and December 31, 2022 Preferred Stock, Value, Issued Business Acquisition [Line Items] Business Acquisition [Line Items] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Senior Housing - Managed Senior Housing Facilities [Member] Senior Housing Facilities [Member] Origination and fundings of loans receivable Payments to Acquire Notes Receivable Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Payment of contingent consideration Payment of contingent consideration Payment for Contingent Consideration Liability, Financing Activities Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Diluted common share (in dollars per share) Earnings Per Share, Diluted Gross Amounts of Recognized Assets / Liabilities Derivative Liability, Subject to Master Netting Arrangement, before Offset PEO Total Compensation Amount PEO Total Compensation Amount Secured debt, net Secured Debt Hedging Relationship [Axis] Hedging Relationship [Axis] Future minimum rental payments from the Company’s properties held for investment under non-cancelable operating leases: Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Abstract] Land Land Receivable [Domain] Receivable [Domain] Other Other [Member] Other [Member] Skilled Nursing/Transitional Care Skilled nursing transitional care facility Skilled Nursing Transitional Care Facilities [Member] Skilled Nursing Transitional Care Facilities [Member] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Significant Unobservable Inputs (Level 3) Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] LIBOR London Interbank Offered Rate (LIBOR) 1 [Member] London Interbank Offered Rate (LIBOR) 1 Line of Credit Revolving Credit Facility Line of Credit [Member] Interest Rate Swap Two Interest Rate Swap Two [Member] Interest Rate Swap Two Basis adjustments Equity Method Investment, Basis Adjustments Equity Method Investment, Basis Adjustments Derivative asset, statement of financial position Derivative Asset, Statement of Financial Position [Extensible Enumeration] Trading Symbol Trading Symbol Number of investments in loans accounted for as real estate joint ventures Real Estate Investments, Joint Ventures, Number Real Estate Investments, Joint Ventures, Number Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Net (loss) income Net (loss) income Net (loss) income Net Income (Loss) Proceeds of insurance Unusual or Infrequent Item, or Both, Insurance Proceeds SOFR Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] Derivative Contract [Domain] Derivative Contract [Domain] Schedule of Notional Amount of Derivatives Instruments Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name Total Lessor, Operating Lease, Payment to be Received Schedule of Equity Method Investments [Table] Schedule of Equity Method Investments [Table] Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Equity Equity, Attributable to Parent [Abstract] Gain (loss) recognized in other comprehensive income, cash flow hedges Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Computation of Basic and Diluted Earnings Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Derivative liability, statement of financial position Derivative Liability, Statement of Financial Position [Extensible Enumeration] Net proceeds from the sales of real estate Proceeds from Sale of Productive Assets Executive Category: Executive Category [Axis] Weighted-average amortization period of intangible assets Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life Thereafter Long-Term Debt, Maturity, After Year Four Long-Term Debt, Maturity, After Year Four 2027 Lessor, Operating Lease, Payment to be Received, Year Four Foreign currency products Foreign Exchange Contract [Member] Financial liabilities: Financial Liabilities Fair Value Disclosure [Abstract] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Significant Accounting Policies [Text Block] Quoted Prices in Active Markets for Identical Assets (Level 1) Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Furniture and equipment Fixtures and Equipment, Gross Name Measure Name Name Forgone Recovery, Individual Name Carrying Amount Reported Value Measurement [Member] Senior Housing Facilities - Managed Communities, Proprietary Development Pipeline Senior Housing Facilities - Managed Communities, Proprietary Development Pipeline [Member] Senior Housing Facilities - Managed Communities, Proprietary Development Pipeline Financial Instrument Performance Status [Domain] Financial Instrument Performance Status [Domain] Equity Components [Axis] Equity Components [Axis] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Hedging Relationship [Domain] Hedging Relationship [Domain] Building and improvements Buildings and Improvements, Gross Measurement Basis [Axis] Measurement Basis [Axis] 2025 Long-Term Debt, Maturity, Year Two Enlivant Joint Venture Enlivant Joint Venture [Member] Enlivant Joint Venture [Member] Underlying Securities Award Underlying Securities Amount Entity Small Business Entity Small Business Local Phone Number Local Phone Number Fair Value Measurement [Domain] Fair Value Measurement [Domain] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Total weighted average contractual interest rate / rate of return Investments, Weighted Average Contractual Rate Investments, Weighted Average Contractual Rate Business Acquisition, By Type [Axis] Business Acquisition, By Type [Axis] Business Acquisition, By Type [Axis] Notional amount Derivative, Notional Amount October 1 through December 31, 2023 Long-Term Debt, Maturity, Remainder of Fiscal Year Common dividends (in dollars per share) Quarterly cash dividend declared on common stock (in dollars per share) Common Stock, Dividends, Per Share, Declared Forward starting interest rate swaps Forward Starting Interest Rate Swaps [Member] Forward Starting Interest Rate Swaps [Member] Measurement Frequency [Axis] Measurement Frequency [Axis] Restricted stock units Restricted Stock Units (RSUs) [Member] Book value Financing Receivable, Nonaccrual Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Table] 5.88% senior unsecured notes due 2027 (“2027 Notes”) 5.88% Senior Unsecured Notes Due 2027 [Member] 5.88% Senior Unsecured Notes Due 2027 Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Acquisition of real estate Payments to Acquire Real Estate Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Income Statement Location [Axis] Income Statement Location [Axis] Schedule of Debt Schedule of Long-Term Debt Instruments [Table Text Block] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Write-off of non-cash rent receivable Write-Off Of Non-Cash Rent Receivable And Intangibles Write-Off Of Non-Cash Rent Receivable And Intangibles Schedule of Real Estate Properties [Table] Schedule of Real Estate Properties [Table] Principal payments on term loans Repayments of Medium-term Notes Schedule of Investment in Joint Ventures Equity Method Investments [Table Text Block] Debt assumed Business Acquisition Debt Assumed Business Acquisition Debt Assumed Shares issued (in shares) Sale of Stock, Number of Shares Issued in Transaction Variable Interest Entities Consolidation, Variable Interest Entity, Policy [Policy Text Block] Total revenues Total revenues Revenues Schedule of Face Values, Carrying Amounts and Fair Values of Financial Instruments Fair Value, by Balance Sheet Grouping [Table Text Block] Product and Service [Domain] Product and Service [Domain] Other Performance Measure, Amount Other Performance Measure, Amount Interest Interest expense Interest Expense, Debt Tenant origination and absorption costs Tenant origination and absorption costs intangible assets Tenant Origination and Absorption Costs [Member] Tenant Origination and Absorption Costs [Member] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Cash Collateral Received Derivative Liability, Subject to Master Netting Arrangement, Collateral, Right to Reclaim Cash Not Offset 5.375% Senior Unsecured Notes Due 2023 5.375% Senior Unsecured Notes Due 2023 [Member] 5.375% Senior Unsecured Notes Due 2023 Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract] Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Anti-dilutive securities not included in computation of diluted earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Award Type [Axis] Award Type [Axis] Net investment in sales type lease Sales-Type Lease, Net Investment in Lease, before Allowance for Credit Loss Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Accounts receivable, prepaid expenses and other assets, net Accounts Receivable, Prepaid Expenses Deferred Financing Costs And Other Assets, Net Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs. Also, includes the sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization. Number of extension options Line Of Credit Facility, Number Of Extension Options Line Of Credit Facility, Number Of Extension Options Number of acquired properties Business Acquisition, Number Of Acquired Properties Business Acquisition, Number Of Acquired Properties Document Quarterly Report Document Quarterly Report Future capital expenditures Capital Expenditures Incurred but Not yet Paid Common dividends Dividends, Common Stock Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Loss on extinguishment of debt Loss on extinguishment of debt Gain (Loss) on Extinguishment of Debt Hedging Designation [Axis] Hedging Designation [Axis] Variable lease revenue Variable Lease, Income Gain (loss) recognized in other comprehensive income, net investment hedges Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Trading Arrangement: Trading Arrangement [Axis] Use of Estimates Use of Estimates, Policy [Policy Text Block] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity File Number Entity File Number Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Offsetting Liabilities: Offsetting Derivative Liabilities [Abstract] Discount Rate Measurement Input, Discount Rate [Member] 2026 Long-Term Debt, Maturity, Year Three Weighted Average Contractual Interest Rate / Rate of Return Financing Receivable, Fixed Interest Rate Financing Fixed Interest Rate Real Estate [Abstract] Real Estate [Abstract] Real Estate [Domain] Real Estate [Domain] Entity Shell Company Entity Shell Company Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Lease intangible assets, net Finite-Lived Intangible Assets, Net Restatement Determination Date Restatement Determination Date Loans receivable and other investments, net Total book value Financing Receivable And Other Investments, Net Amount after allowance and deduction of deferred interest and fees, unamortized costs and premiums and discounts from face amounts, of loans and other investments held in portfolio, including but not limited to, commercial and consumer loans. Includes loans held for sale. Excludes loans and leases covered under loss sharing agreements. Gross Presentation, Effects of Offsetting, and Net Presentation of Derivatives - Liabilities Offsetting Liabilities [Table Text Block] Senior housing - managed Senior Housing - Managed Senior Housing Facilities - Managed Portfolio [Member] Senior Housing Facilities - Managed Portfolio [Member] Counterparty Name [Domain] Counterparty Name [Domain] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash, cash equivalents and restricted cash, beginning of period Cash, cash equivalents and restricted cash, end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Equity interest, investment basis amount Equity Method Investment, Estimated Fair Value Investment Basis Amount Equity Method Investment, Estimated Fair Value Investment Basis Amount Gain of unusual amount Gain on Business Interruption Insurance Recovery Accounts payable and accrued liabilities Accounts Payable and Accrued Liabilities Financial liabilities, carrying amount and fair value Financial liabilities Debt Instrument, Fair Value Disclosure Business Acquisition, By Type [Domain] Business Acquisition, By Type [Domain] [Domain] for Business Acquisition, By Type [Axis] Schedule of Cash Dividends on Common Stock Declared and Paid Schedule of Dividends Declared and Paid [Table Text Block] Schedule of Dividends Declared and Paid [Table Text Block] Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Term Loans Loans Payable [Member] Denominator Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Nonaccrual status: Nonaccrual Status [Abstract] Shares issued (in shares) Common Stock, Shares, Issued Cumulative Distributions in Excess of Net Income Accumulated Distributions in Excess of Net Income [Member] Net (loss) income, per: Earnings Per Share, Basic and Diluted EPS [Abstract] Earnings Per Share, Basic and Diluted EPS Weighted Average Annualized Effective Interest Rate / Rate of Return Preferred Equity Investment, Weighted Average Effective Rate Preferred Equity Investment, Weighted Average Effective Rate Security Exchange Name Security Exchange Name Total Debt, Net Long-Term Debt 2027 Long-Term Debt, Maturity, Year Four Nonaccrual status Nonperforming Financial Instruments [Member] Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Employee Stock Option Employee Stock Option [Member] Foreign currency translation (loss) gain Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Tenant deposits for future real estate taxes, insurance expenditures, and tenant improvements Property Taxes, Insurance, And Tenant Improvement Deposit Liability Property Taxes, Insurance, And Tenant Improvement Deposit Liability DERIVATIVE AND HEDGING INSTRUMENTS Derivative Instruments and Hedging Activities Disclosure [Text Block] Aggregate gross proceeds possible from sales of common stock under equity offering program Sale Of Stock, Maximum Proceeds From Common Stock Issuances Sale Of Stock, Maximum Proceeds From Common Stock Issuances Vandalism And Theft Vandalism And Theft [Member] Vandalism And Theft Properties in sales-type Lessor, Sales-Type Lease, Number of Properties Lessor, Sales-Type Lease, Number of Properties Maximum Maximum [Member] Comprehensive (loss) income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Document Type Document Type Tabular List, Table Tabular List [Table Text Block] Currency Swap Currency Swap [Member] Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Receivable Type [Axis] Receivable Type [Axis] Principal balance Preferred equity investments Preferred Equity Investment, Face Value Preferred Equity Investment, Face Value Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Fixed Rate Fixed Rate Mortgages [Member] Fixed Rate Mortgages [Member] Senior Housing - Leased Senior Housing Facilities - Leased [Member] Senior Housing Facilities - Leased [Member] Subsequent Event [Table] Subsequent Event [Table] Net decrease in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Non-cash interest income Other Noncash Income (Expense) Book value Preferred Equity Investment, Carrying Amount Preferred Equity Investment, Carrying Amount October 1 through December 31, 2023 Lessor, Operating Lease, Payment to be Received, Remainder of Fiscal Year Business Acquisition [Axis] Business Acquisition [Axis] Subsequent event Subsequent Event [Member] Total principal balance Investment Owned, Balance, Principal Amount Derivative [Table] Derivative [Table] Preferred Stock, Number of Shares, Par Value and Other Disclosure [Abstract] Preferred Stock, Number of Shares, Par Value and Other Disclosure [Abstract] Variable Rate [Axis] Variable Rate [Axis] Accounts payable and accrued liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Net loss on sales of real estate Net loss on sales of real estate Gains (Losses) on Sales of Investment Real Estate Income Statement [Abstract] Income Statement [Abstract] 2024 Lessor, Operating Lease, Payment to be Received, Year One Common stock issuance, net (in shares) Stock Issued During Period, Shares, New Issues Title of 12(b) Security Title of 12(b) Security Net loss Disposal Group, Including Discontinued Operation, Operating Income (Loss) Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED) Business Combination Disclosure [Text Block] Fair value of derivatives in a net liability position Fair value Net Amounts of Assets / Liabilities presented in the Balance Sheet Derivative Liability Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Operating Segments Operating Segments [Member] Payments to acquire buildings Payments to Acquire Buildings Proceeds from term loans Proceeds from Issuance of Medium-term Notes Fixed interest rate under swap Derivative, Fixed Interest Rate Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Schedule of Loans Receivable and Other Investments Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Accumulated depreciation Accumulated Depreciation Real Estate Investment Property, Accumulated Depreciation Term loans, net Loans Payable to Bank Entity Tax Identification Number Entity Tax Identification Number Receivables with deteriorated credit quality Financial Asset Acquired with Credit Deterioration [Member] Investment in unconsolidated joint ventures Book Value Equity Method Investments Lease intangible liabilities, net Below Market Lease, Net Statistical Measurement [Axis] Statistical Measurement [Axis] INVESTMENT IN REAL ESTATE PROPERTIES Real Estate Disclosure [Text Block] Balance Sheet Location [Domain] Balance Sheet Location [Domain] IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Entity Interactive Data Current Entity Interactive Data Current Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Impairment of real estate Impairment of real estate Impairment of Real Estate Total Shareholder Return Amount Total Shareholder Return Amount Operating lease expiration term Lessor, Operating Lease, Term of Contract Loss from unconsolidated joint ventures Loss from unconsolidated joint venture Income (Loss) From Equity Method Investments And Other Than Temporary Impairment Income (Loss) From Equity Method Investments And Other Than Temporary Impairment Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Supplemental disclosure of non-cash investing activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Segments [Domain] Segments [Domain] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Measure: Measure [Axis] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Schedule of Additional Information Regarding the Company's Loans Receivable Schedule Of Additional Information, Loans And Financing Receivable [Table Text Block] Schedule Of Additional Information, Loans And Financing Receivable Aggregate principal amount Financial liabilities, face value Debt Instrument, Face Amount Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Equity Method Investment, Nonconsolidated Investee [Domain] Equity Method Investment, Nonconsolidated Investee [Domain] Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Counterparty Name [Axis] Counterparty Name [Axis] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Shares outstanding (in shares) Common Stock, Shares, Outstanding ATM Program Equity Distribution Agreement, ATM Program [Member] Equity Distribution Agreement, ATM Program [Member] Cumulative distributions in excess of net income Accumulated Distributions in Excess of Net Income Recent Real Estate Acquisitions Series of Individually Immaterial Business Acquisitions [Member] Other (expense) income: Other Income and Expenses [Abstract] PEO PEO [Member] Escrow deposits for potential investments Payments For Escrow Deposits For Potential Investments Payments For Escrow Deposits For Potential Investments Schedule of Future Minimum Rental Payments from Non-Cancelable Operating Leases Lessor, Operating Lease, Payment to be Received, Maturity [Table Text Block] Principal balance Loans receivable Financing Receivable, Principal Amount Financing Receivable, Principal Amount Summarized financial information Equity Method Investment, Summarized Financial Information [Abstract] Net proceeds from sales-type lease Proceeds from Lease Payment, Sales-Type and Direct Financing Leases, Investing Activity Other non-cash items Other Operating Activities, Cash Flow Statement Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Net loss Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Total Equity [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Quantity Preferred Equity Investments, Number Preferred Equity Investments, Number of Investments Gross Amounts of Recognized Assets / Liabilities Derivative Asset, Subject to Master Netting Arrangement, before Offset Par value (in dollars per share) Common Stock, Par or Stated Value Per Share Sale of Stock [Axis] Sale of Stock [Axis] Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Gain (loss) reclassified from accumulated other comprehensive income into income , cash flow hedges Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Interest rate swaps Interest Rate Swap Interest Rate Swap [Member] Business Interruption Loss [Domain] Business Interruption Loss [Domain] Debt Instrument [Axis] Debt Instrument [Axis] Total revenues Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Building and improvements Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Buildings Measurement Input Type [Domain] Measurement Input Type [Domain] Credit Facility [Axis] Credit Facility [Axis] Financial Instruments Derivative Liability, Subject to Master Netting Arrangement, Collateral, Right to Reclaim Security Not Offset Schedule of Maturities for Outstanding Debt Schedule of Maturities of Long-Term Debt [Table Text Block] Total liabilities Liabilities BUSINESS Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Consideration, net of closing costs Disposal Group, Including Discontinued Operation, Consideration Accounts receivable, prepaid expenses and other assets, net Increase (Decrease) in Prepaid Expense and Other Assets Accumulated Other Comprehensive Income Total accumulated other comprehensive income AOCI Attributable to Parent [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Measurement Frequency [Domain] Measurement Frequency [Domain] All Executive Categories All Executive Categories [Member] Corporate Level Corporate Segment [Member] Net Amount Derivative Liability, Including Not Subject to Master Netting Arrangement, after Offset and Deduction 2026 Lessor, Operating Lease, Payment to be Received, Year Three Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Financial Instruments Derivative Asset, Subject to Master Netting Arrangement, Collateral, Obligation to Return Security Not Offset Accounting Policies [Line Items] Accounting Policies [Line Items] [Line Items] for Accounting Policies [Table] Specialty Hospitals and Other Specialty Hospitals And Other [Member] Specialty Hospitals And Other [Member] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Subsequent Event [Line Items] Subsequent Event [Line Items] Common stock, $0.01 par value; 500,000,000 shares authorized, 231,219,523 and 231,009,295 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively Common Stock, Value, Issued Quantity Financing Receivable, Number Of Loans Financing Receivable, Number Of Loans General and administrative General and Administrative Expense Interest and other income Interest and Fee Income, Loans and Leases Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Ineffectiveness on cash flow hedges Derivatives, Net Hedge Ineffectiveness Gain (Loss) Derivatives, Net Hedge Ineffectiveness Gain (Loss) Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Senior Notes Senior Notes Senior Notes [Member] Canadian dollar Term Loan Canadian Dollar Term Loan [Member] Canadian Dollar Term Loan [Member] Accrued interest Interest Payable Number of variable interest entities Variable Interest Entity, Number Of Entities Variable Interest Entity, Number Of Entities All Individuals All Individuals [Member] Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Extension period Line Of Credit Facility, Optional Extension Period Line Of Credit Facility, Optional Extension Period Total other (expense) income Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Unconsolidated Joint Venture Schedule of Equity Method Investments [Line Items] Allowance for loan losses Balance at beginning of the period Balance at end of the period Financing Receivable, Allowance for Credit Loss Total expenses Operating And Interest Expense Operating And Interest Expense Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Other Investments: Preferred Equity, Net [Abstract] Preferred Equity, Net [Abstract] Statement [Table] Statement [Table] Current Fiscal Year End Date Current Fiscal Year End Date Issuance of common stock, net Proceeds (Payments) From Issuance Of Stock, Net Of Taxes Paid On Behalf Of Employees Proceeds (Payments) From Issuance Of Stock, Net Of Taxes Paid On Behalf Of Employees PEO Name PEO Name Insurance proceeds Proceeds from Insurance Settlement, Investing Activities Schedule of Accumulated Other Comprehensive Income Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Shares authorized (in shares) Preferred Stock, Shares Authorized Base Rate Base Rate [Member] Gain (loss) recognized in other comprehensive income, cash flow hedges and net investment hedges Other Comprehensive Income (Loss), Cash Flow And Net Investment Hedge, Gain (Loss), Before Reclassification And Tax Other Comprehensive Income (Loss), Cash Flow And Net Investment Hedge, Gain (Loss), Before Reclassification And Tax Shares outstanding (in shares) Preferred Stock, Shares Outstanding Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Senior unsecured notes, net Unsecured Debt Unrealized gain (loss), net of tax: Other Comprehensive Income (Loss), Unrealized Gain (Loss), Net of Tax [Abstract] Other Comprehensive Income (Loss), Unrealized Gain (Loss), Net of Tax [Abstract] Depreciation and amortization Depreciation and amortization Depreciation, Depletion and Amortization Accounts, Notes, Loans and Financing Receivable [Line Items] Accounts, Notes, Loans and Financing Receivable [Line Items] Other income (expense) Other Operating Income (Expense), Net Interest rate (percent) Debt Instrument, Interest Rate, Stated Percentage Marlin Spring Joint Venture Marlin Spring Joint Venture [Member] Marlin Spring Joint Venture Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Business Combination and Asset Acquisition [Abstract] Total equity Beginning balance Ending balance Accumulated other comprehensive income Equity, Attributable to Parent Loans receivable, measurement input Financing Receivable, Measurement Input Financing Receivable, Measurement Input Book value Book value Financing Receivable, after Allowance for Credit Loss Available borrowing capacity Line of Credit Facility, Capacity Available for Trade Purchases Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Credit Agreement Credit Agreement [Member] Fifth Amended and Restated Credit Agreement [Member] Restricted cash Restricted Cash and Cash Equivalents Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Foreign currency translation (loss) gain Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Unrealized gain on cash flow hedges Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Subsequent Events [Abstract] Subsequent Events [Abstract] Principal balance Long-Term Debt, Percentage Bearing Fixed Interest, Amount Not Designated as Hedging Instrument Not designated as hedging instrument Not Designated as Hedging Instrument [Member] Shares issued (in shares) Preferred Stock, Shares Issued Hedging Designation [Domain] Hedging Designation [Domain] Significant Other Observable Inputs (Level 2) Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Net Investment Hedges Net investment Net Investment Hedging [Member] Entity Emerging Growth Company Entity Emerging Growth Company Deferred financing costs Deferred financing costs Deferred financing costs, net Debt Issuance Costs, Net 3.20% senior unsecured notes due 2031 (“2031 Notes”) 3.20% Senior Unsecured Notes Due 2031 [Member] 3.20% Senior Unsecured Notes Due 2031 Fire Fire [Member] Disposal Group Classification [Domain] Disposal Group Classification [Domain] Weighted Average Effective Interest Rate (percent) Weighted average effective interest rate (percent) Effective interest rate Debt Instrument, Interest Rate, Effective Percentage Total consideration Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Effect of Derivative Financial Instruments on the Condensed Consolidated Statements of (Loss) Income and Condensed Consolidated Statements of Equity Derivative Instruments, Gain (Loss) [Table Text Block] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] CDOR Canadian Dollar Offer Rate (CDOR) [Member] Canadian Dollar Offer Rate (CDOR) [Member] Tenant intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Document Fiscal Period Focus Document Fiscal Period Focus Held-for-sale or sold Disposal Group, Held-for-Sale or Disposed of by Sale, Not Discontinued Operations [Member] Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Title Trading Arrangement, Individual Title Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Weighted Average Weighted Average [Member] Common Stock Common Stock [Member] Individual: Individual [Axis] City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code EARNINGS PER COMMON SHARE Earnings Per Share [Text Block] Product and Service [Axis] Product and Service [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Discount, net Discount, net Debt Instrument, Unamortized Discount (Premium), Net U.S. dollar Term Loan U.S. Dollar Term Loan [Member] U.S. Dollar Term Loan [Member] Principal payments on secured debt Repayments of Secured Debt Schedule of Fair Value of Financial Instruments Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Ownership Equity interest in joint venture Equity Method Investment, Ownership Percentage Document Fiscal Year Focus Document Fiscal Year Focus Weighted Average Interest Rate (percent) Debt, Weighted Average Interest Rate 3.90% senior unsecured notes due 2029 (“2029 Notes”) 3.90% Senior Unsecured Notes Due 2029 [Member] Senior Unsecured Notes Due 2029 [Member] Minimum Minimum [Member] Credit risk-related contingent features Credit Risk Contract [Member] Receivables [Abstract] Receivables [Abstract] Distributions of earnings from unconsolidated joint ventures Proceeds from Equity Method Investment, Distribution Exercise Price Award Exercise Price Amount available for issuance Sale Of Stock, Remaining Amount Available For Issuance Sale Of Stock, Remaining Amount Available For Issuance Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Company’s share of net loss Income (Loss) From Equity Method Investments, Before Basis Adjustments Income (Loss) From Equity Method Investments, Before Basis Adjustments Investment in unconsolidated joint ventures Payments to Acquire Interest in Joint Venture Other expense related to derivatives Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Number of properties Number of Properties Number of Real Estate Properties Total other comprehensive income Other comprehensive income Other Comprehensive Income (Loss), Net of Tax Gains included in accumulated other comprehensive income expected to be reclassified into retained earnings in the next 12 months Cash Flow Hedge Gain (Loss) to be Reclassified within 12 Months Disposal Group Classification [Axis] Disposal Group Classification [Axis] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Assets Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Tax withholding obligations incurred on behalf of employees Payment, Tax Withholding, Share-Based Payment Arrangement Land Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Land Liabilities: Derivative Liability [Abstract] Liabilities Liabilities [Abstract] Deferred finance costs Debt Issuance Costs, Gross Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Total liabilities and equity Liabilities and Equity Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Unrealized gain on cash flow hedges Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Basic common share (in dollars per share) Earnings Per Share, Basic Tenant relationships Tenant relationship intangible assets Tenant Relationship [Member] Tenant Relationship [Member] Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Accounting Policies [Abstract] Accounting Policies [Abstract] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Sale of Stock [Domain] Sale of Stock [Domain] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Number of loans receivable investments Financing Receivable, Number Of Loans, Nonaccrual Status Financing Receivable, Number Of Loans, Nonaccrual Status Arrangement Duration Trading Arrangement Duration Repayments of preferred equity investments Repayments Of Preferred Equity Investments Repayments Of Preferred Equity Investments Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Interest Rate Swap One Interest Rate Swap One [Member] Interest Rate Swap One Preferred equity investment book value at acquisition Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value Principles of Consolidation Consolidation, Policy [Policy Text Block] Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Interest expense Interest Expense [Member] Real estate investments, net of accumulated depreciation of $1,002,484 and $913,345 as of September 30, 2023 and December 31, 2022, respectively Total Real Estate Investments, Net Real Estate Investment Property, Net Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Termination Date Trading Arrangement Termination Date Shares authorized (in shares) Common Stock, Shares Authorized Repayments of loans receivable Proceeds from Collection of Notes Receivable Borrowing capacity in certain foreign currencies Line Of Credit Facility, Maximum Borrowing Capacity, Foreign Currency Line Of Credit Facility, Maximum Borrowing Capacity, Foreign Currency Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Total weighted average annualized effective interest rate / rate of return Investments, Weighted Average Effective Rate Investments, Weighted Average Effective Rate Land improvements Land Improvements Derivative Instrument [Axis] Derivative Instrument [Axis] Total Debt Long-Term Debt, Gross Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Security deposit liability Security Deposit Liability All Trading Arrangements All Trading Arrangements [Member] Measurement Input Type [Axis] Measurement Input Type [Axis] Net loss on sale Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal Forward sale agreements term Sale Of Stock, Agreement Term Sale Of Stock, Agreement Term All Adjustments to Compensation All Adjustments to Compensation [Member] Derivative [Line Items] Derivative [Line Items] Award Timing Disclosures [Line Items] Compensation Amount Outstanding Recovery Compensation Amount Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Equity Method Investment, Nonconsolidated Investee [Axis] Equity Method Investment, Nonconsolidated Investee [Axis] Cash Collateral Received Derivative Asset, Subject to Master Netting Arrangement, Collateral, Obligation to Return Cash Not Offset Provision for (recovery of) loan losses and other reserves Provision for (recovery of) loan losses and other reserves Accounts Receivable, Credit Loss Expense (Reversal) Additional paid-in capital Additional Paid in Capital Fair value Net Amounts of Assets / Liabilities presented in the Balance Sheet Financial assets Derivative Asset Deteriorated credit quality: Deteriorated Credit Quality [Abstract] Deteriorated Credit Quality Preferred equity investments, measurement input Preferred Equity Investments, Measurement Input Preferred Equity Investments, Measurement Input Loans receivable Loans Receivable, Fair Value Disclosure Subsequent Event Type [Axis] Subsequent Event Type [Axis] Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Loans Receivable: Financing Receivable, after Allowance for Credit Loss [Abstract] Schedule of Derivative and Financial Instruments Designated as Hedging Instruments Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block] 5.125% senior unsecured notes due 2026 (“2026 Notes”) 5.125% Senior Unsecured Notes Due 2026 [Member] 5.125% Senior Unsecured Notes Due 2026 [Member] Revolving credit facility Long-Term Line Of Credit [Member] Long-Term Line Of Credit Number of loans receivable investments Financing Receivable, Number Of Loans, Impaired Financing Receivable, Number Of Loans, Impaired Book value Financing Receivable, before Allowance for Credit Loss Insider Trading Arrangements [Line Items] Schedule of Real Estate Properties Held for Investment Schedule of Real Estate Properties [Table Text Block] Distributions in excess of earnings from unconsolidated joint ventures Proceeds from Equity Method Investment, Distribution, Return of Capital Term loans, net Loans Payable To Bank [Member] Loans Payable To Bank [Member] Revenue, type, extensible enumeration Revenue, Product and Service [Extensible Enumeration] 2024 Long-Term Debt, Maturity, Year One Shares issued upon vesting (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Entity Registrant Name Entity Registrant Name Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] Dilutive restricted stock units (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Adjustment to Compensation, Amount Adjustment to Compensation Amount Fifth Amended and Restated Credit Agreement Fifth Amended and Restated Credit Agreement [Member] Fifth Amended and Restated Credit Agreement [Member] Document Period End Date Document Period End Date Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Adoption Date Trading Arrangement Adoption Date Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Schedule of Items Measured at Fair Value on a Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Entity Central Index Key Entity Central Index Key Non-cash interest expense Amortization of Debt Issuance Costs and Discounts Dispositions: Disposal Group, Not Discontinued Operation, Disposal Disclosures [Abstract] Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Numerator Net Income (Loss) Available to Common Stockholders, Diluted [Abstract] Income tax expense Income Tax Expense (Benefit) Designated as Hedging Instrument Designated as hedging instrument Designated as Hedging Instrument [Member] Other-than-temporary impairment of unconsolidated joint ventures Equity Method Investment, Other than Temporary Impairment Write-off of uncollectible balances Financing Receivable, Allowance for Credit Loss, Writeoff FAIR VALUE DISCLOSURES Fair Value Disclosures [Text Block] Payments of deferred financing costs Payments of Financing Costs Name Trading Arrangement, Individual Name Provision for loan losses Financing Receivable, Credit Loss, Expense (Reversal) Operating expenses Operating Costs and Expenses Non-cash rental and related revenues Non-Cash Rental And Related Revenues Adjustments Non-Cash Rental And Related Revenues Adjustments Common stock issuance, net Stock Issued During Period, Value, New Issues Equity [Abstract] Equity [Abstract] Ancillary services Health Care, Resident Service, Ancillary Service [Member] Health Care, Resident Service, Ancillary Service North American Health Care, Inc North American Health Care, Inc [Member] North American Health Care, Inc Weighted-average remaining term of operating leases Operating Lease, Weighted Average Remaining Lease Term Resident fees and services Revenue from Contract with Customer, Excluding Assessed Tax Entity [Domain] Entity [Domain] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Amendment Flag Amendment Flag Legal Entity [Axis] Legal Entity [Axis] 2025 Lessor, Operating Lease, Payment to be Received, Year Two Gross Amounts Offset in the Balance Sheet Derivative Liability, Subject to Master Netting Arrangement, Asset Offset Financial Instrument Performance Status [Axis] Financial Instrument Performance Status [Axis] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Principal balance Senior Notes Interest paid Interest Paid, Excluding Capitalized Interest, Operating Activities Net carrying value Disposal Group, Including Discontinued Operation, Assets And Liabilities, Net Disposal Group, Including Discontinued Operation, Assets And Liabilities, Net Credit Facility [Domain] Credit Facility [Domain] Interest rate collars Interest Rate Collar [Member] Interest Rate Collar Number of facilities Disposal Group, Including Discontinued Operations, Number Of Properties Disposal Group, Including Discontinued Operations, Number Of Properties Net Amount Derivative Asset, Including Not Subject to Master Netting Arrangement, after Offset and Deduction Basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Accounting Policies [Table] Accounting Policies [Table] Accounting Policies [Table] Number of interest rate swaps Derivative, Number of Instruments Held Weighted average number of common shares outstanding, diluted (in shares) Diluted weighted average common shares (in shares) Weighted Average Number of Shares Outstanding, Diluted Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Interest rate products Interest Rate Contract [Member] Assets: Derivative Asset [Abstract] Count Derivative Asset, Number of Instruments Held Schedule of Dispositions Disposal Groups, Including Discontinued Operations [Table Text Block] Expenses: Operating Expenses [Abstract] Offsetting Assets: Offsetting Derivative Assets [Abstract] Company Selected Measure Amount Company Selected Measure Amount Additional Paid-in Capital Additional Paid-in Capital [Member] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Total assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Loss from unconsolidated joint ventures Income (Loss) from Equity Method Investments Triple-net portfolio Triple-Net Portfolio [Member] Triple-Net Portfolio [Member] Cover [Abstract] Cover [Abstract] Decrease in loans receivable and other investments due to acquisition of real estate Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed) SUBSEQUENT EVENTS Subsequent Events [Text Block] LOANS RECEIVABLE AND OTHER INVESTMENTS Loans, Notes, Trade and Other Receivables Disclosure [Text Block] Amortization of stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Debt, measurement input Debt Instrument, Measurement Input Recurring Fair Value, Recurring [Member] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Count Derivative Liability, Number of Instruments Held Dividends paid on common stock Payments of Dividends Non-NEOs Non-NEOs [Member] Credit Loss Status [Axis] Credit Loss Status [Axis] Cash flow hedges Cash flow Cash Flow Hedging [Member] Prime Rate Prime Rate [Member] Weighted Average Annualized Effective Interest Rate / Rate of Return Financing Receivable, Effective Interest Rate Financing Receivable, Effective Interest Rate Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] (Loss) income before loss from unconsolidated joint ventures and income tax expense Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Secured Debt Secured Indebtedness Secured Debt [Member] Non-PEO NEO Non-PEO NEO [Member] Equity Component [Domain] Equity Component [Domain] Adjustment to Compensation: Adjustment to Compensation [Axis] Gross Presentation, Effects of Offsetting, and Net Presentation of Derivatives - Assets Offsetting Assets [Table Text Block] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Gross Amounts Offset in the Balance Sheet Derivative Asset, Subject to Master Netting Arrangement, Liability Offset Debt Instrument [Line Items] Debt Instrument [Line Items] Weighted average number of common shares outstanding, basic (in shares) Basic weighted average common shares and common equivalents (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Revenues: Revenues [Abstract] Consolidated Entities [Domain] Consolidated Entities [Domain] Changes in operating assets and liabilities: Increase (Decrease) in Other Operating Assets and Liabilities, Net [Abstract] Number of acquired properties Number Of Real Estate Properties Acquired Number Of Real Estate Properties Acquired Rental and related revenues (Note 4) Operating Lease, Lease Income Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Annum percent unused borrowing fee Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Segments [Axis] Segments [Axis] Statement [Line Items] Statement [Line Items] Additions to real estate Payments to Acquire Furniture and Fixtures Fair Value Estimate of Fair Value Measurement [Member] Other comprehensive income: Other Comprehensive Income (Loss), Net of Tax [Abstract] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Revolving credit facility Amount outstanding under credit facility Long-Term Line of Credit Preferred equity investments Preferred Equity Investment, Fair Value Disclosure Preferred Equity Investment, Fair Value Disclosure Real Estate Properties [Line Items] Real Estate Properties [Line Items] Business Interruption Loss [Axis] Business Interruption Loss [Axis] Real Estate, Type of Property [Axis] Real Estate, Type of Property [Axis] Health Care, Resident Service [Member] EX-101.PRE 10 sbra-20230930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover - shares
 9 Months Ended
Sep. 30, 2023
Nov. 01, 2023
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2023  
Document Transition Report false  
Entity File Number 001-34950  
Entity Registrant Name SABRA HEALTH CARE REIT, INC.  
Entity Incorporation, State or Country Code MD  
Entity Tax Identification Number 27-2560479  
Entity Address, Address Line One 18500 Von Karman Avenue  
Entity Address, Address Line Two Suite 550  
Entity Address, City or Town Irvine  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 92612  
City Area Code 888  
Local Phone Number 393-8248  
Title of 12(b) Security Common stock, $.01 par value  
Trading Symbol SBRA  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   231,219,523
Entity Central Index Key 0001492298  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q3  
Amendment Flag false  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.23.3
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Assets    
Real estate investments, net of accumulated depreciation of $1,002,484 and $913,345 as of September 30, 2023 and December 31, 2022, respectively $ 4,603,014 $ 4,959,343
Loans receivable and other investments, net 417,947 411,396
Investment in unconsolidated joint ventures 135,755 134,962
Cash and cash equivalents 33,256 49,308
Restricted cash 5,602 4,624
Lease intangible assets, net 32,749 40,131
Accounts receivable, prepaid expenses and other assets, net 152,239 147,908
Total assets 5,380,562 5,747,672
Liabilities    
Secured debt, net 47,789 49,232
Revolving credit facility 32,623 196,982
Term loans, net 534,011 526,129
Senior unsecured notes, net 1,735,055 1,734,431
Accounts payable and accrued liabilities 128,039 142,259
Lease intangible liabilities, net 34,192 42,244
Total liabilities 2,511,709 2,691,277
Commitments and contingencies (Note 12)
Equity    
Preferred stock, $0.01 par value; 10,000,000 shares authorized, zero shares issued and outstanding as of September 30, 2023 and December 31, 2022 0 0
Common stock, $0.01 par value; 500,000,000 shares authorized, 231,219,523 and 231,009,295 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively 2,312 2,310
Additional paid-in capital 4,491,917 4,486,967
Cumulative distributions in excess of net income (1,665,045) (1,451,945)
Accumulated other comprehensive income 39,669 19,063
Total equity 2,868,853 3,056,395
Total liabilities and equity $ 5,380,562 $ 5,747,672
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.23.3
CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Assets    
Accumulated depreciation $ 1,002,484 $ 913,345
Preferred Stock, Number of Shares, Par Value and Other Disclosure [Abstract]    
Par value (in dollars per share) $ 0.01 $ 0.01
Shares authorized (in shares) 10,000,000 10,000,000
Shares issued (in shares) 0 0
Shares outstanding (in shares) 0 0
Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]    
Par value (in dollars per share) $ 0.01 $ 0.01
Shares authorized (in shares) 500,000,000 500,000,000
Shares issued (in shares) 231,219,523 231,009,295
Shares outstanding (in shares) 231,219,523 231,009,295
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.3
CONSOLIDATED STATEMENTS OF (LOSS) INCOME - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenues:        
Rental and related revenues (Note 4) $ 93,085 $ 84,214 $ 283,229 $ 297,268
Resident fees and services 59,748 47,610 174,897 133,973
Interest and other income 8,794 8,940 25,991 28,585
Total revenues 161,627 140,764 484,117 459,826
Expenses:        
Depreciation and amortization 43,242 47,427 140,211 137,855
Interest 28,156 27,071 85,024 77,573
General and administrative 10,759 9,676 30,793 28,721
Provision for (recovery of) loan losses and other reserves 328 (217) 549 (12)
Impairment of real estate 0 60,857 7,064 72,602
Total expenses 131,312 186,639 409,008 435,557
Other (expense) income:        
Loss on extinguishment of debt 0 (140) (1,541) (411)
Other income (expense) 2,229 994 2,570 (1,101)
Net loss on sales of real estate (46,545) (80) (75,893) (4,581)
Total other (expense) income (44,316) 774 (74,864) (6,093)
(Loss) income before loss from unconsolidated joint ventures and income tax expense (14,001) (45,101) 245 18,176
Loss from unconsolidated joint ventures (645) (4,384) (2,136) (9,715)
Income tax expense (455) (579) (1,509) (1,118)
Net (loss) income $ (15,101) $ (50,064) $ (3,400) $ 7,343
Net (loss) income, per:        
Basic common share (in dollars per share) $ (0.07) $ (0.22) $ (0.01) $ 0.03
Diluted common share (in dollars per share) $ (0.07) $ (0.22) $ (0.01) $ 0.03
Weighted average number of common shares outstanding, basic (in shares) 231,224,692 230,982,227 231,197,375 230,936,032
Weighted average number of common shares outstanding, diluted (in shares) 231,224,692 230,982,227 231,197,375 231,779,750
Revenue, type, extensible enumeration Health Care, Resident Service [Member] Health Care, Resident Service [Member] Health Care, Resident Service [Member] Health Care, Resident Service [Member]
Triple-net portfolio        
Expenses:        
Operating expenses $ 4,304 $ 5,120 $ 13,243 $ 14,983
Senior housing - managed        
Expenses:        
Operating expenses $ 44,523 $ 36,705 $ 132,124 $ 103,835
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.23.3
CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Statement of Comprehensive Income [Abstract]        
Net (loss) income $ (15,101) $ (50,064) $ (3,400) $ 7,343
Unrealized gain (loss), net of tax:        
Foreign currency translation (loss) gain (1,347) 1,068 (1,948) 3,505
Unrealized gain on cash flow hedges 8,777 7,309 22,554 25,038
Total other comprehensive income 7,430 8,377 20,606 28,543
Comprehensive (loss) income $ (7,671) $ (41,687) $ 17,206 $ 35,886
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.23.3
CONSOLIDATED STATEMENTS OF EQUITY - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Cumulative Distributions in Excess of Net Income
Accumulated Other Comprehensive Income
Beginning balance (in shares) at Dec. 31, 2021   230,398,655      
Beginning balance at Dec. 31, 2021 $ 3,379,530 $ 2,304 $ 4,482,451 $ (1,095,204) $ (10,021)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net (loss) income 7,343     7,343  
Other comprehensive income 28,543       28,543
Amortization of stock-based compensation 6,513   6,513    
Common stock issuance, net (in shares)   577,951      
Common stock issuance, net (4,189) $ 6 (4,195)    
Common dividends (209,007)     (209,007)  
Ending balance (in shares) at Sep. 30, 2022   230,976,606      
Ending balance at Sep. 30, 2022 3,208,733 $ 2,310 4,484,769 (1,296,868) 18,522
Beginning balance (in shares) at Jun. 30, 2022   230,968,872      
Beginning balance at Jun. 30, 2022 3,317,726 $ 2,310 4,482,239 (1,176,968) 10,145
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net (loss) income (50,064)     (50,064)  
Other comprehensive income 8,377       8,377
Amortization of stock-based compensation 2,657   2,657    
Common stock issuance, net (in shares)   7,734      
Common stock issuance, net (127)   (127)    
Common dividends (69,836)     (69,836)  
Ending balance (in shares) at Sep. 30, 2022   230,976,606      
Ending balance at Sep. 30, 2022 3,208,733 $ 2,310 4,484,769 (1,296,868) 18,522
Beginning balance (in shares) at Dec. 31, 2022   231,009,295      
Beginning balance at Dec. 31, 2022 3,056,395 $ 2,310 4,486,967 (1,451,945) 19,063
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net (loss) income (3,400)     (3,400)  
Other comprehensive income 20,606       20,606
Amortization of stock-based compensation 7,090   7,090    
Common stock issuance, net (in shares)   210,228      
Common stock issuance, net (2,138) $ 2 (2,140)    
Common dividends (209,700)     (209,700)  
Ending balance (in shares) at Sep. 30, 2023   231,219,523      
Ending balance at Sep. 30, 2023 2,868,853 $ 2,312 4,491,917 (1,665,045) 39,669
Beginning balance (in shares) at Jun. 30, 2023   231,218,658      
Beginning balance at Jun. 30, 2023 2,943,744 $ 2,312 4,489,107 (1,579,914) 32,239
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net (loss) income (15,101)     (15,101)  
Other comprehensive income 7,430       7,430
Amortization of stock-based compensation 2,900   2,900    
Common stock issuance, net (in shares)   865      
Common stock issuance, net (90)   (90)    
Common dividends (70,030)     (70,030)  
Ending balance (in shares) at Sep. 30, 2023   231,219,523      
Ending balance at Sep. 30, 2023 $ 2,868,853 $ 2,312 $ 4,491,917 $ (1,665,045) $ 39,669
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.23.3
CONSOLIDATED STATEMENTS OF EQUITY (Parenthetical) - $ / shares
 3 Months Ended 9 Months Ended
Aug. 07, 2023
May 03, 2023
Feb. 01, 2023
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Statement of Stockholders' Equity [Abstract]              
Common dividends (in dollars per share) $ 0.30 $ 0.30 $ 0.30 $ 0.30 $ 0.30 $ 0.90 $ 0.90
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.23.3
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Cash flows from operating activities:    
Net (loss) income $ (3,400) $ 7,343
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 140,211 137,855
Non-cash rental and related revenues (6,781) 4,970
Non-cash interest income (380) (1,683)
Non-cash interest expense 9,179 8,300
Stock-based compensation expense 5,468 5,367
Loss on extinguishment of debt 1,541 411
Provision for (recovery of) loan losses and other reserves 549 (12)
Net loss on sales of real estate 75,893 4,581
Impairment of real estate 7,064 72,602
Loss from unconsolidated joint ventures 2,136 9,715
Distributions of earnings from unconsolidated joint ventures 1,705 0
Other non-cash items (3,704) 2,167
Changes in operating assets and liabilities:    
Accounts receivable, prepaid expenses and other assets, net (10,660) (5,631)
Accounts payable and accrued liabilities 3,013 2,161
Net cash provided by operating activities 221,834 248,146
Cash flows from investing activities:    
Acquisition of real estate (39,630) (83,985)
Origination and fundings of loans receivable (9,614) (4,500)
Origination and fundings of preferred equity investments (11,015) (5,813)
Additions to real estate (63,794) (33,809)
Escrow deposits for potential investments 0 (836)
Repayments of loans receivable 8,674 4,885
Repayments of preferred equity investments 4,828 4,173
Investment in unconsolidated joint ventures (4,797) (128,019)
Net proceeds from the sales of real estate 248,222 62,816
Net proceeds from sales-type lease 25,490 0
Insurance proceeds 6,001 0
Distributions in excess of earnings from unconsolidated joint ventures 544 0
Net cash provided by (used in) investing activities 164,909 (185,088)
Cash flows from financing activities:    
Net (repayments of) borrowings from revolving credit facility (165,338) 147,353
Proceeds from term loans 12,188 0
Principal payments on term loans 0 (63,750)
Principal payments on secured debt (1,479) (17,030)
Payments of deferred financing costs (18,135) (6)
Payment of contingent consideration (17,900) (2,500)
Issuance of common stock, net (2,194) (4,394)
Dividends paid on common stock (208,079) (207,861)
Net cash used in financing activities (400,937) (148,188)
Net decrease in cash, cash equivalents and restricted cash (14,194) (85,130)
Effect of foreign currency translation on cash, cash equivalents and restricted cash (880) 392
Cash, cash equivalents and restricted cash, beginning of period 53,932 115,886
Cash, cash equivalents and restricted cash, end of period 38,858 31,148
Supplemental disclosure of cash flow information:    
Interest paid 72,911 68,778
Supplemental disclosure of non-cash investing activities:    
Decrease in loans receivable and other investments due to acquisition of real estate $ 4,644 $ 14,311
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.23.3
BUSINESS
 9 Months Ended
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
BUSINESS BUSINESS
Overview
Sabra Health Care REIT, Inc. (“Sabra” or the “Company”) was incorporated on May 10, 2010 as a wholly owned subsidiary of Sun Healthcare Group, Inc. (“Sun”) and commenced operations on November 15, 2010 following Sabra’s separation from Sun. Sabra elected to be treated as a real estate investment trust (“REIT”) with the filing of its United States (“U.S.”) federal income tax return for the taxable year beginning January 1, 2011. Sabra believes that it has been organized and operated, and it intends to continue to operate, in a manner to qualify as a REIT. Sabra’s primary business consists of acquiring, financing and owning real estate property to be leased to third-party tenants in the healthcare sector. Sabra primarily generates revenues by leasing properties to tenants throughout the U.S. and Canada. Sabra owns substantially all of its assets and properties and conducts its operations through Sabra Health Care Limited Partnership, a Delaware limited partnership (the “Operating Partnership”), of which Sabra is the sole general partner and a wholly owned subsidiary of Sabra is currently the only limited partner, or by subsidiaries of the Operating Partnership. The Company’s investment portfolio is primarily comprised of skilled nursing/transitional care facilities, senior housing communities (“Senior Housing - Leased”), behavioral health facilities and specialty hospitals and other facilities, in each case leased to tenants who are responsible for the operations of these facilities; senior housing communities operated by third-party property managers pursuant to property management agreements (“Senior Housing - Managed”); investments in joint ventures; investments in loans receivable; and preferred equity investments.
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.23.3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 9 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Principles of Consolidation and Basis of Presentation
The accompanying consolidated financial statements include the accounts of Sabra and its wholly owned subsidiaries as of September 30, 2023 and December 31, 2022 and for the three and nine month periods ended September 30, 2023 and 2022. All significant intercompany transactions and balances have been eliminated in consolidation.
The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information as contained within the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification and the rules and regulations of the SEC, including the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the unaudited consolidated financial statements do not include all of the information and footnotes required by GAAP for financial statements. In the opinion of management, the financial statements for the unaudited interim periods presented include all adjustments, which are of a normal and recurring nature, necessary for a fair statement of the results for such periods. Operating results for the three and nine months ended September 30, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023. For further information, refer to the Company’s consolidated financial statements and notes thereto for the year ended December 31, 2022 included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC.
GAAP requires the Company to identify entities for which control is achieved through voting rights or other means and to determine which business enterprise is the primary beneficiary of variable interest entities (“VIEs”). A VIE is broadly defined as an entity with one or more of the following characteristics: (a) the total equity investment at risk is insufficient to finance the entity’s activities without additional subordinated financial support; (b) as a group, the holders of the equity investment at risk lack (i) the ability to make decisions about the entity’s activities through voting or similar rights, (ii) the obligation to absorb the expected losses of the entity, or (iii) the right to receive the expected residual returns of the entity; or (c) the equity investors have voting rights that are not proportional to their economic interests, and substantially all of the entity’s activities either involve, or are conducted on behalf of, an investor that has disproportionately few voting rights. If the Company were determined to be the primary beneficiary of the VIE, the Company would consolidate investments in the VIE. The Company may change its original assessment of a VIE due to events such as modifications of contractual arrangements that affect the characteristics or adequacy of the entity’s equity investments at risk and the disposal of all or a portion of an interest held by the primary beneficiary.
The Company identifies the primary beneficiary of a VIE as the enterprise that has both: (i) the power to direct the activities of the VIE that most significantly impact the entity’s economic performance; and (ii) the obligation to absorb losses or the right to receive benefits of the VIE that could be significant to the entity. The Company performs this analysis on an ongoing basis. As of September 30, 2023, the Company determined that it was not the primary beneficiary of any VIEs.
As it relates to investments in loans, in addition to the Company’s assessment of VIEs and whether the Company is the primary beneficiary of those VIEs, the Company evaluates the loan terms and other pertinent facts to determine whether the loan investment should be accounted for as a loan or as a real estate joint venture. If an investment has the characteristics of a real estate joint venture, including if the Company participates in the majority of the borrower’s expected residual profit, the Company would account for the investment as an investment in a real estate joint venture and not as a loan investment. Expected residual profit is defined as the amount of profit, whether called interest or another name, such as an equity kicker, above a reasonable amount of interest and fees expected to be earned by a lender. At September 30, 2023, none of the Company’s investments in loans were accounted for as real estate joint ventures.
As it relates to investments in joint ventures, the Company assesses any partners’ rights and their impact on the presumption of control of the partnership by any single partner. The Company also applies this guidance to managing member interests in limited liability companies. The Company reassesses its determination of which entity controls the joint venture if: there is a change to the terms or in the exercisability of the rights of any partners or members, the general partner or managing member increases or decreases its ownership interests, or there is an increase or decrease in the number of outstanding ownership interests. As of September 30, 2023, the Company’s determination of which entity controls its investments in joint ventures has not changed as a result of any reassessment.
Use of Estimates
The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates.
Casualty Gains and Losses
Income resulting from insurance recoveries of property damage or business interruption losses is recognized when proceeds are received or contingencies related to the insurance recoveries are resolved.
A vacant facility owned by the Company suffered damages as a result of vandalism and theft. The Company received $6.0 million of net insurance proceeds and recorded a $3.7 million gain related to the property damage during the three and nine months ended September 30, 2023 which is included in other income (expense) on the accompanying consolidated statements of (loss) income.
A fire occurred at one of the Company’s Senior Housing - Managed communities. The Company received $1.1 million of insurance proceeds and recorded $0.5 million of business interruption insurance income during the three and nine months ended September 30, 2023 which is included in other income (expense) on the accompanying consolidated statements of (loss) income. The remaining proceeds were recorded as expense reimbursements in Senior Housing - Managed portfolio operating expenses on the accompanying consolidated statements of (loss) income.
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.23.3
RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED)
 9 Months Ended
Sep. 30, 2023
Business Combination and Asset Acquisition [Abstract]  
RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED) RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED)
During the nine months ended September 30, 2023, the Company acquired one Senior Housing - Leased community and one Senior Housing - Managed community. During the nine months ended September 30, 2022, the Company acquired three Senior Housing - Managed communities. The Senior Housing - Managed community acquired during the nine months ended September 30, 2023 and two of the Senior Housing - Managed communities acquired during the nine months ended September 30, 2022 were part of the Company’s proprietary development pipeline and were previously reflected as preferred equity investments which had a book value of $4.6 million and $14.3 million, respectively, at the time of acquisition. The consideration was allocated as follows (in thousands):
Nine Months Ended September 30,
20232022
Land$3,415 $10,292 
Building and improvements45,333 83,118 
Tenant origination and absorption costs intangible assets2,706 4,887 
Tenant relationship intangible assets20 — 
Total consideration$51,474 $98,297 
The tenant origination and absorption costs intangible assets and tenant relationship intangible assets had weighted average amortization periods as of the respective dates of acquisition of one year and 22 years, respectively, for the acquisitions completed during the nine months ended September 30, 2023. The tenant origination and absorption costs intangible assets had an amortization period as of the date of acquisition of one year for the acquisitions completed during the nine months ended September 30, 2022.
For the three and nine months ended September 30, 2023, the Company recognized $2.6 million and $6.8 million of total revenues, respectively, and $46,000 of net loss and less than $1,000 of net income, respectively, from the facilities acquired during the nine months ended September 30, 2023. For the three and nine months ended September 30, 2022, the Company recognized $3.9 million and $6.0 million of total revenues, respectively, and $0.3 million and $0.9 million of net loss, respectively, from the facilities acquired during the nine months ended September 30, 2022.
During the three months ended June 30, 2023, the Company, in accordance with the terms of the agreements pursuant to which it purchased the facilities, paid $17.9 million in additional consideration related to two Senior Housing - Managed communities that achieved certain performance metrics. This amount is included in real estate investments, net of accumulated depreciation on the accompanying consolidated balance sheets.
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.23.3
INVESTMENT IN REAL ESTATE PROPERTIES
 9 Months Ended
Sep. 30, 2023
Real Estate [Abstract]  
INVESTMENT IN REAL ESTATE PROPERTIES INVESTMENT IN REAL ESTATE PROPERTIES
The Company’s real estate properties held for investment consisted of the following (dollars in thousands):
As of September 30, 2023
Property TypeNumber of
Properties		Number of
Beds/Units		Total
Real Estate
at Cost		Accumulated
Depreciation		Total
Real Estate
Investments, Net
Skilled Nursing/Transitional Care240 26,623 $3,035,231 $(530,290)$2,504,941 
Senior Housing - Leased43 3,473 572,633 (106,063)466,570 
Senior Housing - Managed61 6,041 1,278,352 (250,772)1,027,580 
Behavioral Health18 1,077 492,236 (68,654)423,582 
Specialty Hospitals and Other15 392 225,443 (46,100)179,343 
377 37,606 5,603,895 (1,001,879)4,602,016 
Corporate Level1,603 (605)998 
$5,605,498 $(1,002,484)$4,603,014 
As of December 31, 2022
Property TypeNumber of
Properties		Number of
Beds/Units		Total
Real Estate
at Cost		Accumulated
Depreciation		Total
Real Estate
Investments, Net
Skilled Nursing/Transitional Care264 29,136 $3,385,221 $(492,495)$2,892,726 
Senior Housing - Leased47 3,550 590,694 (97,716)492,978 
Senior Housing - Managed59 5,942 1,205,283 (222,089)983,194 
Behavioral Health17 965 465,143 (58,481)406,662 
Specialty Hospitals and Other15 392 225,443 (42,038)183,405 
402 39,985 5,871,784 (912,819)4,958,965 
Corporate Level904 (526)378 
$5,872,688 $(913,345)$4,959,343 
September 30, 2023December 31, 2022
Building and improvements$4,815,199 $5,034,470 
Furniture and equipment234,882 262,644 
Land improvements10,241 7,085 
Land545,176 568,489 
Total real estate at cost5,605,498 5,872,688 
Accumulated depreciation(1,002,484)(913,345)
Total real estate investments, net$4,603,014 $4,959,343 
Operating Leases
As of September 30, 2023, the substantial majority of the Company’s real estate properties (excluding 61 Senior Housing - Managed communities) were leased under triple-net operating leases with expirations ranging from less than one year to 19 years. As of September 30, 2023, the leases had a weighted average remaining term of eight years. The leases generally include provisions to extend the lease terms and other negotiated terms and conditions. The Company, through its subsidiaries, retains substantially all of the risks and benefits of ownership of the real estate assets leased to the tenants. The Company may receive additional security under these operating leases in the form of letters of credit and security deposits from the lessee or guarantees from the parent of the lessee. Security deposits received in cash related to tenant leases are included in accounts payable and accrued liabilities on the accompanying consolidated balance sheets and totaled $17.0 million and $13.0 million as of September 30, 2023 and December 31, 2022, respectively, and letters of credit deposited with the Company totaled approximately $57 million as of each of September 30, 2023 and December 31, 2022. In addition, the Company’s tenants have deposited with the Company $11.6 million and $13.3 million as of September 30, 2023 and December 31, 2022, respectively, for future real estate taxes, insurance expenditures and tenant improvements related to the Company’s properties and their operations, and these amounts are included in accounts payable and accrued liabilities on the accompanying consolidated balance sheets.
Lessor costs that are paid by the lessor and reimbursed by the lessee are included in the measurement of variable lease revenue and the associated expense. As a result, the Company recognized variable lease revenue and the associated expense of $3.8 million and $11.4 million during the three and nine months ended September 30, 2023, respectively, and $4.3 million and $13.7 million during the three and nine months ended September 30, 2022, respectively.
The Company monitors the creditworthiness of its tenants by evaluating the ability of the tenants to meet their lease obligations to the Company based on the tenants’ financial performance, including, as applicable and appropriate, the evaluation of any parent guarantees (or the guarantees of other related parties) of such lease obligations. The primary basis for the Company’s evaluation of the credit quality of its tenants (and more specifically the tenant’s ability to pay their rent obligations to the Company) is the tenant’s lease coverage ratio as supplemented by the parent’s fixed charge coverage ratio for those entities with a parent guarantee. These coverage ratios include earnings before interest, taxes, depreciation, amortization and rent (“EBITDAR”) to rent and earnings before interest, taxes, depreciation, amortization, rent and management fees (“EBITDARM”) to rent at the lease level and consolidated EBITDAR to total fixed charges at the parent guarantor level when such a guarantee exists. The Company obtains various financial and operational information from the majority of its tenants each month and reviews this information in conjunction with the above-described coverage metrics to identify financial and operational trends, evaluate the impact of the industry’s operational and financial environment (including the impact of
government reimbursement), and evaluate the management of the tenant’s operations. These metrics help the Company identify potential areas of concern relative to its tenants’ credit quality and ultimately the tenant’s ability to generate sufficient liquidity to meet its obligations, including its obligation to continue to pay the rent due to the Company.
During the third quarter of 2022, the Company concluded that its leases with North American Health Care, Inc. should no longer be accounted for on an accrual basis and wrote off $15.6 million of straight-line rent receivable balances related to these leases. The facilities were transitioned to the Ensign Group or Avamere, as applicable, effective February 1, 2023.
For the three and nine months ended September 30, 2023, no tenant relationship represented 10% or more of the Company’s total revenues.
As of September 30, 2023, the future minimum rental payments from the Company’s properties held for investment under non-cancelable operating leases were as follows and may materially differ from actual future rental payments received (in thousands):
October 1 through December 31, 2023$91,919 
2024371,661 
2025366,190 
2026350,583 
2027327,530 
Thereafter1,508,364 
$3,016,247 
Senior Housing - Managed Communities
The Company’s Senior Housing - Managed communities offer residents certain ancillary services that are not contemplated in the lease with each resident (i.e., housekeeping, laundry, guest meals, etc.). These services are provided and paid for in addition to the standard services included in each resident lease (i.e., room and board, standard meals, etc.). The Company bills residents for ancillary services one month in arrears and recognizes revenue as the services are provided, as the Company has no continuing performance obligation related to those services. Resident fees and services include ancillary service revenue of $0.4 million and $1.4 million for the three and nine months ended September 30, 2023, respectively, and $0.4 million and $1.0 million for the three and nine months ended September 30, 2022, respectively.
Capital and Other Expenditures
As of September 30, 2023, the Company’s aggregate commitment for future capital and other expenditures associated with facilities leased under triple-net operating leases was approximately $44 million. These commitments are principally for improvements to its facilities.
Investment in Unconsolidated Joint Ventures
The following is a summary of the Company’s investment in unconsolidated joint ventures (dollars in thousands):
Property Type
Number of
Properties as of
September 30, 2023
Ownership as of
September 30, 2023 (1)
Book Value
September 30, 2023December 31, 2022
Sienna Joint VentureSenior Housing - Managed12 50 %$118,150 $120,269 
Marlin Spring Joint VentureSenior Housing - Managed4 85 %17,605 14,693 
$135,755 $134,962 
(1)    These investments are not consolidated because the Company does not control, through voting rights or other means, the joint ventures.
During the nine months ended September 30, 2023, the Company’s joint venture with Marlin Spring (the “Marlin Spring Joint Venture”) completed the acquisition of one additional senior housing community that is being managed by a third-party property manager. The gross investment in the additional acquisition was CAD $30.0 million, excluding acquisition costs. In addition, the Marlin Spring Joint Venture assumed and financed an aggregate CAD $23.6 million of debt associated with the additional acquisition. The Company’s equity investment in the additional acquisition was CAD $6.1 million.
During the fourth quarter of 2022, due to the confluence of labor shortages, increased labor costs, elevated interest rates and a slower than anticipated recovery in the operating performance of the underlying facilities, the Company concluded that
the estimated fair value of its investment in its joint venture with affiliates of TPG Real Estate, the real estate platform of TPG (the “Enlivant Joint Venture”) had declined to zero based on updated future cash flow analyses. This decline was deemed to be other-than-temporary, and the Company recorded an impairment charge totaling $57.8 million during the three months ended December 31, 2022.
Effective January 1, 2023, the Company discontinued applying the equity method of accounting to the Enlivant Joint Venture, in which it had a 49% equity interest. Effective May 1, 2023, the Company withdrew and resigned its membership in the Enlivant Joint Venture and accordingly, no longer has an equity interest in the Enlivant Joint Venture as of such date.
During the nine months ended September 30, 2022, the Enlivant Joint Venture was a significant equity method investee of the Company. The following table presents summarized financial information for the Enlivant Joint Venture and, except for basis adjustments and loss from unconsolidated joint venture, reflects the historical cost basis of the assets which pre-dated the Company’s investment in the Enlivant Joint Venture (in thousands):
Nine Months Ended September 30, 2022
Total revenues$237,144 
Operating expenses215,293 
Net loss(7,177)
Company’s share of net loss$(3,525)
Basis adjustments5,755 
Loss from unconsolidated joint venture$(9,280)
Certain amounts in the financial information for the Enlivant Joint Venture have been reclassified to conform to Sabra’s presentation. The Company’s share of net loss in the Enlivant Joint Venture reflects its 49% equity interest and excludes certain equity-like compensation expense and the related income tax impact as such expense is not the responsibility of the Company under the terms of the joint venture agreement.
Net Investment in Sales-Type Lease
As of December 31, 2022, the Company had a $25.5 million net investment in one skilled nursing/transitional care facility leased to a tenant under a sales-type lease, as the tenant is obligated to purchase the property at the end of the lease term. During the three months ended March 31, 2023, the tenant purchased the skilled nursing/transitional care facility for net proceeds of $25.5 million as obligated under the terms of the lease.
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.23.3
IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS
 9 Months Ended
Sep. 30, 2023
Discontinued Operations and Disposal Groups [Abstract]  
IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS
Impairment of Real Estate
During the nine months ended September 30, 2023, the Company recognized $7.1 million of real estate impairment related to one skilled nursing/transitional care facility that has sold.
During the nine months ended September 30, 2022, the Company recognized $72.6 million of real estate impairment related to ten skilled nursing/transitional care facilities that have sold.
To estimate the fair value of the impaired facilities, the Company utilized a market approach which considered binding sale agreements, non-binding offers from unrelated third parties or model-derived valuations with significant unobservable inputs (Level 3 measurements), as applicable.
The Company continues to evaluate additional assets for sale as part of its initiative to recycle capital and further improve its portfolio quality. This could lead to a shorter hold period and could result in the determination that the full amount of the Company’s investment is not recoverable, resulting in an impairment charge or loss on sale which could be material.
Dispositions
The following table summarizes the Company’s dispositions for the periods presented (dollars in millions):
Nine Months Ended September 30,
20232022
Number of facilities27 11 
Consideration, net of closing costs$256.2 $62.8 
Net carrying value332.1 67.4 
Net loss on sale$(75.9)$(4.6)
Net loss (1)
$(80.3)$(63.1)
(1)    In addition to net loss on sale, net loss includes impairment of real estate of $7.1 million and $65.8 million for the nine months ended September 30, 2023 and 2022, respectively.
The sale of the disposition facilities does not represent a strategic shift that has or will have a major effect on the Company’s operations and financial results, and therefore the results of operations attributable to these facilities have remained in continuing operations.
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.23.3
LOANS RECEIVABLE AND OTHER INVESTMENTS
 9 Months Ended
Sep. 30, 2023
Receivables [Abstract]  
LOANS RECEIVABLE AND OTHER INVESTMENTS LOANS RECEIVABLE AND OTHER INVESTMENTS
As of September 30, 2023 and December 31, 2022, the Company’s loans receivable and other investments consisted of the following (dollars in thousands):
As of September 30, 2023
Investment
Quantity
as of
September 30, 2023
Property Type
Principal Balance
as of
September 30, 2023 (1)
Book Value
as of
September 30, 2023
Book Value
as of December 31, 2022
Weighted Average Contractual Interest Rate / Rate of ReturnWeighted Average Annualized Effective Interest Rate / Rate of Return
Maturity Date
as of
September 30, 2023
Loans Receivable:
Mortgage2 Behavioral Health$319,000 $319,000 $319,000 7.6 %7.6 %11/01/26 - 01/31/27
Other10 Multiple52,133 48,703 47,936 7.5 %7.0 %08/31/23 - 05/01/29
12 371,133 367,703 366,936 7.6 %7.6 %
Allowance for loan losses— (6,677)(6,611)
$371,133 $361,026 $360,325 
Other Investments:
Preferred Equity5 Skilled Nursing / Senior Housing56,760 56,921 51,071 11.0 %11.0 %N/A
Total 17 $427,893 $417,947 $411,396 8.1 %8.0 %
(1)    Principal balance includes amounts funded and accrued but unpaid interest / preferred return and excludes capitalizable fees.
Additional information regarding the Company’s loans receivable is as follows (dollars in thousands):
Nine Months Ended September 30,
20232022
Allowance for loan losses:
Balance at beginning of the period$6,611 $6,344 
Provision for loan losses549 83 
Write-off of uncollectible balances(483)— 
Balance at end of the period$6,677 $6,427 
September 30, 2023December 31, 2022
Deteriorated credit quality:
Number of loans receivable investments1 1 
Principal balance$1,214 $1,214 
Book value— — 
Nonaccrual status:
Number of loans receivable investments3 3 
Book value$— $— 
As of September 30, 2023 and December 31, 2022, the Company did not consider any preferred equity investments to be impaired, and no preferred equity investments were on nonaccrual status.
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.23.3
DEBT
 9 Months Ended
Sep. 30, 2023
Debt Disclosure [Abstract]  
DEBT DEBT
Secured Indebtedness
The Company’s secured debt consists of the following (dollars in thousands):
As of September 30, 2023
Interest Rate Type
Principal Balance as of
September 30, 2023 (1)
Principal Balance as of
December 31, 2022 (1)
Weighted Average
Interest Rate
Weighted Average
Effective Interest Rate (2)
Maturity
Date
Fixed Rate$48,643 $50,123 2.85 %3.34 %May 2031 - 
August 2051
(1)     Principal balance does not include deferred financing costs, net of $0.9 million as of each of September 30, 2023 and December 31, 2022.
(2)     Weighted average effective interest rate includes private mortgage insurance.
Senior Unsecured Notes
The Company’s senior unsecured notes consist of the following (dollars in thousands):
Principal Balance as of
TitleMaturity Date
September 30, 2023 (1)
December 31, 2022 (1)
5.125% senior unsecured notes due 2026 (“2026 Notes”)
August 15, 2026$500,000 $500,000 
5.88% senior unsecured notes due 2027 (“2027 Notes”)
May 17, 2027100,000 100,000 
3.90% senior unsecured notes due 2029 (“2029 Notes”)
October 15, 2029350,000 350,000 
3.20% senior unsecured notes due 2031 (“2031 Notes”)
December 1, 2031800,000 800,000 
$1,750,000 $1,750,000 
(1)    Principal balance does not include discount, net of $4.1 million and deferred financing costs, net of $10.9 million as of September 30, 2023 and does not include discount, net of $3.5 million and deferred financing costs, net of $12.0 million as of December 31, 2022. In addition, the weighted average effective interest rate as of September 30, 2023 was 4.01%.
The 2026 Notes and the 2027 Notes were assumed as a result of the Company’s merger with Care Capital Properties, Inc. in 2017 and accrue interest at a rate of 5.125% and 5.88%, respectively, per annum. Interest is payable semiannually on February 15 and August 15 of each year for the 2026 Notes and on May 17 and November 17 of each year for the 2027 Notes.
The 2029 Notes were issued by the Operating Partnership and, until redemption of the Company’s previously outstanding 5.375% senior notes due 2023 in October 2019, Sabra Capital Corporation, wholly owned subsidiaries of the Company, and accrue interest at a rate of 3.90% per annum. Interest is payable semiannually on April 15 and October 15 of each year.
The 2031 Notes were issued by the Operating Partnership, a wholly owned subsidiary of the Company, and accrue interest at a rate of 3.20% per annum. Interest is payable semiannually on June 1 and December 1 of each year, commencing on June 1, 2022.
The obligations under the 2027 Notes are fully and unconditionally guaranteed, jointly and severally, on an unsecured basis, by Sabra and one of its non-operating subsidiaries, subject to release under certain customary circumstances. The obligations under the 2026 Notes, 2029 Notes and 2031 Notes are fully and unconditionally guaranteed, on an unsecured basis, by Sabra; provided, however, that such guarantee is subject to release under certain customary circumstances.
The indentures and agreements (the “Senior Notes Indentures”) governing the 2026 Notes, 2027 Notes, 2029 Notes and 2031 Notes (collectively, the “Senior Notes”) include customary events of default and require the Company to comply with specified restrictive covenants. As of September 30, 2023, the Company was in compliance with all applicable financial covenants under the Senior Notes Indentures.
Credit Agreement
On September 9, 2019, the Operating Partnership and Sabra Canadian Holdings, LLC (together, the “Borrowers”), Sabra and the other parties thereto entered into a fifth amended and restated unsecured credit agreement (the “Prior Credit Agreement”).
The Prior Credit Agreement included a $1.0 billion revolving credit facility (the “Prior Revolving Credit Facility”), a $436.3 million U.S. dollar term loan and a CAD $125.0 million Canadian dollar term loan (collectively, the “Prior Term Loans”). Further, up to $175.0 million of the Prior Revolving Credit Facility could be used for borrowings in certain foreign currencies. The Prior Credit Agreement also contained an accordion feature that allowed for an increase in the total available borrowings to $2.75 billion, subject to terms and conditions.
During the three and nine months ended September 30, 2022, the Company recognized $0.1 million and $0.4 million, respectively, of loss on extinguishment of debt related to write-offs of deferred financing costs in connection with the partial pay downs of the U.S. dollar Prior Term Loan.
Borrowings under the Prior Revolving Credit Facility bore interest on the outstanding principal amount at a rate equal to a ratings-based applicable interest margin plus, Canadian Dollar Offered Rate (“CDOR”) for Canadian dollar borrowings, or at the Operating Partnership’s option for U.S. dollar borrowings, either (a) LIBOR or (b) a base rate determined as the greater of (i) the federal funds rate plus 0.5%, (ii) the prime rate, and (iii) one-month LIBOR plus 1.0% (the “Prior Base Rate”). The ratings-based applicable interest margin for borrowings varied based on the Debt Ratings, as defined in the Prior Credit Agreement, and ranged from 0.775% to 1.45% per annum for CDOR or LIBOR based borrowings and 0.00% to 0.45% per annum for borrowings at the Prior Base Rate. In addition, the Operating Partnership paid a facility fee ranging between 0.125% and 0.300% per annum based on the aggregate amount of commitments under the Prior Revolving Credit Facility regardless of amounts outstanding thereunder.
The U.S. dollar Prior Term Loan bore interest on the outstanding principal amount at a rate equal to a ratings-based applicable interest margin plus, at the Operating Partnership’s option, either (a) LIBOR or (b) the Prior Base Rate. The ratings-based applicable interest margin for borrowings varied based on the Debt Ratings and ranged from 0.85% to 1.65% per annum for LIBOR based borrowings and 0.00% to 0.65% per annum for borrowings at the Prior Base Rate. The Canadian dollar Prior Term Loan bore interest on the outstanding principal amount at a rate equal to CDOR plus an interest margin that ranged from 0.85% to 1.65% depending on the Debt Ratings.
On January 4, 2023, the Borrowers, and the other parties thereto entered into a sixth amended and restated unsecured credit agreement (the “Credit Agreement”). During the nine months ended September 30, 2023, the Company recorded $18.1 million of deferred financing costs related to the Credit Agreement and recognized $1.5 million of loss on extinguishment of debt related to write-offs of deferred financing costs in connection with amending and restating the Prior Credit Agreement. No loss on extinguishment of debt was recognized during the three months ended September 30, 2023.
The Credit Agreement includes a $1.0 billion revolving credit facility (the “Revolving Credit Facility”), a $430.0 million U.S. dollar term loan and a CAD $150.0 million Canadian dollar term loan (collectively, the “Term Loans”). Further, up to $350.0 million of the Revolving Credit Facility may be used for borrowings in certain foreign currencies. The Credit
Agreement also contains an accordion feature that can increase the total available borrowings to $2.75 billion, subject to terms and conditions.
The Revolving Credit Facility has a maturity date of January 4, 2027, and includes two six-month extension options. The Term Loans have a maturity date of January 4, 2028.
As of September 30, 2023, there was $32.6 million (CAD $44.3 million) outstanding under the Revolving Credit Facility and $967.4 million available for borrowing.
Borrowings under the Revolving Credit Facility bear interest on the outstanding principal amount at a rate equal to a ratings-based applicable interest margin plus, CDOR for Canadian dollar borrowings, or at the Operating Partnership’s option for U.S. dollar borrowings, either (a) Daily Simple SOFR, as defined in the Credit Agreement, or (b) a base rate determined as the greater of (i) the federal funds rate plus 0.5%, (ii) the prime rate, (iii) Term SOFR, as defined in the Credit Agreement, plus 1.0% (the “Base Rate”), and (iv) 1.00%. The ratings-based applicable interest margin for borrowings will vary based on the Debt Ratings, as defined in the Credit Agreement, and will range from 0.775% to 1.450% per annum for Daily Simple SOFR-based borrowings and 0.00% to 0.450% per annum for borrowings at the Base Rate. As of September 30, 2023, the weighted average interest rate on the Revolving Credit Facility was 6.49%. In addition, the Operating Partnership pays a facility fee ranging between 0.125% and 0.300% per annum based on the aggregate amount of commitments under the Revolving Credit Facility regardless of amounts outstanding thereunder.
The U.S. dollar Term Loan bears interest on the outstanding principal amount at a ratings-based applicable interest margin plus, at the Operating Partnership’s option, either (a) Term SOFR or (b) the Base Rate. The ratings-based applicable interest margin for borrowings will vary based on the Debt Ratings and will range from 0.850% to 1.650% per annum for Term SOFR-based borrowings and 0.00% to 0.650% per annum for borrowings at the Base Rate. As of September 30, 2023, the interest rate on the U.S. dollar Term Loan was 6.66%. The Canadian dollar Term Loan bears interest on the outstanding principal amount at a rate equal CDOR plus an interest margin that will range from 0.850% to 1.650% depending on the Debt Ratings. As of September 30, 2023, the interest rate on the Canadian dollar Term Loan was 6.64%.
The Company has interest rate swaps and interest rate collars that fix and set a cap and floor, respectively, for the SOFR portion of the interest rate for $430.0 million of SOFR-based borrowings under its U.S. dollar Term Loan at a weighted average rate of 2.69% and interest rate swaps that fix the CDOR portion of the interest rate for CAD $150.0 million of CDOR-based borrowings under its Canadian dollar Term Loan at a rate of 1.63%. As of September 30, 2023, the effective interest rate on the U.S. dollar and Canadian dollar Term Loans was 3.94% and 2.88%, respectively. In addition, the Canadian dollar Term Loan and the CAD $44.3 million outstanding as of September 30, 2023 under the Revolving Credit Facility are designated as net investment hedges. See Note 8, “Derivative and Hedging Instruments,” for further information.
The obligations of the Borrowers under the Credit Agreement are guaranteed by the Company and certain of its subsidiaries.
The Credit Agreement contains customary covenants that include restrictions or limitations on the ability to pay dividends, incur additional indebtedness, engage in non-healthcare related business activities, enter into transactions with affiliates and sell or otherwise transfer certain assets as well as customary events of default. The Credit Agreement also requires Sabra, through the Operating Partnership, to comply with specified financial covenants, which include a maximum total leverage ratio, a maximum secured debt leverage ratio, a minimum fixed charge coverage ratio, a maximum unsecured leverage ratio, a minimum tangible net worth requirement and a minimum unsecured interest coverage ratio. As of September 30, 2023, the Company was in compliance with all applicable financial covenants under the Credit Agreement.
Interest Expense
The Company incurred interest expense of $28.2 million and $85.0 million during the three and nine months ended September 30, 2023, respectively, and $27.1 million and $77.6 million during the three and nine months ended September 30, 2022, respectively. Interest expense includes non-cash interest expense of $3.1 million and $9.2 million for the three and nine months ended September 30, 2023, respectively, and $2.8 million and $8.3 million for the three and nine months ended September 30, 2022, respectively. As of September 30, 2023 and December 31, 2022, the Company had $21.1 million and $18.2 million, respectively, of accrued interest included in accounts payable and accrued liabilities on the accompanying consolidated balance sheets.
Maturities
The following is a schedule of maturities for the Company’s outstanding debt as of September 30, 2023 (in thousands): 
Secured
Indebtedness
Revolving Credit
    Facility (1)
Term LoansSenior NotesTotal
October 1 through December 31, 2023$499 $— $— $— $499 
20242,034 — — — 2,034 
20252,089 — — — 2,089 
20262,147 — — 500,000 502,147 
20272,206 32,623 — 100,000 134,829 
Thereafter39,668 — 540,460 1,150,000 1,730,128 
Total Debt48,643 32,623 540,460 1,750,000 2,371,726 
Discount, net— — — (4,075)(4,075)
Deferred financing costs, net(854)— (6,449)(10,870)(18,173)
Total Debt, Net$47,789 $32,623 $534,011 $1,735,055 $2,349,478 
(1)    Revolving Credit Facility is subject to two six-month extension options.
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.23.3
DERIVATIVE AND HEDGING INSTRUMENTS
 9 Months Ended
Sep. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
DERIVATIVE AND HEDGING INSTRUMENTS DERIVATIVE AND HEDGING INSTRUMENTS
The Company is exposed to various market risks, including the potential loss arising from adverse changes in interest rates and foreign exchange rates. The Company enters into derivative financial instruments to manage exposures that arise from business activities that result in the receipt or payment of future known and uncertain cash amounts, the value of which are determined by interest rates and foreign exchange rates. The Company’s derivative financial instruments are used to manage differences in the amount of the Company’s known or expected cash receipts and its known or expected cash payments principally related to the Company’s investments and borrowings.
Certain of the Company’s foreign operations expose the Company to fluctuations of foreign interest rates and exchange rates. These fluctuations may impact the value in the Company’s functional currency, the U.S. dollar, of the Company’s investment in foreign operations, the cash receipts and payments related to these foreign operations and payments of interest and principal under Canadian dollar denominated debt. The Company enters into derivative financial instruments to protect the value of its foreign investments and fix a portion of the interest payments for certain debt obligations. The Company does not enter into derivatives for speculative purposes.
Cash Flow Hedges
The Company’s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish these objectives, the Company primarily uses interest rate swaps and collars as part of its interest rate risk management strategy. As of September 30, 2023, approximately $9.6 million of gains, which are included in accumulated other comprehensive income, are expected to be reclassified into earnings in the next 12 months.
Net Investment Hedges
The Company is exposed to fluctuations in foreign exchange rates on investments it holds in Canada. The Company uses cross currency interest rate swaps to hedge its exposure to changes in foreign exchange rates on these foreign investments.
The following presents the notional amount of derivative instruments as of the dates indicated (in thousands):
September 30, 2023December 31, 2022
Derivatives designated as cash flow hedges:
Denominated in U.S. Dollars (1)
$753,750 $436,250 
Denominated in Canadian Dollars (2)
$300,000 $125,000 
Derivatives designated as net investment hedges:
Denominated in Canadian Dollars$56,300 $55,991 
Financial instruments designated as net investment hedges:
Denominated in Canadian Dollars$194,300 $329,500 
Derivatives not designated as net investment hedges:
Denominated in Canadian Dollars$— $309 
(1) Balance as of September 30, 2023 includes two forward starting interest rate swaps with an effective date of August 2024 and an aggregate notional amount of $323.8 million.
(2)    Balance as of September 30, 2023 includes two forward starting interest rate swaps with an effective date of September 2024 and an aggregate notional amount of CAD $150.0 million.
Derivative and Financial Instruments Designated as Hedging Instruments
The following is a summary of the derivative and financial instruments designated as hedging instruments held by the Company at September 30, 2023 and December 31, 2022 (dollars in thousands):    
Count as of September 30, 2023
Fair Value as ofMaturity Dates
TypeDesignationSeptember 30, 2023December 31, 2022Balance Sheet Location
Assets:
Interest rate swapsCash flow5 $11,986 $11,004 2024 - 2028Accounts receivable, prepaid expenses and other assets, net
Interest rate collarsCash flow2 5,133 6,622 2024Accounts receivable, prepaid expenses and other assets, net
Forward starting interest rate swapsCash flow4 18,164 — 2028Accounts receivable, prepaid expenses and other assets, net
Cross currency interest rate swapsNet investment2 4,048 3,851 2025Accounts receivable, prepaid expenses and other assets, net
$39,331 $21,477 
Liabilities:
CAD borrowings under Revolving Credit FacilityNet investment1 32,623 150,982 2027Revolving credit facility
CAD Term LoanNet investment1 110,460 92,288 2028Term loans, net
$143,083 $243,270 
The following presents the effect of the Company’s derivative and financial instruments designated as hedging instruments on the consolidated statements of (loss) income and the consolidated statements of equity for the three and nine months ended September 30, 2023 and 2022 (in thousands):
Gain (Loss) Recognized in Other Comprehensive Income
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Cash Flow Hedges:
Interest rate products$11,373 $6,817 $28,462 $20,146 
Net Investment Hedges:
Foreign currency products1,140 2,253 349 2,840 
CAD borrowings under Revolving Credit Facility42 8,790 (2,650)11,157 
CAD term loan2,760 5,988 265 7,463 
$15,315 $23,848 $26,426 $41,606 
Gain (Loss) Reclassified from Accumulated Other Comprehensive Income into Income
Three Months Ended September 30,Nine Months Ended September 30,
Income Statement Location2023202220232022
Cash Flow Hedges:
Interest rate productsInterest expense$2,369 $(602)$5,848 $(5,264)
During the three and nine months ended September 30, 2023 and 2022, no cash flow hedges were determined to be ineffective.
Derivatives Not Designated as Hedging Instruments
As of September 30, 2023, the Company’s derivatives were all designated as hedging instruments. During the nine months ended September 30, 2022, the Company recorded $0.1 million of other expense related to the portion of derivatives not designated as hedging instruments and no such expense was recorded during each of the three months ended September 30, 2022 and the three and nine months ended September 30, 2023.
Offsetting Derivatives
The Company enters into master netting arrangements, which reduce credit risk by permitting net settlement of transactions with the same counterparty. The table below presents a gross presentation, the effects of offsetting, and a net presentation of the Company’s derivatives as of September 30, 2023 and December 31, 2022 (in thousands):
As of September 30, 2023
Gross Amounts of Recognized Assets / LiabilitiesGross Amounts Offset in the Balance SheetNet Amounts of Assets / Liabilities presented in the Balance SheetGross Amounts Not Offset in the Balance Sheet
Financial InstrumentsCash Collateral ReceivedNet Amount
Offsetting Assets:
Derivatives$39,331 $— $39,331 $— $— $39,331 
Offsetting Liabilities:
Derivatives$— $— $— $— $— $— 
As of December 31, 2022
Gross Amounts of Recognized Assets / LiabilitiesGross Amounts Offset in the Balance SheetNet Amounts of Assets / Liabilities presented in the Balance SheetGross Amounts Not Offset in the Balance Sheet
Financial InstrumentsCash Collateral ReceivedNet Amount
Offsetting Assets:
Derivatives$21,477 $— $21,477 $— $— $21,477 
Offsetting Liabilities:
Derivatives$— $— $— $— $— $— 
Credit Risk-related Contingent Features
The Company has agreements with each of its derivative counterparties that contain a provision pursuant to which the Company could be declared in default on the derivative obligation if the Company defaults on any of its indebtedness, including a default where repayment of the indebtedness has not been accelerated by the lender. As of September 30, 2023, the Company had no derivatives in a net liability position related to these agreements.
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.23.3
FAIR VALUE DISCLOSURES
 9 Months Ended
Sep. 30, 2023
Fair Value Disclosures [Abstract]  
FAIR VALUE DISCLOSURES FAIR VALUE DISCLOSURES
Under GAAP, the Company is required to measure certain financial instruments at fair value on a recurring basis. In addition, the Company is required to measure other financial instruments and balances at fair value on a non-recurring basis (e.g., carrying value of impaired loans receivable and long-lived assets). Fair value is defined as the price that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The GAAP fair value framework uses a three-tiered approach. Fair value measurements are classified and disclosed in one of the following three categories:
•Level 1: unadjusted quoted prices in active markets that are accessible at the measurement date for identical assets or liabilities;
•Level 2: quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-derived valuations in which significant inputs and significant value drivers are observable in active markets; and
•Level 3: prices or valuation techniques where little or no market data is available that requires inputs that are both significant to the fair value measurement and unobservable.
Financial Instruments
The fair value for certain financial instruments is derived using a combination of market quotes, pricing models and other valuation techniques that involve significant management judgment. The price transparency of financial instruments is a key determinant of the degree of judgment involved in determining the fair value of the Company’s financial instruments.
Financial instruments for which actively quoted prices or pricing parameters are available and whose markets contain orderly transactions will generally have a higher degree of price transparency than financial instruments whose markets are inactive or consist of non-orderly trades. The Company evaluates several factors when determining if a market is inactive or when market transactions are not orderly. The carrying values of cash and cash equivalents, restricted cash, accounts payable, accrued liabilities and the Credit Agreement are reasonable estimates of fair value because of the short-term maturities of these instruments. Fair values for other financial instruments are derived as follows:
Loans receivable: These instruments are presented on the accompanying consolidated balance sheets at their amortized cost and not at fair value. The fair values of the loans receivable were estimated using an internal valuation model that considered the expected cash flows for the loans receivable, as well as the underlying collateral value and other credit enhancements as applicable. The Company utilized discount rates ranging from 8% to 15% with a weighted average rate of 8% in its fair value calculation. As such, the Company classifies these instruments as Level 3.
Preferred equity investments: These instruments are presented on the accompanying consolidated balance sheets at their cost and not at fair value. The fair values of the preferred equity investments were estimated using an internal valuation model that considered the expected future cash flows for the preferred equity investments, the underlying collateral value and other credit enhancements. The Company utilized discount rates ranging from 10% to 15% with a weighted average rate of 11% in its fair value calculation. As such, the Company classifies these instruments as Level 3.
Derivative instruments: The Company’s derivative instruments are presented at fair value on the accompanying consolidated balance sheets. The Company estimates the fair value of derivative instruments, including its interest rate swaps, interest rate collars and cross currency swaps, using the assistance of a third party using inputs that are observable in the market, which include forward yield curves and other relevant information. Although the Company has determined that the majority of the inputs used to value its derivative financial instruments fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with its derivative financial instruments utilize Level 3 inputs, such as estimates of current credit spreads, to evaluate the likelihood of default by itself and its counterparties. The Company has assessed the significance of the impact of the credit valuation adjustments on the overall valuation of its derivative positions and has determined that the credit valuation adjustments are not significant to the overall valuation of its derivative financial instruments. As a result, the Company has determined that its derivative financial instruments valuations in their entirety are classified in Level 2 of the fair value hierarchy.
Senior Notes: These instruments are presented on the accompanying consolidated balance sheets at their outstanding principal balance, net of unamortized deferred financing costs and premiums/discounts and not at fair value. The fair values of the Senior Notes were determined using third-party market quotes derived from orderly trades. As such, the Company classifies these instruments as Level 2.
Secured indebtedness: These instruments are presented on the accompanying consolidated balance sheets at their outstanding principal balance, net of unamortized deferred financing costs and premiums/discounts and not at fair value. The fair values of the Company’s secured debt were estimated using a discounted cash flow analysis based on management’s estimates of current market interest rates for instruments with similar characteristics, including remaining loan term, loan-to-value ratio, type of collateral and other credit enhancements. The Company utilized a rate of 7% in its fair value calculation. As such, the Company classifies these instruments as Level 3.
The following are the face values, carrying amounts and fair values of the Company’s financial instruments as of September 30, 2023 and December 31, 2022 whose carrying amounts do not approximate their fair value (in thousands):
 As of September 30, 2023As of December 31, 2022
 
Face
Value (1)
Carrying
Amount (2)
Fair
Value
Face
Value (1)
Carrying
Amount (2)
Fair
Value
Financial assets:
Loans receivable$371,133 $361,026 $368,437 $370,364 $360,325 $370,188 
Preferred equity investments56,760 56,921 58,697 50,902 51,071 51,995 
Financial liabilities:
Senior Notes1,750,000 1,735,055 1,468,812 1,750,000 1,734,431 1,463,041 
Secured indebtedness48,643 47,789 34,164 50,123 49,232 38,149 
(1)    Face value represents amounts contractually due under the terms of the respective agreements.
(2)    Carrying amount represents the book value of financial instruments, including unamortized premiums/discounts and deferred financing costs.
The Company determined the fair value of financial instruments as of September 30, 2023 whose carrying amounts do not approximate their fair value with valuation methods utilizing the following types of inputs (in thousands):
Fair Value Measurements Using
TotalQuoted Prices in
Active Markets for
Identical Assets
(Level 1)		Significant Other
Observable Inputs
(Level 2)		Significant
Unobservable Inputs
(Level 3)
Financial assets:
Loans receivable$368,437 $— $— $368,437 
Preferred equity investments58,697 — — 58,697 
Financial liabilities:
Senior Notes1,468,812 — 1,468,812 — 
Secured indebtedness34,164 — — 34,164 
Disclosure of the fair value of financial instruments is based on pertinent information available to the Company at the applicable dates and requires a significant amount of judgment. Transaction volume for certain of the Company’s financial instruments remains relatively low, which has made the estimation of fair values difficult. Therefore, both the actual results and the Company’s estimate of fair value at a future date could be materially different.
Items Measured at Fair Value on a Recurring Basis
During the nine months ended September 30, 2023, the Company recorded the following amounts measured at fair value (in thousands):
Fair Value Measurements Using
TotalQuoted Prices in
Active Markets for
Identical Assets
(Level 1)		Significant Other
Observable Inputs
(Level 2)		Significant
Unobservable Inputs
(Level 3)
Recurring Basis:
Financial assets:
Interest rate swaps$11,986 $— $11,986 $— 
Interest rate collars5,133 — 5,133 — 
Forward starting interest rate swaps18,164 — 18,164 — 
Cross currency interest rate swaps4,048 — 4,048 — 
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.23.3
EQUITY
 9 Months Ended
Sep. 30, 2023
Equity [Abstract]  
EQUITY EQUITY
Common Stock
On February 23, 2023, the Company established an at-the-market equity offering program (the “ATM Program”) pursuant to which shares of its common stock having an aggregate gross sales price of up to $500.0 million may be sold from time to time (i) by the Company through a consortium of banks acting as sales agents or directly to the banks acting as principals or (ii) by a consortium of banks acting as forward sellers on behalf of any forward purchasers pursuant to a forward sale agreement. The use of a forward sale agreement would allow the Company to lock in a share price on the sale of shares at the time the agreement is effective, but defer receiving the proceeds from the sale of the shares until a later date. The Company may also elect to cash settle or net share settle all or a portion of its obligations under any forward sale agreement. The forward sale agreements have a one year term during which time the Company may settle the forward sales by delivery of physical shares of common stock to the forward purchasers or, at the Company’s election, in cash or net shares. The forward sale price that the Company expects to receive upon settlement will be the initial forward price established upon the effective date, subject to adjustments for (i) the forward purchasers’ stock borrowing costs and (ii) certain fixed price reductions during the term of the agreement.
During the three and nine months ended September 30, 2023, no shares were sold under the ATM Program and the Company did not utilize the forward feature of the ATM Program. As of September 30, 2023, the Company had $500.0 million available under the ATM Program.
The following table lists the cash dividends on common stock declared and paid by the Company during the nine months ended September 30, 2023:
Declaration Date Record Date Amount Per Share Dividend Payable Date
February 1, 2023 February 13, 2023 $0.30  February 28, 2023
May 3, 2023May 16, 2023$0.30 May 31, 2023
August 7, 2023August 17, 2023$0.30 August 31, 2023
During the nine months ended September 30, 2023, the Company issued 0.2 million shares of common stock as a result of restricted stock unit vestings.
Upon any payment of shares to team members as a result of restricted stock unit vestings, the team members’ related tax withholding obligation will generally be satisfied by the Company reducing the number of shares to be delivered by a number of shares necessary to satisfy the related applicable tax withholding obligation. During the nine months ended September 30, 2023 and 2022, the Company incurred $1.4 million and $3.3 million, respectively, in tax withholding obligations on behalf of its team members that were satisfied through a reduction in the number of shares delivered to those participants.
Accumulated Other Comprehensive Income
The following is a summary of the Company’s accumulated other comprehensive income (in thousands):
September 30, 2023December 31, 2022
Foreign currency translation (loss) gain$(780)$1,168 
Unrealized gain on cash flow hedges40,449 17,895 
Total accumulated other comprehensive income$39,669 $19,063 
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.23.3
EARNINGS PER COMMON SHARE
 9 Months Ended
Sep. 30, 2023
Earnings Per Share [Abstract]  
EARNINGS PER COMMON SHARE EARNINGS PER COMMON SHARE
The following table illustrates the computation of basic and diluted earnings per share for the three and nine months ended September 30, 2023 and 2022 (in thousands, except share and per share amounts):
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Numerator
Net (loss) income$(15,101)$(50,064)$(3,400)$7,343 
Denominator
Basic weighted average common shares and common equivalents231,224,692 230,982,227 231,197,375 230,936,032 
Dilutive restricted stock units— — — 843,718 
Diluted weighted average common shares231,224,692 230,982,227 231,197,375 231,779,750 
Net (loss) income, per:
Basic common share$(0.07)$(0.22)$(0.01)$0.03 
Diluted common share$(0.07)$(0.22)$(0.01)$0.03 
During the three and nine months ended September 30, 2023, approximately 1.6 million and 1.4 million restricted stock units, respectively, were not included in computing diluted earnings per share because they were considered anti-dilutive. During the three and nine months ended September 30, 2022, approximately 1.0 million and 10,500 restricted stock units, respectively, were not included in computing diluted earnings per share because they were considered anti-dilutive.
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.23.3
COMMITMENTS AND CONTINGENCIES
 9 Months Ended
Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES
Environmental
As an owner of real estate, the Company is subject to various environmental laws of federal, state and local governments. The Company is not aware of any environmental liability that could have a material adverse effect on its financial condition or results of operations. However, changes in applicable environmental laws and regulations, the uses and conditions of properties in the vicinity of the Company’s properties, the activities of its tenants and other environmental conditions of which the Company is unaware with respect to the properties could result in future environmental liabilities. As of September 30, 2023, the Company does not expect that compliance with existing environmental laws will have a material adverse effect on the Company’s financial condition and results of operations.
Legal Matters
From time to time, the Company and its subsidiaries are party to legal proceedings that arise in the ordinary course of its business. Management is not aware of any legal proceedings where the likelihood of a loss contingency is reasonably possible and the amount or range of reasonably possible losses is material to the Company’s results of operations, financial condition or cash flows.
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.23.3
SUBSEQUENT EVENTS
 9 Months Ended
Sep. 30, 2023
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS SUBSEQUENT EVENTS
The Company evaluates subsequent events up until the date the consolidated financial statements are issued.
Dividend Declaration
On November 6, 2023, the Company’s board of directors declared a quarterly cash dividend of $0.30 per share of common stock. The dividend will be paid on November 30, 2023 to common stockholders of record as of the close of business on November 17, 2023.
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.23.3
Pay vs Performance Disclosure - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Pay vs Performance Disclosure        
Net (loss) income $ (15,101) $ (50,064) $ (3,400) $ 7,343
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.23.3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
 9 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
Principles of Consolidation The accompanying consolidated financial statements include the accounts of Sabra and its wholly owned subsidiaries as of September 30, 2023 and December 31, 2022 and for the three and nine month periods ended September 30, 2023 and 2022. All significant intercompany transactions and balances have been eliminated in consolidation.
Basis of Presentation The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information as contained within the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification and the rules and regulations of the SEC, including the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the unaudited consolidated financial statements do not include all of the information and footnotes required by GAAP for financial statements. In the opinion of management, the financial statements for the unaudited interim periods presented include all adjustments, which are of a normal and recurring nature, necessary for a fair statement of the results for such periods. Operating results for the three and nine months ended September 30, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023. For further information, refer to the Company’s consolidated financial statements and notes thereto for the year ended December 31, 2022 included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC.
Variable Interest Entities GAAP requires the Company to identify entities for which control is achieved through voting rights or other means and to determine which business enterprise is the primary beneficiary of variable interest entities (“VIEs”). A VIE is broadly defined as an entity with one or more of the following characteristics: (a) the total equity investment at risk is insufficient to finance the entity’s activities without additional subordinated financial support; (b) as a group, the holders of the equity investment at risk lack (i) the ability to make decisions about the entity’s activities through voting or similar rights, (ii) the obligation to absorb the expected losses of the entity, or (iii) the right to receive the expected residual returns of the entity; or (c) the equity investors have voting rights that are not proportional to their economic interests, and substantially all of the entity’s activities either involve, or are conducted on behalf of, an investor that has disproportionately few voting rights. If the Company were determined to be the primary beneficiary of the VIE, the Company would consolidate investments in the VIE. The Company may change its original assessment of a VIE due to events such as modifications of contractual arrangements that affect the characteristics or adequacy of the entity’s equity investments at risk and the disposal of all or a portion of an interest held by the primary beneficiary.
The Company identifies the primary beneficiary of a VIE as the enterprise that has both: (i) the power to direct the activities of the VIE that most significantly impact the entity’s economic performance; and (ii) the obligation to absorb losses or the right to receive benefits of the VIE that could be significant to the entity. The Company performs this analysis on an ongoing basis. As of September 30, 2023, the Company determined that it was not the primary beneficiary of any VIEs.
As it relates to investments in loans, in addition to the Company’s assessment of VIEs and whether the Company is the primary beneficiary of those VIEs, the Company evaluates the loan terms and other pertinent facts to determine whether the loan investment should be accounted for as a loan or as a real estate joint venture. If an investment has the characteristics of a real estate joint venture, including if the Company participates in the majority of the borrower’s expected residual profit, the Company would account for the investment as an investment in a real estate joint venture and not as a loan investment. Expected residual profit is defined as the amount of profit, whether called interest or another name, such as an equity kicker, above a reasonable amount of interest and fees expected to be earned by a lender. At September 30, 2023, none of the Company’s investments in loans were accounted for as real estate joint ventures.
As it relates to investments in joint ventures, the Company assesses any partners’ rights and their impact on the presumption of control of the partnership by any single partner. The Company also applies this guidance to managing member interests in limited liability companies. The Company reassesses its determination of which entity controls the joint venture if: there is a change to the terms or in the exercisability of the rights of any partners or members, the general partner or managing member increases or decreases its ownership interests, or there is an increase or decrease in the number of outstanding ownership interests.
Use of Estimates The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates.
Fair Value of Financial Instruments
Under GAAP, the Company is required to measure certain financial instruments at fair value on a recurring basis. In addition, the Company is required to measure other financial instruments and balances at fair value on a non-recurring basis (e.g., carrying value of impaired loans receivable and long-lived assets). Fair value is defined as the price that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The GAAP fair value framework uses a three-tiered approach. Fair value measurements are classified and disclosed in one of the following three categories:
•Level 1: unadjusted quoted prices in active markets that are accessible at the measurement date for identical assets or liabilities;
•Level 2: quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-derived valuations in which significant inputs and significant value drivers are observable in active markets; and
•Level 3: prices or valuation techniques where little or no market data is available that requires inputs that are both significant to the fair value measurement and unobservable.
Financial Instruments
The fair value for certain financial instruments is derived using a combination of market quotes, pricing models and other valuation techniques that involve significant management judgment. The price transparency of financial instruments is a key determinant of the degree of judgment involved in determining the fair value of the Company’s financial instruments.
Financial instruments for which actively quoted prices or pricing parameters are available and whose markets contain orderly transactions will generally have a higher degree of price transparency than financial instruments whose markets are inactive or consist of non-orderly trades. The Company evaluates several factors when determining if a market is inactive or when market transactions are not orderly. The carrying values of cash and cash equivalents, restricted cash, accounts payable, accrued liabilities and the Credit Agreement are reasonable estimates of fair value because of the short-term maturities of these instruments. Fair values for other financial instruments are derived as follows:
Loans receivable: These instruments are presented on the accompanying consolidated balance sheets at their amortized cost and not at fair value. The fair values of the loans receivable were estimated using an internal valuation model that considered the expected cash flows for the loans receivable, as well as the underlying collateral value and other credit enhancements as applicable. The Company utilized discount rates ranging from 8% to 15% with a weighted average rate of 8% in its fair value calculation. As such, the Company classifies these instruments as Level 3.
Preferred equity investments: These instruments are presented on the accompanying consolidated balance sheets at their cost and not at fair value. The fair values of the preferred equity investments were estimated using an internal valuation model that considered the expected future cash flows for the preferred equity investments, the underlying collateral value and other credit enhancements. The Company utilized discount rates ranging from 10% to 15% with a weighted average rate of 11% in its fair value calculation. As such, the Company classifies these instruments as Level 3.
Derivative instruments: The Company’s derivative instruments are presented at fair value on the accompanying consolidated balance sheets. The Company estimates the fair value of derivative instruments, including its interest rate swaps, interest rate collars and cross currency swaps, using the assistance of a third party using inputs that are observable in the market, which include forward yield curves and other relevant information. Although the Company has determined that the majority of the inputs used to value its derivative financial instruments fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with its derivative financial instruments utilize Level 3 inputs, such as estimates of current credit spreads, to evaluate the likelihood of default by itself and its counterparties. The Company has assessed the significance of the impact of the credit valuation adjustments on the overall valuation of its derivative positions and has determined that the credit valuation adjustments are not significant to the overall valuation of its derivative financial instruments. As a result, the Company has determined that its derivative financial instruments valuations in their entirety are classified in Level 2 of the fair value hierarchy.
Senior Notes: These instruments are presented on the accompanying consolidated balance sheets at their outstanding principal balance, net of unamortized deferred financing costs and premiums/discounts and not at fair value. The fair values of the Senior Notes were determined using third-party market quotes derived from orderly trades. As such, the Company classifies these instruments as Level 2.
Secured indebtedness: These instruments are presented on the accompanying consolidated balance sheets at their outstanding principal balance, net of unamortized deferred financing costs and premiums/discounts and not at fair value. The fair values of the Company’s secured debt were estimated using a discounted cash flow analysis based on management’s estimates of current market interest rates for instruments with similar characteristics, including remaining loan term, loan-to-value ratio, type of collateral and other credit enhancements. The Company utilized a rate of 7% in its fair value calculation. As such, the Company classifies these instruments as Level 3.
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.23.3
RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED) (Tables)
 9 Months Ended
Sep. 30, 2023
Business Combination and Asset Acquisition [Abstract]  
Schedule of Purchase Price Allocation The consideration was allocated as follows (in thousands):
Nine Months Ended September 30,
20232022
Land$3,415 $10,292 
Building and improvements45,333 83,118 
Tenant origination and absorption costs intangible assets2,706 4,887 
Tenant relationship intangible assets20 — 
Total consideration$51,474 $98,297 
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.23.3
INVESTMENT IN REAL ESTATE PROPERTIES (Tables)
 9 Months Ended
Sep. 30, 2023
Real Estate [Abstract]  
Schedule of Real Estate Properties Held for Investment
The Company’s real estate properties held for investment consisted of the following (dollars in thousands):
As of September 30, 2023
Property TypeNumber of
Properties		Number of
Beds/Units		Total
Real Estate
at Cost		Accumulated
Depreciation		Total
Real Estate
Investments, Net
Skilled Nursing/Transitional Care240 26,623 $3,035,231 $(530,290)$2,504,941 
Senior Housing - Leased43 3,473 572,633 (106,063)466,570 
Senior Housing - Managed61 6,041 1,278,352 (250,772)1,027,580 
Behavioral Health18 1,077 492,236 (68,654)423,582 
Specialty Hospitals and Other15 392 225,443 (46,100)179,343 
377 37,606 5,603,895 (1,001,879)4,602,016 
Corporate Level1,603 (605)998 
$5,605,498 $(1,002,484)$4,603,014 
As of December 31, 2022
Property TypeNumber of
Properties		Number of
Beds/Units		Total
Real Estate
at Cost		Accumulated
Depreciation		Total
Real Estate
Investments, Net
Skilled Nursing/Transitional Care264 29,136 $3,385,221 $(492,495)$2,892,726 
Senior Housing - Leased47 3,550 590,694 (97,716)492,978 
Senior Housing - Managed59 5,942 1,205,283 (222,089)983,194 
Behavioral Health17 965 465,143 (58,481)406,662 
Specialty Hospitals and Other15 392 225,443 (42,038)183,405 
402 39,985 5,871,784 (912,819)4,958,965 
Corporate Level904 (526)378 
$5,872,688 $(913,345)$4,959,343 
September 30, 2023December 31, 2022
Building and improvements$4,815,199 $5,034,470 
Furniture and equipment234,882 262,644 
Land improvements10,241 7,085 
Land545,176 568,489 
Total real estate at cost5,605,498 5,872,688 
Accumulated depreciation(1,002,484)(913,345)
Total real estate investments, net$4,603,014 $4,959,343 
Schedule of Future Minimum Rental Payments from Non-Cancelable Operating Leases
As of September 30, 2023, the future minimum rental payments from the Company’s properties held for investment under non-cancelable operating leases were as follows and may materially differ from actual future rental payments received (in thousands):
October 1 through December 31, 2023$91,919 
2024371,661 
2025366,190 
2026350,583 
2027327,530 
Thereafter1,508,364 
$3,016,247 
Schedule of Investment in Joint Ventures
The following is a summary of the Company’s investment in unconsolidated joint ventures (dollars in thousands):
Property Type
Number of
Properties as of
September 30, 2023
Ownership as of
September 30, 2023 (1)
Book Value
September 30, 2023December 31, 2022
Sienna Joint VentureSenior Housing - Managed12 50 %$118,150 $120,269 
Marlin Spring Joint VentureSenior Housing - Managed4 85 %17,605 14,693 
$135,755 $134,962 
(1)    These investments are not consolidated because the Company does not control, through voting rights or other means, the joint ventures.
During the nine months ended September 30, 2022, the Enlivant Joint Venture was a significant equity method investee of the Company. The following table presents summarized financial information for the Enlivant Joint Venture and, except for basis adjustments and loss from unconsolidated joint venture, reflects the historical cost basis of the assets which pre-dated the Company’s investment in the Enlivant Joint Venture (in thousands):
Nine Months Ended September 30, 2022
Total revenues$237,144 
Operating expenses215,293 
Net loss(7,177)
Company’s share of net loss$(3,525)
Basis adjustments5,755 
Loss from unconsolidated joint venture$(9,280)
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.23.3
IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS (Tables)
 9 Months Ended
Sep. 30, 2023
Discontinued Operations and Disposal Groups [Abstract]  
Schedule of Dispositions
The following table summarizes the Company’s dispositions for the periods presented (dollars in millions):
Nine Months Ended September 30,
20232022
Number of facilities27 11 
Consideration, net of closing costs$256.2 $62.8 
Net carrying value332.1 67.4 
Net loss on sale$(75.9)$(4.6)
Net loss (1)
$(80.3)$(63.1)
(1)    In addition to net loss on sale, net loss includes impairment of real estate of $7.1 million and $65.8 million for the nine months ended September 30, 2023 and 2022, respectively.
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.23.3
LOANS RECEIVABLE AND OTHER INVESTMENTS (Tables)
 9 Months Ended
Sep. 30, 2023
Receivables [Abstract]  
Schedule of Loans Receivable and Other Investments
As of September 30, 2023 and December 31, 2022, the Company’s loans receivable and other investments consisted of the following (dollars in thousands):
As of September 30, 2023
Investment
Quantity
as of
September 30, 2023
Property Type
Principal Balance
as of
September 30, 2023 (1)
Book Value
as of
September 30, 2023
Book Value
as of December 31, 2022
Weighted Average Contractual Interest Rate / Rate of ReturnWeighted Average Annualized Effective Interest Rate / Rate of Return
Maturity Date
as of
September 30, 2023
Loans Receivable:
Mortgage2 Behavioral Health$319,000 $319,000 $319,000 7.6 %7.6 %11/01/26 - 01/31/27
Other10 Multiple52,133 48,703 47,936 7.5 %7.0 %08/31/23 - 05/01/29
12 371,133 367,703 366,936 7.6 %7.6 %
Allowance for loan losses— (6,677)(6,611)
$371,133 $361,026 $360,325 
Other Investments:
Preferred Equity5 Skilled Nursing / Senior Housing56,760 56,921 51,071 11.0 %11.0 %N/A
Total 17 $427,893 $417,947 $411,396 8.1 %8.0 %
(1)    Principal balance includes amounts funded and accrued but unpaid interest / preferred return and excludes capitalizable fees.
Schedule of Additional Information Regarding the Company's Loans Receivable
Additional information regarding the Company’s loans receivable is as follows (dollars in thousands):
Nine Months Ended September 30,
20232022
Allowance for loan losses:
Balance at beginning of the period$6,611 $6,344 
Provision for loan losses549 83 
Write-off of uncollectible balances(483)— 
Balance at end of the period$6,677 $6,427 
September 30, 2023December 31, 2022
Deteriorated credit quality:
Number of loans receivable investments1 1 
Principal balance$1,214 $1,214 
Book value— — 
Nonaccrual status:
Number of loans receivable investments3 3 
Book value$— $— 
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.23.3
DEBT (Tables)
 9 Months Ended
Sep. 30, 2023
Debt Disclosure [Abstract]  
Schedule of Debt
The Company’s secured debt consists of the following (dollars in thousands):
As of September 30, 2023
Interest Rate Type
Principal Balance as of
September 30, 2023 (1)
Principal Balance as of
December 31, 2022 (1)
Weighted Average
Interest Rate
Weighted Average
Effective Interest Rate (2)
Maturity
Date
Fixed Rate$48,643 $50,123 2.85 %3.34 %May 2031 - 
August 2051
(1)     Principal balance does not include deferred financing costs, net of $0.9 million as of each of September 30, 2023 and December 31, 2022.
(2)     Weighted average effective interest rate includes private mortgage insurance.
The Company’s senior unsecured notes consist of the following (dollars in thousands):
Principal Balance as of
TitleMaturity Date
September 30, 2023 (1)
December 31, 2022 (1)
5.125% senior unsecured notes due 2026 (“2026 Notes”)
August 15, 2026$500,000 $500,000 
5.88% senior unsecured notes due 2027 (“2027 Notes”)
May 17, 2027100,000 100,000 
3.90% senior unsecured notes due 2029 (“2029 Notes”)
October 15, 2029350,000 350,000 
3.20% senior unsecured notes due 2031 (“2031 Notes”)
December 1, 2031800,000 800,000 
$1,750,000 $1,750,000 
(1)    Principal balance does not include discount, net of $4.1 million and deferred financing costs, net of $10.9 million as of September 30, 2023 and does not include discount, net of $3.5 million and deferred financing costs, net of $12.0 million as of December 31, 2022. In addition, the weighted average effective interest rate as of September 30, 2023 was 4.01%.
Schedule of Maturities for Outstanding Debt
The following is a schedule of maturities for the Company’s outstanding debt as of September 30, 2023 (in thousands): 
Secured
Indebtedness
Revolving Credit
    Facility (1)
Term LoansSenior NotesTotal
October 1 through December 31, 2023$499 $— $— $— $499 
20242,034 — — — 2,034 
20252,089 — — — 2,089 
20262,147 — — 500,000 502,147 
20272,206 32,623 — 100,000 134,829 
Thereafter39,668 — 540,460 1,150,000 1,730,128 
Total Debt48,643 32,623 540,460 1,750,000 2,371,726 
Discount, net— — — (4,075)(4,075)
Deferred financing costs, net(854)— (6,449)(10,870)(18,173)
Total Debt, Net$47,789 $32,623 $534,011 $1,735,055 $2,349,478 
(1)    Revolving Credit Facility is subject to two six-month extension options.
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.23.3
DERIVATIVE AND HEDGING INSTRUMENTS (Tables)
 9 Months Ended
Sep. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Notional Amount of Derivatives Instruments
The following presents the notional amount of derivative instruments as of the dates indicated (in thousands):
September 30, 2023December 31, 2022
Derivatives designated as cash flow hedges:
Denominated in U.S. Dollars (1)
$753,750 $436,250 
Denominated in Canadian Dollars (2)
$300,000 $125,000 
Derivatives designated as net investment hedges:
Denominated in Canadian Dollars$56,300 $55,991 
Financial instruments designated as net investment hedges:
Denominated in Canadian Dollars$194,300 $329,500 
Derivatives not designated as net investment hedges:
Denominated in Canadian Dollars$— $309 
(1) Balance as of September 30, 2023 includes two forward starting interest rate swaps with an effective date of August 2024 and an aggregate notional amount of $323.8 million.
(2)    Balance as of September 30, 2023 includes two forward starting interest rate swaps with an effective date of September 2024 and an aggregate notional amount of CAD $150.0 million.
Schedule of Derivative and Financial Instruments Designated as Hedging Instruments
The following is a summary of the derivative and financial instruments designated as hedging instruments held by the Company at September 30, 2023 and December 31, 2022 (dollars in thousands):    
Count as of September 30, 2023
Fair Value as ofMaturity Dates
TypeDesignationSeptember 30, 2023December 31, 2022Balance Sheet Location
Assets:
Interest rate swapsCash flow5 $11,986 $11,004 2024 - 2028Accounts receivable, prepaid expenses and other assets, net
Interest rate collarsCash flow2 5,133 6,622 2024Accounts receivable, prepaid expenses and other assets, net
Forward starting interest rate swapsCash flow4 18,164 — 2028Accounts receivable, prepaid expenses and other assets, net
Cross currency interest rate swapsNet investment2 4,048 3,851 2025Accounts receivable, prepaid expenses and other assets, net
$39,331 $21,477 
Liabilities:
CAD borrowings under Revolving Credit FacilityNet investment1 32,623 150,982 2027Revolving credit facility
CAD Term LoanNet investment1 110,460 92,288 2028Term loans, net
$143,083 $243,270 
Effect of Derivative Financial Instruments on the Condensed Consolidated Statements of (Loss) Income and Condensed Consolidated Statements of Equity
The following presents the effect of the Company’s derivative and financial instruments designated as hedging instruments on the consolidated statements of (loss) income and the consolidated statements of equity for the three and nine months ended September 30, 2023 and 2022 (in thousands):
Gain (Loss) Recognized in Other Comprehensive Income
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Cash Flow Hedges:
Interest rate products$11,373 $6,817 $28,462 $20,146 
Net Investment Hedges:
Foreign currency products1,140 2,253 349 2,840 
CAD borrowings under Revolving Credit Facility42 8,790 (2,650)11,157 
CAD term loan2,760 5,988 265 7,463 
$15,315 $23,848 $26,426 $41,606 
Gain (Loss) Reclassified from Accumulated Other Comprehensive Income into Income
Three Months Ended September 30,Nine Months Ended September 30,
Income Statement Location2023202220232022
Cash Flow Hedges:
Interest rate productsInterest expense$2,369 $(602)$5,848 $(5,264)
Gross Presentation, Effects of Offsetting, and Net Presentation of Derivatives - Assets The table below presents a gross presentation, the effects of offsetting, and a net presentation of the Company’s derivatives as of September 30, 2023 and December 31, 2022 (in thousands):
As of September 30, 2023
Gross Amounts of Recognized Assets / LiabilitiesGross Amounts Offset in the Balance SheetNet Amounts of Assets / Liabilities presented in the Balance SheetGross Amounts Not Offset in the Balance Sheet
Financial InstrumentsCash Collateral ReceivedNet Amount
Offsetting Assets:
Derivatives$39,331 $— $39,331 $— $— $39,331 
Offsetting Liabilities:
Derivatives$— $— $— $— $— $— 
As of December 31, 2022
Gross Amounts of Recognized Assets / LiabilitiesGross Amounts Offset in the Balance SheetNet Amounts of Assets / Liabilities presented in the Balance SheetGross Amounts Not Offset in the Balance Sheet
Financial InstrumentsCash Collateral ReceivedNet Amount
Offsetting Assets:
Derivatives$21,477 $— $21,477 $— $— $21,477 
Offsetting Liabilities:
Derivatives$— $— $— $— $— $— 
Gross Presentation, Effects of Offsetting, and Net Presentation of Derivatives - Liabilities The table below presents a gross presentation, the effects of offsetting, and a net presentation of the Company’s derivatives as of September 30, 2023 and December 31, 2022 (in thousands):
As of September 30, 2023
Gross Amounts of Recognized Assets / LiabilitiesGross Amounts Offset in the Balance SheetNet Amounts of Assets / Liabilities presented in the Balance SheetGross Amounts Not Offset in the Balance Sheet
Financial InstrumentsCash Collateral ReceivedNet Amount
Offsetting Assets:
Derivatives$39,331 $— $39,331 $— $— $39,331 
Offsetting Liabilities:
Derivatives$— $— $— $— $— $— 
As of December 31, 2022
Gross Amounts of Recognized Assets / LiabilitiesGross Amounts Offset in the Balance SheetNet Amounts of Assets / Liabilities presented in the Balance SheetGross Amounts Not Offset in the Balance Sheet
Financial InstrumentsCash Collateral ReceivedNet Amount
Offsetting Assets:
Derivatives$21,477 $— $21,477 $— $— $21,477 
Offsetting Liabilities:
Derivatives$— $— $— $— $— $— 
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.23.3
FAIR VALUE DISCLOSURES (Tables)
 9 Months Ended
Sep. 30, 2023
Fair Value Disclosures [Abstract]  
Schedule of Face Values, Carrying Amounts and Fair Values of Financial Instruments
The following are the face values, carrying amounts and fair values of the Company’s financial instruments as of September 30, 2023 and December 31, 2022 whose carrying amounts do not approximate their fair value (in thousands):
 As of September 30, 2023As of December 31, 2022
 
Face
Value (1)
Carrying
Amount (2)
Fair
Value
Face
Value (1)
Carrying
Amount (2)
Fair
Value
Financial assets:
Loans receivable$371,133 $361,026 $368,437 $370,364 $360,325 $370,188 
Preferred equity investments56,760 56,921 58,697 50,902 51,071 51,995 
Financial liabilities:
Senior Notes1,750,000 1,735,055 1,468,812 1,750,000 1,734,431 1,463,041 
Secured indebtedness48,643 47,789 34,164 50,123 49,232 38,149 
(1)    Face value represents amounts contractually due under the terms of the respective agreements.
(2)    Carrying amount represents the book value of financial instruments, including unamortized premiums/discounts and deferred financing costs.
Schedule of Fair Value of Financial Instruments
The Company determined the fair value of financial instruments as of September 30, 2023 whose carrying amounts do not approximate their fair value with valuation methods utilizing the following types of inputs (in thousands):
Fair Value Measurements Using
TotalQuoted Prices in
Active Markets for
Identical Assets
(Level 1)		Significant Other
Observable Inputs
(Level 2)		Significant
Unobservable Inputs
(Level 3)
Financial assets:
Loans receivable$368,437 $— $— $368,437 
Preferred equity investments58,697 — — 58,697 
Financial liabilities:
Senior Notes1,468,812 — 1,468,812 — 
Secured indebtedness34,164 — — 34,164 
Schedule of Items Measured at Fair Value on a Recurring Basis
During the nine months ended September 30, 2023, the Company recorded the following amounts measured at fair value (in thousands):
Fair Value Measurements Using
TotalQuoted Prices in
Active Markets for
Identical Assets
(Level 1)		Significant Other
Observable Inputs
(Level 2)		Significant
Unobservable Inputs
(Level 3)
Recurring Basis:
Financial assets:
Interest rate swaps$11,986 $— $11,986 $— 
Interest rate collars5,133 — 5,133 — 
Forward starting interest rate swaps18,164 — 18,164 — 
Cross currency interest rate swaps4,048 — 4,048 — 
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.23.3
EQUITY (Tables)
 9 Months Ended
Sep. 30, 2023
Equity [Abstract]  
Schedule of Cash Dividends on Common Stock Declared and Paid
The following table lists the cash dividends on common stock declared and paid by the Company during the nine months ended September 30, 2023:
Declaration Date Record Date Amount Per Share Dividend Payable Date
February 1, 2023 February 13, 2023 $0.30  February 28, 2023
May 3, 2023May 16, 2023$0.30 May 31, 2023
August 7, 2023August 17, 2023$0.30 August 31, 2023
Schedule of Accumulated Other Comprehensive Income
The following is a summary of the Company’s accumulated other comprehensive income (in thousands):
September 30, 2023December 31, 2022
Foreign currency translation (loss) gain$(780)$1,168 
Unrealized gain on cash flow hedges40,449 17,895 
Total accumulated other comprehensive income$39,669 $19,063 
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.23.3
EARNINGS PER COMMON SHARE (Tables)
 9 Months Ended
Sep. 30, 2023
Earnings Per Share [Abstract]  
Computation of Basic and Diluted Earnings Per Share
The following table illustrates the computation of basic and diluted earnings per share for the three and nine months ended September 30, 2023 and 2022 (in thousands, except share and per share amounts):
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Numerator
Net (loss) income$(15,101)$(50,064)$(3,400)$7,343 
Denominator
Basic weighted average common shares and common equivalents231,224,692 230,982,227 231,197,375 230,936,032 
Dilutive restricted stock units— — — 843,718 
Diluted weighted average common shares231,224,692 230,982,227 231,197,375 231,779,750 
Net (loss) income, per:
Basic common share$(0.07)$(0.22)$(0.01)$0.03 
Diluted common share$(0.07)$(0.22)$(0.01)$0.03 
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.23.3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
USD ($)
variableInterestEntity
investment
Sep. 30, 2023
USD ($)
variableInterestEntity
investment
Accounting Policies [Line Items]    
Number of investments in loans accounted for as real estate joint ventures | investment 0 0
Vandalism And Theft    
Accounting Policies [Line Items]    
Proceeds of insurance $ 6.0 $ 6.0
Gain of unusual amount 3.7 3.7
Fire    
Accounting Policies [Line Items]    
Proceeds of insurance 1.1 1.1
Gain of unusual amount $ 0.5 $ 0.5
Primary beneficiary    
Accounting Policies [Line Items]    
Number of variable interest entities | variableInterestEntity 0 0
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.23.3
RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED) - Narrative (Details)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
USD ($)
Jun. 30, 2023
USD ($)
property
Sep. 30, 2022
USD ($)
Sep. 30, 2023
USD ($)
property
Sep. 30, 2022
USD ($)
property
Business Acquisition [Line Items]          
Payment of contingent consideration       $ 17,900 $ 2,500
Recent Real Estate Acquisitions          
Business Acquisition [Line Items]          
Total revenues $ 2,600   $ 3,900 6,800 6,000
Net (loss) income (less than in nine months ended 2023) $ 46   $ 300 $ 1 $ 900
Recent Real Estate Acquisitions | Tenant origination and absorption costs          
Business Acquisition [Line Items]          
Weighted-average amortization period of intangible assets       1 year 1 year
Recent Real Estate Acquisitions | Tenant relationships          
Business Acquisition [Line Items]          
Weighted-average amortization period of intangible assets       22 years  
Recent Real Estate Acquisitions | Senior Housing - Leased          
Business Acquisition [Line Items]          
Number of acquired properties | property       1  
Recent Real Estate Acquisitions | Senior Housing - Managed          
Business Acquisition [Line Items]          
Number of acquired properties | property       1 3
Preferred equity investment book value at acquisition       $ 4,600 $ 14,300
Payment of contingent consideration   $ 17,900      
Number of properties | property   2      
Recent Real Estate Acquisitions | Senior Housing Facilities - Managed Communities, Proprietary Development Pipeline          
Business Acquisition [Line Items]          
Number of acquired properties | property         2
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.23.3
RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED) - Purchase Price Allocation for Recent Real Estate Acquisitions (Details) - Recent Real Estate Acquisitions - USD ($)
$ in Thousands
Sep. 30, 2023
Sep. 30, 2022
Business Acquisition [Line Items]    
Land $ 3,415 $ 10,292
Building and improvements 45,333 83,118
Total consideration 51,474 98,297
Tenant origination and absorption costs intangible assets    
Business Acquisition [Line Items]    
Tenant intangible assets 2,706 4,887
Tenant relationship intangible assets    
Business Acquisition [Line Items]    
Tenant intangible assets $ 20 $ 0
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.23.3
INVESTMENT IN REAL ESTATE PROPERTIES - Real Estate Properties Held for Investment (Details)
$ in Thousands
Sep. 30, 2023
USD ($)
bed
facility
Dec. 31, 2022
USD ($)
facility
bed
Real Estate Properties [Line Items]    
Building and improvements $ 4,815,199 $ 5,034,470
Furniture and equipment 234,882 262,644
Land improvements 10,241 7,085
Land 545,176 568,489
Total Real Estate at Cost 5,605,498 5,872,688
Accumulated Depreciation (1,002,484) (913,345)
Total Real Estate Investments, Net $ 4,603,014 $ 4,959,343
Operating Segments    
Real Estate Properties [Line Items]    
Number of Properties | facility 377 402
Number of Beds/Units | bed 37,606 39,985
Total Real Estate at Cost $ 5,603,895 $ 5,871,784
Accumulated Depreciation (1,001,879) (912,819)
Total Real Estate Investments, Net $ 4,602,016 $ 4,958,965
Operating Segments | Skilled Nursing/Transitional Care    
Real Estate Properties [Line Items]    
Number of Properties | facility 240 264
Number of Beds/Units | bed 26,623 29,136
Total Real Estate at Cost $ 3,035,231 $ 3,385,221
Accumulated Depreciation (530,290) (492,495)
Total Real Estate Investments, Net $ 2,504,941 $ 2,892,726
Operating Segments | Senior Housing - Leased    
Real Estate Properties [Line Items]    
Number of Properties | facility 43 47
Number of Beds/Units | bed 3,473 3,550
Total Real Estate at Cost $ 572,633 $ 590,694
Accumulated Depreciation (106,063) (97,716)
Total Real Estate Investments, Net $ 466,570 $ 492,978
Operating Segments | Senior Housing - Managed    
Real Estate Properties [Line Items]    
Number of Properties | facility 61 59
Number of Beds/Units | bed 6,041 5,942
Total Real Estate at Cost $ 1,278,352 $ 1,205,283
Accumulated Depreciation (250,772) (222,089)
Total Real Estate Investments, Net $ 1,027,580 $ 983,194
Operating Segments | Behavioral Health    
Real Estate Properties [Line Items]    
Number of Properties | facility 18 17
Number of Beds/Units | bed 1,077 965
Total Real Estate at Cost $ 492,236 $ 465,143
Accumulated Depreciation (68,654) (58,481)
Total Real Estate Investments, Net $ 423,582 $ 406,662
Operating Segments | Specialty Hospitals and Other    
Real Estate Properties [Line Items]    
Number of Properties | facility 15 15
Number of Beds/Units | bed 392 392
Total Real Estate at Cost $ 225,443 $ 225,443
Accumulated Depreciation (46,100) (42,038)
Total Real Estate Investments, Net 179,343 183,405
Corporate Level    
Real Estate Properties [Line Items]    
Total Real Estate at Cost 1,603 904
Accumulated Depreciation (605) (526)
Total Real Estate Investments, Net $ 998 $ 378
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.23.3
INVESTMENT IN REAL ESTATE PROPERTIES - Operating Leases Narrative (Details)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
USD ($)
facility
Sep. 30, 2022
USD ($)
Sep. 30, 2023
USD ($)
facility
Sep. 30, 2022
USD ($)
Dec. 31, 2022
USD ($)
facility
Real Estate Properties [Line Items]          
Weighted-average remaining term of operating leases 8 years   8 years    
Security deposit liability $ 17.0   $ 17.0   $ 13.0
Letters of credit deposited 57.0   57.0   57.0
Tenant deposits for future real estate taxes, insurance expenditures, and tenant improvements 11.6   11.6   $ 13.3
Variable lease revenue $ 3.8 $ 4.3 $ 11.4 $ 13.7  
North American Health Care, Inc          
Real Estate Properties [Line Items]          
Write-off of non-cash rent receivable   $ 15.6      
Minimum          
Real Estate Properties [Line Items]          
Operating lease expiration term 1 year   1 year    
Maximum          
Real Estate Properties [Line Items]          
Operating lease expiration term 19 years   19 years    
Operating Segments          
Real Estate Properties [Line Items]          
Number of properties | facility 377   377   402
Operating Segments | Senior Housing - Managed          
Real Estate Properties [Line Items]          
Number of properties | facility 61   61   59
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.23.3
INVESTMENT IN REAL ESTATE PROPERTIES - Future Minimum Rental Payments Receivable for Properties Held for Investment Under Non-Cancelable Operating Leases (Details)
$ in Thousands
Sep. 30, 2023
USD ($)
Future minimum rental payments from the Company’s properties held for investment under non-cancelable operating leases:  
October 1 through December 31, 2023 $ 91,919
2024 371,661
2025 366,190
2026 350,583
2027 327,530
Thereafter 1,508,364
Total $ 3,016,247
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.23.3
INVESTMENT IN REAL ESTATE PROPERTIES - Senior Housing - Managed Communities Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Disaggregation of Revenue [Line Items]        
Resident fees and services $ 59,748 $ 47,610 $ 174,897 $ 133,973
Ancillary services        
Disaggregation of Revenue [Line Items]        
Resident fees and services $ 400 $ 400 $ 1,400 $ 1,000
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.23.3
INVESTMENT IN REAL ESTATE PROPERTIES - Capital and Other Expenditures Narrative (Details)
$ in Millions
 9 Months Ended
Sep. 30, 2023
USD ($)
Real Estate [Abstract]  
Future capital expenditures $ 44
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.23.3
INVESTMENT IN REAL ESTATE PROPERTIES - Schedule of Investment in Joint Ventures (Details)
$ in Thousands, $ in Millions
Sep. 30, 2023
USD ($)
property
Sep. 30, 2023
CAD ($)
property
Dec. 31, 2022
USD ($)
Unconsolidated Joint Venture      
Book Value $ 135,755   $ 134,962
Sienna Joint Venture      
Unconsolidated Joint Venture      
Ownership 50.00% 50.00%  
Book Value $ 118,150   120,269
Marlin Spring Joint Venture      
Unconsolidated Joint Venture      
Ownership 85.00% 85.00%  
Book Value $ 17,605   $ 14,693
Senior Housing - Managed | Marlin Spring Joint Venture      
Unconsolidated Joint Venture      
Book Value   $ 6.1  
Senior Housing - Managed | Sienna Joint Venture      
Unconsolidated Joint Venture      
Number of properties | property 12 12  
Senior Housing - Managed | Marlin Spring Joint Venture      
Unconsolidated Joint Venture      
Number of properties | property 4 4  
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.23.3
INVESTMENT IN REAL ESTATE PROPERTIES - Investment in Unconsolidated Joint Venture Narrative (Details)
$ in Thousands, $ in Millions
 3 Months Ended 9 Months Ended
Dec. 31, 2022
USD ($)
Sep. 30, 2023
CAD ($)
Sep. 30, 2023
USD ($)
property
Sep. 30, 2023
CAD ($)
property
Jan. 01, 2023
Unconsolidated Joint Venture          
Investment in unconsolidated joint ventures $ 134,962   $ 135,755    
Marlin Spring Joint Venture          
Unconsolidated Joint Venture          
Investment in unconsolidated joint ventures 14,693   $ 17,605    
Equity interest in joint venture     85.00% 85.00%  
Marlin Spring Joint Venture | Senior Housing - Managed          
Unconsolidated Joint Venture          
Number of acquired properties | property     1 1  
Payments to acquire buildings   $ 30.0      
Investment in unconsolidated joint ventures       $ 6.1  
Enlivant Joint Venture          
Unconsolidated Joint Venture          
Equity interest, investment basis amount 0        
Other-than-temporary impairment of unconsolidated joint ventures $ 57,800        
Equity interest in joint venture         49.00%
Marlin Spring Joint Venture | Marlin Spring Joint Venture | Senior Housing - Managed          
Unconsolidated Joint Venture          
Debt assumed       $ 23.6  
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.23.3
INVESTMENT IN REAL ESTATE PROPERTIES - Summarized Financial Data of Unconsolidated Joint Venture (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Summarized financial information        
Total revenues $ 161,627 $ 140,764 $ 484,117 $ 459,826
Loss from unconsolidated joint venture $ (645) $ (4,384) $ (2,136) (9,715)
Enlivant Joint Venture        
Summarized financial information        
Total revenues       237,144
Operating expenses       215,293
Net loss       (7,177)
Company’s share of net loss       (3,525)
Basis adjustments       5,755
Loss from unconsolidated joint venture       $ (9,280)
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.23.3
INVESTMENT IN REAL ESTATE PROPERTIES - Net Investment in Sales-Type Lease Narrative (Details)
$ in Thousands
 3 Months Ended 9 Months Ended
Mar. 31, 2023
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Dec. 31, 2022
USD ($)
property
Real Estate Properties [Line Items]        
Net proceeds from sales-type lease   $ 25,490 $ 0  
Skilled nursing transitional care facility        
Real Estate Properties [Line Items]        
Net investment in sales type lease       $ 25,500
Properties in sales-type | property       1
Net proceeds from sales-type lease $ 25,500      
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.23.3
IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS - Narrative (Details)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
USD ($)
facility
Sep. 30, 2022
USD ($)
facility
Sep. 30, 2023
USD ($)
facility
Sep. 30, 2022
USD ($)
facility
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Impairment of real estate | $ $ 0 $ 60,857 $ 7,064 $ 72,602
Held-for-sale or sold | Skilled nursing transitional care facility        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Number of properties | facility 1 10 1 10
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.23.3
IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS - Dispositions (Details)
$ in Millions
 9 Months Ended
Sep. 30, 2023
USD ($)
facility
Sep. 30, 2022
USD ($)
facility
Dispositions:    
Number of facilities | facility 27 11
Consideration, net of closing costs $ 256.2 $ 62.8
Net carrying value 332.1 67.4
Net loss on sale (75.9) (4.6)
Net loss (80.3) (63.1)
Impairment upon disposal $ 7.1 $ 65.8
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.23.3
LOANS RECEIVABLE AND OTHER INVESTMENTS - Composition of Loans Receivable and Other Investments (Details)
$ in Thousands
Sep. 30, 2023
USD ($)
loan
investment
preferredEquityInvestment
Dec. 31, 2022
USD ($)
Sep. 30, 2022
USD ($)
Dec. 31, 2021
USD ($)
Loans Receivable:        
Quantity | loan 12      
Principal balance $ 371,133 $ 370,364    
Book value 367,703 366,936    
Allowance for loan losses (6,677) (6,611) $ (6,427) $ (6,344)
Book value $ 361,026 360,325    
Weighted Average Contractual Interest Rate / Rate of Return 7.60%      
Weighted Average Annualized Effective Interest Rate / Rate of Return 7.60%      
Other Investments:        
Quantity | preferredEquityInvestment 5      
Principal balance $ 56,760 50,902    
Book value $ 56,921 51,071    
Weighted Average Contractual Interest Rate / Rate of Return 11.00%      
Weighted Average Annualized Effective Interest Rate / Rate of Return 11.00%      
Total quantity | investment 17      
Total principal balance $ 427,893      
Total book value $ 417,947 411,396    
Total weighted average contractual interest rate / rate of return 8.10%      
Total weighted average annualized effective interest rate / rate of return 8.00%      
Mortgage        
Loans Receivable:        
Quantity | loan 2      
Principal balance $ 319,000      
Book value $ 319,000 319,000    
Weighted Average Contractual Interest Rate / Rate of Return 7.60%      
Weighted Average Annualized Effective Interest Rate / Rate of Return 7.60%      
Other        
Loans Receivable:        
Quantity | loan 10      
Principal balance $ 52,133      
Book value $ 48,703 $ 47,936    
Weighted Average Contractual Interest Rate / Rate of Return 7.50%      
Weighted Average Annualized Effective Interest Rate / Rate of Return 7.00%      
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.23.3
LOANS RECEIVABLE AND OTHER INVESTMENTS - Schedule of Additional Information Regarding the Company's Loans Receivable (Details)
$ in Thousands
 9 Months Ended
Sep. 30, 2023
USD ($)
loan
Sep. 30, 2022
USD ($)
Dec. 31, 2022
USD ($)
loan
Financing Receivable, Allowance for Credit Loss [Roll Forward]      
Balance at beginning of the period $ 6,611 $ 6,344  
Provision for loan losses 549 83  
Write-off of uncollectible balances (483) 0  
Balance at end of the period 6,677 $ 6,427  
Deteriorated credit quality:      
Principal balance 371,133   $ 370,364
Book value $ 361,026   $ 360,325
Nonaccrual status      
Nonaccrual status:      
Number of loans receivable investments | loan 3   3
Book value $ 0   $ 0
Receivables with deteriorated credit quality      
Deteriorated credit quality:      
Number of loans receivable investments | loan 1   1
Principal balance $ 1,214   $ 1,214
Book value $ 0   $ 0
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.23.3
DEBT - Secured Indebtedness (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Debt Instrument [Line Items]    
Deferred financing costs $ 18,173  
Secured Debt    
Debt Instrument [Line Items]    
Deferred financing costs 854 $ 900
Secured Debt | Fixed Rate    
Debt Instrument [Line Items]    
Principal balance $ 48,643 $ 50,123
Weighted Average Interest Rate (percent) 2.85%  
Weighted Average Effective Interest Rate (percent) 3.34%  
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.23.3
DEBT - Senior Unsecured Notes (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Debt Instrument [Line Items]    
Discount, net $ 4,075  
Deferred financing costs 18,173  
Senior Notes    
Debt Instrument [Line Items]    
Principal balance 1,750,000 $ 1,750,000
Discount, net 4,075 3,500
Deferred financing costs $ 10,870 12,000
Weighted average effective interest rate (percent) 4.01%  
Senior Notes | 5.125% senior unsecured notes due 2026 (“2026 Notes”)    
Debt Instrument [Line Items]    
Interest rate (percent) 5.125%  
Principal balance $ 500,000 500,000
Senior Notes | 5.88% senior unsecured notes due 2027 (“2027 Notes”)    
Debt Instrument [Line Items]    
Interest rate (percent) 5.88%  
Principal balance $ 100,000 100,000
Senior Notes | 3.90% senior unsecured notes due 2029 (“2029 Notes”)    
Debt Instrument [Line Items]    
Interest rate (percent) 3.90%  
Principal balance $ 350,000 350,000
Senior Notes | 3.20% senior unsecured notes due 2031 (“2031 Notes”)    
Debt Instrument [Line Items]    
Interest rate (percent) 3.20%  
Principal balance $ 800,000 $ 800,000
XML 61 R51.htm IDEA: XBRL DOCUMENT v3.23.3
DEBT - Senior Unsecured Notes Narrative (Details) - Senior Notes
Sep. 30, 2023
5.125% senior unsecured notes due 2026 (“2026 Notes”)  
Debt Instrument [Line Items]  
Interest rate (percent) 5.125%
5.88% senior unsecured notes due 2027 (“2027 Notes”)  
Debt Instrument [Line Items]  
Interest rate (percent) 5.88%
5.375% Senior Unsecured Notes Due 2023  
Debt Instrument [Line Items]  
Interest rate (percent) 5.375%
3.90% senior unsecured notes due 2029 (“2029 Notes”)  
Debt Instrument [Line Items]  
Interest rate (percent) 3.90%
3.20% senior unsecured notes due 2031 (“2031 Notes”)  
Debt Instrument [Line Items]  
Interest rate (percent) 3.20%
XML 62 R52.htm IDEA: XBRL DOCUMENT v3.23.3
DEBT - Credit Agreement Narrative (Details)
 3 Months Ended 9 Months Ended
Jan. 04, 2023
USD ($)
extensionOption
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2023
CAD ($)
Jan. 04, 2023
CAD ($)
extensionOption
Dec. 31, 2022
USD ($)
Sep. 09, 2019
USD ($)
Sep. 09, 2019
CAD ($)
Debt Instrument [Line Items]                    
Loss on extinguishment of debt   $ 0 $ 140,000 $ 1,541,000 $ 411,000          
Amount outstanding under credit facility   32,623,000   32,623,000       $ 196,982,000    
Credit Agreement                    
Debt Instrument [Line Items]                    
Loss on extinguishment of debt   0                
Deferred finance costs   18,100,000   18,100,000            
Credit Agreement | Revolving Credit Facility                    
Debt Instrument [Line Items]                    
Borrowing capacity $ 1,000,000,000               $ 1,000,000,000  
Borrowing capacity in certain foreign currencies $ 350,000,000               175,000,000  
Basis spread on variable rate 1.00%                  
Number of extension options | extensionOption 2           2      
Extension period 6 months                  
Amount outstanding under credit facility   32,600,000   32,600,000   $ 44,300,000        
Available borrowing capacity   $ 967,400,000   $ 967,400,000            
Interest rate   6.49%   6.49%   6.49%        
Credit Agreement | Revolving Credit Facility | Minimum                    
Debt Instrument [Line Items]                    
Annum percent unused borrowing fee 0.125%     0.125%            
Credit Agreement | Revolving Credit Facility | Maximum                    
Debt Instrument [Line Items]                    
Annum percent unused borrowing fee 0.30%     0.30%            
Credit Agreement | Revolving Credit Facility | Prime Rate                    
Debt Instrument [Line Items]                    
Basis spread on variable rate 0.50%     0.50%            
Credit Agreement | Revolving Credit Facility | Base Rate                    
Debt Instrument [Line Items]                    
Basis spread on variable rate 1.00%     1.00%            
Credit Agreement | Revolving Credit Facility | Base Rate | Minimum                    
Debt Instrument [Line Items]                    
Basis spread on variable rate 0.00%     0.00%            
Credit Agreement | Revolving Credit Facility | Base Rate | Maximum                    
Debt Instrument [Line Items]                    
Basis spread on variable rate 0.45%     0.45%            
Credit Agreement | Revolving Credit Facility | LIBOR | Minimum                    
Debt Instrument [Line Items]                    
Basis spread on variable rate       0.775%            
Credit Agreement | Revolving Credit Facility | LIBOR | Maximum                    
Debt Instrument [Line Items]                    
Basis spread on variable rate       1.45%            
Credit Agreement | Revolving Credit Facility | SOFR | Minimum                    
Debt Instrument [Line Items]                    
Basis spread on variable rate 0.775%                  
Credit Agreement | Revolving Credit Facility | SOFR | Maximum                    
Debt Instrument [Line Items]                    
Basis spread on variable rate 1.45%                  
Credit Agreement | Line of Credit                    
Debt Instrument [Line Items]                    
Borrowing capacity $ 2,750,000,000               2,750,000,000  
U.S. dollar Term Loan | Credit Agreement                    
Debt Instrument [Line Items]                    
Aggregate principal amount $ 430,000,000               $ 436,300,000  
Loss on extinguishment of debt     $ 100,000   $ 400,000          
Interest rate   6.66%   6.66%   6.66%        
Effective interest rate   3.94%   3.94%   3.94%        
U.S. dollar Term Loan | Credit Agreement | Interest rate swaps                    
Debt Instrument [Line Items]                    
Aggregate principal amount   $ 430,000,000   $ 430,000,000            
Fixed interest rate under swap   2.69%   2.69%   2.69%        
U.S. dollar Term Loan | Credit Agreement | Base Rate | Minimum                    
Debt Instrument [Line Items]                    
Basis spread on variable rate 0.00%     0.00%            
U.S. dollar Term Loan | Credit Agreement | Base Rate | Maximum                    
Debt Instrument [Line Items]                    
Basis spread on variable rate 0.65%     0.65%            
U.S. dollar Term Loan | Credit Agreement | LIBOR | Minimum                    
Debt Instrument [Line Items]                    
Basis spread on variable rate       0.85%            
U.S. dollar Term Loan | Credit Agreement | LIBOR | Maximum                    
Debt Instrument [Line Items]                    
Basis spread on variable rate       1.65%            
U.S. dollar Term Loan | Credit Agreement | SOFR | Minimum                    
Debt Instrument [Line Items]                    
Basis spread on variable rate 0.85%                  
U.S. dollar Term Loan | Credit Agreement | SOFR | Maximum                    
Debt Instrument [Line Items]                    
Basis spread on variable rate 1.65%                  
U.S. dollar Term Loan | Fifth Amended and Restated Credit Agreement                    
Debt Instrument [Line Items]                    
Loss on extinguishment of debt       $ 1,500,000            
Canadian dollar Term Loan | Credit Agreement                    
Debt Instrument [Line Items]                    
Aggregate principal amount             $ 150,000,000     $ 125,000,000
Interest rate   6.64%   6.64%   6.64%        
Effective interest rate   2.88%   2.88%   2.88%        
Canadian dollar Term Loan | Credit Agreement | Interest rate swaps                    
Debt Instrument [Line Items]                    
Aggregate principal amount           $ 150,000,000        
Fixed interest rate under swap   1.63%   1.63%   1.63%        
Canadian dollar Term Loan | Credit Agreement | CDOR | Minimum                    
Debt Instrument [Line Items]                    
Basis spread on variable rate 0.85%     0.85%            
Canadian dollar Term Loan | Credit Agreement | CDOR | Maximum                    
Debt Instrument [Line Items]                    
Basis spread on variable rate 1.65%     1.65%            
XML 63 R53.htm IDEA: XBRL DOCUMENT v3.23.3
DEBT - Interest Expense Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Debt Disclosure [Abstract]          
Interest expense $ 28,156 $ 27,071 $ 85,024 $ 77,573  
Non-cash interest expense 3,100 $ 2,800 9,179 $ 8,300  
Accrued interest $ 21,100   $ 21,100   $ 18,200
XML 64 R54.htm IDEA: XBRL DOCUMENT v3.23.3
DEBT - Schedule of Maturities for Outstanding Debt (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Debt Instrument [Line Items]    
October 1 through December 31, 2023 $ 499  
2024 2,034  
2025 2,089  
2026 502,147  
2027 134,829  
Thereafter 1,730,128  
Total Debt 2,371,726  
Discount, net (4,075)  
Deferred financing costs, net (18,173)  
Total Debt, Net 2,349,478  
Secured Indebtedness    
Debt Instrument [Line Items]    
October 1 through December 31, 2023 499  
2024 2,034  
2025 2,089  
2026 2,147  
2027 2,206  
Thereafter 39,668  
Total Debt 48,643  
Discount, net 0  
Deferred financing costs, net (854) $ (900)
Total Debt, Net 47,789  
Revolving Credit Facility    
Debt Instrument [Line Items]    
October 1 through December 31, 2023 0  
2024 0  
2025 0  
2026 0  
2027 32,623  
Thereafter 0  
Total Debt 32,623  
Discount, net 0  
Deferred financing costs, net 0  
Total Debt, Net 32,623  
Term Loans    
Debt Instrument [Line Items]    
October 1 through December 31, 2023 0  
2024 0  
2025 0  
2026 0  
2027 0  
Thereafter 540,460  
Total Debt 540,460  
Discount, net 0  
Deferred financing costs, net (6,449)  
Total Debt, Net 534,011  
Senior Notes    
Debt Instrument [Line Items]    
October 1 through December 31, 2023 0  
2024 0  
2025 0  
2026 500,000  
2027 100,000  
Thereafter 1,150,000  
Total Debt 1,750,000  
Discount, net (4,075) (3,500)
Deferred financing costs, net (10,870) $ (12,000)
Total Debt, Net $ 1,735,055  
XML 65 R55.htm IDEA: XBRL DOCUMENT v3.23.3
DERIVATIVE AND HEDGING INSTRUMENTS - Narrative (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Derivative [Line Items]          
Fair value of derivatives in a net liability position $ 0   $ 0   $ 0
Credit risk-related contingent features          
Derivative [Line Items]          
Fair value of derivatives in a net liability position 0   0    
Cash flow hedges | Interest rate swaps          
Derivative [Line Items]          
Ineffectiveness on cash flow hedges 0 $ 0 0 $ 0  
Designated as Hedging Instrument          
Derivative [Line Items]          
Fair value of derivatives in a net liability position 143,083,000   143,083,000   $ 243,270,000
Designated as Hedging Instrument | Cash flow hedges          
Derivative [Line Items]          
Gains included in accumulated other comprehensive income expected to be reclassified into retained earnings in the next 12 months     9,600,000    
Not Designated as Hedging Instrument | Cross currency interest rate swaps          
Derivative [Line Items]          
Other expense related to derivatives $ 0 $ 0 $ 0 $ 100,000  
XML 66 R56.htm IDEA: XBRL DOCUMENT v3.23.3
DERIVATIVE AND HEDGING INSTRUMENTS - Notional Amount of Derivatives Instruments (Details)
Sep. 30, 2023
USD ($)
derivative
Sep. 30, 2023
CAD ($)
derivative
Dec. 31, 2022
USD ($)
Dec. 31, 2022
CAD ($)
Cash flow hedges | Designated as hedging instrument        
Derivative [Line Items]        
Notional amount $ 753,750,000   $ 436,250,000  
Cash flow hedges | Designated as hedging instrument | Cross currency interest rate swaps        
Derivative [Line Items]        
Notional amount   $ 300,000,000   $ 125,000,000
Cash flow hedges | Designated as hedging instrument | Interest Rate Swap        
Derivative [Line Items]        
Number of interest rate swaps | derivative 2 2    
Cash flow hedges | Designated as hedging instrument | Interest Rate Swap One        
Derivative [Line Items]        
Notional amount $ 323,800,000      
Cash flow hedges | Designated as hedging instrument | Interest Rate Swap Two        
Derivative [Line Items]        
Notional amount   $ 150,000,000    
Net Investment Hedges | Designated as hedging instrument        
Derivative [Line Items]        
Notional amount   194,300,000   329,500,000
Net Investment Hedges | Designated as hedging instrument | Cross currency interest rate swaps        
Derivative [Line Items]        
Notional amount   56,300,000   55,991,000
Net Investment Hedges | Not designated as hedging instrument | Cross currency interest rate swaps        
Derivative [Line Items]        
Notional amount   $ 0   $ 309,000
XML 67 R57.htm IDEA: XBRL DOCUMENT v3.23.3
DERIVATIVE AND HEDGING INSTRUMENTS - Derivative and Financial Instruments Designated as Hedging Instruments (Details)
$ in Thousands
Sep. 30, 2023
USD ($)
instrument
Dec. 31, 2022
USD ($)
Assets:    
Fair value $ 39,331 $ 21,477
Liabilities:    
Fair value $ 0 $ 0
Derivative liability, statement of financial position   Accounts payable and accrued liabilities, Revolving credit facility, Term loans, net
Derivative asset, statement of financial position Accounts receivable, prepaid expenses and other assets, net  
Designated as hedging instrument    
Assets:    
Fair value $ 39,331 $ 21,477
Liabilities:    
Fair value $ 143,083 243,270
Designated as hedging instrument | Interest rate swaps | Cash flow    
Assets:    
Count | instrument 5  
Fair value $ 11,986 11,004
Designated as hedging instrument | Interest rate collars | Cash flow    
Assets:    
Count | instrument 2  
Fair value $ 5,133 6,622
Designated as hedging instrument | Forward starting interest rate swaps | Cash flow    
Assets:    
Count | instrument 4  
Fair value $ 18,164 0
Designated as hedging instrument | Cross currency interest rate swaps | Net investment    
Assets:    
Count | instrument 2  
Fair value $ 4,048 3,851
Designated as hedging instrument | Currency Swap | Net investment | Revolving credit facility    
Liabilities:    
Count | instrument 1  
Fair value $ 32,623 150,982
Designated as hedging instrument | Currency Swap | Net investment | Term loans, net    
Liabilities:    
Count | instrument 1  
Fair value $ 110,460 $ 92,288
XML 68 R58.htm IDEA: XBRL DOCUMENT v3.23.3
DERIVATIVE AND HEDGING INSTRUMENTS - Effect of Derivative Financial Instruments on the Condensed Consolidated Statements of (Loss) Income and Condensed Consolidated Statements of Equity (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Derivative Instruments, Gain (Loss) [Line Items]        
Gain (loss) recognized in other comprehensive income, cash flow hedges and net investment hedges $ 15,315 $ 23,848 $ 26,426 $ 41,606
Interest rate products        
Derivative Instruments, Gain (Loss) [Line Items]        
Gain (loss) recognized in other comprehensive income, cash flow hedges 11,373 6,817 28,462 20,146
Interest rate products | Interest expense        
Derivative Instruments, Gain (Loss) [Line Items]        
Gain (loss) reclassified from accumulated other comprehensive income into income , cash flow hedges 2,369 (602) 5,848 (5,264)
Foreign currency products        
Derivative Instruments, Gain (Loss) [Line Items]        
Gain (loss) recognized in other comprehensive income, net investment hedges 1,140 2,253 349 2,840
Currency Swap        
Derivative Instruments, Gain (Loss) [Line Items]        
Gain (loss) recognized in other comprehensive income, net investment hedges 2,760 5,988 265 7,463
Currency Swap | Revolving Credit Facility        
Derivative Instruments, Gain (Loss) [Line Items]        
Gain (loss) recognized in other comprehensive income, net investment hedges $ 42 $ 8,790 $ (2,650) $ 11,157
XML 69 R59.htm IDEA: XBRL DOCUMENT v3.23.3
DERIVATIVE AND HEDGING INSTRUMENTS - Gross Presentation, Effects of Offsetting, and Net Presentation of Derivatives (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Offsetting Assets:    
Gross Amounts of Recognized Assets / Liabilities $ 39,331 $ 21,477
Gross Amounts Offset in the Balance Sheet 0 0
Net Amounts of Assets / Liabilities presented in the Balance Sheet 39,331 21,477
Financial Instruments 0 0
Cash Collateral Received 0 0
Net Amount 39,331 21,477
Offsetting Liabilities:    
Gross Amounts of Recognized Assets / Liabilities 0 0
Gross Amounts Offset in the Balance Sheet 0 0
Net Amounts of Assets / Liabilities presented in the Balance Sheet 0 0
Financial Instruments 0 0
Cash Collateral Received 0 0
Net Amount $ 0 $ 0
XML 70 R60.htm IDEA: XBRL DOCUMENT v3.23.3
FAIR VALUE DISCLOSURES - Narrative (Details) - Discount Rate
Sep. 30, 2023
Minimum  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Loans receivable, measurement input 0.08
Preferred equity investments, measurement input 0.10
Maximum  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Loans receivable, measurement input 0.15
Preferred equity investments, measurement input 0.15
Weighted Average  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Loans receivable, measurement input 0.08
Preferred equity investments, measurement input 0.11
Weighted Average | Secured Indebtedness  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Debt, measurement input 0.07
XML 71 R61.htm IDEA: XBRL DOCUMENT v3.23.3
FAIR VALUE DISCLOSURES - Face Values, Carrying Amounts and Fair Values of Financial Instruments (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Financial assets:    
Loans receivable $ 371,133 $ 370,364
Preferred equity investments 56,760 50,902
Senior Notes    
Financial liabilities:    
Financial liabilities, face value 1,750,000 1,750,000
Secured Indebtedness    
Financial liabilities:    
Financial liabilities, face value 48,643 50,123
Carrying Amount    
Financial assets:    
Loans receivable 361,026 360,325
Preferred equity investments 56,921 51,071
Carrying Amount | Senior Notes    
Financial liabilities:    
Financial liabilities, carrying amount and fair value 1,735,055 1,734,431
Carrying Amount | Secured Indebtedness    
Financial liabilities:    
Financial liabilities, carrying amount and fair value 47,789 49,232
Fair Value    
Financial assets:    
Loans receivable 368,437 370,188
Preferred equity investments 58,697 51,995
Fair Value | Senior Notes    
Financial liabilities:    
Financial liabilities, carrying amount and fair value 1,468,812 1,463,041
Fair Value | Secured Indebtedness    
Financial liabilities:    
Financial liabilities, carrying amount and fair value $ 34,164 $ 38,149
XML 72 R62.htm IDEA: XBRL DOCUMENT v3.23.3
FAIR VALUE DISCLOSURES - Fair Value of Financial Instruments (Details) - Recurring
$ in Thousands
Sep. 30, 2023
USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Loans receivable $ 368,437
Preferred equity investments 58,697
Senior Notes  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Financial liabilities 1,468,812
Secured Indebtedness  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Financial liabilities 34,164
Quoted Prices in Active Markets for Identical Assets (Level 1)  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Loans receivable 0
Preferred equity investments 0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Senior Notes  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Financial liabilities 0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Secured Indebtedness  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Financial liabilities 0
Significant Other Observable Inputs (Level 2)  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Loans receivable 0
Preferred equity investments 0
Significant Other Observable Inputs (Level 2) | Senior Notes  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Financial liabilities 1,468,812
Significant Other Observable Inputs (Level 2) | Secured Indebtedness  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Financial liabilities 0
Significant Unobservable Inputs (Level 3)  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Loans receivable 368,437
Preferred equity investments 58,697
Significant Unobservable Inputs (Level 3) | Senior Notes  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Financial liabilities 0
Significant Unobservable Inputs (Level 3) | Secured Indebtedness  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Financial liabilities $ 34,164
XML 73 R63.htm IDEA: XBRL DOCUMENT v3.23.3
FAIR VALUE DISCLOSURES - Items Measured at Fair Value on a Recurring Basis (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial assets $ 39,331 $ 21,477
Recurring | Interest rate swaps    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial assets 11,986  
Recurring | Interest rate collars    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial assets 5,133  
Recurring | Forward starting interest rate swaps    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial assets 18,164  
Recurring | Cross currency interest rate swaps    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial assets 4,048  
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Interest rate swaps    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial assets 0  
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Interest rate collars    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial assets 0  
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Forward starting interest rate swaps    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial assets 0  
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Cross currency interest rate swaps    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial assets 0  
Recurring | Significant Other Observable Inputs (Level 2) | Interest rate swaps    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial assets 11,986  
Recurring | Significant Other Observable Inputs (Level 2) | Interest rate collars    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial assets 5,133  
Recurring | Significant Other Observable Inputs (Level 2) | Forward starting interest rate swaps    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial assets 18,164  
Recurring | Significant Other Observable Inputs (Level 2) | Cross currency interest rate swaps    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial assets 4,048  
Recurring | Significant Unobservable Inputs (Level 3) | Interest rate swaps    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial assets 0  
Recurring | Significant Unobservable Inputs (Level 3) | Interest rate collars    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial assets 0  
Recurring | Significant Unobservable Inputs (Level 3) | Forward starting interest rate swaps    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial assets 0  
Recurring | Significant Unobservable Inputs (Level 3) | Cross currency interest rate swaps    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial assets $ 0  
XML 74 R64.htm IDEA: XBRL DOCUMENT v3.23.3
EQUITY - Common Stock (Details) - USD ($)
 3 Months Ended 9 Months Ended
Feb. 23, 2023
Sep. 30, 2023
Sep. 30, 2023
Sep. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Tax withholding obligations incurred on behalf of employees     $ 1,400,000 $ 3,300,000
Restricted stock units        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Shares issued upon vesting (in shares)     200,000  
ATM Program        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Aggregate gross proceeds possible from sales of common stock under equity offering program $ 500,000,000      
Forward sale agreements term 1 year      
Shares issued (in shares)   0 0  
Amount available for issuance   $ 500,000,000 $ 500,000,000  
XML 75 R65.htm IDEA: XBRL DOCUMENT v3.23.3
EQUITY - Cash Dividends on Common Stock Declared and Paid (Details) - $ / shares
 3 Months Ended 9 Months Ended
Aug. 07, 2023
May 03, 2023
Feb. 01, 2023
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Equity [Abstract]              
Common dividends (in dollars per share) $ 0.30 $ 0.30 $ 0.30 $ 0.30 $ 0.30 $ 0.90 $ 0.90
XML 76 R66.htm IDEA: XBRL DOCUMENT v3.23.3
EQUITY - Accumulated Other Comprehensive Income (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Jun. 30, 2023
Dec. 31, 2022
Sep. 30, 2022
Jun. 30, 2022
Dec. 31, 2021
Total Equity [Line Items]            
Accumulated other comprehensive income $ 2,868,853 $ 2,943,744 $ 3,056,395 $ 3,208,733 $ 3,317,726 $ 3,379,530
Total accumulated other comprehensive income            
Total Equity [Line Items]            
Accumulated other comprehensive income 39,669 $ 32,239 19,063 $ 18,522 $ 10,145 $ (10,021)
Foreign currency translation (loss) gain            
Total Equity [Line Items]            
Accumulated other comprehensive income (780)   1,168      
Unrealized gain on cash flow hedges            
Total Equity [Line Items]            
Accumulated other comprehensive income $ 40,449   $ 17,895      
XML 77 R67.htm IDEA: XBRL DOCUMENT v3.23.3
EARNINGS PER COMMON SHARE - Computation of Basic and Diluted Earnings Per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Numerator        
Net (loss) income $ (15,101) $ (50,064) $ (3,400) $ 7,343
Denominator        
Basic weighted average common shares and common equivalents (in shares) 231,224,692 230,982,227 231,197,375 230,936,032
Dilutive restricted stock units (in shares) 0 0 0 843,718
Diluted weighted average common shares (in shares) 231,224,692 230,982,227 231,197,375 231,779,750
Net (loss) income, per:        
Basic common share (in dollars per share) $ (0.07) $ (0.22) $ (0.01) $ 0.03
Diluted common share (in dollars per share) $ (0.07) $ (0.22) $ (0.01) $ 0.03
XML 78 R68.htm IDEA: XBRL DOCUMENT v3.23.3
EARNINGS PER COMMON SHARE - Narrative (Details) - shares
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Restricted stock units        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Anti-dilutive securities not included in computation of diluted earnings per share (in shares) 1,600,000 1,000,000 1,400,000 10,500
XML 79 R69.htm IDEA: XBRL DOCUMENT v3.23.3
SUBSEQUENT EVENTS (Details) - $ / shares
 3 Months Ended 9 Months Ended
Nov. 06, 2023
Aug. 07, 2023
May 03, 2023
Feb. 01, 2023
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Subsequent Event [Line Items]                
Quarterly cash dividend declared on common stock (in dollars per share)   $ 0.30 $ 0.30 $ 0.30 $ 0.30 $ 0.30 $ 0.90 $ 0.90
Subsequent event                
Subsequent Event [Line Items]                
Quarterly cash dividend declared on common stock (in dollars per share) $ 0.30              
XML 80 sbra-20230930_htm.xml IDEA: XBRL DOCUMENT 0001492298 2023-01-01 2023-09-30 0001492298 2023-11-01 0001492298 2023-09-30 0001492298 2022-12-31 0001492298 2023-07-01 2023-09-30 0001492298 2022-07-01 2022-09-30 0001492298 2022-01-01 2022-09-30 0001492298 sbra:TripleNetPortfolioMember 2023-07-01 2023-09-30 0001492298 sbra:TripleNetPortfolioMember 2022-07-01 2022-09-30 0001492298 sbra:TripleNetPortfolioMember 2023-01-01 2023-09-30 0001492298 sbra:TripleNetPortfolioMember 2022-01-01 2022-09-30 0001492298 sbra:SeniorHousingFacilitiesManagedPortfolioMember 2023-07-01 2023-09-30 0001492298 sbra:SeniorHousingFacilitiesManagedPortfolioMember 2022-07-01 2022-09-30 0001492298 sbra:SeniorHousingFacilitiesManagedPortfolioMember 2023-01-01 2023-09-30 0001492298 sbra:SeniorHousingFacilitiesManagedPortfolioMember 2022-01-01 2022-09-30 0001492298 us-gaap:CommonStockMember 2022-06-30 0001492298 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001492298 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2022-06-30 0001492298 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001492298 2022-06-30 0001492298 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2022-07-01 2022-09-30 0001492298 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0001492298 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001492298 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001492298 us-gaap:CommonStockMember 2022-09-30 0001492298 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001492298 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2022-09-30 0001492298 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0001492298 2022-09-30 0001492298 us-gaap:CommonStockMember 2023-06-30 0001492298 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001492298 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2023-06-30 0001492298 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001492298 2023-06-30 0001492298 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2023-07-01 2023-09-30 0001492298 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0001492298 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001492298 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001492298 us-gaap:CommonStockMember 2023-09-30 0001492298 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001492298 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2023-09-30 0001492298 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001492298 us-gaap:CommonStockMember 2021-12-31 0001492298 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001492298 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2021-12-31 0001492298 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001492298 2021-12-31 0001492298 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2022-01-01 2022-09-30 0001492298 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-09-30 0001492298 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-09-30 0001492298 us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001492298 us-gaap:CommonStockMember 2022-12-31 0001492298 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001492298 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2022-12-31 0001492298 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001492298 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2023-01-01 2023-09-30 0001492298 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-09-30 0001492298 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-09-30 0001492298 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001492298 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2023-09-30 0001492298 sbra:VandalismAndTheftMember 2023-07-01 2023-09-30 0001492298 sbra:VandalismAndTheftMember 2023-01-01 2023-09-30 0001492298 us-gaap:FireMember 2023-07-01 2023-09-30 0001492298 us-gaap:FireMember 2023-01-01 2023-09-30 0001492298 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember sbra:SeniorHousingFacilitiesLeasedMember 2023-01-01 2023-09-30 0001492298 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember sbra:SeniorHousingFacilitiesManagedPortfolioMember 2023-01-01 2023-09-30 0001492298 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember sbra:SeniorHousingFacilitiesManagedPortfolioMember 2022-01-01 2022-09-30 0001492298 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember sbra:SeniorHousingFacilitiesManagedCommunitiesProprietaryDevelopmentPipelineMember 2022-01-01 2022-09-30 0001492298 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2023-09-30 0001492298 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2022-09-30 0001492298 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember sbra:TenantOriginationAndAbsorptionCostsMember 2023-09-30 0001492298 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember sbra:TenantOriginationAndAbsorptionCostsMember 2022-09-30 0001492298 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember sbra:TenantRelationshipMember 2023-09-30 0001492298 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember sbra:TenantRelationshipMember 2022-09-30 0001492298 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember sbra:TenantOriginationAndAbsorptionCostsMember 2023-01-01 2023-09-30 0001492298 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember sbra:TenantRelationshipMember 2023-01-01 2023-09-30 0001492298 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember sbra:TenantOriginationAndAbsorptionCostsMember 2022-01-01 2022-09-30 0001492298 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2023-07-01 2023-09-30 0001492298 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2023-01-01 2023-09-30 0001492298 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2022-07-01 2022-09-30 0001492298 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2022-01-01 2022-09-30 0001492298 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember sbra:SeniorHousingFacilitiesManagedPortfolioMember 2023-04-01 2023-06-30 0001492298 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember sbra:SeniorHousingFacilitiesManagedPortfolioMember 2023-06-30 0001492298 us-gaap:OperatingSegmentsMember sbra:SkilledNursingTransitionalCareFacilitiesMember 2023-09-30 0001492298 us-gaap:OperatingSegmentsMember sbra:SeniorHousingFacilitiesLeasedMember 2023-09-30 0001492298 us-gaap:OperatingSegmentsMember sbra:SeniorHousingFacilitiesManagedPortfolioMember 2023-09-30 0001492298 us-gaap:OperatingSegmentsMember sbra:BehavioralHealthMember 2023-09-30 0001492298 us-gaap:OperatingSegmentsMember sbra:SpecialtyHospitalsAndOtherMember 2023-09-30 0001492298 us-gaap:OperatingSegmentsMember 2023-09-30 0001492298 us-gaap:CorporateMember 2023-09-30 0001492298 us-gaap:OperatingSegmentsMember sbra:SkilledNursingTransitionalCareFacilitiesMember 2022-12-31 0001492298 us-gaap:OperatingSegmentsMember sbra:SeniorHousingFacilitiesLeasedMember 2022-12-31 0001492298 us-gaap:OperatingSegmentsMember sbra:SeniorHousingFacilitiesManagedPortfolioMember 2022-12-31 0001492298 us-gaap:OperatingSegmentsMember sbra:BehavioralHealthMember 2022-12-31 0001492298 us-gaap:OperatingSegmentsMember sbra:SpecialtyHospitalsAndOtherMember 2022-12-31 0001492298 us-gaap:OperatingSegmentsMember 2022-12-31 0001492298 us-gaap:CorporateMember 2022-12-31 0001492298 srt:MinimumMember 2023-09-30 0001492298 srt:MaximumMember 2023-09-30 0001492298 sbra:NorthAmericanHealthCareIncMember 2022-07-01 2022-09-30 0001492298 sbra:HealthCareResidentServiceAncillaryServiceMember 2023-07-01 2023-09-30 0001492298 sbra:HealthCareResidentServiceAncillaryServiceMember 2023-01-01 2023-09-30 0001492298 sbra:HealthCareResidentServiceAncillaryServiceMember 2022-07-01 2022-09-30 0001492298 sbra:HealthCareResidentServiceAncillaryServiceMember 2022-01-01 2022-09-30 0001492298 sbra:SeniorHousingFacilitiesMember sbra:SiennaJointVentureMember 2023-09-30 0001492298 sbra:SiennaJointVentureMember 2023-09-30 0001492298 sbra:SiennaJointVentureMember 2022-12-31 0001492298 sbra:SeniorHousingFacilitiesMember sbra:MarlinSpringJointVentureMember 2023-09-30 0001492298 sbra:MarlinSpringJointVentureMember 2023-09-30 0001492298 sbra:MarlinSpringJointVentureMember 2022-12-31 0001492298 sbra:SeniorHousingFacilitiesMember sbra:MarlinSpringJointVentureMember 2023-09-30 0001492298 sbra:SeniorHousingFacilitiesMember sbra:MarlinSpringJointVentureMember 2023-01-01 2023-09-30 0001492298 sbra:SeniorHousingFacilitiesMember sbra:MarlinSpringJointVentureMember sbra:MarlinSpringJointVentureMember 2023-09-30 0001492298 sbra:EnlivantJointVentureMember 2022-10-01 2022-12-31 0001492298 sbra:EnlivantJointVentureMember 2023-01-01 0001492298 sbra:EnlivantJointVentureMember 2022-01-01 2022-09-30 0001492298 sbra:SkilledNursingTransitionalCareFacilitiesMember 2022-12-31 0001492298 sbra:SkilledNursingTransitionalCareFacilitiesMember 2023-01-01 2023-03-31 0001492298 sbra:SkilledNursingTransitionalCareFacilitiesMember us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember 2023-09-30 0001492298 sbra:SkilledNursingTransitionalCareFacilitiesMember us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember 2022-09-30 0001492298 sbra:MortgageLoansReceivableMember 2023-09-30 0001492298 sbra:MortgageLoansReceivableMember 2022-12-31 0001492298 sbra:OtherMember 2023-09-30 0001492298 sbra:OtherMember 2022-12-31 0001492298 us-gaap:FinancialAssetAcquiredWithCreditDeteriorationMember 2023-09-30 0001492298 us-gaap:FinancialAssetAcquiredWithCreditDeteriorationMember 2022-12-31 0001492298 us-gaap:NonperformingFinancingReceivableMember 2023-09-30 0001492298 us-gaap:NonperformingFinancingReceivableMember 2022-12-31 0001492298 sbra:FixedRateMortgagesMember us-gaap:SecuredDebtMember 2023-09-30 0001492298 sbra:FixedRateMortgagesMember us-gaap:SecuredDebtMember 2022-12-31 0001492298 us-gaap:SecuredDebtMember 2023-09-30 0001492298 us-gaap:SecuredDebtMember 2022-12-31 0001492298 sbra:A5.125SeniorUnsecuredNotesDue2026Member us-gaap:SeniorNotesMember 2023-09-30 0001492298 sbra:A5.125SeniorUnsecuredNotesDue2026Member us-gaap:SeniorNotesMember 2022-12-31 0001492298 sbra:A5.88SeniorUnsecuredNotesDue2027Member us-gaap:SeniorNotesMember 2023-09-30 0001492298 sbra:A5.88SeniorUnsecuredNotesDue2027Member us-gaap:SeniorNotesMember 2022-12-31 0001492298 sbra:A3.90SeniorUnsecuredNotesDue2029Member us-gaap:SeniorNotesMember 2023-09-30 0001492298 sbra:A3.90SeniorUnsecuredNotesDue2029Member us-gaap:SeniorNotesMember 2022-12-31 0001492298 sbra:A320SeniorUnsecuredNotesDue2031Member us-gaap:SeniorNotesMember 2023-09-30 0001492298 sbra:A320SeniorUnsecuredNotesDue2031Member us-gaap:SeniorNotesMember 2022-12-31 0001492298 us-gaap:SeniorNotesMember 2023-09-30 0001492298 us-gaap:SeniorNotesMember 2022-12-31 0001492298 sbra:A5375SeniorUnsecuredNotesDue2023Member us-gaap:SeniorNotesMember 2023-09-30 0001492298 us-gaap:RevolvingCreditFacilityMember sbra:CreditAgreementMember 2019-09-09 0001492298 sbra:CreditAgreementMember sbra:U.S.DollarTermLoanMember 2019-09-09 0001492298 sbra:CreditAgreementMember sbra:CanadianDollarTermLoanMember 2019-09-09 0001492298 us-gaap:LineOfCreditMember sbra:CreditAgreementMember 2019-09-09 0001492298 sbra:CreditAgreementMember sbra:U.S.DollarTermLoanMember 2022-07-01 2022-09-30 0001492298 sbra:CreditAgreementMember sbra:U.S.DollarTermLoanMember 2022-01-01 2022-09-30 0001492298 us-gaap:RevolvingCreditFacilityMember sbra:CreditAgreementMember us-gaap:PrimeRateMember 2023-01-01 2023-09-30 0001492298 us-gaap:RevolvingCreditFacilityMember sbra:CreditAgreementMember us-gaap:BaseRateMember 2023-01-01 2023-09-30 0001492298 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember sbra:CreditAgreementMember sbra:LondonInterbankOfferedRateLIBOR1Member 2023-01-01 2023-09-30 0001492298 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember sbra:CreditAgreementMember sbra:LondonInterbankOfferedRateLIBOR1Member 2023-01-01 2023-09-30 0001492298 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember sbra:CreditAgreementMember us-gaap:BaseRateMember 2023-01-01 2023-09-30 0001492298 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember sbra:CreditAgreementMember us-gaap:BaseRateMember 2023-01-01 2023-09-30 0001492298 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember sbra:CreditAgreementMember 2023-01-01 2023-09-30 0001492298 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember sbra:CreditAgreementMember 2023-01-01 2023-09-30 0001492298 srt:MinimumMember sbra:CreditAgreementMember sbra:U.S.DollarTermLoanMember sbra:LondonInterbankOfferedRateLIBOR1Member 2023-01-01 2023-09-30 0001492298 srt:MaximumMember sbra:CreditAgreementMember sbra:U.S.DollarTermLoanMember sbra:LondonInterbankOfferedRateLIBOR1Member 2023-01-01 2023-09-30 0001492298 srt:MinimumMember sbra:CreditAgreementMember sbra:U.S.DollarTermLoanMember us-gaap:BaseRateMember 2023-01-01 2023-09-30 0001492298 srt:MaximumMember sbra:CreditAgreementMember sbra:U.S.DollarTermLoanMember us-gaap:BaseRateMember 2023-01-01 2023-09-30 0001492298 srt:MinimumMember sbra:CreditAgreementMember sbra:CanadianDollarTermLoanMember sbra:CanadianDollarOfferRateCDORMember 2023-01-01 2023-09-30 0001492298 srt:MaximumMember sbra:CreditAgreementMember sbra:CanadianDollarTermLoanMember sbra:CanadianDollarOfferRateCDORMember 2023-01-01 2023-09-30 0001492298 sbra:CreditAgreementMember 2023-09-30 0001492298 sbra:FifthAmendedandRestatedCreditAgreementMember sbra:U.S.DollarTermLoanMember 2023-01-01 2023-09-30 0001492298 sbra:CreditAgreementMember 2023-07-01 2023-09-30 0001492298 us-gaap:RevolvingCreditFacilityMember sbra:CreditAgreementMember 2023-01-04 0001492298 sbra:CreditAgreementMember sbra:U.S.DollarTermLoanMember 2023-01-04 0001492298 sbra:CreditAgreementMember sbra:CanadianDollarTermLoanMember 2023-01-04 0001492298 us-gaap:LineOfCreditMember sbra:CreditAgreementMember 2023-01-04 0001492298 us-gaap:RevolvingCreditFacilityMember sbra:CreditAgreementMember 2023-01-04 2023-01-04 0001492298 us-gaap:RevolvingCreditFacilityMember sbra:CreditAgreementMember 2023-09-30 0001492298 us-gaap:RevolvingCreditFacilityMember sbra:CreditAgreementMember us-gaap:PrimeRateMember 2023-01-04 2023-01-04 0001492298 us-gaap:RevolvingCreditFacilityMember sbra:CreditAgreementMember us-gaap:BaseRateMember 2023-01-04 2023-01-04 0001492298 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember sbra:CreditAgreementMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2023-01-04 2023-01-04 0001492298 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember sbra:CreditAgreementMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2023-01-04 2023-01-04 0001492298 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember sbra:CreditAgreementMember us-gaap:BaseRateMember 2023-01-04 2023-01-04 0001492298 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember sbra:CreditAgreementMember us-gaap:BaseRateMember 2023-01-04 2023-01-04 0001492298 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember sbra:CreditAgreementMember 2023-01-04 2023-01-04 0001492298 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember sbra:CreditAgreementMember 2023-01-04 2023-01-04 0001492298 srt:MinimumMember sbra:CreditAgreementMember sbra:U.S.DollarTermLoanMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2023-01-04 2023-01-04 0001492298 srt:MaximumMember sbra:CreditAgreementMember sbra:U.S.DollarTermLoanMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2023-01-04 2023-01-04 0001492298 srt:MinimumMember sbra:CreditAgreementMember sbra:U.S.DollarTermLoanMember us-gaap:BaseRateMember 2023-01-04 2023-01-04 0001492298 srt:MaximumMember sbra:CreditAgreementMember sbra:U.S.DollarTermLoanMember us-gaap:BaseRateMember 2023-01-04 2023-01-04 0001492298 sbra:CreditAgreementMember sbra:U.S.DollarTermLoanMember 2023-09-30 0001492298 srt:MinimumMember sbra:CreditAgreementMember sbra:CanadianDollarTermLoanMember sbra:CanadianDollarOfferRateCDORMember 2023-01-04 2023-01-04 0001492298 srt:MaximumMember sbra:CreditAgreementMember sbra:CanadianDollarTermLoanMember sbra:CanadianDollarOfferRateCDORMember 2023-01-04 2023-01-04 0001492298 sbra:CreditAgreementMember sbra:CanadianDollarTermLoanMember 2023-09-30 0001492298 sbra:CreditAgreementMember us-gaap:InterestRateSwapMember sbra:U.S.DollarTermLoanMember 2023-09-30 0001492298 sbra:CreditAgreementMember us-gaap:InterestRateSwapMember sbra:CanadianDollarTermLoanMember 2023-09-30 0001492298 us-gaap:LineOfCreditMember 2023-09-30 0001492298 us-gaap:LoansPayableMember 2023-09-30 0001492298 us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-01-01 2023-09-30 0001492298 us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-09-30 0001492298 us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0001492298 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-09-30 0001492298 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0001492298 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-09-30 0001492298 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0001492298 us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-09-30 0001492298 us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0001492298 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:NondesignatedMember 2023-09-30 0001492298 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:NondesignatedMember 2022-12-31 0001492298 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-09-30 0001492298 sbra:InterestRateSwapOneMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-09-30 0001492298 sbra:InterestRateSwapTwoMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-09-30 0001492298 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0001492298 sbra:InterestRateCollarMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-09-30 0001492298 sbra:InterestRateCollarMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0001492298 sbra:ForwardStartingInterestRateSwapsMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-09-30 0001492298 sbra:ForwardStartingInterestRateSwapsMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0001492298 us-gaap:DesignatedAsHedgingInstrumentMember 2023-09-30 0001492298 us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0001492298 sbra:LongTermLineOfCreditMember us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-09-30 0001492298 sbra:LongTermLineOfCreditMember us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0001492298 sbra:LoansPayableToBankMember us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-09-30 0001492298 sbra:LoansPayableToBankMember us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0001492298 us-gaap:InterestRateContractMember 2023-07-01 2023-09-30 0001492298 us-gaap:InterestRateContractMember 2022-07-01 2022-09-30 0001492298 us-gaap:InterestRateContractMember 2023-01-01 2023-09-30 0001492298 us-gaap:InterestRateContractMember 2022-01-01 2022-09-30 0001492298 us-gaap:ForeignExchangeContractMember 2023-07-01 2023-09-30 0001492298 us-gaap:ForeignExchangeContractMember 2022-07-01 2022-09-30 0001492298 us-gaap:ForeignExchangeContractMember 2023-01-01 2023-09-30 0001492298 us-gaap:ForeignExchangeContractMember 2022-01-01 2022-09-30 0001492298 us-gaap:RevolvingCreditFacilityMember us-gaap:CurrencySwapMember 2023-07-01 2023-09-30 0001492298 us-gaap:RevolvingCreditFacilityMember us-gaap:CurrencySwapMember 2022-07-01 2022-09-30 0001492298 us-gaap:RevolvingCreditFacilityMember us-gaap:CurrencySwapMember 2023-01-01 2023-09-30 0001492298 us-gaap:RevolvingCreditFacilityMember us-gaap:CurrencySwapMember 2022-01-01 2022-09-30 0001492298 us-gaap:CurrencySwapMember 2023-07-01 2023-09-30 0001492298 us-gaap:CurrencySwapMember 2022-07-01 2022-09-30 0001492298 us-gaap:CurrencySwapMember 2023-01-01 2023-09-30 0001492298 us-gaap:CurrencySwapMember 2022-01-01 2022-09-30 0001492298 us-gaap:InterestRateContractMember us-gaap:InterestExpenseMember 2023-07-01 2023-09-30 0001492298 us-gaap:InterestRateContractMember us-gaap:InterestExpenseMember 2022-07-01 2022-09-30 0001492298 us-gaap:InterestRateContractMember us-gaap:InterestExpenseMember 2023-01-01 2023-09-30 0001492298 us-gaap:InterestRateContractMember us-gaap:InterestExpenseMember 2022-01-01 2022-09-30 0001492298 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2022-01-01 2022-09-30 0001492298 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2022-07-01 2022-09-30 0001492298 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2023-01-01 2023-09-30 0001492298 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2023-07-01 2023-09-30 0001492298 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NondesignatedMember 2022-01-01 2022-09-30 0001492298 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NondesignatedMember 2023-07-01 2023-09-30 0001492298 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NondesignatedMember 2022-07-01 2022-09-30 0001492298 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NondesignatedMember 2023-01-01 2023-09-30 0001492298 us-gaap:CreditRiskContractMember 2023-09-30 0001492298 srt:MinimumMember us-gaap:MeasurementInputDiscountRateMember 2023-09-30 0001492298 srt:MaximumMember us-gaap:MeasurementInputDiscountRateMember 2023-09-30 0001492298 srt:WeightedAverageMember us-gaap:MeasurementInputDiscountRateMember 2023-09-30 0001492298 srt:WeightedAverageMember us-gaap:SecuredDebtMember us-gaap:MeasurementInputDiscountRateMember 2023-09-30 0001492298 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2023-09-30 0001492298 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-09-30 0001492298 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2022-12-31 0001492298 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2022-12-31 0001492298 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:SeniorNotesMember 2023-09-30 0001492298 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:SeniorNotesMember 2023-09-30 0001492298 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:SeniorNotesMember 2022-12-31 0001492298 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:SeniorNotesMember 2022-12-31 0001492298 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:SecuredDebtMember 2023-09-30 0001492298 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:SecuredDebtMember 2023-09-30 0001492298 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:SecuredDebtMember 2022-12-31 0001492298 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:SecuredDebtMember 2022-12-31 0001492298 us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001492298 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001492298 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001492298 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001492298 us-gaap:FairValueMeasurementsRecurringMember us-gaap:SeniorNotesMember 2023-09-30 0001492298 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:SeniorNotesMember 2023-09-30 0001492298 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:SeniorNotesMember 2023-09-30 0001492298 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:SeniorNotesMember 2023-09-30 0001492298 us-gaap:FairValueMeasurementsRecurringMember us-gaap:SecuredDebtMember 2023-09-30 0001492298 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:SecuredDebtMember 2023-09-30 0001492298 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:SecuredDebtMember 2023-09-30 0001492298 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:SecuredDebtMember 2023-09-30 0001492298 us-gaap:InterestRateSwapMember us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001492298 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001492298 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001492298 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001492298 sbra:InterestRateCollarMember us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001492298 sbra:InterestRateCollarMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001492298 sbra:InterestRateCollarMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001492298 sbra:InterestRateCollarMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001492298 sbra:ForwardStartingInterestRateSwapsMember us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001492298 sbra:ForwardStartingInterestRateSwapsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001492298 sbra:ForwardStartingInterestRateSwapsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001492298 sbra:ForwardStartingInterestRateSwapsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001492298 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001492298 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001492298 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001492298 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001492298 sbra:EquityDistributionAgreementATMProgramMember 2023-02-23 2023-02-23 0001492298 sbra:EquityDistributionAgreementATMProgramMember 2023-01-01 2023-09-30 0001492298 sbra:EquityDistributionAgreementATMProgramMember 2023-07-01 2023-09-30 0001492298 sbra:EquityDistributionAgreementATMProgramMember 2023-09-30 0001492298 2023-02-01 2023-02-01 0001492298 2023-05-03 2023-05-03 0001492298 2023-08-07 2023-08-07 0001492298 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0001492298 us-gaap:AccumulatedTranslationAdjustmentMember 2023-09-30 0001492298 us-gaap:AccumulatedTranslationAdjustmentMember 2022-12-31 0001492298 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-09-30 0001492298 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-12-31 0001492298 us-gaap:RestrictedStockUnitsRSUMember 2023-07-01 2023-09-30 0001492298 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0001492298 us-gaap:RestrictedStockUnitsRSUMember 2022-07-01 2022-09-30 0001492298 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-09-30 0001492298 us-gaap:SubsequentEventMember 2023-11-06 2023-11-06 shares iso4217:USD iso4217:USD shares sbra:variableInterestEntity sbra:investment sbra:property sbra:facility sbra:bed pure iso4217:CAD sbra:loan sbra:preferredEquityInvestment sbra:extensionOption sbra:derivative sbra:instrument 0001492298 --12-31 2023 Q3 false http://fasb.org/us-gaap/2023#HealthCareResidentServiceMember http://fasb.org/us-gaap/2023#HealthCareResidentServiceMember http://fasb.org/us-gaap/2023#HealthCareResidentServiceMember http://fasb.org/us-gaap/2023#HealthCareResidentServiceMember http://www.sabrahealth.com/20230930#AccountsReceivablePrepaidExpensesDeferredFinancingCostsAndOtherAssetsNet http://fasb.org/us-gaap/2023#AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent http://fasb.org/us-gaap/2023#LineOfCredit http://fasb.org/us-gaap/2023#LoansPayableToBank http://fasb.org/us-gaap/2023#AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent http://fasb.org/us-gaap/2023#LineOfCredit http://fasb.org/us-gaap/2023#LoansPayableToBank http://www.sabrahealth.com/20230930#AccountsReceivablePrepaidExpensesDeferredFinancingCostsAndOtherAssetsNet 10-Q true 2023-09-30 false 001-34950 SABRA HEALTH CARE REIT, INC. MD 27-2560479 18500 Von Karman Avenue Suite 550 Irvine CA 92612 888 393-8248 Common stock, $.01 par value SBRA NASDAQ Yes Yes Large Accelerated Filer false false false 231219523 1002484000 913345000 4603014000 4959343000 417947000 411396000 135755000 134962000 33256000 49308000 5602000 4624000 32749000 40131000 152239000 147908000 5380562000 5747672000 47789000 49232000 32623000 196982000 534011000 526129000 1735055000 1734431000 128039000 142259000 34192000 42244000 2511709000 2691277000 0.01 0.01 10000000 10000000 0 0 0 0 0 0 0.01 0.01 500000000 500000000 231219523 231219523 231009295 231009295 2312000 2310000 4491917000 4486967000 1665045000 1451945000 39669000 19063000 2868853000 3056395000 5380562000 5747672000 93085000 84214000 283229000 297268000 59748000 47610000 174897000 133973000 8794000 8940000 25991000 28585000 161627000 140764000 484117000 459826000 43242000 47427000 140211000 137855000 28156000 27071000 85024000 77573000 4304000 5120000 13243000 14983000 44523000 36705000 132124000 103835000 10759000 9676000 30793000 28721000 328000 -217000 549000 -12000 0 60857000 7064000 72602000 131312000 186639000 409008000 435557000 0 -140000 -1541000 -411000 2229000 994000 2570000 -1101000 -46545000 -80000 -75893000 -4581000 -44316000 774000 -74864000 -6093000 -14001000 -45101000 245000 18176000 -645000 -4384000 -2136000 -9715000 455000 579000 1509000 1118000 -15101000 -50064000 -3400000 7343000 -0.07 -0.22 -0.01 0.03 -0.07 -0.22 -0.01 0.03 231224692 230982227 231197375 230936032 231224692 230982227 231197375 231779750 -15101000 -50064000 -3400000 7343000 -1347000 1068000 -1948000 3505000 8777000 7309000 22554000 25038000 7430000 8377000 20606000 28543000 -7671000 -41687000 17206000 35886000 230968872 2310000 4482239000 -1176968000 10145000 3317726000 -50064000 -50064000 8377000 8377000 2657000 2657000 7734 -127000 -127000 0.30 69836000 69836000 230976606 2310000 4484769000 -1296868000 18522000 3208733000 231218658 2312000 4489107000 -1579914000 32239000 2943744000 -15101000 -15101000 7430000 7430000 2900000 2900000 865 -90000 -90000 0.30 70030000 70030000 231219523 2312000 4491917000 -1665045000 39669000 2868853000 230398655 2304000 4482451000 -1095204000 -10021000 3379530000 7343000 7343000 28543000 28543000 6513000 6513000 577951 6000 -4195000 -4189000 0.90 209007000 209007000 230976606 2310000 4484769000 -1296868000 18522000 3208733000 231009295 2310000 4486967000 -1451945000 19063000 3056395000 -3400000 -3400000 20606000 20606000 7090000 7090000 210228 2000 -2140000 -2138000 0.90 209700000 209700000 231219523 2312000 4491917000 -1665045000 39669000 2868853000 -3400000 7343000 140211000 137855000 -6781000 4970000 380000 1683000 9179000 8300000 5468000 5367000 -1541000 -411000 549000 -12000 -75893000 -4581000 7064000 72602000 -2136000 -9715000 1705000 0 -3704000 2167000 10660000 5631000 3013000 2161000 221834000 248146000 39630000 83985000 9614000 4500000 11015000 5813000 63794000 33809000 0 836000 8674000 4885000 -4828000 -4173000 4797000 128019000 248222000 62816000 25490000 0 6001000 0 544000 0 164909000 -185088000 -165338000 147353000 12188000 0 0 63750000 1479000 17030000 18135000 6000 17900000 2500000 -2194000 -4394000 208079000 207861000 -400937000 -148188000 -14194000 -85130000 -880000 392000 53932000 115886000 38858000 31148000 72911000 68778000 4644000 14311000 BUSINESS<div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sabra Health Care REIT, Inc. (“Sabra” or the “Company”) was incorporated on May 10, 2010 as a wholly owned subsidiary of Sun Healthcare Group, Inc. (“Sun”) and commenced operations on November 15, 2010 following Sabra’s separation from Sun. Sabra elected to be treated as a real estate investment trust (“REIT”) with the filing of its United States (“U.S.”) federal income tax return for the taxable year beginning January 1, 2011. Sabra believes that it has been organized and operated, and it intends to continue to operate, in a manner to qualify as a REIT. Sabra’s primary business consists of acquiring, financing and owning real estate property to be leased to third-party tenants in the healthcare sector. Sabra primarily generates revenues by leasing properties to tenants throughout the U.S. and Canada. Sabra owns substantially all of its assets and properties and conducts its operations through Sabra Health Care Limited Partnership, a Delaware limited partnership (the “Operating Partnership”), of which Sabra is the sole general partner and a wholly owned subsidiary of Sabra is currently the only limited partner, or by subsidiaries of the Operating Partnership. The Company’s investment portfolio is primarily comprised of skilled nursing/transitional care facilities, senior housing communities (“Senior Housing - Leased”), behavioral health facilities and specialty hospitals and other facilities, in each case leased to tenants who are responsible for the operations of these facilities; senior housing communities operated by third-party property managers pursuant to property management agreements (“Senior Housing - Managed”); investments in joint ventures; investments in loans receivable; and preferred equity investments.</span></div> SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation and Basis of Presentation</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements include the accounts of Sabra and its wholly owned subsidiaries as of September 30, 2023 and December 31, 2022 and for the three and nine month periods ended September 30, 2023 and 2022. All significant intercompany transactions and balances have been eliminated in consolidation. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information as contained within the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification and the rules and regulations of the SEC, including the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the unaudited consolidated financial statements do not include all of the information and footnotes required by GAAP for financial statements. In the opinion of management, the financial statements for the unaudited interim periods presented include all adjustments, which are of a normal and recurring nature, necessary for a fair statement of the results for such periods. Operating results for the three and nine months ended September 30, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023. For further information, refer to the Company’s consolidated financial statements and notes thereto for the year ended December 31, 2022 included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GAAP requires the Company to identify entities for which control is achieved through voting rights or other means and to determine which business enterprise is the primary beneficiary of variable interest entities (“VIEs”). A VIE is broadly defined as an entity with one or more of the following characteristics: (a) the total equity investment at risk is insufficient to finance the entity’s activities without additional subordinated financial support; (b) as a group, the holders of the equity investment at risk lack (i) the ability to make decisions about the entity’s activities through voting or similar rights, (ii) the obligation to absorb the expected losses of the entity, or (iii) the right to receive the expected residual returns of the entity; or (c) the equity investors have voting rights that are not proportional to their economic interests, and substantially all of the entity’s activities either involve, or are conducted on behalf of, an investor that has disproportionately few voting rights. If the Company were determined to be the primary beneficiary of the VIE, the Company would consolidate investments in the VIE. The Company may change its original assessment of a VIE due to events such as modifications of contractual arrangements that affect the characteristics or adequacy of the entity’s equity investments at risk and the disposal of all or a portion of an interest held by the primary beneficiary.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company identifies the primary beneficiary of a VIE as the enterprise that has both: (i) the power to direct the activities of the VIE that most significantly impact the entity’s economic performance; and (ii) the obligation to absorb losses or the right to receive benefits of the VIE that could be significant to the entity. The Company performs this analysis on an ongoing basis. As of September 30, 2023, the Company determined that it was not the primary beneficiary of any VIEs.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As it relates to investments in loans, in addition to the Company’s assessment of VIEs and whether the Company is the primary beneficiary of those VIEs, the Company evaluates the loan terms and other pertinent facts to determine whether the loan investment should be accounted for as a loan or as a real estate joint venture. If an investment has the characteristics of a real estate joint venture, including if the Company participates in the majority of the borrower’s expected residual profit, the Company would account for the investment as an investment in a real estate joint venture and not as a loan investment. Expected residual profit is defined as the amount of profit, whether called interest or another name, such as an equity kicker, above a reasonable amount of interest and fees expected to be earned by a lender. At September 30, 2023, none of the Company’s investments in loans were accounted for as real estate joint ventures.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As it relates to investments in joint ventures, the Company assesses any partners’ rights and their impact on the presumption of control of the partnership by any single partner. The Company also applies this guidance to managing member interests in limited liability companies. The Company reassesses its determination of which entity controls the joint venture if: there is a change to the terms or in the exercisability of the rights of any partners or members, the general partner or managing member increases or decreases its ownership interests, or there is an increase or decrease in the number of outstanding ownership interests. As of September 30, 2023, the Company’s determination of which entity controls its investments in joint ventures has not changed as a result of any reassessment.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Casualty Gains and Losses</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income resulting from insurance recoveries of property damage or business interruption losses is recognized when proceeds are received or contingencies related to the insurance recoveries are resolved.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A vacant facility owned by the Company suffered damages as a result of vandalism and theft. The Company received $6.0 million of net insurance proceeds and recorded a $3.7 million gain related to the property damage during the three and nine months ended September 30, 2023 which is included in other income (expense) on the accompanying consolidated statements of (loss) income.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A fire occurred at one of the Company’s Senior Housing - Managed communities. The Company received $1.1 million of insurance proceeds and recorded $0.5 million of business interruption insurance income during the three and nine months ended September 30, 2023 which is included in other income (expense) on the accompanying consolidated statements of (loss) income. The remaining proceeds were recorded as expense reimbursements in Senior Housing - Managed portfolio operating expenses on the accompanying consolidated statements of (loss) income.</span></div> The accompanying consolidated financial statements include the accounts of Sabra and its wholly owned subsidiaries as of September 30, 2023 and December 31, 2022 and for the three and nine month periods ended September 30, 2023 and 2022. All significant intercompany transactions and balances have been eliminated in consolidation. The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information as contained within the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification and the rules and regulations of the SEC, including the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the unaudited consolidated financial statements do not include all of the information and footnotes required by GAAP for financial statements. In the opinion of management, the financial statements for the unaudited interim periods presented include all adjustments, which are of a normal and recurring nature, necessary for a fair statement of the results for such periods. Operating results for the three and nine months ended September 30, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023. For further information, refer to the Company’s consolidated financial statements and notes thereto for the year ended December 31, 2022 included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC. GAAP requires the Company to identify entities for which control is achieved through voting rights or other means and to determine which business enterprise is the primary beneficiary of variable interest entities (“VIEs”). A VIE is broadly defined as an entity with one or more of the following characteristics: (a) the total equity investment at risk is insufficient to finance the entity’s activities without additional subordinated financial support; (b) as a group, the holders of the equity investment at risk lack (i) the ability to make decisions about the entity’s activities through voting or similar rights, (ii) the obligation to absorb the expected losses of the entity, or (iii) the right to receive the expected residual returns of the entity; or (c) the equity investors have voting rights that are not proportional to their economic interests, and substantially all of the entity’s activities either involve, or are conducted on behalf of, an investor that has disproportionately few voting rights. If the Company were determined to be the primary beneficiary of the VIE, the Company would consolidate investments in the VIE. The Company may change its original assessment of a VIE due to events such as modifications of contractual arrangements that affect the characteristics or adequacy of the entity’s equity investments at risk and the disposal of all or a portion of an interest held by the primary beneficiary.<div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company identifies the primary beneficiary of a VIE as the enterprise that has both: (i) the power to direct the activities of the VIE that most significantly impact the entity’s economic performance; and (ii) the obligation to absorb losses or the right to receive benefits of the VIE that could be significant to the entity. The Company performs this analysis on an ongoing basis. As of September 30, 2023, the Company determined that it was not the primary beneficiary of any VIEs.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As it relates to investments in loans, in addition to the Company’s assessment of VIEs and whether the Company is the primary beneficiary of those VIEs, the Company evaluates the loan terms and other pertinent facts to determine whether the loan investment should be accounted for as a loan or as a real estate joint venture. If an investment has the characteristics of a real estate joint venture, including if the Company participates in the majority of the borrower’s expected residual profit, the Company would account for the investment as an investment in a real estate joint venture and not as a loan investment. Expected residual profit is defined as the amount of profit, whether called interest or another name, such as an equity kicker, above a reasonable amount of interest and fees expected to be earned by a lender. At September 30, 2023, none of the Company’s investments in loans were accounted for as real estate joint ventures.</span></div>As it relates to investments in joint ventures, the Company assesses any partners’ rights and their impact on the presumption of control of the partnership by any single partner. The Company also applies this guidance to managing member interests in limited liability companies. The Company reassesses its determination of which entity controls the joint venture if: there is a change to the terms or in the exercisability of the rights of any partners or members, the general partner or managing member increases or decreases its ownership interests, or there is an increase or decrease in the number of outstanding ownership interests. 0 0 The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates. 6000000 6000000 3700000 3700000 1100000 1100000 500000 500000 RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED)<div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2023, the Company acquired one Senior Housing - Leased community and one Senior Housing - Managed community. During the nine months ended September 30, 2022, the Company acquired three Senior Housing - Managed communities. The Senior Housing - Managed community acquired during the nine months ended September 30, 2023 and two of the Senior Housing - Managed communities acquired during the nine months ended September 30, 2022 were part of the Company’s proprietary development pipeline and were previously reflected as preferred equity investments which had a book value of $4.6 million and $14.3 million, respectively, at the time of acquisition. The consideration was allocated as follows (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:58.371%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,415 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,292 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and improvements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,333 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,118 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tenant origination and absorption costs intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,706 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,887 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tenant relationship intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,474 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,297 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:7pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tenant origination and absorption costs intangible assets and tenant relationship intangible assets had weighted average amortization periods as of the respective dates of acquisition of one year and 22 years, respectively, for the acquisitions completed during the nine months ended September 30, 2023. The tenant origination and absorption costs intangible assets had an amortization period as of the date of acquisition of one year for the acquisitions completed during the nine months ended September 30, 2022.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2023, the Company recognized $2.6 million and $6.8 million of total revenues, respectively, and $46,000 of net loss and less than $1,000 of net income, respectively, from the facilities acquired during the nine months ended September 30, 2023. For the three and nine months ended September 30, 2022, the Company recognized $3.9 million and $6.0 million of total revenues, respectively, and $0.3 million and $0.9 million of net loss, respectively, from the facilities acquired during the nine months ended September 30, 2022.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2023, the Company, in accordance with the terms of the agreements pursuant to which it purchased the facilities, paid $17.9 million in additional consideration related to two Senior Housing - Managed communities that achieved certain performance metrics. This amount is included in real estate investments, net of accumulated depreciation on the accompanying consolidated balance sheets.</span></div> 1 1 3 2 4600000 14300000 The consideration was allocated as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:58.371%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,415 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,292 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and improvements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,333 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,118 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tenant origination and absorption costs intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,706 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,887 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tenant relationship intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,474 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,297 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> 3415000 10292000 45333000 83118000 2706000 4887000 20000 0 51474000 98297000 P1Y P22Y P1Y 2600000 6800000 46000 1000 3900000 6000000 300000 900000 17900000 2 INVESTMENT IN REAL ESTATE PROPERTIES<div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s real estate properties held for investment consisted of the following (dollars in thousands):</span></div><div style="margin-top:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">As of September 30, 2023</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:32.528%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.616%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.616%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property Type</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of<br/>Properties</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of<br/>Beds/Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total<br/>Real Estate<br/>at Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Depreciation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total<br/>Real Estate<br/>Investments, Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Skilled Nursing/Transitional Care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,623 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,035,231 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(530,290)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,504,941 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Housing - Leased</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,473 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572,633 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106,063)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466,570 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Housing - Managed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,041 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,278,352 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(250,772)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,027,580 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Behavioral Health</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,077 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492,236 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68,654)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423,582 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specialty Hospitals and Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,443 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46,100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,343 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,606 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,603,895 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,001,879)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,602,016 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Level</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,603 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(605)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">998 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,605,498 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,002,484)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,603,014 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">As of December 31, 2022 </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:32.528%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.616%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.616%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property Type</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of<br/>Properties</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of<br/>Beds/Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total<br/>Real Estate<br/>at Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Depreciation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total<br/>Real Estate<br/>Investments, Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Skilled Nursing/Transitional Care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,136 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,385,221 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(492,495)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,892,726 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Housing - Leased</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,550 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590,694 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97,716)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492,978 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Housing - Managed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,942 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,205,283 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(222,089)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">983,194 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Behavioral Health</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">965 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465,143 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58,481)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406,662 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specialty Hospitals and Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,443 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,038)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,405 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,985 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,871,784 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(912,819)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,958,965 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Level</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">904 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(526)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,872,688 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(913,345)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,959,343 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,815,199 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,034,470 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234,882 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,644 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,241 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,085 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545,176 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568,489 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total real estate at cost</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,605,498 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,872,688 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,002,484)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(913,345)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total real estate investments, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,603,014 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,959,343 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, the substantial majority of the Company’s real estate properties (excluding 61 Senior Housing - Managed communities) were leased under triple-net operating leases with expirations ranging from less than one year to 19 years. As of September 30, 2023, the leases had a weighted average remaining term of eight years. The leases generally include provisions to extend the lease terms and other negotiated terms and conditions. The Company, through its subsidiaries, retains substantially all of the risks and benefits of ownership of the real estate assets leased to the tenants. The Company may receive additional security under these operating leases in the form of letters of credit and security deposits from the lessee or guarantees from the parent of the lessee. Security deposits received in cash related to tenant leases are included in accounts payable and accrued liabilities on the accompanying consolidated balance sheets and totaled $17.0 million and $13.0 million as of September 30, 2023 and December 31, 2022, respectively, and letters of credit deposited with the Company totaled approximately $57 million as of each of September 30, 2023 and December 31, 2022. In addition, the Company’s tenants have deposited with the Company $11.6 million and $13.3 million as of September 30, 2023 and December 31, 2022, respectively, for future real estate taxes, insurance expenditures and tenant improvements related to the Company’s properties and their operations, and these amounts are included in accounts payable and accrued liabilities on the accompanying consolidated balance sheets.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lessor costs that are paid by the lessor and reimbursed by the lessee are included in the measurement of variable lease revenue and the associated expense. As a result, the Company recognized variable lease revenue and the associated expense of $3.8 million and $11.4 million </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the three and nine months ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2023, respectively, and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$4.3 million and $13.7 million during the three and nine months ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company monitors the creditworthiness of its tenants by evaluating the ability of the tenants to meet their lease obligations to the Company based on the tenants’ financial performance, including, as applicable and appropriate, the evaluation of any parent guarantees (or the guarantees of other related parties) of such lease obligations. The primary basis for the Company’s evaluation of the credit quality of its tenants (and more specifically the tenant’s ability to pay their rent obligations to the Company) is the tenant’s lease coverage ratio as supplemented by the parent’s fixed charge coverage ratio for those entities with a parent guarantee. These coverage ratios include earnings before interest, taxes, depreciation, amortization and rent (“EBITDAR”) to rent and earnings before interest, taxes, depreciation, amortization, rent and management fees (“EBITDARM”) to rent at the lease level and consolidated EBITDAR to total fixed charges at the parent guarantor level when such a guarantee exists. The Company obtains various financial and operational information from the majority of its tenants each month and reviews this information in conjunction with the above-described coverage metrics to identify financial and operational trends, evaluate the impact of the industry’s operational and financial environment (including the impact of </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">government reimbursement), and evaluate the management of the tenant’s operations. These metrics help the Company identify potential areas of concern relative to its tenants’ credit quality and ultimately the tenant’s ability to generate sufficient liquidity to meet its obligations, including its obligation to continue to pay the rent due to the Company.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2022, the Company concluded that its leases with North American Health Care, Inc. should no longer be accounted for on an accrual basis and wrote off $15.6 million of straight-line rent receivable balances related to these leases. The facilities were transitioned to the Ensign Group or Avamere, as applicable, effective February 1, 2023.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2023, no tenant relationship represented 10% or more of the Company’s total revenues.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, the future minimum rental payments from the Company’s properties held for investment under non-cancelable operating leases were as follows and may materially differ from actual future rental payments received (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:79.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 1 through December 31, 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,919 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371,661 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366,190 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,583 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327,530 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,508,364 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,016,247 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Housing - Managed Communities</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s Senior Housing - Managed communities offer residents certain ancillary services that are not contemplated in the lease with each resident (i.e., housekeeping, laundry, guest meals, etc.). These services are provided and paid for in addition to the standard services included in each resident lease (i.e., room and board, standard meals, etc.). The Company bills residents for ancillary services one month in arrears and recognizes revenue as the services are provided, as the Company has no continuing performance obligation related to those services. Resident fees and services include ancillary service revenue of $0.4 million and $1.4 million for the three and nine months ended September 30, 2023, respectively, and $0.4 million and $1.0 million for the three and nine months ended September 30, 2022, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Capital and Other Expenditures</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, the Company’s aggregate commitment for future capital and other expenditures associated with facilities leased under triple-net operating leases was approximately $44 million. These commitments are principally for improvements to its facilities.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investment in Unconsolidated Joint Ventures</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company’s investment in unconsolidated joint ventures (dollars in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.800%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.505%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Property Type</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Properties as of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">September 30, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Ownership as of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">September 30, 2023 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Book Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">September 30, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sienna Joint Venture</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Housing - Managed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,150 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,269 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marlin Spring Joint Venture</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Housing - Managed</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,605 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,693 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,755 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,962 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">These investments are not consolidated because the Company does not control, through voting rights or other means, the joint ventures.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2023, the Company’s joint venture with Marlin Spring (the “Marlin Spring Joint Venture”) completed the acquisition of one additional senior housing community that is being managed by a third-party property manager. The gross investment in the additional acquisition was CAD $30.0 million, excluding acquisition costs. In addition, the Marlin Spring Joint Venture assumed and financed an aggregate CAD $23.6 million of debt associated with the additional acquisition. The Company’s equity investment in the additional acquisition was CAD $6.1 million.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2022, due to the confluence of labor shortages, increased labor costs, elevated interest rates and a slower than anticipated recovery in the operating performance of the underlying facilities, the Company concluded that </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the estimated fair value of its investment in its joint venture with affiliates of TPG Real Estate, the real estate platform of TPG (the “Enlivant Joint Venture”) had declined to zero based on updated future cash flow analyses. This decline was deemed to be other-than-temporary, and the Company recorded an impairment charge totaling $57.8 million during the three months ended December 31, 2022.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2023, the Company discontinued applying the equity method of accounting to the Enlivant Joint Venture, in which it had a 49% equity interest. Effective May 1, 2023, the Company withdrew and resigned its membership in the Enlivant Joint Venture and accordingly, no longer has an equity interest in the Enlivant Joint Venture as of such date.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2022, the Enlivant Joint Venture was a significant equity method investee of the Company. The following table presents summarized financial information for the Enlivant Joint Venture and, except for basis adjustments and loss from unconsolidated joint venture, reflects the historical cost basis of the assets which pre-dated the Company’s investment in the Enlivant Joint Venture (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:39.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.814%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.814%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.818%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237,144 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,293 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,177)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Company’s share of net loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,525)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basis adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,755 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from unconsolidated joint venture</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,280)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain amounts in the financial information for the Enlivant Joint Venture have been reclassified to conform to Sabra’s presentation. The Company’s share of net loss in the Enlivant Joint Venture reflects its 49% equity interest and excludes certain equity-like compensation expense and the related income tax impact as such expense is not the responsibility of the Company under the terms of the joint venture agreement.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Investment in Sales-Type Lease</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the Company had a $25.5 million net investment in one skilled nursing/transitional care facility leased to a tenant under a sales-type lease, as the tenant is obligated to purchase the property at the end of the lease term. During the three months ended March 31, 2023, the tenant purchased the skilled nursing/transitional care facility for net proceeds of $25.5 million as obligated under the terms of the lease.</span></div> <div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s real estate properties held for investment consisted of the following (dollars in thousands):</span></div><div style="margin-top:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">As of September 30, 2023</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:32.528%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.616%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.616%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property Type</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of<br/>Properties</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of<br/>Beds/Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total<br/>Real Estate<br/>at Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Depreciation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total<br/>Real Estate<br/>Investments, Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Skilled Nursing/Transitional Care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,623 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,035,231 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(530,290)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,504,941 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Housing - Leased</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,473 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572,633 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106,063)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466,570 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Housing - Managed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,041 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,278,352 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(250,772)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,027,580 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Behavioral Health</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,077 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492,236 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68,654)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423,582 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specialty Hospitals and Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,443 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46,100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,343 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,606 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,603,895 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,001,879)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,602,016 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Level</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,603 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(605)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">998 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,605,498 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,002,484)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,603,014 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">As of December 31, 2022 </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:32.528%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.616%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.616%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property Type</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of<br/>Properties</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of<br/>Beds/Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total<br/>Real Estate<br/>at Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Depreciation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total<br/>Real Estate<br/>Investments, Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Skilled Nursing/Transitional Care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,136 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,385,221 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(492,495)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,892,726 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Housing - Leased</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,550 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590,694 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97,716)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492,978 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Housing - Managed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,942 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,205,283 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(222,089)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">983,194 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Behavioral Health</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">965 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465,143 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58,481)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406,662 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specialty Hospitals and Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,443 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,038)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,405 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,985 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,871,784 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(912,819)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,958,965 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Level</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">904 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(526)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,872,688 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(913,345)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,959,343 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,815,199 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,034,470 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234,882 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,644 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,241 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,085 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545,176 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568,489 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total real estate at cost</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,605,498 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,872,688 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,002,484)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(913,345)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total real estate investments, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,603,014 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,959,343 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 240 26623 3035231000 530290000 2504941000 43 3473 572633000 106063000 466570000 61 6041 1278352000 250772000 1027580000 18 1077 492236000 68654000 423582000 15 392 225443000 46100000 179343000 377 37606 5603895000 1001879000 4602016000 1603000 605000 998000 5605498000 1002484000 4603014000 264 29136 3385221000 492495000 2892726000 47 3550 590694000 97716000 492978000 59 5942 1205283000 222089000 983194000 17 965 465143000 58481000 406662000 15 392 225443000 42038000 183405000 402 39985 5871784000 912819000 4958965000 904000 526000 378000 5872688000 913345000 4959343000 4815199000 5034470000 234882000 262644000 10241000 7085000 545176000 568489000 5605498000 5872688000 1002484000 913345000 4603014000 4959343000 61 P1Y P19Y P8Y 17000000 13000000 57000000 57000000 11600000 13300000 3800000 11400000 4300000 13700000 15600000 <div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, the future minimum rental payments from the Company’s properties held for investment under non-cancelable operating leases were as follows and may materially differ from actual future rental payments received (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:79.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 1 through December 31, 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,919 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371,661 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366,190 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,583 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327,530 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,508,364 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,016,247 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 91919000 371661000 366190000 350583000 327530000 1508364000 3016247000 400000 1400000 400000 1000000 44000000 <div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company’s investment in unconsolidated joint ventures (dollars in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.800%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.505%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Property Type</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Properties as of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">September 30, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Ownership as of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">September 30, 2023 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Book Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">September 30, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sienna Joint Venture</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Housing - Managed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,150 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,269 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marlin Spring Joint Venture</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Housing - Managed</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,605 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,693 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,755 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,962 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">These investments are not consolidated because the Company does not control, through voting rights or other means, the joint ventures.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2022, the Enlivant Joint Venture was a significant equity method investee of the Company. The following table presents summarized financial information for the Enlivant Joint Venture and, except for basis adjustments and loss from unconsolidated joint venture, reflects the historical cost basis of the assets which pre-dated the Company’s investment in the Enlivant Joint Venture (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:39.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.814%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.814%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.818%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237,144 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,293 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,177)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Company’s share of net loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,525)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basis adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,755 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from unconsolidated joint venture</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,280)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 12 0.50 118150000 120269000 4 0.85 17605000 14693000 135755000 134962000 1 30000000 23600000 6100000 0 57800000 0.49 237144000 215293000 -7177000 -3525000 5755000 -9280000 0.49 25500000 1 25500000 IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS<div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment of Real Estate</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2023, the Company recognized $7.1 million of real estate impairment related to one skilled nursing/transitional care facility that has sold.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2022, the Company recognized $72.6 million of real estate impairment related to ten skilled nursing/transitional care facilities that have sold.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To estimate the fair value of the impaired facilities, the Company utilized a market approach which considered binding sale agreements, non-binding offers from unrelated third parties or model-derived valuations with significant unobservable inputs (Level 3 measurements), as applicable.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to evaluate additional assets for sale as part of its initiative to recycle capital and further improve its portfolio quality. This could lead to a shorter hold period and could result in the determination that the full amount of the Company’s investment is not recoverable, resulting in an impairment charge or loss on sale which could be material.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dispositions</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s dispositions for the periods presented (dollars in millions):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of facilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration, net of closing costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net carrying value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss on sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In addition to net loss on sale, net loss includes impairment of real estate of $7.1 million and $65.8 million for the nine months ended September 30, 2023 and 2022, respectively.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sale of the disposition facilities does not represent a strategic shift that has or will have a major effect on the Company’s operations and financial results, and therefore the results of operations attributable to these facilities have remained in continuing operations.</span></div> 7100000 1 72600000 10 <div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s dispositions for the periods presented (dollars in millions):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of facilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration, net of closing costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net carrying value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss on sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In addition to net loss on sale, net loss includes impairment of real estate of $7.1 million and $65.8 million for the nine months ended September 30, 2023 and 2022, respectively.</span></div> 27 11 256200000 62800000 332100000 67400000 -75900000 -4600000 -80300000 -63100000 7100000 65800000 LOANS RECEIVABLE AND OTHER INVESTMENTS<div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023 and December 31, 2022, the Company’s loans receivable and other investments consisted of the following (dollars in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.269%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Investment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Quantity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">as of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">September 30, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Property Type</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Principal Balance</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">as of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">September 30, 2023 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Book Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">as of </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">September 30, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Book Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">as of December 31, 2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Contractual Interest Rate / Rate of Return</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Annualized Effective Interest Rate / Rate of Return</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Maturity Date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">as of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">September 30, 2023</span></div></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Loans Receivable: </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Behavioral Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/01/26 - 01/31/27</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Multiple</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,133 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,703 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,936 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">08/31/23 - 05/01/29</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371,133 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367,703 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366,936 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for loan losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,677)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,611)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371,133 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361,026 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360,325 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Preferred Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Skilled Nursing / Senior Housing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,760 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,921 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,071 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427,893 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417,947 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411,396 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Principal balance includes amounts funded and accrued but unpaid interest / preferred return and excludes capitalizable fees.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information regarding the Company’s loans receivable is as follows (dollars in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for loan losses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of the period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,611 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,344 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for loan losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-off of uncollectible balances</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(483)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,677 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,427 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deteriorated credit quality:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of loans receivable investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,214 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,214 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Book value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonaccrual status:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of loans receivable investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Book value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023 and December 31, 2022, the Company did not consider any preferred equity investments to be impaired, and no preferred equity investments were on nonaccrual status.</span></div> <div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023 and December 31, 2022, the Company’s loans receivable and other investments consisted of the following (dollars in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.269%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Investment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Quantity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">as of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">September 30, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Property Type</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Principal Balance</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">as of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">September 30, 2023 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Book Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">as of </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">September 30, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Book Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">as of December 31, 2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Contractual Interest Rate / Rate of Return</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Annualized Effective Interest Rate / Rate of Return</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Maturity Date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">as of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">September 30, 2023</span></div></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Loans Receivable: </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Behavioral Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/01/26 - 01/31/27</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Multiple</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,133 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,703 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,936 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">08/31/23 - 05/01/29</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371,133 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367,703 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366,936 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for loan losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,677)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,611)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371,133 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361,026 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360,325 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Preferred Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Skilled Nursing / Senior Housing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,760 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,921 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,071 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427,893 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417,947 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411,396 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Principal balance includes amounts funded and accrued but unpaid interest / preferred return and excludes capitalizable fees.</span></div> 2 319000000 319000000 319000000 0.076 0.076 10 52133000 48703000 47936000 0.075 0.070 12 371133000 367703000 366936000 0.076 0.076 6677000 6611000 371133000 361026000 360325000 5 56760000 56921000 51071000 0.110 0.110 17 427893000 417947000 411396000 0.081 0.080 <div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information regarding the Company’s loans receivable is as follows (dollars in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for loan losses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of the period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,611 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,344 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for loan losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-off of uncollectible balances</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(483)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,677 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,427 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deteriorated credit quality:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of loans receivable investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,214 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,214 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Book value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonaccrual status:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of loans receivable investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Book value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 6611000 6344000 549000 83000 483000 0 6677000 6427000 1 1 1214000 1214000 0 0 3 3 0 0 DEBT<div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Secured Indebtedness</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s secured debt consists of the following (dollars in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest Rate Type</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Principal Balance as of<br/>September 30, 2023 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Principal Balance as of<br/>December 31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted Average<br/>Interest Rate</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted Average <br/>Effective Interest Rate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Maturity<br/>Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed Rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,643 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,123 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.85 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.34 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2031 - <br/>August 2051</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:4pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Principal balance does not include deferred financing costs, net of $0.9 million as of each of September 30, 2023 and December 31, 2022.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Weighted average effective interest rate includes private mortgage insurance.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Unsecured Notes</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s senior unsecured notes consist of the following (dollars in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.694%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Principal Balance as of </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Maturity Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2023 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2022 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.125% senior unsecured notes due 2026 (“2026 Notes”)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 15, 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.88% senior unsecured notes due 2027 (“2027 Notes”)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 17, 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.90% senior unsecured notes due 2029 (“2029 Notes”)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 15, 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.20% senior unsecured notes due 2031 (“2031 Notes”)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 1, 2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Principal balance does not include discount, net of $4.1 million and deferred financing costs, net of $10.9 million as of September 30, 2023 and does not include discount, net of $3.5 million and deferred financing costs, net of $12.0 million as of December 31, 2022. In addition, the weighted average effective interest rate as of September 30, 2023 was 4.01%.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2026 Notes and the 2027 Notes were assumed as a result of the Company’s merger with Care Capital Properties, Inc. in 2017 and accrue interest at a rate of 5.125% and 5.88%, respectively, per annum. Interest is payable semiannually on February 15 and August 15 of each year for the 2026 Notes and on May 17 and November 17 of each year for the 2027 Notes.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2029 Notes were issued by the Operating Partnership and, until redemption of the Company’s previously outstanding 5.375% senior notes due 2023 in October 2019, Sabra Capital Corporation, wholly owned subsidiaries of the Company, and accrue interest at a rate of 3.90% per annum. Interest is payable semiannually on April 15 and October 15 of each year.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2031 Notes were issued by the Operating Partnership, a wholly owned subsidiary of the Company, and accrue interest at a rate of 3.20% per annum. Interest is payable semiannually on June 1 and December 1 of each year, commencing on June 1, 2022.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The obligations under the 2027 Notes are fully and unconditionally guaranteed, jointly and severally, on an unsecured basis, by Sabra and one of its non-operating subsidiaries, subject to release under certain customary circumstances. The obligations under the 2026 Notes, 2029 Notes and 2031 Notes are fully and unconditionally guaranteed, on an unsecured basis, by Sabra; provided, however, that such guarantee is subject to release under certain customary circumstances.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The indentures and agreements (the “Senior Notes Indentures”) governing the 2026 Notes, 2027 Notes, 2029 Notes and 2031 Notes (collectively, the “Senior Notes”) include customary events of default and require the Company to comply with specified restrictive covenants. As of September 30, 2023, the Company was in compliance with all applicable financial covenants under the Senior Notes Indentures.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit Agreement</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 9, 2019, the Operating Partnership and Sabra Canadian Holdings, LLC (together, the “Borrowers”), Sabra and the other parties thereto entered into a fifth amended and restated unsecured credit agreement (the “Prior Credit Agreement”).</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Prior Credit Agreement included a $1.0 billion revolving credit facility (the “Prior Revolving Credit Facility”), a $436.3 million U.S. dollar term loan and a CAD $125.0 million Canadian dollar term loan (collectively, the “Prior Term Loans”). Further, up to $175.0 million of the Prior Revolving Credit Facility could be used for borrowings in certain foreign currencies. The Prior Credit Agreement also contained an accordion feature that allowed for an increase in the total available borrowings to $2.75 billion, subject to terms and conditions.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2022, the Company recognized $0.1 million and $0.4 million, respectively, of loss on extinguishment of debt related to write-offs of deferred financing costs in connection with the partial pay downs of the U.S. dollar Prior Term Loan.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Prior Revolving Credit Facility bore interest on the outstanding principal amount at a rate equal to a ratings-based applicable interest margin plus, Canadian Dollar Offered Rate (“CDOR”) for Canadian dollar borrowings, or at the Operating Partnership’s option for U.S. dollar borrowings, either (a) LIBOR or (b) a base rate determined as the greater of (i) the federal funds rate plus 0.5%, (ii) the prime rate, and (iii) one-month LIBOR plus 1.0% (the “Prior Base Rate”). The ratings-based applicable interest margin for borrowings varied based on the Debt Ratings, as defined in the Prior Credit Agreement, and ranged from 0.775% to 1.45% per annum for CDOR or LIBOR based borrowings and 0.00% to 0.45% per annum for borrowings at the Prior Base Rate. In addition, the Operating Partnership paid a facility fee ranging between 0.125% and 0.300% per annum based on the aggregate amount of commitments under the Prior Revolving Credit Facility regardless of amounts outstanding thereunder.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. dollar Prior Term Loan bore interest on the outstanding principal amount at a rate equal to a ratings-based applicable interest margin plus, at the Operating Partnership’s option, either (a) LIBOR or (b) the Prior Base Rate. The ratings-based applicable interest margin for borrowings varied based on the Debt Ratings and ranged from 0.85% to 1.65% per annum for LIBOR based borrowings and 0.00% to 0.65% per annum for borrowings at the Prior Base Rate. The Canadian dollar Prior Term Loan bore interest on the outstanding principal amount at a rate equal to CDOR plus an interest margin that ranged from 0.85% to 1.65% depending on the Debt Ratings.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 4, 2023, the Borrowers, and the other parties thereto entered into a sixth amended and restated unsecured credit agreement (the “Credit Agreement”). During the nine months ended September 30, 2023, the Company recorded $18.1 million of deferred financing costs related to the Credit Agreement and recognized $1.5 million of loss on extinguishment of debt related to write-offs of deferred financing costs in connection with amending and restating the Prior Credit Agreement. No loss on extinguishment of debt was recognized during the three months ended September 30, 2023.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement includes a $1.0 billion revolving credit facility (the “Revolving Credit Facility”), a $430.0 million U.S. dollar term loan and a CAD $150.0 million Canadian dollar term loan (collectively, the “Term Loans”). Further, up to $350.0 million of the Revolving Credit Facility may be used for borrowings in certain foreign currencies. The Credit </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreement also contains an accordion feature that can increase the total available borrowings to $2.75 billion, subject to terms and conditions.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Revolving Credit Facility has a maturity date of January 4, 2027, and includes two six-month extension options. The Term Loans have a maturity date of January 4, 2028.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, there was $32.6 million (CAD $44.3 million) outstanding under the Revolving Credit Facility and $967.4 million available for borrowing.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Revolving Credit Facility bear interest on the outstanding principal amount at a rate equal to a ratings-based applicable interest margin plus, CDOR for Canadian dollar borrowings, or at the Operating Partnership’s option for U.S. dollar borrowings, either (a) Daily Simple SOFR, as defined in the Credit Agreement, or (b) a base rate determined as the greater of (i) the federal funds rate plus 0.5%, (ii) the prime rate, (iii) Term SOFR, as defined in the Credit Agreement, plus 1.0% (the “Base Rate”), and (iv) 1.00%. The ratings-based applicable interest margin for borrowings will vary based on the Debt Ratings, as defined in the Credit Agreement, and will range from 0.775% to 1.450% per annum for Daily Simple SOFR-based borrowings and 0.00% to 0.450% per annum for borrowings at the Base Rate. As of September 30, 2023, the weighted average interest rate on the Revolving Credit Facility was 6.49%. In addition, the Operating Partnership pays a facility fee ranging between 0.125% and 0.300% per annum based on the aggregate amount of commitments under the Revolving Credit Facility regardless of amounts outstanding thereunder.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. dollar Term Loan bears interest on the outstanding principal amount at a ratings-based applicable interest margin plus, at the Operating Partnership’s option, either (a) Term SOFR or (b) the Base Rate. The ratings-based applicable interest margin for borrowings will vary based on the Debt Ratings and will range from 0.850% to 1.650% per annum for Term SOFR-based borrowings and 0.00% to 0.650% per annum for borrowings at the Base Rate. As of September 30, 2023, the interest rate on the U.S. dollar Term Loan was 6.66%. The Canadian dollar Term Loan bears interest on the outstanding principal amount at a rate equal CDOR plus an interest margin that will range from 0.850% to 1.650% depending on the Debt Ratings. As of September 30, 2023, the interest rate on the Canadian dollar Term Loan was 6.64%.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has interest rate swaps and interest rate collars that fix and set a cap and floor, respectively, for the SOFR portion of the interest rate for $430.0 million of SOFR-based borrowings under its U.S. dollar Term Loan at a weighted average rate of 2.69% and interest rate swaps that fix the CDOR portion of the interest rate for CAD $150.0 million of CDOR-based borrowings under its Canadian dollar Term Loan at a rate of 1.63%. As of September 30, 2023, the effective interest rate on the U.S. dollar and Canadian dollar Term Loans was 3.94% and 2.88%, respectively. In addition, the Canadian dollar Term Loan and the CAD $44.3 million outstanding as of September 30, 2023 under the Revolving Credit Facility are designated as net investment hedges. See Note 8, “Derivative and Hedging Instruments,” for further information.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The obligations of the Borrowers under the Credit Agreement are guaranteed by the Company and certain of its subsidiaries.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement contains customary covenants that include restrictions or limitations on the ability to pay dividends, incur additional indebtedness, engage in non-healthcare related business activities, enter into transactions with affiliates and sell or otherwise transfer certain assets as well as customary events of default. The Credit Agreement also requires Sabra, through the Operating Partnership, to comply with specified financial covenants, which include a maximum total leverage ratio, a maximum secured debt leverage ratio, a minimum fixed charge coverage ratio, a maximum unsecured leverage ratio, a minimum tangible net worth requirement and a minimum unsecured interest coverage ratio. As of September 30, 2023, the Company was in compliance with all applicable financial covenants under the Credit Agreement.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred interest expense of $28.2 million and $85.0 million during the three and nine months ended September 30, 2023, respectively, and $27.1 million and $77.6 million during the three and nine months ended September 30, 2022, respectively. Interest expense includes non-cash interest expense of $3.1 million and $9.2 million for the three and nine months ended September 30, 2023, respectively, and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.8 million and $8.3 million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the three and nine months ended September 30, 2022, respectively. As of September 30, 2023 and December 31, 2022, the Company had $21.1 million and $18.2 million, respectively, of accrued interest included in accounts payable and accrued liabilities on the accompanying consolidated balance sheets. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Maturities</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a schedule of maturities for the Company’s outstanding debt as of September 30, 2023 (in thousands): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Secured<br/>Indebtedness</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revolving Credit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">    Facility </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Term Loans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Senior Notes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 1 through December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,034 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,034 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,089 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,089 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,147 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502,147 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,206 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,623 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,829 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,668 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540,460 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,150,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,730,128 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,643 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,623 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540,460 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,371,726 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,075)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,075)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred financing costs, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(854)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,449)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,870)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,173)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Debt, Net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,789 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,623 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534,011 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735,055 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,349,478 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Revolving Credit Facility is subject to two six-month extension options.</span></div> <div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s secured debt consists of the following (dollars in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest Rate Type</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Principal Balance as of<br/>September 30, 2023 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Principal Balance as of<br/>December 31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted Average<br/>Interest Rate</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted Average <br/>Effective Interest Rate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Maturity<br/>Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed Rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,643 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,123 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.85 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.34 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2031 - <br/>August 2051</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:4pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Principal balance does not include deferred financing costs, net of $0.9 million as of each of September 30, 2023 and December 31, 2022.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Weighted average effective interest rate includes private mortgage insurance.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s senior unsecured notes consist of the following (dollars in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.694%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Principal Balance as of </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Maturity Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2023 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2022 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.125% senior unsecured notes due 2026 (“2026 Notes”)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 15, 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.88% senior unsecured notes due 2027 (“2027 Notes”)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 17, 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.90% senior unsecured notes due 2029 (“2029 Notes”)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 15, 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.20% senior unsecured notes due 2031 (“2031 Notes”)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 1, 2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Principal balance does not include discount, net of $4.1 million and deferred financing costs, net of $10.9 million as of September 30, 2023 and does not include discount, net of $3.5 million and deferred financing costs, net of $12.0 million as of December 31, 2022. In addition, the weighted average effective interest rate as of September 30, 2023 was 4.01%.</span></div> 48643000 50123000 0.0285 0.0334 900000 900000 0.05125 500000000 500000000 0.0588 100000000 100000000 0.0390 350000000 350000000 0.0320 800000000 800000000 1750000000 1750000000 4100000 10900000 3500000 12000000 0.0401 0.05125 0.0588 0.05375 0.0390 0.0320 1000000000 436300000 125000000 175000000 2750000000 -100000 -400000 0.005 0.010 0.00775 0.0145 0.0000 0.0045 0.00125 0.00300 0.0085 0.0165 0.0000 0.0065 0.0085 0.0165 18100000 -1500000 0 1000000000 430000000 150000000 350000000 2750000000 2 P6M 32600000 44300000 967400000 0.005 0.010 0.0100 0.00775 0.01450 0.0000 0.00450 0.0649 0.00125 0.00300 0.00850 0.01650 0.0000 0.00650 0.0666 0.00850 0.01650 0.0664 430000000 0.0269 150000000 0.0163 0.0394 0.0288 44300000 28200000 85000000 27100000 77600000 3100000 9200000 2800000 8300000 21100000 18200000 <div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a schedule of maturities for the Company’s outstanding debt as of September 30, 2023 (in thousands): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Secured<br/>Indebtedness</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revolving Credit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">    Facility </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Term Loans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Senior Notes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 1 through December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,034 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,034 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,089 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,089 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,147 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502,147 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,206 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,623 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,829 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,668 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540,460 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,150,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,730,128 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,643 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,623 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540,460 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,371,726 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,075)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,075)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred financing costs, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(854)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,449)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,870)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,173)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Debt, Net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,789 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,623 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534,011 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735,055 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,349,478 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Revolving Credit Facility is subject to two six-month extension options.</span></div> 499000 0 0 0 499000 2034000 0 0 0 2034000 2089000 0 0 0 2089000 2147000 0 0 500000000 502147000 2206000 32623000 0 100000000 134829000 39668000 0 540460000 1150000000 1730128000 48643000 32623000 540460000 1750000000 2371726000 0 0 0 4075000 4075000 854000 0 6449000 10870000 18173000 47789000 32623000 534011000 1735055000 2349478000 2 P6M DERIVATIVE AND HEDGING INSTRUMENTS<div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to various market risks, including the potential loss arising from adverse changes in interest rates and foreign exchange rates. The Company enters into derivative financial instruments to manage exposures that arise from business activities that result in the receipt or payment of future known and uncertain cash amounts, the value of which are determined by interest rates and foreign exchange rates. The Company’s derivative financial instruments are used to manage differences in the amount of the Company’s known or expected cash receipts and its known or expected cash payments principally related to the Company’s investments and borrowings. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company’s foreign operations expose the Company to fluctuations of foreign interest rates and exchange rates. These fluctuations may impact the value in the Company’s functional currency, the U.S. dollar, of the Company’s investment in foreign operations, the cash receipts and payments related to these foreign operations and payments of interest and principal under Canadian dollar denominated debt. The Company enters into derivative financial instruments to protect the value of its foreign investments and fix a portion of the interest payments for certain debt obligations. The Company does not enter into derivatives for speculative purposes.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flow Hedges</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish these objectives, the Company primarily uses interest rate swaps and collars as part of its interest rate risk management strategy. As of September 30, 2023, approximately $9.6 million of gains, which are included in accumulated other comprehensive income, are expected to be reclassified into earnings in the next 12 months.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Investment Hedges</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to fluctuations in foreign exchange rates on investments it holds in Canada. The Company uses cross currency interest rate swaps to hedge its exposure to changes in foreign exchange rates on these foreign investments. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents the notional amount of derivative instruments as of the dates indicated (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:60.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.521%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominated in U.S. Dollars </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">753,750 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436,250 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominated in Canadian Dollars </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as net investment hedges:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominated in Canadian Dollars</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,991 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial instruments designated as net investment hedges:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominated in Canadian Dollars</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194,300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as net investment hedges:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominated in Canadian Dollars</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Balance as of September 30, 2023 includes two forward starting interest rate swaps with an effective date of August 2024 and an aggregate notional amount of $323.8 million.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Balance as of September 30, 2023 includes two forward starting interest rate swaps with an effective date of September 2024 and an aggregate notional amount of CAD $150.0 million.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Derivative and Financial Instruments Designated as Hedging Instruments</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the derivative and financial instruments designated as hedging instruments held by the Company at September 30, 2023 and December 31, 2022 (dollars in thousands):    </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:17.631%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.289%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.717%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.013%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Count as of September 30, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value as of</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Maturity Dates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Type</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Designation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-838"><span style="-sec-ix-hidden:f-839"><span style="-sec-ix-hidden:f-840"><span style="-sec-ix-hidden:f-841">Balance Sheet Location</span></span></span></span></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,986 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,004 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 - 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, prepaid expenses and other assets, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate collars</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,133 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,622 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, prepaid expenses and other assets, net</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward starting interest rate swaps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,164 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, prepaid expenses and other assets, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross currency interest rate swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,048 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,851 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, prepaid expenses and other assets, net</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,331 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,477 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CAD borrowings under Revolving Credit Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,623 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,982 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving credit facility</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CAD Term Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,460 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,288 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loans, net</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,083 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,270 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents the effect of the Company’s derivative and financial instruments designated as hedging instruments on the consolidated statements of (loss) income and the consolidated statements of equity for the three and nine months ended September 30, 2023 and 2022 (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.549%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (Loss) Recognized in Other Comprehensive Income</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flow Hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate products</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,373 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,817 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,462 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,146 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Investment Hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency products</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,140 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,253 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,840 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CAD borrowings under Revolving Credit Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,790 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,650)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,157 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CAD term loan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,760 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,988 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,463 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,315 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,848 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,426 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,606 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:21.886%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.375%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (Loss) Reclassified from Accumulated Other Comprehensive Income into Income</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income Statement Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flow Hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate products</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,369 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(602)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,848 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,264)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2023 and 2022, no cash flow hedges were determined to be ineffective. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives Not Designated as Hedging Instruments</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, the Company’s derivatives were all designated as hedging instruments. During the nine months ended September 30, 2022, the Company recorded $0.1 million of other expense related to the portion of derivatives not designated as hedging instruments and no such expense was recorded during each of the three months ended September 30, 2022 and the three and nine months ended September 30, 2023.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Offsetting Derivatives</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into master netting arrangements, which reduce credit risk by permitting net settlement of transactions with the same counterparty. The table below presents a gross presentation, the effects of offsetting, and a net presentation of the Company’s derivatives as of September 30, 2023 and December 31, 2022 (in thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:19.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.429%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.341%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of September 30, 2023</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross Amounts of Recognized Assets / Liabilities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross Amounts Offset in the Balance Sheet</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net Amounts of Assets / Liabilities presented in the Balance Sheet</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross Amounts Not Offset in the Balance Sheet</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash Collateral Received</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Offsetting Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,331 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,331 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,331 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Offsetting Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:19.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.429%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.341%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31, 2022</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross Amounts of Recognized Assets / Liabilities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross Amounts Offset in the Balance Sheet</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net Amounts of Assets / Liabilities presented in the Balance Sheet</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross Amounts Not Offset in the Balance Sheet</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash Collateral Received</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Offsetting Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,477 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,477 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,477 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Offsetting Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit Risk-related Contingent Features </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreements with each of its derivative counterparties that contain a provision pursuant to which the Company could be declared in default on the derivative obligation if the Company defaults on any of its indebtedness, including a default where repayment of the indebtedness has not been accelerated by the lender. As of September 30, 2023, the Company had no derivatives in a net liability position related to these agreements.</span></div> 9600000 <div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents the notional amount of derivative instruments as of the dates indicated (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:60.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.521%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominated in U.S. Dollars </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">753,750 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436,250 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominated in Canadian Dollars </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as net investment hedges:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominated in Canadian Dollars</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,991 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial instruments designated as net investment hedges:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominated in Canadian Dollars</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194,300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as net investment hedges:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominated in Canadian Dollars</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Balance as of September 30, 2023 includes two forward starting interest rate swaps with an effective date of August 2024 and an aggregate notional amount of $323.8 million.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Balance as of September 30, 2023 includes two forward starting interest rate swaps with an effective date of September 2024 and an aggregate notional amount of CAD $150.0 million.</span></div> 753750000 436250000 300000000 125000000 56300000 55991000 194300000 329500000 0 309000 2 323800000 2 150000000 <div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the derivative and financial instruments designated as hedging instruments held by the Company at September 30, 2023 and December 31, 2022 (dollars in thousands):    </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:17.631%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.289%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.717%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.013%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Count as of September 30, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value as of</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Maturity Dates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Type</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Designation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-838"><span style="-sec-ix-hidden:f-839"><span style="-sec-ix-hidden:f-840"><span style="-sec-ix-hidden:f-841">Balance Sheet Location</span></span></span></span></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,986 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,004 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 - 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, prepaid expenses and other assets, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate collars</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,133 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,622 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, prepaid expenses and other assets, net</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward starting interest rate swaps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,164 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, prepaid expenses and other assets, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross currency interest rate swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,048 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,851 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, prepaid expenses and other assets, net</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,331 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,477 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CAD borrowings under Revolving Credit Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,623 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,982 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving credit facility</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CAD Term Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,460 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,288 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loans, net</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,083 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,270 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div> 5 11986000 11004000 2 5133000 6622000 4 18164000 0 2 4048000 3851000 39331000 21477000 1 32623000 150982000 1 110460000 92288000 143083000 243270000 <div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents the effect of the Company’s derivative and financial instruments designated as hedging instruments on the consolidated statements of (loss) income and the consolidated statements of equity for the three and nine months ended September 30, 2023 and 2022 (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.549%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (Loss) Recognized in Other Comprehensive Income</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flow Hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate products</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,373 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,817 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,462 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,146 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Investment Hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency products</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,140 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,253 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,840 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CAD borrowings under Revolving Credit Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,790 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,650)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,157 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CAD term loan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,760 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,988 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,463 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,315 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,848 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,426 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,606 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:21.886%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.375%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (Loss) Reclassified from Accumulated Other Comprehensive Income into Income</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income Statement Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flow Hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate products</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,369 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(602)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,848 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,264)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 11373000 6817000 28462000 20146000 1140000 2253000 349000 2840000 42000 8790000 -2650000 11157000 2760000 5988000 265000 7463000 15315000 23848000 26426000 41606000 2369000 -602000 5848000 -5264000 0 0 0 0 -100000 0 0 0 The table below presents a gross presentation, the effects of offsetting, and a net presentation of the Company’s derivatives as of September 30, 2023 and December 31, 2022 (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:19.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.429%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.341%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of September 30, 2023</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross Amounts of Recognized Assets / Liabilities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross Amounts Offset in the Balance Sheet</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net Amounts of Assets / Liabilities presented in the Balance Sheet</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross Amounts Not Offset in the Balance Sheet</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash Collateral Received</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Offsetting Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,331 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,331 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,331 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Offsetting Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:19.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.429%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.341%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31, 2022</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross Amounts of Recognized Assets / Liabilities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross Amounts Offset in the Balance Sheet</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net Amounts of Assets / Liabilities presented in the Balance Sheet</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross Amounts Not Offset in the Balance Sheet</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash Collateral Received</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Offsetting Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,477 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,477 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,477 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Offsetting Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> The table below presents a gross presentation, the effects of offsetting, and a net presentation of the Company’s derivatives as of September 30, 2023 and December 31, 2022 (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:19.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.429%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.341%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of September 30, 2023</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross Amounts of Recognized Assets / Liabilities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross Amounts Offset in the Balance Sheet</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net Amounts of Assets / Liabilities presented in the Balance Sheet</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross Amounts Not Offset in the Balance Sheet</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash Collateral Received</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Offsetting Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,331 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,331 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,331 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Offsetting Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:19.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.429%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.341%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31, 2022</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross Amounts of Recognized Assets / Liabilities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross Amounts Offset in the Balance Sheet</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net Amounts of Assets / Liabilities presented in the Balance Sheet</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross Amounts Not Offset in the Balance Sheet</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash Collateral Received</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Offsetting Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,477 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,477 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,477 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Offsetting Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 39331000 0 39331000 0 0 39331000 0 0 0 0 0 0 21477000 0 21477000 0 0 21477000 0 0 0 0 0 0 0 FAIR VALUE DISCLOSURES<div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under GAAP, the Company is required to measure certain financial instruments at fair value on a recurring basis. In addition, the Company is required to measure other financial instruments and balances at fair value on a non-recurring basis (e.g., carrying value of impaired loans receivable and long-lived assets). Fair value is defined as the price that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The GAAP fair value framework uses a three-tiered approach. Fair value measurements are classified and disclosed in one of the following three categories: </span></div><div style="margin-top:3pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">Level 1: unadjusted quoted prices in active markets that are accessible at the measurement date for identical assets or liabilities; </span></div><div style="margin-top:3pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">Level 2: quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-derived valuations in which significant inputs and significant value drivers are observable in active markets; and </span></div><div style="margin-top:3pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">Level 3: prices or valuation techniques where little or no market data is available that requires inputs that are both significant to the fair value measurement and unobservable. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Instruments</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value for certain financial instruments is derived using a combination of market quotes, pricing models and other valuation techniques that involve significant management judgment. The price transparency of financial instruments is a key determinant of the degree of judgment involved in determining the fair value of the Company’s financial instruments.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments for which actively quoted prices or pricing parameters are available and whose markets contain orderly transactions will generally have a higher degree of price transparency than financial instruments whose markets are inactive or consist of non-orderly trades. The Company evaluates several factors when determining if a market is inactive or when market transactions are not orderly. The carrying values of cash and cash equivalents, restricted cash, accounts payable, accrued liabilities and the Credit Agreement are reasonable estimates of fair value because of the short-term maturities of these instruments. Fair values for other financial instruments are derived as follows:</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loans receivable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: These instruments are presented on the accompanying consolidated balance sheets at their amortized cost and not at fair value. The fair values of the loans receivable were estimated using an internal valuation model that considered the expected cash flows for the loans receivable, as well as the underlying collateral value and other credit enhancements as applicable. The Company utilized discount rates ranging from 8% to 15% with a weighted average rate of 8% in its fair value calculation. As such, the Company classifies these instruments as Level 3.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preferred equity investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: These instruments are presented on the accompanying consolidated balance sheets at their cost and not at fair value. The fair values of the preferred equity investments were estimated using an internal valuation model that considered the expected future cash flows for the preferred equity investments, the underlying collateral value and other credit enhancements. The Company utilized discount rates ranging from 10% to 15% with a weighted average rate of 11% in its fair value calculation. As such, the Company classifies these instruments as Level 3.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company’s derivative instruments are presented at fair value on the accompanying consolidated balance sheets. The Company estimates the fair value of derivative instruments, including its interest rate swaps, interest rate collars and cross currency swaps, using the assistance of a third party using inputs that are observable in the market, which include forward yield curves and other relevant information. Although the Company has determined that the majority of the inputs used to value its derivative financial instruments fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with its derivative financial instruments utilize Level 3 inputs, such as estimates of current credit spreads, to evaluate the likelihood of default by itself and its counterparties. The Company has assessed the significance of the impact of the credit valuation adjustments on the overall valuation of its derivative positions and has determined that the credit valuation adjustments are not significant to the overall valuation of its derivative financial instruments. As a result, the Company has determined that its derivative financial instruments valuations in their entirety are classified in Level 2 of the fair value hierarchy.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: These instruments are presented on the accompanying consolidated balance sheets at their outstanding principal balance, net of unamortized deferred financing costs and premiums/discounts and not at fair value. The fair values of the Senior Notes were determined using third-party market quotes derived from orderly trades. As such, the Company classifies these instruments as Level 2.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Secured indebtedness</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: These instruments are presented on the accompanying consolidated balance sheets at their outstanding principal balance, net of unamortized deferred financing costs and premiums/discounts and not at fair value. The fair values of the Company’s secured debt were estimated using a discounted cash flow analysis based on management’s estimates of current market interest rates for instruments with similar characteristics, including remaining loan term, loan-to-value ratio, type of collateral and other credit enhancements. The Company utilized a rate of 7% in its fair value calculation. As such, the Company classifies these instruments as Level 3.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are the face values, carrying amounts and fair values of the Company’s financial instruments as of September 30, 2023 and December 31, 2022 whose carrying amounts do not approximate their fair value (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:28.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.913%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.913%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.915%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Face<br/>Value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Face<br/>Value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying<br/>Amount </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loans receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371,133 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361,026 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368,437 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370,364 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360,325 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370,188 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred equity investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,760 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,921 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,697 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,902 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,071 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,995 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735,055 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,468,812 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,734,431 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,463,041 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Secured indebtedness</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,643 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,789 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,164 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,123 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,232 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,149 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Face value represents amounts contractually due under the terms of the respective agreements.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Carrying amount represents the book value of financial instruments, including unamortized premiums/discounts and deferred financing costs.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the fair value of financial instruments as of September 30, 2023 whose carrying amounts do not approximate their fair value with valuation methods utilizing the following types of inputs (in thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:33.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.171%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.905%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.905%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.909%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quoted Prices in<br/>Active Markets for<br/>Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Significant Other<br/>Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Significant<br/>Unobservable Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loans receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368,437 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368,437 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred equity investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,697 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,697 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,468,812 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,468,812 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Secured indebtedness</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,164 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,164 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disclosure of the fair value of financial instruments is based on pertinent information available to the Company at the applicable dates and requires a significant amount of judgment. Transaction volume for certain of the Company’s financial instruments remains relatively low, which has made the estimation of fair values difficult. Therefore, both the actual results and the Company’s estimate of fair value at a future date could be materially different.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Items Measured at Fair Value on a Recurring Basis</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2023, the Company recorded the following amounts measured at fair value (in thousands): </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:33.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.171%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.905%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.905%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.909%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quoted Prices in<br/>Active Markets for<br/>Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Significant Other<br/>Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Significant<br/>Unobservable Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recurring Basis:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,986 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,986 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate collars</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,133 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,133 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward starting interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,164 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,164 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross currency interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,048 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,048 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> <div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under GAAP, the Company is required to measure certain financial instruments at fair value on a recurring basis. In addition, the Company is required to measure other financial instruments and balances at fair value on a non-recurring basis (e.g., carrying value of impaired loans receivable and long-lived assets). Fair value is defined as the price that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The GAAP fair value framework uses a three-tiered approach. Fair value measurements are classified and disclosed in one of the following three categories: </span></div><div style="margin-top:3pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">Level 1: unadjusted quoted prices in active markets that are accessible at the measurement date for identical assets or liabilities; </span></div><div style="margin-top:3pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">Level 2: quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-derived valuations in which significant inputs and significant value drivers are observable in active markets; and </span></div><div style="margin-top:3pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">Level 3: prices or valuation techniques where little or no market data is available that requires inputs that are both significant to the fair value measurement and unobservable. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Instruments</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value for certain financial instruments is derived using a combination of market quotes, pricing models and other valuation techniques that involve significant management judgment. The price transparency of financial instruments is a key determinant of the degree of judgment involved in determining the fair value of the Company’s financial instruments.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments for which actively quoted prices or pricing parameters are available and whose markets contain orderly transactions will generally have a higher degree of price transparency than financial instruments whose markets are inactive or consist of non-orderly trades. The Company evaluates several factors when determining if a market is inactive or when market transactions are not orderly. The carrying values of cash and cash equivalents, restricted cash, accounts payable, accrued liabilities and the Credit Agreement are reasonable estimates of fair value because of the short-term maturities of these instruments. Fair values for other financial instruments are derived as follows:</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loans receivable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: These instruments are presented on the accompanying consolidated balance sheets at their amortized cost and not at fair value. The fair values of the loans receivable were estimated using an internal valuation model that considered the expected cash flows for the loans receivable, as well as the underlying collateral value and other credit enhancements as applicable. The Company utilized discount rates ranging from 8% to 15% with a weighted average rate of 8% in its fair value calculation. As such, the Company classifies these instruments as Level 3.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preferred equity investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: These instruments are presented on the accompanying consolidated balance sheets at their cost and not at fair value. The fair values of the preferred equity investments were estimated using an internal valuation model that considered the expected future cash flows for the preferred equity investments, the underlying collateral value and other credit enhancements. The Company utilized discount rates ranging from 10% to 15% with a weighted average rate of 11% in its fair value calculation. As such, the Company classifies these instruments as Level 3.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company’s derivative instruments are presented at fair value on the accompanying consolidated balance sheets. The Company estimates the fair value of derivative instruments, including its interest rate swaps, interest rate collars and cross currency swaps, using the assistance of a third party using inputs that are observable in the market, which include forward yield curves and other relevant information. Although the Company has determined that the majority of the inputs used to value its derivative financial instruments fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with its derivative financial instruments utilize Level 3 inputs, such as estimates of current credit spreads, to evaluate the likelihood of default by itself and its counterparties. The Company has assessed the significance of the impact of the credit valuation adjustments on the overall valuation of its derivative positions and has determined that the credit valuation adjustments are not significant to the overall valuation of its derivative financial instruments. As a result, the Company has determined that its derivative financial instruments valuations in their entirety are classified in Level 2 of the fair value hierarchy.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: These instruments are presented on the accompanying consolidated balance sheets at their outstanding principal balance, net of unamortized deferred financing costs and premiums/discounts and not at fair value. The fair values of the Senior Notes were determined using third-party market quotes derived from orderly trades. As such, the Company classifies these instruments as Level 2.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Secured indebtedness</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: These instruments are presented on the accompanying consolidated balance sheets at their outstanding principal balance, net of unamortized deferred financing costs and premiums/discounts and not at fair value. The fair values of the Company’s secured debt were estimated using a discounted cash flow analysis based on management’s estimates of current market interest rates for instruments with similar characteristics, including remaining loan term, loan-to-value ratio, type of collateral and other credit enhancements. The Company utilized a rate of 7% in its fair value calculation. As such, the Company classifies these instruments as Level 3.</span></div> 0.08 0.15 0.08 0.10 0.15 0.11 0.07 <div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are the face values, carrying amounts and fair values of the Company’s financial instruments as of September 30, 2023 and December 31, 2022 whose carrying amounts do not approximate their fair value (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:28.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.913%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.913%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.915%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Face<br/>Value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Face<br/>Value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying<br/>Amount </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loans receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371,133 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361,026 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368,437 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370,364 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360,325 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370,188 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred equity investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,760 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,921 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,697 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,902 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,071 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,995 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735,055 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,468,812 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,734,431 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,463,041 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Secured indebtedness</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,643 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,789 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,164 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,123 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,232 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,149 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Face value represents amounts contractually due under the terms of the respective agreements.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Carrying amount represents the book value of financial instruments, including unamortized premiums/discounts and deferred financing costs.</span></div> 371133000 361026000 368437000 370364000 360325000 370188000 56760000 56921000 58697000 50902000 51071000 51995000 1750000000 1735055000 1468812000 1750000000 1734431000 1463041000 48643000 47789000 34164000 50123000 49232000 38149000 <div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the fair value of financial instruments as of September 30, 2023 whose carrying amounts do not approximate their fair value with valuation methods utilizing the following types of inputs (in thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:33.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.171%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.905%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.905%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.909%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quoted Prices in<br/>Active Markets for<br/>Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Significant Other<br/>Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Significant<br/>Unobservable Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loans receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368,437 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368,437 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred equity investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,697 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,697 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,468,812 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,468,812 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Secured indebtedness</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,164 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,164 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 368437000 0 0 368437000 58697000 0 0 58697000 1468812000 0 1468812000 0 34164000 0 0 34164000 <div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2023, the Company recorded the following amounts measured at fair value (in thousands): </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:33.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.171%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.905%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.905%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.909%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quoted Prices in<br/>Active Markets for<br/>Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Significant Other<br/>Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Significant<br/>Unobservable Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recurring Basis:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,986 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,986 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate collars</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,133 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,133 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward starting interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,164 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,164 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross currency interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,048 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,048 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 11986000 0 11986000 0 5133000 0 5133000 0 18164000 0 18164000 0 4048000 0 4048000 0 EQUITY<div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 23, 2023, the Company established an at-the-market equity offering program (the “ATM Program”) pursuant to which shares of its common stock having an aggregate gross sales price of up to $500.0 million may be sold from time to time (i) by the Company through a consortium of banks acting as sales agents or directly to the banks acting as principals or (ii) by a consortium of banks acting as forward sellers on behalf of any forward purchasers pursuant to a forward sale agreement. The use of a forward sale agreement would allow the Company to lock in a share price on the sale of shares at the time the agreement is effective, but defer receiving the proceeds from the sale of the shares until a later date. The Company may also elect to cash settle or net share settle all or a portion of its obligations under any forward sale agreement. The forward sale agreements have a one year term during which time the Company may settle the forward sales by delivery of physical shares of common stock to the forward purchasers or, at the Company’s election, in cash or net shares. The forward sale price that the Company expects to receive upon settlement will be the initial forward price established upon the effective date, subject to adjustments for (i) the forward purchasers’ stock borrowing costs and (ii) certain fixed price reductions during the term of the agreement.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2023, no shares were sold under the ATM Program and the Company did not utilize the forward feature of the ATM Program. As of September 30, 2023, the Company had $500.0 million available under the ATM Program.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table lists the cash dividends on common stock declared and paid by the Company during the nine months ended September 30, 2023:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:24.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.708%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.708%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.080%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.590%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.308%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Declaration Date</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Record Date</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount Per Share</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend Payable Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 13, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 3, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 16, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 7, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 17, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 31, 2023</span></td></tr></table></div><div style="margin-top:7pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2023, the Company issued 0.2 million shares of common stock as a result of restricted stock unit vestings.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon any payment of shares to team members as a result of restricted stock unit vestings, the team members’ related tax withholding obligation will generally be satisfied by the Company reducing the number of shares to be delivered by a number of shares necessary to satisfy the related applicable tax withholding obligation. During the nine months ended September 30, 2023 and 2022, the Company incurred $1.4 million and $3.3 million, respectively, in tax withholding obligations on behalf of its team members that were satisfied through a reduction in the number of shares delivered to those participants.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company’s accumulated other comprehensive income (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:65.419%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.905%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.908%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation (loss) gain</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(780)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,168 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on cash flow hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,449 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,895 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accumulated other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,669 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,063 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 500000000 P1Y 0 0 500000000 <div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table lists the cash dividends on common stock declared and paid by the Company during the nine months ended September 30, 2023:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:24.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.708%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.708%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.080%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.590%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.308%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Declaration Date</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Record Date</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount Per Share</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend Payable Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 13, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 3, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 16, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 7, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 17, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 31, 2023</span></td></tr></table></div> 0.30 0.30 0.30 200000 1400000 3300000 <div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company’s accumulated other comprehensive income (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:65.419%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.905%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.908%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation (loss) gain</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(780)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,168 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on cash flow hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,449 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,895 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accumulated other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,669 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,063 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> -780000 1168000 40449000 17895000 39669000 19063000 EARNINGS PER COMMON SHARE<div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table illustrates the computation of basic and diluted earnings per share for the three and nine months ended September 30, 2023 and 2022 (in thousands, except share and per share amounts):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.514%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.771%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,064)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,400)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,343 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted average common shares and common equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,224,692 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,982,227 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,197,375 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,936,032 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">843,718 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average common shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,224,692 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,982,227 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,197,375 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,779,750 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income, per:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic common share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.07)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.03 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted common share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.07)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.22)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.03 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2023, approximately 1.6 million and 1.4 million restricted stock units, respectively, were not included in computing diluted earnings per share because they were considered anti-dilutive. During the three and nine months ended September 30, 2022, approximately 1.0 million and 10,500 restricted stock units, respectively, were not included in computing diluted earnings per share because they were considered anti-dilutive.</span></div> <div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table illustrates the computation of basic and diluted earnings per share for the three and nine months ended September 30, 2023 and 2022 (in thousands, except share and per share amounts):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.514%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.771%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,064)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,400)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,343 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted average common shares and common equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,224,692 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,982,227 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,197,375 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,936,032 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">843,718 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average common shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,224,692 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,982,227 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,197,375 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,779,750 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income, per:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic common share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.07)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.03 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted common share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.07)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.22)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.03 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> -15101000 -50064000 -3400000 7343000 231224692 230982227 231197375 230936032 0 0 0 843718 231224692 230982227 231197375 231779750 -0.07 -0.22 -0.01 0.03 -0.07 -0.22 -0.01 0.03 1600000 1400000 1000000 10500 COMMITMENTS AND CONTINGENCIES<div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As an owner of real estate, the Company is subject to various environmental laws of federal, state and local governments. The Company is not aware of any environmental liability that could have a material adverse effect on its financial condition or results of operations. However, changes in applicable environmental laws and regulations, the uses and conditions of properties in the vicinity of the Company’s properties, the activities of its tenants and other environmental conditions of which the Company is unaware with respect to the properties could result in future environmental liabilities. As of September 30, 2023, the Company does not expect that compliance with existing environmental laws will have a material adverse effect on the Company’s financial condition and results of operations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Matters</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company and its subsidiaries are party to legal proceedings that arise in the ordinary course of its business. Management is not aware of any legal proceedings where the likelihood of a loss contingency is reasonably possible and the amount or range of reasonably possible losses is material to the Company’s results of operations, financial condition or cash flows.</span></div> SUBSEQUENT EVENTS<div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates subsequent events up until the date the consolidated financial statements are issued.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividend Declaration</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 6, 2023, the Company’s board of directors declared a quarterly cash dividend of $0.30 per share of common stock. The dividend will be paid on November 30, 2023 to common stockholders of record as of the close of business on November 17, 2023.</span></div> 0.30 EXCEL 81 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 83 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 84 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 307 312 1 false 91 0 false 15 false false R1.htm 0000001 - Document - Cover Sheet http://www.sabrahealth.com/role/Cover Cover Cover 1 false false R2.htm 0000002 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 0000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - CONSOLIDATED STATEMENTS OF (LOSS) INCOME Sheet http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFLOSSINCOME CONSOLIDATED STATEMENTS OF (LOSS) INCOME Statements 4 false false R5.htm 0000005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME Sheet http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME Statements 5 false false R6.htm 0000006 - Statement - CONSOLIDATED STATEMENTS OF EQUITY Sheet http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY CONSOLIDATED STATEMENTS OF EQUITY Statements 6 false false R7.htm 0000007 - Statement - CONSOLIDATED STATEMENTS OF EQUITY (Parenthetical) Sheet http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFEQUITYParenthetical CONSOLIDATED STATEMENTS OF EQUITY (Parenthetical) Statements 7 false false R8.htm 0000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 8 false false R9.htm 0000009 - Disclosure - BUSINESS Sheet http://www.sabrahealth.com/role/BUSINESS BUSINESS Notes 9 false false R10.htm 0000010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 10 false false R11.htm 0000011 - Disclosure - RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED) Sheet http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATED RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED) Notes 11 false false R12.htm 0000012 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES Sheet http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIES INVESTMENT IN REAL ESTATE PROPERTIES Notes 12 false false R13.htm 0000013 - Disclosure - IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS Sheet http://www.sabrahealth.com/role/IMPAIRMENTOFREALESTATEANDDISPOSITIONS IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS Notes 13 false false R14.htm 0000014 - Disclosure - LOANS RECEIVABLE AND OTHER INVESTMENTS Sheet http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTS LOANS RECEIVABLE AND OTHER INVESTMENTS Notes 14 false false R15.htm 0000015 - Disclosure - DEBT Sheet http://www.sabrahealth.com/role/DEBT DEBT Notes 15 false false R16.htm 0000016 - Disclosure - DERIVATIVE AND HEDGING INSTRUMENTS Sheet http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTS DERIVATIVE AND HEDGING INSTRUMENTS Notes 16 false false R17.htm 0000017 - Disclosure - FAIR VALUE DISCLOSURES Sheet http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURES FAIR VALUE DISCLOSURES Notes 17 false false R18.htm 0000018 - Disclosure - EQUITY Sheet http://www.sabrahealth.com/role/EQUITY EQUITY Notes 18 false false R19.htm 0000019 - Disclosure - EARNINGS PER COMMON SHARE Sheet http://www.sabrahealth.com/role/EARNINGSPERCOMMONSHARE EARNINGS PER COMMON SHARE Notes 19 false false R20.htm 0000020 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.sabrahealth.com/role/COMMITMENTSANDCONTINGENCIES COMMITMENTS AND CONTINGENCIES Notes 20 false false R21.htm 0000021 - Disclosure - SUBSEQUENT EVENTS Sheet http://www.sabrahealth.com/role/SUBSEQUENTEVENTS SUBSEQUENT EVENTS Notes 21 false false R22.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 22 false false R23.htm 9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 23 false false R24.htm 9954472 - Disclosure - RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED) (Tables) Sheet http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDTables RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED) (Tables) Tables http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATED 24 false false R25.htm 9954473 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES (Tables) Sheet http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESTables INVESTMENT IN REAL ESTATE PROPERTIES (Tables) Tables http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIES 25 false false R26.htm 9954474 - Disclosure - IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS (Tables) Sheet http://www.sabrahealth.com/role/IMPAIRMENTOFREALESTATEANDDISPOSITIONSTables IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS (Tables) Tables http://www.sabrahealth.com/role/IMPAIRMENTOFREALESTATEANDDISPOSITIONS 26 false false R27.htm 9954475 - Disclosure - LOANS RECEIVABLE AND OTHER INVESTMENTS (Tables) Sheet http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSTables LOANS RECEIVABLE AND OTHER INVESTMENTS (Tables) Tables http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTS 27 false false R28.htm 9954476 - Disclosure - DEBT (Tables) Sheet http://www.sabrahealth.com/role/DEBTTables DEBT (Tables) Tables http://www.sabrahealth.com/role/DEBT 28 false false R29.htm 9954477 - Disclosure - DERIVATIVE AND HEDGING INSTRUMENTS (Tables) Sheet http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSTables DERIVATIVE AND HEDGING INSTRUMENTS (Tables) Tables http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTS 29 false false R30.htm 9954478 - Disclosure - FAIR VALUE DISCLOSURES (Tables) Sheet http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESTables FAIR VALUE DISCLOSURES (Tables) Tables http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURES 30 false false R31.htm 9954479 - Disclosure - EQUITY (Tables) Sheet http://www.sabrahealth.com/role/EQUITYTables EQUITY (Tables) Tables http://www.sabrahealth.com/role/EQUITY 31 false false R32.htm 9954480 - Disclosure - EARNINGS PER COMMON SHARE (Tables) Sheet http://www.sabrahealth.com/role/EARNINGSPERCOMMONSHARETables EARNINGS PER COMMON SHARE (Tables) Tables http://www.sabrahealth.com/role/EARNINGSPERCOMMONSHARE 32 false false R33.htm 9954481 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Sheet http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Details http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies 33 false false R34.htm 9954482 - Disclosure - RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED) - Narrative (Details) Sheet http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDNarrativeDetails RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED) - Narrative (Details) Details http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDTables 34 false false R35.htm 9954483 - Disclosure - RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED) - Purchase Price Allocation for Recent Real Estate Acquisitions (Details) Sheet http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDPurchasePriceAllocationforRecentRealEstateAcquisitionsDetails RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED) - Purchase Price Allocation for Recent Real Estate Acquisitions (Details) Details http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDTables 35 false false R36.htm 9954484 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES - Real Estate Properties Held for Investment (Details) Sheet http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails INVESTMENT IN REAL ESTATE PROPERTIES - Real Estate Properties Held for Investment (Details) Details 36 false false R37.htm 9954485 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES - Operating Leases Narrative (Details) Sheet http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESOperatingLeasesNarrativeDetails INVESTMENT IN REAL ESTATE PROPERTIES - Operating Leases Narrative (Details) Details 37 false false R38.htm 9954486 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES - Future Minimum Rental Payments Receivable for Properties Held for Investment Under Non-Cancelable Operating Leases (Details) Sheet http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESFutureMinimumRentalPaymentsReceivableforPropertiesHeldforInvestmentUnderNonCancelableOperatingLeasesDetails INVESTMENT IN REAL ESTATE PROPERTIES - Future Minimum Rental Payments Receivable for Properties Held for Investment Under Non-Cancelable Operating Leases (Details) Details 38 false false R39.htm 9954487 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES - Senior Housing - Managed Communities Narrative (Details) Sheet http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESSeniorHousingManagedCommunitiesNarrativeDetails INVESTMENT IN REAL ESTATE PROPERTIES - Senior Housing - Managed Communities Narrative (Details) Details 39 false false R40.htm 9954488 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES - Capital and Other Expenditures Narrative (Details) Sheet http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESCapitalandOtherExpendituresNarrativeDetails INVESTMENT IN REAL ESTATE PROPERTIES - Capital and Other Expenditures Narrative (Details) Details 40 false false R41.htm 9954489 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES - Schedule of Investment in Joint Ventures (Details) Sheet http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESScheduleofInvestmentinJointVenturesDetails INVESTMENT IN REAL ESTATE PROPERTIES - Schedule of Investment in Joint Ventures (Details) Details 41 false false R42.htm 9954490 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES - Investment in Unconsolidated Joint Venture Narrative (Details) Sheet http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESInvestmentinUnconsolidatedJointVentureNarrativeDetails INVESTMENT IN REAL ESTATE PROPERTIES - Investment in Unconsolidated Joint Venture Narrative (Details) Details 42 false false R43.htm 9954491 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES - Summarized Financial Data of Unconsolidated Joint Venture (Details) Sheet http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESSummarizedFinancialDataofUnconsolidatedJointVentureDetails INVESTMENT IN REAL ESTATE PROPERTIES - Summarized Financial Data of Unconsolidated Joint Venture (Details) Details 43 false false R44.htm 9954492 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES - Net Investment in Sales-Type Lease Narrative (Details) Sheet http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESNetInvestmentinSalesTypeLeaseNarrativeDetails INVESTMENT IN REAL ESTATE PROPERTIES - Net Investment in Sales-Type Lease Narrative (Details) Details 44 false false R45.htm 9954493 - Disclosure - IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS - Narrative (Details) Sheet http://www.sabrahealth.com/role/IMPAIRMENTOFREALESTATEANDDISPOSITIONSNarrativeDetails IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS - Narrative (Details) Details 45 false false R46.htm 9954494 - Disclosure - IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS - Dispositions (Details) Sheet http://www.sabrahealth.com/role/IMPAIRMENTOFREALESTATEANDDISPOSITIONSDispositionsDetails IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS - Dispositions (Details) Details 46 false false R47.htm 9954495 - Disclosure - LOANS RECEIVABLE AND OTHER INVESTMENTS - Composition of Loans Receivable and Other Investments (Details) Sheet http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails LOANS RECEIVABLE AND OTHER INVESTMENTS - Composition of Loans Receivable and Other Investments (Details) Details 47 false false R48.htm 9954496 - Disclosure - LOANS RECEIVABLE AND OTHER INVESTMENTS - Schedule of Additional Information Regarding the Company's Loans Receivable (Details) Sheet http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSScheduleofAdditionalInformationRegardingtheCompanysLoansReceivableDetails LOANS RECEIVABLE AND OTHER INVESTMENTS - Schedule of Additional Information Regarding the Company's Loans Receivable (Details) Details 48 false false R49.htm 9954497 - Disclosure - DEBT - Secured Indebtedness (Details) Sheet http://www.sabrahealth.com/role/DEBTSecuredIndebtednessDetails DEBT - Secured Indebtedness (Details) Details 49 false false R50.htm 9954498 - Disclosure - DEBT - Senior Unsecured Notes (Details) Notes http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesDetails DEBT - Senior Unsecured Notes (Details) Details 50 false false R51.htm 9954499 - Disclosure - DEBT - Senior Unsecured Notes Narrative (Details) Notes http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesNarrativeDetails DEBT - Senior Unsecured Notes Narrative (Details) Details 51 false false R52.htm 9954500 - Disclosure - DEBT - Credit Agreement Narrative (Details) Sheet http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails DEBT - Credit Agreement Narrative (Details) Details 52 false false R53.htm 9954501 - Disclosure - DEBT - Interest Expense Narrative (Details) Sheet http://www.sabrahealth.com/role/DEBTInterestExpenseNarrativeDetails DEBT - Interest Expense Narrative (Details) Details 53 false false R54.htm 9954502 - Disclosure - DEBT - Schedule of Maturities for Outstanding Debt (Details) Sheet http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails DEBT - Schedule of Maturities for Outstanding Debt (Details) Details 54 false false R55.htm 9954503 - Disclosure - DERIVATIVE AND HEDGING INSTRUMENTS - Narrative (Details) Sheet http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNarrativeDetails DERIVATIVE AND HEDGING INSTRUMENTS - Narrative (Details) Details 55 false false R56.htm 9954504 - Disclosure - DERIVATIVE AND HEDGING INSTRUMENTS - Notional Amount of Derivatives Instruments (Details) Sheet http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNotionalAmountofDerivativesInstrumentsDetails DERIVATIVE AND HEDGING INSTRUMENTS - Notional Amount of Derivatives Instruments (Details) Details 56 false false R57.htm 9954505 - Disclosure - DERIVATIVE AND HEDGING INSTRUMENTS - Derivative and Financial Instruments Designated as Hedging Instruments (Details) Sheet http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSDerivativeandFinancialInstrumentsDesignatedasHedgingInstrumentsDetails DERIVATIVE AND HEDGING INSTRUMENTS - Derivative and Financial Instruments Designated as Hedging Instruments (Details) Details 57 false false R58.htm 9954506 - Disclosure - DERIVATIVE AND HEDGING INSTRUMENTS - Effect of Derivative Financial Instruments on the Condensed Consolidated Statements of (Loss) Income and Condensed Consolidated Statements of Equity (Details) Sheet http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSEffectofDerivativeFinancialInstrumentsontheCondensedConsolidatedStatementsofLossIncomeandCondensedConsolidatedStatementsofEquityDetails DERIVATIVE AND HEDGING INSTRUMENTS - Effect of Derivative Financial Instruments on the Condensed Consolidated Statements of (Loss) Income and Condensed Consolidated Statements of Equity (Details) Details 58 false false R59.htm 9954507 - Disclosure - DERIVATIVE AND HEDGING INSTRUMENTS - Gross Presentation, Effects of Offsetting, and Net Presentation of Derivatives (Details) Sheet http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSGrossPresentationEffectsofOffsettingandNetPresentationofDerivativesDetails DERIVATIVE AND HEDGING INSTRUMENTS - Gross Presentation, Effects of Offsetting, and Net Presentation of Derivatives (Details) Details 59 false false R60.htm 9954508 - Disclosure - FAIR VALUE DISCLOSURES - Narrative (Details) Sheet http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESNarrativeDetails FAIR VALUE DISCLOSURES - Narrative (Details) Details 60 false false R61.htm 9954509 - Disclosure - FAIR VALUE DISCLOSURES - Face Values, Carrying Amounts and Fair Values of Financial Instruments (Details) Sheet http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFaceValuesCarryingAmountsandFairValuesofFinancialInstrumentsDetails FAIR VALUE DISCLOSURES - Face Values, Carrying Amounts and Fair Values of Financial Instruments (Details) Details 61 false false R62.htm 9954510 - Disclosure - FAIR VALUE DISCLOSURES - Fair Value of Financial Instruments (Details) Sheet http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFairValueofFinancialInstrumentsDetails FAIR VALUE DISCLOSURES - Fair Value of Financial Instruments (Details) Details 62 false false R63.htm 9954511 - Disclosure - FAIR VALUE DISCLOSURES - Items Measured at Fair Value on a Recurring Basis (Details) Sheet http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESItemsMeasuredatFairValueonaRecurringBasisDetails FAIR VALUE DISCLOSURES - Items Measured at Fair Value on a Recurring Basis (Details) Details 63 false false R64.htm 9954512 - Disclosure - EQUITY - Common Stock (Details) Sheet http://www.sabrahealth.com/role/EQUITYCommonStockDetails EQUITY - Common Stock (Details) Details 64 false false R65.htm 9954513 - Disclosure - EQUITY - Cash Dividends on Common Stock Declared and Paid (Details) Sheet http://www.sabrahealth.com/role/EQUITYCashDividendsonCommonStockDeclaredandPaidDetails EQUITY - Cash Dividends on Common Stock Declared and Paid (Details) Details 65 false false R66.htm 9954514 - Disclosure - EQUITY - Accumulated Other Comprehensive Income (Details) Sheet http://www.sabrahealth.com/role/EQUITYAccumulatedOtherComprehensiveIncomeDetails EQUITY - Accumulated Other Comprehensive Income (Details) Details 66 false false R67.htm 9954515 - Disclosure - EARNINGS PER COMMON SHARE - Computation of Basic and Diluted Earnings Per Share (Details) Sheet http://www.sabrahealth.com/role/EARNINGSPERCOMMONSHAREComputationofBasicandDilutedEarningsPerShareDetails EARNINGS PER COMMON SHARE - Computation of Basic and Diluted Earnings Per Share (Details) Details 67 false false R68.htm 9954516 - Disclosure - EARNINGS PER COMMON SHARE - Narrative (Details) Sheet http://www.sabrahealth.com/role/EARNINGSPERCOMMONSHARENarrativeDetails EARNINGS PER COMMON SHARE - Narrative (Details) Details 68 false false R69.htm 9954517 - Disclosure - SUBSEQUENT EVENTS (Details) Sheet http://www.sabrahealth.com/role/SUBSEQUENTEVENTSDetails SUBSEQUENT EVENTS (Details) Details http://www.sabrahealth.com/role/SUBSEQUENTEVENTS 69 false false All Reports Book All Reports sbra-20230930.htm sbra-20230930.xsd sbra-20230930_cal.xml sbra-20230930_def.xml sbra-20230930_lab.xml sbra-20230930_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 86 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "sbra-20230930.htm": { "nsprefix": "sbra", "nsuri": "http://www.sabrahealth.com/20230930", "dts": { "inline": { "local": [ "sbra-20230930.htm" ] }, "schema": { "local": [ "sbra-20230930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" ] }, "calculationLink": { "local": [ "sbra-20230930_cal.xml" ] }, "definitionLink": { "local": [ "sbra-20230930_def.xml" ] }, "labelLink": { "local": [ "sbra-20230930_lab.xml" ] }, "presentationLink": { "local": [ "sbra-20230930_pre.xml" ] } }, "keyStandard": 259, "keyCustom": 53, "axisStandard": 34, "axisCustom": 1, "memberStandard": 45, "memberCustom": 37, "hidden": { "total": 13, "http://fasb.org/us-gaap/2023": 8, "http://xbrl.sec.gov/dei/2023": 5 }, "contextCount": 307, "entityCount": 1, "segmentCount": 91, "elementCount": 646, "unitCount": 15, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 895, "http://xbrl.sec.gov/dei/2023": 30 }, "report": { "R1": { "role": "http://www.sabrahealth.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS", "longName": "0000002 - Statement - CONSOLIDATED BALANCE SHEETS", "shortName": "CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:RealEstateInvestmentPropertyNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "unique": true } }, "R3": { "role": "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "longName": "0000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:RealEstateInvestmentPropertyAccumulatedDepreciation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRealEstatePropertiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "unique": true } }, "R4": { "role": "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFLOSSINCOME", "longName": "0000004 - Statement - CONSOLIDATED STATEMENTS OF (LOSS) INCOME", "shortName": "CONSOLIDATED STATEMENTS OF (LOSS) INCOME", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:OperatingLeaseLeaseIncome", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:OperatingLeaseLeaseIncome", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME", "longName": "0000005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME", "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "unique": true } }, "R6": { "role": "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY", "longName": "0000006 - Statement - CONSOLIDATED STATEMENTS OF EQUITY", "shortName": "CONSOLIDATED STATEMENTS OF EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-43", "name": "us-gaap:SharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-43", "name": "us-gaap:SharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFEQUITYParenthetical", "longName": "0000007 - Statement - CONSOLIDATED STATEMENTS OF EQUITY (Parenthetical)", "shortName": "CONSOLIDATED STATEMENTS OF EQUITY (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-297", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "sbra:ScheduleOfDividendsDeclaredAndPaidTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true }, "uniqueAnchor": null }, "R8": { "role": "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "longName": "0000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "sbra:NonCashRentalAndRelatedRevenuesAdjustments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "unique": true } }, "R9": { "role": "http://www.sabrahealth.com/role/BUSINESS", "longName": "0000009 - Disclosure - BUSINESS", "shortName": "BUSINESS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES", "longName": "0000010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATED", "longName": "0000011 - Disclosure - RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED)", "shortName": "RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIES", "longName": "0000012 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES", "shortName": "INVESTMENT IN REAL ESTATE PROPERTIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RealEstateDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RealEstateDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.sabrahealth.com/role/IMPAIRMENTOFREALESTATEANDDISPOSITIONS", "longName": "0000013 - Disclosure - IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS", "shortName": "IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTS", "longName": "0000014 - Disclosure - LOANS RECEIVABLE AND OTHER INVESTMENTS", "shortName": "LOANS RECEIVABLE AND OTHER INVESTMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.sabrahealth.com/role/DEBT", "longName": "0000015 - Disclosure - DEBT", "shortName": "DEBT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTS", "longName": "0000016 - Disclosure - DERIVATIVE AND HEDGING INSTRUMENTS", "shortName": "DERIVATIVE AND HEDGING INSTRUMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURES", "longName": "0000017 - Disclosure - FAIR VALUE DISCLOSURES", "shortName": "FAIR VALUE DISCLOSURES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.sabrahealth.com/role/EQUITY", "longName": "0000018 - Disclosure - EQUITY", "shortName": "EQUITY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.sabrahealth.com/role/EARNINGSPERCOMMONSHARE", "longName": "0000019 - Disclosure - EARNINGS PER COMMON SHARE", "shortName": "EARNINGS PER COMMON SHARE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.sabrahealth.com/role/COMMITMENTSANDCONTINGENCIES", "longName": "0000020 - Disclosure - COMMITMENTS AND CONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.sabrahealth.com/role/SUBSEQUENTEVENTS", "longName": "0000021 - Disclosure - SUBSEQUENT EVENTS", "shortName": "SUBSEQUENT EVENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true } }, "R22": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true }, "uniqueAnchor": null }, "R23": { "role": "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies", "longName": "9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDTables", "longName": "9954472 - Disclosure - RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED) (Tables)", "shortName": "RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED) (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESTables", "longName": "9954473 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES (Tables)", "shortName": "INVESTMENT IN REAL ESTATE PROPERTIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRealEstatePropertiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRealEstatePropertiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.sabrahealth.com/role/IMPAIRMENTOFREALESTATEANDDISPOSITIONSTables", "longName": "9954474 - Disclosure - IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS (Tables)", "shortName": "IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSTables", "longName": "9954475 - Disclosure - LOANS RECEIVABLE AND OTHER INVESTMENTS (Tables)", "shortName": "LOANS RECEIVABLE AND OTHER INVESTMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.sabrahealth.com/role/DEBTTables", "longName": "9954476 - Disclosure - DEBT (Tables)", "shortName": "DEBT (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSTables", "longName": "9954477 - Disclosure - DERIVATIVE AND HEDGING INSTRUMENTS (Tables)", "shortName": "DERIVATIVE AND HEDGING INSTRUMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESTables", "longName": "9954478 - Disclosure - FAIR VALUE DISCLOSURES (Tables)", "shortName": "FAIR VALUE DISCLOSURES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.sabrahealth.com/role/EQUITYTables", "longName": "9954479 - Disclosure - EQUITY (Tables)", "shortName": "EQUITY (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "sbra:ScheduleOfDividendsDeclaredAndPaidTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "sbra:ScheduleOfDividendsDeclaredAndPaidTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.sabrahealth.com/role/EARNINGSPERCOMMONSHARETables", "longName": "9954480 - Disclosure - EARNINGS PER COMMON SHARE (Tables)", "shortName": "EARNINGS PER COMMON SHARE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails", "longName": "9954481 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "c-3", "name": "sbra:RealEstateInvestmentsJointVenturesNumber", "unitRef": "investment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-61", "name": "us-gaap:UnusualOrInfrequentItemInsuranceProceeds", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "unique": true } }, "R34": { "role": "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDNarrativeDetails", "longName": "9954482 - Disclosure - RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED) - Narrative (Details)", "shortName": "RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED) - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-78", "name": "us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "unique": true } }, "R35": { "role": "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDPurchasePriceAllocationforRecentRealEstateAcquisitionsDetails", "longName": "9954483 - Disclosure - RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED) - Purchase Price Allocation for Recent Real Estate Acquisitions (Details)", "shortName": "RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED) - Purchase Price Allocation for Recent Real Estate Acquisitions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c-69", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLand", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-69", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLand", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails", "longName": "9954484 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES - Real Estate Properties Held for Investment (Details)", "shortName": "INVESTMENT IN REAL ESTATE PROPERTIES - Real Estate Properties Held for Investment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:BuildingsAndImprovementsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:BuildingsAndImprovementsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESOperatingLeasesNarrativeDetails", "longName": "9954485 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES - Operating Leases Narrative (Details)", "shortName": "INVESTMENT IN REAL ESTATE PROPERTIES - Operating Leases Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:SecurityDepositLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "unique": true } }, "R38": { "role": "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESFutureMinimumRentalPaymentsReceivableforPropertiesHeldforInvestmentUnderNonCancelableOperatingLeasesDetails", "longName": "9954486 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES - Future Minimum Rental Payments Receivable for Properties Held for Investment Under Non-Cancelable Operating Leases (Details)", "shortName": "INVESTMENT IN REAL ESTATE PROPERTIES - Future Minimum Rental Payments Receivable for Properties Held for Investment Under Non-Cancelable Operating Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESSeniorHousingManagedCommunitiesNarrativeDetails", "longName": "9954487 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES - Senior Housing - Managed Communities Narrative (Details)", "shortName": "INVESTMENT IN REAL ESTATE PROPERTIES - Senior Housing - Managed Communities Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-101", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "unique": true } }, "R40": { "role": "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESCapitalandOtherExpendituresNarrativeDetails", "longName": "9954488 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES - Capital and Other Expenditures Narrative (Details)", "shortName": "INVESTMENT IN REAL ESTATE PROPERTIES - Capital and Other Expenditures Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CapitalExpendituresIncurredButNotYetPaid", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CapitalExpendituresIncurredButNotYetPaid", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESScheduleofInvestmentinJointVenturesDetails", "longName": "9954489 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES - Schedule of Investment in Joint Ventures (Details)", "shortName": "INVESTMENT IN REAL ESTATE PROPERTIES - Schedule of Investment in Joint Ventures (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:EquityMethodInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-106", "name": "us-gaap:EquityMethodInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:EquityMethodInvestmentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "unique": true } }, "R42": { "role": "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESInvestmentinUnconsolidatedJointVentureNarrativeDetails", "longName": "9954490 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES - Investment in Unconsolidated Joint Venture Narrative (Details)", "shortName": "INVESTMENT IN REAL ESTATE PROPERTIES - Investment in Unconsolidated Joint Venture Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:EquityMethodInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-112", "name": "us-gaap:PaymentsToAcquireBuildings", "unitRef": "cad", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "unique": true } }, "R43": { "role": "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESSummarizedFinancialDataofUnconsolidatedJointVentureDetails", "longName": "9954491 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES - Summarized Financial Data of Unconsolidated Joint Venture (Details)", "shortName": "INVESTMENT IN REAL ESTATE PROPERTIES - Summarized Financial Data of Unconsolidated Joint Venture (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-116", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "unique": true } }, "R44": { "role": "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESNetInvestmentinSalesTypeLeaseNarrativeDetails", "longName": "9954492 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES - Net Investment in Sales-Type Lease Narrative (Details)", "shortName": "INVESTMENT IN REAL ESTATE PROPERTIES - Net Investment in Sales-Type Lease Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-117", "name": "us-gaap:SalesTypeLeaseNetInvestmentInLease", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "unique": true } }, "R45": { "role": "http://www.sabrahealth.com/role/IMPAIRMENTOFREALESTATEANDDISPOSITIONSNarrativeDetails", "longName": "9954493 - Disclosure - IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS - Narrative (Details)", "shortName": "IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:ImpairmentOfRealEstate", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true }, "uniqueAnchor": null }, "R46": { "role": "http://www.sabrahealth.com/role/IMPAIRMENTOFREALESTATEANDDISPOSITIONSDispositionsDetails", "longName": "9954494 - Disclosure - IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS - Dispositions (Details)", "shortName": "IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS - Dispositions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-1", "name": "sbra:DisposalGroupIncludingDiscontinuedOperationsNumberOfProperties", "unitRef": "facility", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "sbra:DisposalGroupIncludingDiscontinuedOperationsNumberOfProperties", "unitRef": "facility", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails", "longName": "9954495 - Disclosure - LOANS RECEIVABLE AND OTHER INVESTMENTS - Composition of Loans Receivable and Other Investments (Details)", "shortName": "LOANS RECEIVABLE AND OTHER INVESTMENTS - Composition of Loans Receivable and Other Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-3", "name": "sbra:FinancingReceivableNumberOfLoans", "unitRef": "loan", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "sbra:FinancingReceivableNumberOfLoans", "unitRef": "loan", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSScheduleofAdditionalInformationRegardingtheCompanysLoansReceivableDetails", "longName": "9954496 - Disclosure - LOANS RECEIVABLE AND OTHER INVESTMENTS - Schedule of Additional Information Regarding the Company's Loans Receivable (Details)", "shortName": "LOANS RECEIVABLE AND OTHER INVESTMENTS - Schedule of Additional Information Regarding the Company's Loans Receivable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:FinancingReceivableAllowanceForCreditLosses", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "sbra:ScheduleOfAdditionalInformationLoansAndFinancingReceivableTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ProvisionForLoanLossesExpensed", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "sbra:ScheduleOfAdditionalInformationLoansAndFinancingReceivableTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "unique": true } }, "R49": { "role": "http://www.sabrahealth.com/role/DEBTSecuredIndebtednessDetails", "longName": "9954497 - Disclosure - DEBT - Secured Indebtedness (Details)", "shortName": "DEBT - Secured Indebtedness (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:DeferredFinanceCostsNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-129", "name": "us-gaap:LongtermDebtPercentageBearingFixedInterestAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "unique": true } }, "R50": { "role": "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesDetails", "longName": "9954498 - Disclosure - DEBT - Senior Unsecured Notes (Details)", "shortName": "DEBT - Senior Unsecured Notes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-141", "name": "us-gaap:SeniorNotes", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "unique": true } }, "R51": { "role": "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesNarrativeDetails", "longName": "9954499 - Disclosure - DEBT - Senior Unsecured Notes Narrative (Details)", "shortName": "DEBT - Senior Unsecured Notes Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-133", "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-143", "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "unique": true } }, "R52": { "role": "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails", "longName": "9954500 - Disclosure - DEBT - Credit Agreement Narrative (Details)", "shortName": "DEBT - Credit Agreement Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-166", "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "unique": true } }, "R53": { "role": "http://www.sabrahealth.com/role/DEBTInterestExpenseNarrativeDetails", "longName": "9954501 - Disclosure - DEBT - Interest Expense Narrative (Details)", "shortName": "DEBT - Interest Expense Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:InterestExpenseDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:InterestPayableCurrentAndNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "unique": true } }, "R54": { "role": "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails", "longName": "9954502 - Disclosure - DEBT - Schedule of Maturities for Outstanding Debt (Details)", "shortName": "DEBT - Schedule of Maturities for Outstanding Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNarrativeDetails", "longName": "9954503 - Disclosure - DERIVATIVE AND HEDGING INSTRUMENTS - Narrative (Details)", "shortName": "DERIVATIVE AND HEDGING INSTRUMENTS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:DerivativeLiabilities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-241", "name": "sbra:DerivativesNetHedgeIneffectivenessGainLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "sbra:DerivativesNetHedgeIneffectivenessGainLoss", "sbra:DerivativesNetHedgeIneffectivenessGainLoss", "sbra:DerivativesNetHedgeIneffectivenessGainLoss", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "unique": true } }, "R56": { "role": "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNotionalAmountofDerivativesInstrumentsDetails", "longName": "9954504 - Disclosure - DERIVATIVE AND HEDGING INSTRUMENTS - Notional Amount of Derivatives Instruments (Details)", "shortName": "DERIVATIVE AND HEDGING INSTRUMENTS - Notional Amount of Derivatives Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-194", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-194", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSDerivativeandFinancialInstrumentsDesignatedasHedgingInstrumentsDetails", "longName": "9954505 - Disclosure - DERIVATIVE AND HEDGING INSTRUMENTS - Derivative and Financial Instruments Designated as Hedging Instruments (Details)", "shortName": "DERIVATIVE AND HEDGING INSTRUMENTS - Derivative and Financial Instruments Designated as Hedging Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:DerivativeAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-212", "name": "us-gaap:DerivativeAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "unique": true } }, "R58": { "role": "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSEffectofDerivativeFinancialInstrumentsontheCondensedConsolidatedStatementsofLossIncomeandCondensedConsolidatedStatementsofEquityDetails", "longName": "9954506 - Disclosure - DERIVATIVE AND HEDGING INSTRUMENTS - Effect of Derivative Financial Instruments on the Condensed Consolidated Statements of (Loss) Income and Condensed Consolidated Statements of Equity (Details)", "shortName": "DERIVATIVE AND HEDGING INSTRUMENTS - Effect of Derivative Financial Instruments on the Condensed Consolidated Statements of (Loss) Income and Condensed Consolidated Statements of Equity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-5", "name": "sbra:OtherComprehensiveIncomeLossCashFlowAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "sbra:OtherComprehensiveIncomeLossCashFlowAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSGrossPresentationEffectsofOffsettingandNetPresentationofDerivativesDetails", "longName": "9954507 - Disclosure - DERIVATIVE AND HEDGING INSTRUMENTS - Gross Presentation, Effects of Offsetting, and Net Presentation of Derivatives (Details)", "shortName": "DERIVATIVE AND HEDGING INSTRUMENTS - Gross Presentation, Effects of Offsetting, and Net Presentation of Derivatives (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESNarrativeDetails", "longName": "9954508 - Disclosure - FAIR VALUE DISCLOSURES - Narrative (Details)", "shortName": "FAIR VALUE DISCLOSURES - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-247", "name": "sbra:FinancingReceivableMeasurementInput", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-247", "name": "sbra:FinancingReceivableMeasurementInput", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFaceValuesCarryingAmountsandFairValuesofFinancialInstrumentsDetails", "longName": "9954509 - Disclosure - FAIR VALUE DISCLOSURES - Face Values, Carrying Amounts and Fair Values of Financial Instruments (Details)", "shortName": "FAIR VALUE DISCLOSURES - Face Values, Carrying Amounts and Fair Values of Financial Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-3", "name": "sbra:FinancingReceivablePrincipalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-141", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "unique": true } }, "R62": { "role": "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFairValueofFinancialInstrumentsDetails", "longName": "9954510 - Disclosure - FAIR VALUE DISCLOSURES - Fair Value of Financial Instruments (Details)", "shortName": "FAIR VALUE DISCLOSURES - Fair Value of Financial Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-263", "name": "us-gaap:LoansReceivableFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-263", "name": "us-gaap:LoansReceivableFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESItemsMeasuredatFairValueonaRecurringBasisDetails", "longName": "9954511 - Disclosure - FAIR VALUE DISCLOSURES - Items Measured at Fair Value on a Recurring Basis (Details)", "shortName": "FAIR VALUE DISCLOSURES - Items Measured at Fair Value on a Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:DerivativeAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-275", "name": "us-gaap:DerivativeAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "unique": true } }, "R64": { "role": "http://www.sabrahealth.com/role/EQUITYCommonStockDetails", "longName": "9954512 - Disclosure - EQUITY - Common Stock (Details)", "shortName": "EQUITY - Common Stock (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.sabrahealth.com/role/EQUITYCashDividendsonCommonStockDeclaredandPaidDetails", "longName": "9954513 - Disclosure - EQUITY - Cash Dividends on Common Stock Declared and Paid (Details)", "shortName": "EQUITY - Cash Dividends on Common Stock Declared and Paid (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-297", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "sbra:ScheduleOfDividendsDeclaredAndPaidTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true }, "uniqueAnchor": null }, "R66": { "role": "http://www.sabrahealth.com/role/EQUITYAccumulatedOtherComprehensiveIncomeDetails", "longName": "9954514 - Disclosure - EQUITY - Accumulated Other Comprehensive Income (Details)", "shortName": "EQUITY - Accumulated Other Comprehensive Income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-299", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "unique": true } }, "R67": { "role": "http://www.sabrahealth.com/role/EARNINGSPERCOMMONSHAREComputationofBasicandDilutedEarningsPerShareDetails", "longName": "9954515 - Disclosure - EARNINGS PER COMMON SHARE - Computation of Basic and Diluted Earnings Per Share (Details)", "shortName": "EARNINGS PER COMMON SHARE - Computation of Basic and Diluted Earnings Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "unique": true } }, "R68": { "role": "http://www.sabrahealth.com/role/EARNINGSPERCOMMONSHARENarrativeDetails", "longName": "9954516 - Disclosure - EARNINGS PER COMMON SHARE - Narrative (Details)", "shortName": "EARNINGS PER COMMON SHARE - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c-303", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-303", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true, "unique": true } }, "R69": { "role": "http://www.sabrahealth.com/role/SUBSEQUENTEVENTSDetails", "longName": "9954517 - Disclosure - SUBSEQUENT EVENTS (Details)", "shortName": "SUBSEQUENT EVENTS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c-297", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "sbra:ScheduleOfDividendsDeclaredAndPaidTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-307", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20230930.htm", "unique": true } } }, "tag": { "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTS" ], "lang": { "en-us": { "role": { "terseLabel": "LOANS RECEIVABLE AND OTHER INVESTMENTS", "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]", "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses." } } }, "auth_ref": [ "r816" ] }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "presentation": [ "http://www.sabrahealth.com/role/IMPAIRMENTOFREALESTATEANDDISPOSITIONSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Dispositions", "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r14", "r23", "r33", "r122", "r123", "r124", "r125", "r126", "r127", "r129", "r130", "r131", "r163" ] }, "us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentOtherThanTemporaryImpairment", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESInvestmentinUnconsolidatedJointVentureNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other-than-temporary impairment of unconsolidated joint ventures", "label": "Equity Method Investment, Other than Temporary Impairment", "documentation": "This item represents an other than temporary decline in value that has been recognized against an investment accounted for under the equity method of accounting. The excess of the carrying amount over the fair value of the investment represents the amount of the write down which is or was reflected in earnings. The written down value is a new cost basis with the adjusted value of the investment becoming its new carrying value subject to the equity accounting method. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity which would justify the carrying amount of the investment." } } }, "auth_ref": [ "r818" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentDomain", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESOperatingLeasesNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Domain]", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r305", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r341", "r342", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r681", "r797", "r864" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFLOSSINCOME": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFLOSSINCOME" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Income tax expense", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r189", "r200", "r261", "r262", "r289", "r447", "r450", "r539" ] }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentOwnershipPercentage", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESInvestmentinUnconsolidatedJointVentureNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESScheduleofInvestmentinJointVenturesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Ownership", "terseLabel": "Equity interest in joint venture", "label": "Equity Method Investment, Ownership Percentage", "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." } } }, "auth_ref": [ "r309" ] }, "us-gaap_UnsecuredDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnsecuredDebt", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Senior unsecured notes, net", "label": "Unsecured Debt", "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of uncollateralized debt obligations (with maturities initially due after one year or beyond the operating cycle if longer)." } } }, "auth_ref": [ "r32", "r179", "r863" ] }, "sbra_NetIncomeLossAttributableToCommonStockholdersAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "NetIncomeLossAttributableToCommonStockholdersAbstract", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFLOSSINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Net (loss) income, per:", "label": "Net Income (Loss) Attributable To Common Stockholders [Abstract]", "documentation": "Net income (loss) attributable to common stockholders" } } }, "auth_ref": [] }, "sbra_LineOfCreditFacilityOptionalExtensionPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "LineOfCreditFacilityOptionalExtensionPeriod", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails", "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Extension period", "label": "Line Of Credit Facility, Optional Extension Period", "documentation": "Line Of Credit Facility, Optional Extension Period" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfSecuredDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfSecuredDebt", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Principal payments on secured debt", "label": "Repayments of Secured Debt", "documentation": "The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt." } } }, "auth_ref": [ "r51" ] }, "sbra_SaleOfStockRemainingAmountAvailableForIssuance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "SaleOfStockRemainingAmountAvailableForIssuance", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/EQUITYCommonStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount available for issuance", "label": "Sale Of Stock, Remaining Amount Available For Issuance", "documentation": "Sale Of Stock, Remaining Amount Available For Issuance" } } }, "auth_ref": [] }, "sbra_NumberOfRealEstatePropertiesAcquired": { "xbrltype": "integerItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "NumberOfRealEstatePropertiesAcquired", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESInvestmentinUnconsolidatedJointVentureNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of acquired properties", "label": "Number Of Real Estate Properties Acquired", "documentation": "Number Of Real Estate Properties Acquired" } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": [ "http://www.sabrahealth.com/role/EQUITYAccumulatedOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total Equity [Line Items]", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r228", "r229", "r488", "r490", "r491", "r492", "r493", "r494" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" ], "lang": { "en-us": { "role": { "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r156", "r243" ] }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CarryingReportedAmountFairValueDisclosureMember", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFaceValuesCarryingAmountsandFairValuesofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying Amount", "label": "Reported Value Measurement [Member]", "documentation": "Measured as reported on the statement of financial position (balance sheet)." } } }, "auth_ref": [ "r108", "r109" ] }, "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentNonconsolidatedInvesteeAxis", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESSummarizedFinancialDataofUnconsolidatedJointVentureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Axis]", "label": "Equity Method Investment, Nonconsolidated Investee [Axis]", "documentation": "Information by nonconsolidated equity method investee. Excludes information consolidated by reporting entity." } } }, "auth_ref": [ "r208", "r246", "r312", "r486" ] }, "sbra_OtherComprehensiveIncomeLossUnrealizedGainLossNetofTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "OtherComprehensiveIncomeLossUnrealizedGainLossNetofTaxAbstract", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain (loss), net of tax:", "label": "Other Comprehensive Income (Loss), Unrealized Gain (Loss), Net of Tax [Abstract]", "documentation": "Other Comprehensive Income (Loss), Unrealized Gain (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "presentation": [ "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Purchase Price Allocation", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree." } } }, "auth_ref": [ "r171" ] }, "sbra_A3.90SeniorUnsecuredNotesDue2029Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "A3.90SeniorUnsecuredNotesDue2029Member", "presentation": [ "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesDetails", "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "3.90% senior unsecured notes due 2029 (\u201c2029 Notes\u201d)", "label": "3.90% Senior Unsecured Notes Due 2029 [Member]", "documentation": "Senior Unsecured Notes Due 2029 [Member]" } } }, "auth_ref": [] }, "srt_WeightedAverageMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "WeightedAverageMember", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average", "label": "Weighted Average [Member]" } } }, "auth_ref": [ "r664", "r665", "r853", "r855", "r858" ] }, "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentNonconsolidatedInvesteeDomain", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESSummarizedFinancialDataofUnconsolidatedJointVentureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Domain]", "label": "Equity Method Investment, Nonconsolidated Investee [Domain]", "documentation": "Nonconsolidated equity method investee. Excludes information consolidated by reporting entity." } } }, "auth_ref": [ "r208", "r246", "r312", "r486" ] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.sabrahealth.com/role/EARNINGSPERCOMMONSHARENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r56" ] }, "sbra_DerivativesNetHedgeIneffectivenessGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "DerivativesNetHedgeIneffectivenessGainLoss", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ineffectiveness on cash flow hedges", "label": "Derivatives, Net Hedge Ineffectiveness Gain (Loss)", "documentation": "Derivatives, Net Hedge Ineffectiveness Gain (Loss)" } } }, "auth_ref": [] }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PortionAtFairValueFairValueDisclosureMember", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFaceValuesCarryingAmountsandFairValuesofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Portion at Fair Value Measurement", "label": "Portion at Fair Value Measurement [Member]", "documentation": "Measured at fair value for financial reporting purposes." } } }, "auth_ref": [ "r484" ] }, "sbra_PreferredEquityInvestmentsNumber": { "xbrltype": "integerItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "PreferredEquityInvestmentsNumber", "calculation": { "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails": { "parentTag": "sbra_NumberOfInvestments", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Quantity", "label": "Preferred Equity Investments, Number", "documentation": "Preferred Equity Investments, Number of Investments" } } }, "auth_ref": [] }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EstimateOfFairValueFairValueDisclosureMember", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFaceValuesCarryingAmountsandFairValuesofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "label": "Estimate of Fair Value Measurement [Member]", "documentation": "Measured as an estimate of fair value." } } }, "auth_ref": [ "r372", "r485", "r683", "r684" ] }, "us-gaap_DerivativeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLineItems", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNarrativeDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNotionalAmountofDerivativesInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Line Items]", "label": "Derivative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r471" ] }, "sbra_OtherComprehensiveIncomeLossCashFlowAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "OtherComprehensiveIncomeLossCashFlowAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSEffectofDerivativeFinancialInstrumentsontheCondensedConsolidatedStatementsofLossIncomeandCondensedConsolidatedStatementsofEquityDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSEffectofDerivativeFinancialInstrumentsontheCondensedConsolidatedStatementsofLossIncomeandCondensedConsolidatedStatementsofEquityDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Gain (loss) recognized in other comprehensive income, cash flow hedges and net investment hedges", "label": "Other Comprehensive Income (Loss), Cash Flow And Net Investment Hedge, Gain (Loss), Before Reclassification And Tax", "documentation": "Other Comprehensive Income (Loss), Cash Flow And Net Investment Hedge, Gain (Loss), Before Reclassification And Tax" } } }, "auth_ref": [] }, "us-gaap_NumberOfUnitsInRealEstateProperty": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfUnitsInRealEstateProperty", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number\u00a0of Beds/Units", "label": "Number of Units in Real Estate Property", "documentation": "The number of units in a real estate property owned as of the balance sheet date." } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r139", "r180", "r531", "r704", "r809", "r820", "r846" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESOperatingLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r247", "r248", "r362", "r392", "r505", "r671", "r672" ] }, "sbra_EarningsPerShareBasicAndDilutedEPSAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "EarningsPerShareBasicAndDilutedEPSAbstract", "presentation": [ "http://www.sabrahealth.com/role/EARNINGSPERCOMMONSHAREComputationofBasicandDilutedEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net (loss) income, per:", "label": "Earnings Per Share, Basic and Diluted EPS [Abstract]", "documentation": "Earnings Per Share, Basic and Diluted EPS" } } }, "auth_ref": [] }, "us-gaap_CommonStockDividendsPerShareDeclared": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockDividendsPerShareDeclared", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFEQUITYParenthetical", "http://www.sabrahealth.com/role/EQUITYCashDividendsonCommonStockDeclaredandPaidDetails", "http://www.sabrahealth.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common dividends (in dollars per share)", "verboseLabel": "Quarterly cash dividend declared on common stock (in dollars per share)", "label": "Common Stock, Dividends, Per Share, Declared", "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding." } } }, "auth_ref": [ "r169" ] }, "sbra_EquityMethodInvestmentEstimatedFairValueInvestmentBasisAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "EquityMethodInvestmentEstimatedFairValueInvestmentBasisAmount", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESInvestmentinUnconsolidatedJointVentureNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity interest, investment basis amount", "label": "Equity Method Investment, Estimated Fair Value Investment Basis Amount", "documentation": "Equity Method Investment, Estimated Fair Value Investment Basis Amount" } } }, "auth_ref": [] }, "us-gaap_DerivativeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeTable", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNarrativeDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNotionalAmountofDerivativesInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Table]", "label": "Derivative [Table]", "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item." } } }, "auth_ref": [ "r19", "r82", "r83", "r85", "r88", "r92", "r96", "r99", "r100", "r104", "r471" ] }, "us-gaap_DerivativeAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssetsAbstract", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSDerivativeandFinancialInstrumentsDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets:", "label": "Derivative Asset [Abstract]" } } }, "auth_ref": [] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r784" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of stock-based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r70", "r71", "r415" ] }, "sbra_ForwardStartingInterestRateSwapsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "ForwardStartingInterestRateSwapsMember", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSDerivativeandFinancialInstrumentsDesignatedasHedgingInstrumentsDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESItemsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forward starting interest rate swaps", "label": "Forward Starting Interest Rate Swaps [Member]", "documentation": "Forward Starting Interest Rate Swaps [Member]" } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsGainLossLineItems", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSEffectofDerivativeFinancialInstrumentsontheCondensedConsolidatedStatementsofLossIncomeandCondensedConsolidatedStatementsofEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r462" ] }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingSegmentsMember", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESOperatingLeasesNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Segments", "label": "Operating Segments [Member]", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r293", "r294", "r295", "r296", "r297", "r302" ] }, "sbra_BehavioralHealthMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "BehavioralHealthMember", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Behavioral Health", "label": "Behavioral Health [Member]", "documentation": "Behavioral Health" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/IMPAIRMENTOFREALESTATEANDDISPOSITIONSDispositionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss", "label": "Disposal Group, Including Discontinued Operation, Operating Income (Loss)", "documentation": "Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r128" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "sbra_NumberOfInvestments": { "xbrltype": "integerItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "NumberOfInvestments", "calculation": { "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total quantity", "label": "Number Of Investments", "documentation": "Number Of Investments" } } }, "auth_ref": [] }, "sbra_NonCashRentalAndRelatedRevenuesAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "NonCashRentalAndRelatedRevenuesAdjustments", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash rental and related revenues", "label": "Non-Cash Rental And Related Revenues Adjustments", "documentation": "Non-Cash Rental And Related Revenues Adjustments" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r52", "r209", "r668" ] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSDerivativeandFinancialInstrumentsDesignatedasHedgingInstrumentsDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSEffectofDerivativeFinancialInstrumentsontheCondensedConsolidatedStatementsofLossIncomeandCondensedConsolidatedStatementsofEquityDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNarrativeDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNotionalAmountofDerivativesInstrumentsDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESItemsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Contract [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r576", "r579", "r592", "r593", "r594", "r596", "r597", "r598", "r599", "r601", "r602", "r603", "r604", "r614", "r615", "r616", "r617", "r620", "r621", "r622", "r623", "r637", "r639", "r643", "r646", "r707", "r709" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NumberOfRealEstateProperties": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfRealEstateProperties", "presentation": [ "http://www.sabrahealth.com/role/IMPAIRMENTOFREALESTATEANDDISPOSITIONSNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESOperatingLeasesNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESScheduleofInvestmentinJointVenturesDetails", "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of properties", "verboseLabel": "Number\u00a0of Properties", "label": "Number of Real Estate Properties", "documentation": "The number of real estate properties owned as of the balance sheet date." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "sbra_ProceedsPaymentsFromIssuanceOfStockNetOfTaxesPaidOnBehalfOfEmployees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "ProceedsPaymentsFromIssuanceOfStockNetOfTaxesPaidOnBehalfOfEmployees", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock, net", "label": "Proceeds (Payments) From Issuance Of Stock, Net Of Taxes Paid On Behalf Of Employees", "documentation": "Proceeds (Payments) From Issuance Of Stock, Net Of Taxes Paid On Behalf Of Employees" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESNetInvestmentinSalesTypeLeaseNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net proceeds from sales-type lease", "label": "Proceeds from Lease Payment, Sales-Type and Direct Financing Leases, Investing Activity", "documentation": "Amount of cash inflow from principal payment received from sales-type and direct financing leases classified as investing activity." } } }, "auth_ref": [ "r191" ] }, "sbra_PreferredEquityInvestmentWeightedAverageEffectiveRate": { "xbrltype": "percentItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "PreferredEquityInvestmentWeightedAverageEffectiveRate", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Annualized Effective Interest Rate / Rate of Return", "label": "Preferred Equity Investment, Weighted Average Effective Rate", "documentation": "Preferred Equity Investment, Weighted Average Effective Rate" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Equity", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssets", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSGrossPresentationEffectsofOffsettingandNetPresentationofDerivativesDetails": { "parentTag": "us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSDerivativeandFinancialInstrumentsDesignatedasHedgingInstrumentsDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSGrossPresentationEffectsofOffsettingandNetPresentationofDerivativesDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESItemsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value", "totalLabel": "Net Amounts of Assets / Liabilities presented in the Balance Sheet", "verboseLabel": "Financial assets", "label": "Derivative Asset", "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r215", "r218", "r485", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r578", "r579", "r593", "r594", "r637", "r642", "r643", "r644", "r646", "r647", "r672", "r709", "r867" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "sbra_SkilledNursingTransitionalCareFacilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "SkilledNursingTransitionalCareFacilitiesMember", "presentation": [ "http://www.sabrahealth.com/role/IMPAIRMENTOFREALESTATEANDDISPOSITIONSNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESNetInvestmentinSalesTypeLeaseNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Skilled Nursing/Transitional Care", "terseLabel": "Skilled nursing transitional care facility", "label": "Skilled Nursing Transitional Care Facilities [Member]", "documentation": "Skilled Nursing Transitional Care Facilities [Member]" } } }, "auth_ref": [] }, "sbra_FinancingReceivableEffectiveInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "FinancingReceivableEffectiveInterestRate", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Annualized Effective Interest Rate / Rate of Return", "label": "Financing Receivable, Effective Interest Rate", "documentation": "Financing Receivable, Effective Interest Rate" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY", "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFLOSSINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r250", "r251", "r252", "r279", "r515", "r565", "r568", "r580", "r581", "r582", "r583", "r584", "r585", "r588", "r590", "r591", "r592", "r593", "r594", "r596", "r597", "r598", "r599", "r601", "r602", "r603", "r604", "r605", "r607", "r609", "r610", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r626", "r710" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r783" ] }, "sbra_MarlinSpringJointVentureMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "MarlinSpringJointVentureMember", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESInvestmentinUnconsolidatedJointVentureNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESScheduleofInvestmentinJointVenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Marlin Spring Joint Venture", "label": "Marlin Spring Joint Venture [Member]", "documentation": "Marlin Spring Joint Venture" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.sabrahealth.com/role/EQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "EQUITY", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r166", "r245", "r389", "r391", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r472", "r629", "r630", "r651" ] }, "us-gaap_PaymentsOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfFinancingCosts", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments of deferred financing costs", "label": "Payments of Financing Costs", "documentation": "The cash outflow for loan and debt issuance costs." } } }, "auth_ref": [ "r49" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromInsuranceSettlementInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromInsuranceSettlementInvestingActivities", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Insurance proceeds", "label": "Proceeds from Insurance Settlement, Investing Activities", "documentation": "Amount of cash inflow for proceeds from settlement of insurance claim, classified as investing activities. Excludes insurance settlement classified as operating activities." } } }, "auth_ref": [ "r7", "r44" ] }, "sbra_InvestmentsWeightedAverageContractualRate": { "xbrltype": "percentItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "InvestmentsWeightedAverageContractualRate", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total weighted average contractual interest rate / rate of return", "label": "Investments, Weighted Average Contractual Rate", "documentation": "Investments, Weighted Average Contractual Rate" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Lease intangible assets, net", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r159", "r516" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.sabrahealth.com/role/EQUITYCommonStockDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443" ] }, "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/IMPAIRMENTOFREALESTATEANDDISPOSITIONSDispositionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss on sale", "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal", "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations." } } }, "auth_ref": [ "r337", "r807", "r825" ] }, "sbra_BusinessAcquisitionNumberOfAcquiredProperties": { "xbrltype": "integerItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "BusinessAcquisitionNumberOfAcquiredProperties", "presentation": [ "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of acquired properties", "label": "Business Acquisition, Number Of Acquired Properties", "documentation": "Business Acquisition, Number Of Acquired Properties" } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.sabrahealth.com/role/EQUITYCommonStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r414", "r416", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443" ] }, "sbra_PreferredEquityInvestmentFaceValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "PreferredEquityInvestmentFaceValue", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails": { "parentTag": "us-gaap_InvestmentOwnedBalancePrincipalAmount", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFaceValuesCarryingAmountsandFairValuesofFinancialInstrumentsDetails", "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Principal balance", "verboseLabel": "Preferred equity investments", "label": "Preferred Equity Investment, Face Value", "documentation": "Preferred Equity Investment, Face Value" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.sabrahealth.com/role/EQUITYCommonStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r414", "r416", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443" ] }, "us-gaap_BuildingsAndImprovementsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BuildingsAndImprovementsGross", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails": { "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Building and improvements", "label": "Buildings and Improvements, Gross", "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing." } } }, "auth_ref": [ "r161" ] }, "sbra_TripleNetPortfolioMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "TripleNetPortfolioMember", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFLOSSINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Triple-net portfolio", "label": "Triple-Net Portfolio [Member]", "documentation": "Triple-Net Portfolio [Member]" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "sbra_ScheduleOfAdditionalInformationLoansAndFinancingReceivableTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "ScheduleOfAdditionalInformationLoansAndFinancingReceivableTableTextBlock", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Additional Information Regarding the Company's Loans Receivable", "label": "Schedule Of Additional Information, Loans And Financing Receivable [Table Text Block]", "documentation": "Schedule Of Additional Information, Loans And Financing Receivable" } } }, "auth_ref": [] }, "us-gaap_UnusualOrInfrequentItemInsuranceProceeds": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnusualOrInfrequentItemInsuranceProceeds", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds of insurance", "label": "Unusual or Infrequent Item, or Both, Insurance Proceeds", "documentation": "Amount of insurance proceeds for an event or transaction that is unusual in nature or infrequent in occurrence, or both." } } }, "auth_ref": [ "r148" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.sabrahealth.com/role/EARNINGSPERCOMMONSHARETables" ], "lang": { "en-us": { "role": { "terseLabel": "Computation of Basic and Diluted Earnings Per Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r814" ] }, "sbra_RealEstateInvestmentsJointVenturesNumber": { "xbrltype": "integerItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "RealEstateInvestmentsJointVenturesNumber", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of investments in loans accounted for as real estate joint ventures", "label": "Real Estate Investments, Joint Ventures, Number", "documentation": "Real Estate Investments, Joint Ventures, Number" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESSummarizedFinancialDataofUnconsolidatedJointVentureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss", "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r173", "r246", "r253", "r281", "r294", "r300", "r302", "r312", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r475", "r486", "r533", "r677", "r832" ] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFLOSSINCOME": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 }, "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFLOSSINCOME", "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss on extinguishment of debt", "negatedLabel": "Loss on extinguishment of debt", "label": "Gain (Loss) on Extinguishment of Debt", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": [ "r10", "r66", "r67" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDNarrativeDetails", "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDPurchasePriceAllocationforRecentRealEstateAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r333", "r334", "r335", "r336", "r516", "r517" ] }, "sbra_SeniorHousingFacilitiesManagedCommunitiesProprietaryDevelopmentPipelineMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "SeniorHousingFacilitiesManagedCommunitiesProprietaryDevelopmentPipelineMember", "presentation": [ "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Housing Facilities - Managed Communities, Proprietary Development Pipeline", "label": "Senior Housing Facilities - Managed Communities, Proprietary Development Pipeline [Member]", "documentation": "Senior Housing Facilities - Managed Communities, Proprietary Development Pipeline" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfMediumTermNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfMediumTermNotes", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from term loans", "label": "Proceeds from Issuance of Medium-term Notes", "documentation": "The cash inflow from a debt funding received on a regular basis with maturities ranging from 5-10 years." } } }, "auth_ref": [ "r48" ] }, "sbra_BusinessAcquisitionByTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "BusinessAcquisitionByTypeDomain", "presentation": [ "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, By Type [Domain]", "label": "Business Acquisition, By Type [Domain]", "documentation": "[Domain] for Business Acquisition, By Type [Axis]" } } }, "auth_ref": [] }, "us-gaap_DerivativeLiabilityNumberOfInstrumentsHeld": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilityNumberOfInstrumentsHeld", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSDerivativeandFinancialInstrumentsDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Count", "label": "Derivative Liability, Number of Instruments Held", "documentation": "The number of derivative instruments of a particular derivative liability or group of derivative liabilities held by the entity." } } }, "auth_ref": [ "r84", "r85" ] }, "us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/IMPAIRMENTOFREALESTATEANDDISPOSITIONSDispositionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment upon disposal", "label": "Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down", "documentation": "Amount, before tax, of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a disposal group. Excludes discontinued operations." } } }, "auth_ref": [ "r10", "r11", "r162" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r707", "r708", "r709", "r711", "r712", "r713", "r716", "r811", "r812", "r844", "r866", "r870" ] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails", "http://www.sabrahealth.com/role/DEBTSecuredIndebtednessDetails", "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred financing costs", "verboseLabel": "Deferred financing costs", "negatedTerseLabel": "Deferred financing costs, net", "label": "Debt Issuance Costs, Net", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r112", "r837" ] }, "sbra_VariableInterestEntityNumberOfEntities": { "xbrltype": "integerItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "VariableInterestEntityNumberOfEntities", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of variable interest entities", "label": "Variable Interest Entity, Number Of Entities", "documentation": "Variable Interest Entity, Number Of Entities" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRealEstatePropertiesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRealEstatePropertiesTable", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESNetInvestmentinSalesTypeLeaseNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESOperatingLeasesNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Real Estate Properties [Table]", "label": "Schedule of Real Estate Properties [Table]", "documentation": "Schedule detailing quantitative information concerning real estate properties and units within those properties by ownership of the property." } } }, "auth_ref": [] }, "sbra_LongTermDebtMaturityAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "LongTermDebtMaturityAfterYearFour", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Long-Term Debt, Maturity, After Year Four", "documentation": "Long-Term Debt, Maturity, After Year Four" } } }, "auth_ref": [] }, "us-gaap_DerivativeLiabilityFairValueGrossAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilityFairValueGrossAsset", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSGrossPresentationEffectsofOffsettingandNetPresentationofDerivativesDetails": { "parentTag": "us-gaap_DerivativeLiabilities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSGrossPresentationEffectsofOffsettingandNetPresentationofDerivativesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gross Amounts Offset in the Balance Sheet", "label": "Derivative Liability, Subject to Master Netting Arrangement, Asset Offset", "documentation": "Fair value of asset associated with financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r24", "r30", "r93", "r644", "r645", "r670" ] }, "us-gaap_DerivativeAssetNumberOfInstrumentsHeld": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssetNumberOfInstrumentsHeld", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSDerivativeandFinancialInstrumentsDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Count", "label": "Derivative Asset, Number of Instruments Held", "documentation": "The number of derivative instruments of a particular derivative asset or group of derivative assets held by the entity." } } }, "auth_ref": [ "r84", "r85" ] }, "sbra_VandalismAndTheftMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "VandalismAndTheftMember", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vandalism And Theft", "label": "Vandalism And Theft [Member]", "documentation": "Vandalism And Theft" } } }, "auth_ref": [] }, "sbra_NorthAmericanHealthCareIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "NorthAmericanHealthCareIncMember", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESOperatingLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "North American Health Care, Inc", "label": "North American Health Care, Inc [Member]", "documentation": "North American Health Care, Inc" } } }, "auth_ref": [] }, "us-gaap_HedgingDesignationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingDesignationDomain", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSDerivativeandFinancialInstrumentsDesignatedasHedgingInstrumentsDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNarrativeDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNotionalAmountofDerivativesInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Domain]", "label": "Hedging Designation [Domain]", "documentation": "Designation of purpose of derivative instrument." } } }, "auth_ref": [ "r19" ] }, "us-gaap_DerivativeAssetFairValueGrossLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssetFairValueGrossLiability", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSGrossPresentationEffectsofOffsettingandNetPresentationofDerivativesDetails": { "parentTag": "us-gaap_DerivativeAssets", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSGrossPresentationEffectsofOffsettingandNetPresentationofDerivativesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gross Amounts Offset in the Balance Sheet", "label": "Derivative Asset, Subject to Master Netting Arrangement, Liability Offset", "documentation": "Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r24", "r30", "r93", "r644", "r645" ] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTS" ], "lang": { "en-us": { "role": { "terseLabel": "DERIVATIVE AND HEDGING INSTRUMENTS", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts." } } }, "auth_ref": [ "r174", "r463", "r471" ] }, "sbra_A5375SeniorUnsecuredNotesDue2023Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "A5375SeniorUnsecuredNotesDue2023Member", "presentation": [ "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "5.375% Senior Unsecured Notes Due 2023", "label": "5.375% Senior Unsecured Notes Due 2023 [Member]", "documentation": "5.375% Senior Unsecured Notes Due 2023" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.sabrahealth.com/role/SUBSEQUENTEVENTS" ], "lang": { "en-us": { "role": { "terseLabel": "SUBSEQUENT EVENTS", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r507", "r509" ] }, "sbra_SeniorHousingFacilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "SeniorHousingFacilitiesMember", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESInvestmentinUnconsolidatedJointVentureNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESScheduleofInvestmentinJointVenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Housing - Managed", "label": "Senior Housing Facilities [Member]", "documentation": "Senior Housing Facilities [Member]" } } }, "auth_ref": [] }, "us-gaap_FireMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FireMember", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fire", "label": "Fire [Member]", "documentation": "Oxidation process that releases energy in the form of light and heat (flames) and often creates smoke." } } }, "auth_ref": [] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESSeniorHousingManagedCommunitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r405", "r688", "r689", "r690", "r691", "r692", "r693", "r694" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies (Note 12)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r38", "r118", "r526", "r587" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "sbra_TenantRelationshipMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "TenantRelationshipMember", "presentation": [ "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDNarrativeDetails", "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDPurchasePriceAllocationforRecentRealEstateAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tenant relationships", "verboseLabel": "Tenant relationship intangible assets", "label": "Tenant Relationship [Member]", "documentation": "Tenant Relationship [Member]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupNotDiscontinuedOperationDisposalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupNotDiscontinuedOperationDisposalDisclosuresAbstract", "presentation": [ "http://www.sabrahealth.com/role/IMPAIRMENTOFREALESTATEANDDISPOSITIONSDispositionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dispositions:", "label": "Disposal Group, Not Discontinued Operation, Disposal Disclosures [Abstract]" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other expense related to derivatives", "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net", "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments." } } }, "auth_ref": [ "r97", "r796" ] }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosureItemAmountsDomain", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFaceValuesCarryingAmountsandFairValuesofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement [Domain]", "label": "Fair Value Measurement [Domain]", "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value." } } }, "auth_ref": [ "r372", "r683", "r684" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDNarrativeDetails", "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDPurchasePriceAllocationforRecentRealEstateAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r63", "r64" ] }, "us-gaap_InterestRateSwapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestRateSwapMember", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSDerivativeandFinancialInstrumentsDesignatedasHedgingInstrumentsDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNarrativeDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNotionalAmountofDerivativesInstrumentsDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESItemsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Interest rate swaps", "terseLabel": "Interest Rate Swap", "label": "Interest Rate Swap [Member]", "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period." } } }, "auth_ref": [ "r666", "r714", "r715" ] }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Loss from unconsolidated joint ventures", "label": "Income (Loss) from Equity Method Investments", "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)." } } }, "auth_ref": [ "r10", "r143", "r181", "r288", "r307", "r532" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in\u00a0Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r444", "r445", "r446", "r567", "r811", "r812", "r813", "r844", "r870" ] }, "us-gaap_DebtInstrumentFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFairValue", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFaceValuesCarryingAmountsandFairValuesofFinancialInstrumentsDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFairValueofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Financial liabilities, carrying amount and fair value", "terseLabel": "Financial liabilities", "label": "Debt Instrument, Fair Value Disclosure", "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable." } } }, "auth_ref": [ "r372", "r485", "r683", "r684" ] }, "us-gaap_ForeignExchangeContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignExchangeContractMember", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSEffectofDerivativeFinancialInstrumentsontheCondensedConsolidatedStatementsofLossIncomeandCondensedConsolidatedStatementsofEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency products", "label": "Foreign Exchange Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates." } } }, "auth_ref": [ "r672", "r695", "r701" ] }, "us-gaap_DerivativeLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilitiesAbstract", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSDerivativeandFinancialInstrumentsDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities:", "label": "Derivative Liability [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilities", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSGrossPresentationEffectsofOffsettingandNetPresentationofDerivativesDetails": { "parentTag": "us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSDerivativeandFinancialInstrumentsDesignatedasHedgingInstrumentsDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSGrossPresentationEffectsofOffsettingandNetPresentationofDerivativesDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of derivatives in a net liability position", "netLabel": "Fair value", "totalLabel": "Net Amounts of Assets / Liabilities presented in the Balance Sheet", "label": "Derivative Liability", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r215", "r218", "r485", "r569", "r570", "r571", "r572", "r574", "r575", "r576", "r578", "r579", "r601", "r603", "r604", "r639", "r640", "r642", "r643", "r644", "r646", "r647", "r672", "r867" ] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFaceValuesCarryingAmountsandFairValuesofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate principal amount", "verboseLabel": "Financial liabilities, face value", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r111", "r114", "r359", "r497", "r683", "r684" ] }, "us-gaap_InterestExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseMember", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSEffectofDerivativeFinancialInstrumentsontheCondensedConsolidatedStatementsofLossIncomeandCondensedConsolidatedStatementsofEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "label": "Interest Expense [Member]", "documentation": "Primary financial statement caption encompassing interest expense." } } }, "auth_ref": [ "r25" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.sabrahealth.com/role/EARNINGSPERCOMMONSHAREComputationofBasicandDilutedEarningsPerShareDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFLOSSINCOME", "http://www.sabrahealth.com/role/EARNINGSPERCOMMONSHAREComputationofBasicandDilutedEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average number of common shares outstanding, diluted (in shares)", "totalLabel": "Diluted weighted average common shares (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r265", "r273" ] }, "us-gaap_InterestRateContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestRateContractMember", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSEffectofDerivativeFinancialInstrumentsontheCondensedConsolidatedStatementsofLossIncomeandCondensedConsolidatedStatementsofEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate products", "label": "Interest Rate Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate." } } }, "auth_ref": [ "r666", "r672", "r695" ] }, "us-gaap_TypeOfRevenueExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfRevenueExtensibleList", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFLOSSINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue, type, extensible enumeration", "label": "Revenue, Product and Service [Extensible Enumeration]", "documentation": "Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.sabrahealth.com/role/EARNINGSPERCOMMONSHAREComputationofBasicandDilutedEarningsPerShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFLOSSINCOME", "http://www.sabrahealth.com/role/EARNINGSPERCOMMONSHAREComputationofBasicandDilutedEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average number of common shares outstanding, basic (in shares)", "verboseLabel": "Basic weighted average common shares and common equivalents (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r264", "r273" ] }, "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityInterestRateAtPeriodEnd", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate", "label": "Line of Credit Facility, Interest Rate at Period End", "documentation": "The effective interest rate at the end of the reporting period." } } }, "auth_ref": [ "r34" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowing capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r34" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFairValueofFinancialInstrumentsDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESItemsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [] }, "us-gaap_CreditRiskContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditRiskContractMember", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit risk-related contingent features", "label": "Credit Risk Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to the creditworthiness or the credit spread of an entity." } } }, "auth_ref": [ "r672", "r695", "r702" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFairValueofFinancialInstrumentsDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESItemsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r372", "r407", "r408", "r409", "r410", "r411", "r412", "r510", "r511", "r512", "r683", "r684", "r695", "r696", "r697" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDPurchasePriceAllocationforRecentRealEstateAcquisitionsDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDPurchasePriceAllocationforRecentRealEstateAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tenant intangible assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date." } } }, "auth_ref": [ "r75", "r76" ] }, "us-gaap_DerivativeCollateralObligationToReturnSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeCollateralObligationToReturnSecurities", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSGrossPresentationEffectsofOffsettingandNetPresentationofDerivativesDetails": { "parentTag": "us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSGrossPresentationEffectsofOffsettingandNetPresentationofDerivativesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Financial Instruments", "label": "Derivative Asset, Subject to Master Netting Arrangement, Collateral, Obligation to Return Security Not Offset", "documentation": "Amount of obligation to return securities collateral under master netting arrangements that have not been offset against derivative assets." } } }, "auth_ref": [ "r28", "r216", "r670" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r781" ] }, "us-gaap_CreditLossStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditLossStatusAxis", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSScheduleofAdditionalInformationRegardingtheCompanysLoansReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Loss Status [Axis]", "label": "Credit Loss Status [Axis]", "documentation": "Information by credit loss status of financial asset." } } }, "auth_ref": [ "r817", "r821", "r824" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDPurchasePriceAllocationforRecentRealEstateAcquisitionsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDPurchasePriceAllocationforRecentRealEstateAcquisitionsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total consideration", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": [ "r75", "r76" ] }, "us-gaap_CreditLossStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditLossStatusDomain", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSScheduleofAdditionalInformationRegardingtheCompanysLoansReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Loss Status [Domain]", "label": "Credit Loss Status [Domain]", "documentation": "Credit loss status of financial asset." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock Option", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFairValueofFinancialInstrumentsDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESItemsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Other Observable Inputs (Level 2)", "verboseLabel": "Significant Other Observable Inputs (Level 2)", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r372", "r407", "r412", "r478", "r511", "r683", "r684", "r695", "r696", "r697" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFairValueofFinancialInstrumentsDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESItemsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)", "verboseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r372", "r407", "r412", "r478", "r510", "r695", "r696", "r697" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r177", "r210", "r246", "r281", "r295", "r301", "r312", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r453", "r456", "r486", "r525", "r600", "r704", "r719", "r832", "r833", "r851" ] }, "us-gaap_ReceivableTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReceivableTypeDomain", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Receivable [Domain]", "label": "Receivable [Domain]", "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates." } } }, "auth_ref": [ "r40" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r781" ] }, "us-gaap_DerivativeCollateralRightToReclaimSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeCollateralRightToReclaimSecurities", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSGrossPresentationEffectsofOffsettingandNetPresentationofDerivativesDetails": { "parentTag": "us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSGrossPresentationEffectsofOffsettingandNetPresentationofDerivativesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Financial Instruments", "label": "Derivative Liability, Subject to Master Netting Arrangement, Collateral, Right to Reclaim Security Not Offset", "documentation": "Amount of right to receive securities collateral under master netting arrangements that have not been offset against derivative liabilities." } } }, "auth_ref": [ "r28", "r216", "r670" ] }, "us-gaap_OperatingCostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingCostsAndExpenses", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFLOSSINCOME": { "parentTag": "sbra_OperatingAndInterestExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFLOSSINCOME", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESSummarizedFinancialDataofUnconsolidatedJointVentureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses", "label": "Operating Costs and Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense." } } }, "auth_ref": [] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY", "http://www.sabrahealth.com/role/EQUITYAccumulatedOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r18", "r39", "r205", "r228", "r229", "r230", "r250", "r251", "r252", "r254", "r260", "r262", "r279", "r313", "r314", "r403", "r444", "r445", "r446", "r448", "r449", "r465", "r466", "r467", "r468", "r469", "r470", "r473", "r488", "r490", "r491", "r492", "r493", "r494", "r504", "r558", "r559", "r560", "r567", "r626" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFairValueofFinancialInstrumentsDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESItemsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Unobservable Inputs (Level 3)", "verboseLabel": "Significant Unobservable Inputs (Level 3)", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r372", "r407", "r408", "r409", "r410", "r411", "r412", "r478", "r512", "r683", "r684", "r695", "r696", "r697" ] }, "us-gaap_LineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCredit", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving credit facility", "verboseLabel": "Amount outstanding under credit facility", "label": "Long-Term Line of Credit", "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r32", "r179", "r863" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://www.sabrahealth.com/role/EQUITYCommonStockDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY", "http://www.sabrahealth.com/role/EQUITYAccumulatedOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r18", "r205", "r228", "r229", "r230", "r250", "r251", "r252", "r254", "r260", "r262", "r279", "r313", "r314", "r403", "r444", "r445", "r446", "r448", "r449", "r465", "r466", "r467", "r468", "r469", "r470", "r473", "r488", "r490", "r491", "r492", "r493", "r494", "r504", "r558", "r559", "r560", "r567", "r626" ] }, "us-gaap_NonaccrualStatusAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonaccrualStatusAbstract", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSScheduleofAdditionalInformationRegardingtheCompanysLoansReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nonaccrual status:", "label": "Nonaccrual Status [Abstract]" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESOperatingLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r345", "r346", "r347", "r348", "r413", "r514", "r557", "r578", "r579", "r631", "r633", "r634", "r635", "r648", "r664", "r665", "r678", "r687", "r700", "r706", "r836", "r853", "r854", "r855", "r856", "r857", "r858" ] }, "us-gaap_LineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditMember", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails", "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Line of Credit", "terseLabel": "Revolving Credit Facility", "label": "Line of Credit [Member]", "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails", "http://www.sabrahealth.com/role/DEBTSecuredIndebtednessDetails", "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesDetails" ], "lang": { "en-us": { "role": { "netLabel": "Weighted Average Effective Interest Rate (percent)", "terseLabel": "Weighted average effective interest rate (percent)", "verboseLabel": "Effective interest rate", "label": "Debt Instrument, Interest Rate, Effective Percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r36", "r111", "r387", "r497" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesDetails", "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate (percent)", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r36", "r360" ] }, "us-gaap_FinancialInstrumentPerformanceStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentPerformanceStatusAxis", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSScheduleofAdditionalInformationRegardingtheCompanysLoansReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument Performance Status [Axis]", "label": "Financial Instrument Performance Status [Axis]", "documentation": "Information by category of performance or non-performance status of financial instruments." } } }, "auth_ref": [ "r823" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESOperatingLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r345", "r346", "r347", "r348", "r406", "r413", "r440", "r441", "r442", "r513", "r514", "r557", "r578", "r579", "r631", "r633", "r634", "r635", "r648", "r664", "r665", "r678", "r687", "r700", "r706", "r709", "r827", "r836", "r854", "r855", "r856", "r857", "r858" ] }, "us-gaap_FinancialInstrumentPerformanceStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentPerformanceStatusDomain", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSScheduleofAdditionalInformationRegardingtheCompanysLoansReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument Performance Status [Domain]", "label": "Financial Instrument Performance Status [Domain]", "documentation": "Category of performance or non-performance status of financial instruments, including but not limited to, financing receivables, loans, debt, and investments." } } }, "auth_ref": [] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r781" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY", "http://www.sabrahealth.com/role/EQUITYAccumulatedOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "verboseLabel": "Accumulated other comprehensive income", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r135", "r137", "r138", "r157", "r589", "r606", "r627", "r628", "r704", "r719", "r809", "r820", "r846", "r870" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r788" ] }, "us-gaap_NotesReceivableGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesReceivableGross", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails": { "parentTag": "us-gaap_NotesReceivableNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails" ], "lang": { "en-us": { "role": { "netLabel": "Book value", "label": "Financing Receivable, before Allowance for Credit Loss", "documentation": "Amortized cost, before allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease." } } }, "auth_ref": [ "r199", "r201", "r202", "r211", "r320", "r322", "r679", "r680", "r798", "r822" ] }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedTranslationAdjustmentMember", "presentation": [ "http://www.sabrahealth.com/role/EQUITYAccumulatedOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation (loss) gain", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent." } } }, "auth_ref": [ "r3", "r17", "r42", "r229", "r230", "r490", "r491", "r492", "r493", "r494", "r801" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r781" ] }, "us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total revenues", "label": "Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual", "documentation": "This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period." } } }, "auth_ref": [ "r73" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESOperatingLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r345", "r346", "r347", "r348", "r413", "r514", "r557", "r578", "r579", "r631", "r633", "r634", "r635", "r648", "r664", "r665", "r678", "r687", "r700", "r706", "r836", "r853", "r854", "r855", "r856", "r857", "r858" ] }, "us-gaap_CashFlowHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowHedgingMember", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSDerivativeandFinancialInstrumentsDesignatedasHedgingInstrumentsDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNarrativeDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNotionalAmountofDerivativesInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flow hedges", "verboseLabel": "Cash flow", "label": "Cash Flow Hedging [Member]", "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk." } } }, "auth_ref": [ "r86" ] }, "us-gaap_OperatingLeaseLeaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLeaseIncome", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFLOSSINCOME": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFLOSSINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Rental and related revenues (Note 4)", "label": "Operating Lease, Lease Income", "documentation": "Amount of operating lease income from lease payments and variable lease payments paid and payable to lessor. Includes, but is not limited to, variable lease payments not included in measurement of lease receivable." } } }, "auth_ref": [ "r278", "r499", "r501" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY", "http://www.sabrahealth.com/role/EQUITYAccumulatedOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income", "verboseLabel": "Total accumulated other comprehensive income", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r1", "r17", "r42", "r466", "r469", "r504", "r558", "r559", "r801", "r802", "r803", "r811", "r812", "r813" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESOperatingLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r345", "r346", "r347", "r348", "r406", "r413", "r440", "r441", "r442", "r513", "r514", "r557", "r578", "r579", "r631", "r633", "r634", "r635", "r648", "r664", "r665", "r678", "r687", "r700", "r706", "r709", "r827", "r836", "r854", "r855", "r856", "r857", "r858" ] }, "us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net (loss) income (less than in nine months ended 2023)", "label": "Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual", "documentation": "This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period." } } }, "auth_ref": [ "r73" ] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeAxis", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type [Axis]", "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r479" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r729", "r740", "r750", "r775" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r731", "r742", "r752", "r777" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://www.sabrahealth.com/role/BUSINESS" ], "lang": { "en-us": { "role": { "terseLabel": "BUSINESS", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r120", "r172", "r563", "r564" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r733", "r744", "r754", "r779" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r9" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r789" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESInvestmentinUnconsolidatedJointVentureNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESScheduleofInvestmentinJointVenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal Entity [Axis]", "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_FixturesAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FixturesAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails": { "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Furniture and equipment", "label": "Fixtures and Equipment, Gross", "documentation": "Amount before accumulated depreciation of fixtures and equipment. Includes, but is not limited to, machinery, equipment, and engines." } } }, "auth_ref": [] }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeFairValueOfDerivativeAsset", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSGrossPresentationEffectsofOffsettingandNetPresentationofDerivativesDetails": { "parentTag": "us-gaap_DerivativeAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSGrossPresentationEffectsofOffsettingandNetPresentationofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Amounts of Recognized Assets / Liabilities", "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset", "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement." } } }, "auth_ref": [ "r26", "r93", "r141", "r214", "r672" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r730", "r741", "r751", "r776" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSEffectofDerivativeFinancialInstrumentsontheCondensedConsolidatedStatementsofLossIncomeandCondensedConsolidatedStatementsofEquityDetails": { "parentTag": "sbra_OtherComprehensiveIncomeLossCashFlowAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSEffectofDerivativeFinancialInstrumentsontheCondensedConsolidatedStatementsofLossIncomeandCondensedConsolidatedStatementsofEquityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Gain (loss) recognized in other comprehensive income, cash flow hedges", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r219", "r220", "r459", "r460", "r464" ] }, "us-gaap_BaseRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BaseRateMember", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Base Rate", "label": "Base Rate [Member]", "documentation": "Minimum rate investor will accept." } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r732", "r743", "r753", "r778" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r732", "r743", "r753", "r770", "r778" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain on cash flow hedges", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax", "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r219", "r220" ] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateDomain", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Domain]", "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "us-gaap_DerivativeFixedInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeFixedInterestRate", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fixed interest rate under swap", "label": "Derivative, Fixed Interest Rate", "documentation": "Fixed interest rate related to the interest rate derivative." } } }, "auth_ref": [] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateAxis", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Axis]", "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation (loss) gain", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r2" ] }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "presentation": [ "http://www.sabrahealth.com/role/EQUITYAccumulatedOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain on cash flow hedges", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r221", "r229", "r230", "r455", "r673", "r801" ] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFLOSSINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Expenses:", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityMethodInvestmentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentsTextBlock", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Investment in Joint Ventures", "label": "Equity Method Investments [Table Text Block]", "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information." } } }, "auth_ref": [ "r308" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME", "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "totalLabel": "Total other comprehensive income", "terseLabel": "Other comprehensive income", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r18", "r29", "r224", "r227", "r232", "r488", "r489", "r494", "r519", "r535", "r801", "r802" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSEffectofDerivativeFinancialInstrumentsontheCondensedConsolidatedStatementsofLossIncomeandCondensedConsolidatedStatementsofEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain (loss) reclassified from accumulated other comprehensive income into income , cash flow hedges", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax", "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r198", "r220", "r222" ] }, "us-gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupClassificationDomain", "presentation": [ "http://www.sabrahealth.com/role/IMPAIRMENTOFREALESTATEANDDISPOSITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification [Domain]", "label": "Disposal Group Classification [Domain]", "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r732", "r743", "r753", "r778" ] }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeFairValueOfDerivativeLiability", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSGrossPresentationEffectsofOffsettingandNetPresentationofDerivativesDetails": { "parentTag": "us-gaap_DerivativeLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSGrossPresentationEffectsofOffsettingandNetPresentationofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Amounts of Recognized Assets / Liabilities", "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset", "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement." } } }, "auth_ref": [ "r26", "r93", "r141", "r214", "r672" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r788" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r732", "r743", "r753", "r778" ] }, "us-gaap_PrimeRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrimeRateMember", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prime Rate", "label": "Prime Rate [Member]", "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupClassificationAxis", "presentation": [ "http://www.sabrahealth.com/role/IMPAIRMENTOFREALESTATEANDDISPOSITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification [Axis]", "label": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": [ "r207" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r733", "r744", "r754", "r779" ] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r732", "r743", "r753", "r778" ] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "calculation": { "http://www.sabrahealth.com/role/EARNINGSPERCOMMONSHAREComputationofBasicandDilutedEarningsPerShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/EARNINGSPERCOMMONSHAREComputationofBasicandDilutedEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dilutive restricted stock units (in shares)", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": [ "r267", "r268", "r269", "r273", "r417" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r732", "r743", "r753", "r778" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, $0.01 par value; 10,000,000 shares authorized, zero shares issued and outstanding as of September\u00a030, 2023 and December\u00a031, 2022", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r134", "r528", "r704" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.sabrahealth.com/role/EARNINGSPERCOMMONSHARENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r56" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r782" ] }, "us-gaap_InvestmentOwnedBalancePrincipalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentOwnedBalancePrincipalAmount", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total principal balance", "label": "Investment Owned, Balance, Principal Amount", "documentation": "Amount of principal of investment owned." } } }, "auth_ref": [ "r569", "r577", "r632", "r636", "r649", "r709" ] }, "us-gaap_OffsettingLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OffsettingLiabilitiesTableTextBlock", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Presentation, Effects of Offsetting, and Net Presentation of Derivatives - Liabilities", "label": "Offsetting Liabilities [Table Text Block]", "documentation": "Tabular disclosure of derivative and other financial liabilities that are subject to offsetting, including master netting arrangements." } } }, "auth_ref": [ "r140", "r217" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.sabrahealth.com/role/EARNINGSPERCOMMONSHARENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Gains included in accumulated other comprehensive income expected to be reclassified into retained earnings in the next 12 months", "label": "Cash Flow Hedge Gain (Loss) to be Reclassified within 12 Months", "documentation": "The estimated net amount of existing gains or losses on cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months." } } }, "auth_ref": [ "r105" ] }, "us-gaap_ReceivablesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReceivablesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Receivables [Abstract]", "label": "Receivables [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock, Number of Shares, Par Value and Other Disclosure [Abstract]", "label": "Preferred Stock, Number of Shares, Par Value and Other Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.sabrahealth.com/role/EARNINGSPERCOMMONSHARENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Anti-dilutive securities not included in computation of diluted earnings per share (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r274" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income:", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember", "presentation": [ "http://www.sabrahealth.com/role/IMPAIRMENTOFREALESTATEANDDISPOSITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Held-for-sale or sold", "label": "Disposal Group, Held-for-Sale or Disposed of by Sale, Not Discontinued Operations [Member]", "documentation": "Disposal group that either has been sold or is classified as held-for-sale. Excludes disposals classified as discontinued operations." } } }, "auth_ref": [ "r4", "r11", "r23" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]", "label": "Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]" } } }, "auth_ref": [] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r734", "r745", "r755", "r780" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r723" ] }, "us-gaap_LongtermDebtPercentageBearingFixedInterestAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtPercentageBearingFixedInterestAmount", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/DEBTSecuredIndebtednessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Principal balance", "label": "Long-Term Debt, Percentage Bearing Fixed Interest, Amount", "documentation": "The portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate." } } }, "auth_ref": [] }, "us-gaap_LoansPayableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LoansPayableMember", "presentation": [ "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loans", "label": "Loans Payable [Member]", "documentation": "Borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Long-Term Debt, Maturity, Year One", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r12", "r249", "r376" ] }, "us-gaap_ImpairmentOfRealEstate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOfRealEstate", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFLOSSINCOME": { "parentTag": "sbra_OperatingAndInterestExpense", "weight": 1.0, "order": 4.0 }, "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFLOSSINCOME", "http://www.sabrahealth.com/role/IMPAIRMENTOFREALESTATEANDDISPOSITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of real estate", "verboseLabel": "Impairment of real estate", "label": "Impairment of Real Estate", "documentation": "The charge against earnings in the period to reduce the carrying amount of real property to fair value." } } }, "auth_ref": [ "r807", "r826" ] }, "us-gaap_PaymentsOfDividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDividends", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Dividends paid on common stock", "label": "Payments of Dividends", "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests." } } }, "auth_ref": [ "r50" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r786" ] }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSEffectofDerivativeFinancialInstrumentsontheCondensedConsolidatedStatementsofLossIncomeandCondensedConsolidatedStatementsofEquityDetails": { "parentTag": "sbra_OtherComprehensiveIncomeLossCashFlowAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSEffectofDerivativeFinancialInstrumentsontheCondensedConsolidatedStatementsofLossIncomeandCondensedConsolidatedStatementsofEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain (loss) recognized in other comprehensive income, net investment hedges", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax", "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge." } } }, "auth_ref": [ "r461" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r789" ] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosure of non-cash investing activities:", "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LoansPayableToBank": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LoansPayableToBank", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Term loans, net", "label": "Loans Payable to Bank", "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of loans from a bank with maturities initially due after one year or beyond the normal operating cycle if longer." } } }, "auth_ref": [ "r32", "r179", "r863" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r790" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r756" ] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": [ "http://www.sabrahealth.com/role/DEBTTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Debt", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": [ "r37", "r68", "r69", "r110", "r111", "r114", "r119", "r167", "r168", "r683", "r685", "r810" ] }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeNumberOfInstrumentsHeld": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeNumberOfInstrumentsHeld", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNotionalAmountofDerivativesInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of interest rate swaps", "label": "Derivative, Number of Instruments Held", "documentation": "The number of derivative instruments of a particular group held by the entity." } } }, "auth_ref": [ "r84", "r85", "r578", "r637", "r638", "r641", "r709" ] }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeNotionalAmount", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNotionalAmountofDerivativesInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notional amount", "label": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": [ "r840", "r841" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r787" ] }, "sbra_FinancingReceivableNumberOfLoansImpaired": { "xbrltype": "integerItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "FinancingReceivableNumberOfLoansImpaired", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSScheduleofAdditionalInformationRegardingtheCompanysLoansReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of loans receivable investments", "label": "Financing Receivable, Number Of Loans, Impaired", "documentation": "Financing Receivable, Number Of Loans, Impaired" } } }, "auth_ref": [] }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByBalanceSheetGroupingTextBlock", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Face Values, Carrying Amounts and Fair Values of Financial Instruments", "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]", "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } }, "auth_ref": [ "r106", "r108" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r762" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r57", "r58", "r59", "r194", "r195", "r196", "r197" ] }, "sbra_CanadianDollarOfferRateCDORMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "CanadianDollarOfferRateCDORMember", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CDOR", "label": "Canadian Dollar Offer Rate (CDOR) [Member]", "documentation": "Canadian Dollar Offer Rate (CDOR) [Member]" } } }, "auth_ref": [] }, "sbra_FifthAmendedandRestatedCreditAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "FifthAmendedandRestatedCreditAgreementMember", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fifth Amended and Restated Credit Agreement", "label": "Fifth Amended and Restated Credit Agreement [Member]", "documentation": "Fifth Amended and Restated Credit Agreement [Member]" } } }, "auth_ref": [] }, "sbra_IncomeLossFromEquityMethodInvestmentsBeforeBasisAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "IncomeLossFromEquityMethodInvestmentsBeforeBasisAdjustments", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESSummarizedFinancialDataofUnconsolidatedJointVentureDetails": { "parentTag": "sbra_IncomeLossFromEquityMethodInvestmentsAndOtherThanTemporaryImpairment", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESSummarizedFinancialDataofUnconsolidatedJointVentureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Company\u2019s share of net loss", "label": "Income (Loss) From Equity Method Investments, Before Basis Adjustments", "documentation": "Income (Loss) From Equity Method Investments, Before Basis Adjustments" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred equity investment book value at acquisition", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value", "documentation": "Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages." } } }, "auth_ref": [ "r21" ] }, "sbra_LoansPayableToBankMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "LoansPayableToBankMember", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSDerivativeandFinancialInstrumentsDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term loans, net", "label": "Loans Payable To Bank [Member]", "documentation": "Loans Payable To Bank [Member]" } } }, "auth_ref": [] }, "sbra_InterestRateSwapTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "InterestRateSwapTwoMember", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNotionalAmountofDerivativesInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap Two", "label": "Interest Rate Swap Two [Member]", "documentation": "Interest Rate Swap Two" } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r770" ] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.sabrahealth.com/role/DEBT" ], "lang": { "en-us": { "role": { "terseLabel": "DEBT", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r165", "r244", "r358", "r364", "r365", "r366", "r367", "r368", "r369", "r374", "r381", "r382", "r384" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r728", "r739", "r749", "r774" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r721" ] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "EquityMethodInvesteeNameDomain", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESInvestmentinUnconsolidatedJointVentureNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESScheduleofInvestmentinJointVenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Domain]", "label": "Investment, Name [Domain]" } } }, "auth_ref": [ "r309", "r310", "r311" ] }, "us-gaap_VariableLeaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableLeaseIncome", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESOperatingLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable lease revenue", "label": "Variable Lease, Income", "documentation": "Amount of variable lease payments from operating, direct financing, and sales-type leases, excluding amount included in measurement of lease receivable." } } }, "auth_ref": [ "r502" ] }, "sbra_BusinessAcquisitionByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "BusinessAcquisitionByTypeAxis", "presentation": [ "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, By Type [Axis]", "label": "Business Acquisition, By Type [Axis]", "documentation": "Business Acquisition, By Type [Axis]" } } }, "auth_ref": [] }, "us-gaap_OtherOperatingIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherOperatingIncomeExpenseNet", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFLOSSINCOME": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFLOSSINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Other income (expense)", "label": "Other Operating Income (Expense), Net", "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations." } } }, "auth_ref": [] }, "sbra_LongTermLineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "LongTermLineOfCreditMember", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSDerivativeandFinancialInstrumentsDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving credit facility", "label": "Long-Term Line Of Credit [Member]", "documentation": "Long-Term Line Of Credit" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRealEstatePropertiesTableTextBlock", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Real Estate Properties Held for Investment", "label": "Schedule of Real Estate Properties [Table Text Block]", "documentation": "Tabular disclosure of real estate properties and units in those properties that are included in the discussion of the nature of an entity's operations." } } }, "auth_ref": [] }, "sbra_CreditAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "CreditAgreementMember", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Agreement", "label": "Credit Agreement [Member]", "documentation": "Fifth Amended and Restated Credit Agreement [Member]" } } }, "auth_ref": [] }, "sbra_FinancingReceivableAndOtherInvestmentsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "FinancingReceivableAndOtherInvestmentsNet", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loans receivable and other investments, net", "totalLabel": "Total book value", "label": "Financing Receivable And Other Investments, Net", "documentation": "Amount after allowance and deduction of deferred interest and fees, unamortized costs and premiums and discounts from face amounts, of loans and other investments held in portfolio, including but not limited to, commercial and consumer loans. Includes loans held for sale. Excludes loans and leases covered under loss sharing agreements." } } }, "auth_ref": [] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r762" ] }, "us-gaap_LandImprovements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LandImprovements", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails": { "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Land improvements", "label": "Land Improvements", "documentation": "Amount before accumulated depreciation and depletion of additions or improvements to real estate held for productive use. Examples include, but are not limited to, walkways, driveways, fences, and parking lots." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedBuildings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedBuildings", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDPurchasePriceAllocationforRecentRealEstateAcquisitionsDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDPurchasePriceAllocationforRecentRealEstateAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Building and improvements", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Buildings", "documentation": "Amount of facility held for productive use including, but not limited to, office, production, storage and distribution facilities, acquired at the acquisition date." } } }, "auth_ref": [ "r76" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "sbra_FinancialAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "FinancialAssetsAbstract", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFaceValuesCarryingAmountsandFairValuesofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial assets:", "label": "Financial Assets [Abstract]", "documentation": "Financial Assets [Abstract]" } } }, "auth_ref": [] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r762" ] }, "sbra_WriteOffOfNonCashRentReceivableAndIntangibles": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "WriteOffOfNonCashRentReceivableAndIntangibles", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESOperatingLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Write-off of non-cash rent receivable", "label": "Write-Off Of Non-Cash Rent Receivable And Intangibles", "documentation": "Write-Off Of Non-Cash Rent Receivable And Intangibles" } } }, "auth_ref": [] }, "us-gaap_RestrictedCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "label": "Restricted Cash and Cash Equivalents", "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r52", "r176", "r209", "r242", "r527" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r770" ] }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annum percent unused borrowing fee", "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage", "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility." } } }, "auth_ref": [] }, "sbra_PaymentsForPreferredEquityInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "PaymentsForPreferredEquityInvestments", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Origination and fundings of preferred equity investments", "label": "Payments For Preferred Equity Investments", "documentation": "Payments For Preferred Equity Investments" } } }, "auth_ref": [] }, "sbra_SpecialtyHospitalsAndOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "SpecialtyHospitalsAndOtherMember", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Specialty Hospitals and Other", "label": "Specialty Hospitals And Other [Member]", "documentation": "Specialty Hospitals And Other [Member]" } } }, "auth_ref": [] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r763" ] }, "sbra_LineOfCreditFacilityNumberOfExtensionOptions": { "xbrltype": "integerItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "LineOfCreditFacilityNumberOfExtensionOptions", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails", "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of extension options", "label": "Line Of Credit Facility, Number Of Extension Options", "documentation": "Line Of Credit Facility, Number Of Extension Options" } } }, "auth_ref": [] }, "sbra_PreferredEquityInvestmentsMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "PreferredEquityInvestmentsMeasurementInput", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred equity investments, measurement input", "label": "Preferred Equity Investments, Measurement Input", "documentation": "Preferred Equity Investments, Measurement Input" } } }, "auth_ref": [] }, "sbra_AccountingPoliciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "AccountingPoliciesLineItems", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Line Items]", "label": "Accounting Policies [Line Items]", "documentation": "[Line Items] for Accounting Policies [Table]" } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r757" ] }, "us-gaap_RealEstateDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstateDisclosureTextBlock", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIES" ], "lang": { "en-us": { "role": { "terseLabel": "INVESTMENT IN REAL ESTATE PROPERTIES", "label": "Real Estate Disclosure [Text Block]", "documentation": "The entire disclosure for certain real estate investment financial statements, real estate investment trust operating support agreements, real estate owned, retail land sales, time share transactions, as well as other real estate related disclosures." } } }, "auth_ref": [ "r184", "r185", "r186", "r187", "r188" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY", "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFLOSSINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r250", "r251", "r252", "r279", "r515", "r565", "r568", "r580", "r581", "r582", "r583", "r584", "r585", "r588", "r590", "r591", "r592", "r593", "r594", "r596", "r597", "r598", "r599", "r601", "r602", "r603", "r604", "r605", "r607", "r609", "r610", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r626", "r710" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r770" ] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseDebt", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFLOSSINCOME": { "parentTag": "sbra_OperatingAndInterestExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFLOSSINCOME", "http://www.sabrahealth.com/role/DEBTInterestExpenseNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest", "verboseLabel": "Interest expense", "label": "Interest Expense, Debt", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": [ "r146", "r378", "r388", "r685", "r686" ] }, "sbra_EquityMethodInvestmentBasisAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "EquityMethodInvestmentBasisAdjustments", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESSummarizedFinancialDataofUnconsolidatedJointVentureDetails": { "parentTag": "sbra_IncomeLossFromEquityMethodInvestmentsAndOtherThanTemporaryImpairment", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESSummarizedFinancialDataofUnconsolidatedJointVentureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basis adjustments", "label": "Equity Method Investment, Basis Adjustments", "documentation": "Equity Method Investment, Basis Adjustments" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURES" ], "lang": { "en-us": { "role": { "terseLabel": "FAIR VALUE DISCLOSURES", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r476" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r763" ] }, "sbra_LettersOfCreditDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "LettersOfCreditDeposits", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESOperatingLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Letters of credit deposited", "label": "Letters Of Credit Deposits", "documentation": "Letters Of Credit Deposits" } } }, "auth_ref": [] }, "sbra_BusinessAcquisitionDebtAssumed": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "BusinessAcquisitionDebtAssumed", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESInvestmentinUnconsolidatedJointVentureNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt assumed", "label": "Business Acquisition Debt Assumed", "documentation": "Business Acquisition Debt Assumed" } } }, "auth_ref": [] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails", "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails", "http://www.sabrahealth.com/role/DEBTSecuredIndebtednessDetails", "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesDetails", "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesNarrativeDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFaceValuesCarryingAmountsandFairValuesofFinancialInstrumentsDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFairValueofFinancialInstrumentsDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r37" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r763" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r726", "r737", "r747", "r772" ] }, "sbra_PreferredEquityInvestmentWeightedAverageContractualRate": { "xbrltype": "percentItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "PreferredEquityInvestmentWeightedAverageContractualRate", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Contractual Interest Rate / Rate of Return", "label": "Preferred Equity Investment, Weighted Average Contractual Rate", "documentation": "Preferred Equity Investment, Weighted Average Contractual Rate" } } }, "auth_ref": [] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFairValueofFinancialInstrumentsDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESItemsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r372", "r407", "r408", "r409", "r410", "r411", "r412", "r478", "r510", "r511", "r512", "r683", "r684", "r695", "r696", "r697" ] }, "us-gaap_BusinessInterruptionLossDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessInterruptionLossDomain", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Interruption Loss [Domain]", "label": "Business Interruption Loss [Domain]", "documentation": "Type or name of business interruption loss." } } }, "auth_ref": [ "r149" ] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://www.sabrahealth.com/role/EQUITYCommonStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued (in shares)", "label": "Sale of Stock, Number of Shares Issued in Transaction", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "sbra_AccountsReceivablePrepaidExpensesDeferredFinancingCostsAndOtherAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "AccountsReceivablePrepaidExpensesDeferredFinancingCostsAndOtherAssetsNet", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, prepaid expenses and other assets, net", "label": "Accounts Receivable, Prepaid Expenses Deferred Financing Costs And Other Assets, Net", "documentation": "Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs. Also, includes the sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value of Financial Instruments", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]", "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances." } } }, "auth_ref": [ "r22", "r106", "r107", "r175" ] }, "sbra_TenantOriginationAndAbsorptionCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "TenantOriginationAndAbsorptionCostsMember", "presentation": [ "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDNarrativeDetails", "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDPurchasePriceAllocationforRecentRealEstateAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tenant origination and absorption costs", "verboseLabel": "Tenant origination and absorption costs intangible assets", "label": "Tenant Origination and Absorption Costs [Member]", "documentation": "Tenant Origination and Absorption Costs [Member]" } } }, "auth_ref": [] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r781" ] }, "sbra_PaymentsForEscrowDepositsForPotentialInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "PaymentsForEscrowDepositsForPotentialInvestments", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Escrow deposits for potential investments", "label": "Payments For Escrow Deposits For Potential Investments", "documentation": "Payments For Escrow Deposits For Potential Investments" } } }, "auth_ref": [] }, "us-gaap_LessorOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeaseTermOfContract", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESOperatingLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease expiration term", "label": "Lessor, Operating Lease, Term of Contract", "documentation": "Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r850" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r770" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r763" ] }, "sbra_A5.125SeniorUnsecuredNotesDue2026Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "A5.125SeniorUnsecuredNotesDue2026Member", "presentation": [ "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesDetails", "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "5.125% senior unsecured notes due 2026 (\u201c2026 Notes\u201d)", "label": "5.125% Senior Unsecured Notes Due 2026 [Member]", "documentation": "5.125% Senior Unsecured Notes Due 2026 [Member]" } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r735", "r743", "r753", "r770", "r778", "r782", "r790" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r763" ] }, "sbra_FinancingReceivableFixedInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "FinancingReceivableFixedInterestRate", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Contractual Interest Rate / Rate of Return", "label": "Financing Receivable, Fixed Interest Rate", "documentation": "Financing Fixed Interest Rate" } } }, "auth_ref": [] }, "sbra_FinancingReceivableNumberOfLoans": { "xbrltype": "integerItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "FinancingReceivableNumberOfLoans", "calculation": { "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails": { "parentTag": "sbra_NumberOfInvestments", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Quantity", "label": "Financing Receivable, Number Of Loans", "documentation": "Financing Receivable, Number Of Loans" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://www.sabrahealth.com/role/EQUITYTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accumulated Other Comprehensive Income", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r42", "r847", "r848" ] }, "us-gaap_NotesReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesReceivableNet", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails": { "parentTag": "sbra_FinancingReceivableAndOtherInvestmentsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails", "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSScheduleofAdditionalInformationRegardingtheCompanysLoansReceivableDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Book value", "terseLabel": "Book value", "label": "Financing Receivable, after Allowance for Credit Loss", "documentation": "Amortized cost, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease." } } }, "auth_ref": [ "r306", "r322", "r595" ] }, "sbra_InterestRateCollarMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "InterestRateCollarMember", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSDerivativeandFinancialInstrumentsDesignatedasHedgingInstrumentsDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESItemsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate collars", "label": "Interest Rate Collar [Member]", "documentation": "Interest Rate Collar" } } }, "auth_ref": [] }, "sbra_FixedRateMortgagesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "FixedRateMortgagesMember", "presentation": [ "http://www.sabrahealth.com/role/DEBTSecuredIndebtednessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fixed Rate", "label": "Fixed Rate Mortgages [Member]", "documentation": "Fixed Rate Mortgages [Member]" } } }, "auth_ref": [] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r735", "r743", "r753", "r770", "r778", "r782", "r790" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r763" ] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": [ "http://www.sabrahealth.com/role/DEBTTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Maturities for Outstanding Debt", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": [ "r12" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r763" ] }, "sbra_IncomeLossFromEquityMethodInvestmentsAndOtherThanTemporaryImpairment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "IncomeLossFromEquityMethodInvestmentsAndOtherThanTemporaryImpairment", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFLOSSINCOME": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 }, "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESSummarizedFinancialDataofUnconsolidatedJointVentureDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFLOSSINCOME", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESSummarizedFinancialDataofUnconsolidatedJointVentureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss from unconsolidated joint ventures", "totalLabel": "Loss from unconsolidated joint venture", "label": "Income (Loss) From Equity Method Investments And Other Than Temporary Impairment", "documentation": "Income (Loss) From Equity Method Investments And Other Than Temporary Impairment" } } }, "auth_ref": [] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r134", "r390" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESOperatingLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average remaining term of operating leases", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r498", "r703" ] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://www.sabrahealth.com/role/EQUITYCommonStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Domain]", "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r725", "r736", "r746", "r771" ] }, "sbra_InvestmentsWeightedAverageEffectiveRate": { "xbrltype": "percentItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "InvestmentsWeightedAverageEffectiveRate", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total weighted average annualized effective interest rate / rate of return", "label": "Investments, Weighted Average Effective Rate", "documentation": "Investments, Weighted Average Effective Rate" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLand": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLand", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDPurchasePriceAllocationforRecentRealEstateAcquisitionsDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDPurchasePriceAllocationforRecentRealEstateAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Land", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Land", "documentation": "Amount of real estate acquired, at the acquisition date." } } }, "auth_ref": [ "r76" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFairValueofFinancialInstrumentsDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESItemsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r477", "r478", "r480", "r481", "r483" ] }, "sbra_U.S.DollarTermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "U.S.DollarTermLoanMember", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. dollar Term Loan", "label": "U.S. Dollar Term Loan [Member]", "documentation": "U.S. Dollar Term Loan [Member]" } } }, "auth_ref": [] }, "us-gaap_BusinessInterruptionLossAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessInterruptionLossAxis", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Interruption Loss [Axis]", "label": "Business Interruption Loss [Axis]", "documentation": "Information by business interruption loss." } } }, "auth_ref": [ "r149" ] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSDerivativeandFinancialInstrumentsDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Axis]", "label": "Balance Sheet Location [Axis]", "documentation": "Information by location on balance sheet (statement of financial position)." } } }, "auth_ref": [] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r764" ] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total Debt", "label": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r32", "r179", "r385" ] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "presentation": [ "http://www.sabrahealth.com/role/IMPAIRMENTOFREALESTATEANDDISPOSITIONS" ], "lang": { "en-us": { "role": { "terseLabel": "IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS", "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r121", "r160" ] }, "sbra_HealthCareResidentServiceAncillaryServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "HealthCareResidentServiceAncillaryServiceMember", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESSeniorHousingManagedCommunitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ancillary services", "label": "Health Care, Resident Service, Ancillary Service [Member]", "documentation": "Health Care, Resident Service, Ancillary Service" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r769" ] }, "sbra_LessorOperatingLeasePaymentToBeReceivedAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "LessorOperatingLeasePaymentToBeReceivedAfterYearFour", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESFutureMinimumRentalPaymentsReceivableforPropertiesHeldforInvestmentUnderNonCancelableOperatingLeasesDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESFutureMinimumRentalPaymentsReceivableforPropertiesHeldforInvestmentUnderNonCancelableOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessor, Operating Lease, Payment To Be Received, After Year Four", "documentation": "Lessor, Operating Lease, Payment To Be Received, After Year Four" } } }, "auth_ref": [] }, "sbra_SiennaJointVentureMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "SiennaJointVentureMember", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESScheduleofInvestmentinJointVenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sienna Joint Venture", "label": "Sienna Joint Venture [Member]", "documentation": "Sienna Joint Venture" } } }, "auth_ref": [] }, "sbra_DeterioratedCreditQualityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "DeterioratedCreditQualityAbstract", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSScheduleofAdditionalInformationRegardingtheCompanysLoansReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deteriorated credit quality:", "label": "Deteriorated Credit Quality [Abstract]", "documentation": "Deteriorated Credit Quality" } } }, "auth_ref": [] }, "sbra_LondonInterbankOfferedRateLIBOR1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "LondonInterbankOfferedRateLIBOR1Member", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "LIBOR", "label": "London Interbank Offered Rate (LIBOR) 1 [Member]", "documentation": "London Interbank Offered Rate (LIBOR) 1" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r766" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r239" ] }, "sbra_EquityDistributionAgreementATMProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "EquityDistributionAgreementATMProgramMember", "presentation": [ "http://www.sabrahealth.com/role/EQUITYCommonStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ATM Program", "label": "Equity Distribution Agreement, ATM Program [Member]", "documentation": "Equity Distribution Agreement, ATM Program [Member]" } } }, "auth_ref": [] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r727", "r738", "r748", "r773" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r765" ] }, "us-gaap_GainsLossesOnSalesOfInvestmentRealEstate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainsLossesOnSalesOfInvestmentRealEstate", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFLOSSINCOME": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 }, "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 14.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFLOSSINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss on sales of real estate", "negatedTerseLabel": "Net loss on sales of real estate", "label": "Gains (Losses) on Sales of Investment Real Estate", "documentation": "The net gain (loss) resulting from sales and other disposals of real estate owned for investment purposes." } } }, "auth_ref": [ "r190", "r192", "r193", "r804", "r805", "r807", "r860", "r869" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFLOSSINCOME", "http://www.sabrahealth.com/role/EARNINGSPERCOMMONSHAREComputationofBasicandDilutedEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted common share (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r234", "r255", "r256", "r257", "r258", "r259", "r266", "r271", "r272", "r273", "r277", "r474", "r475", "r521", "r537", "r675" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Shares authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r134", "r588" ] }, "sbra_DisposalGroupIncludingDiscontinuedOperationsNumberOfProperties": { "xbrltype": "integerItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "DisposalGroupIncludingDiscontinuedOperationsNumberOfProperties", "presentation": [ "http://www.sabrahealth.com/role/IMPAIRMENTOFREALESTATEANDDISPOSITIONSDispositionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of facilities", "label": "Disposal Group, Including Discontinued Operations, Number Of Properties", "documentation": "Disposal Group, Including Discontinued Operations, Number Of Properties" } } }, "auth_ref": [] }, "sbra_LineOfCreditFacilityMaximumBorrowingCapacityForeignCurrency": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "LineOfCreditFacilityMaximumBorrowingCapacityForeignCurrency", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowing capacity in certain foreign currencies", "label": "Line Of Credit Facility, Maximum Borrowing Capacity, Foreign Currency", "documentation": "Line Of Credit Facility, Maximum Borrowing Capacity, Foreign Currency" } } }, "auth_ref": [] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Shares outstanding (in shares)", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r134", "r588", "r606", "r870", "r871" ] }, "sbra_PreferredEquityInvestmentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "PreferredEquityInvestmentCarryingAmount", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails": { "parentTag": "sbra_FinancingReceivableAndOtherInvestmentsNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Book value", "label": "Preferred Equity Investment, Carrying Amount", "documentation": "Preferred Equity Investment, Carrying Amount" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r239" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "sbra_AccountingPoliciesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "AccountingPoliciesTable", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Table]", "label": "Accounting Policies [Table]", "documentation": "Accounting Policies [Table]" } } }, "auth_ref": [] }, "us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSDerivativeandFinancialInstrumentsDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative asset, statement of financial position", "label": "Derivative Asset, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes derivative asset." } } }, "auth_ref": [ "r458" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r725", "r736", "r746", "r771" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r767" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r768" ] }, "sbra_PropertyTaxesInsuranceAndTenantImprovementDepositLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "PropertyTaxesInsuranceAndTenantImprovementDepositLiability", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESOperatingLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tenant deposits for future real estate taxes, insurance expenditures, and tenant improvements", "label": "Property Taxes, Insurance, And Tenant Improvement Deposit Liability", "documentation": "Property Taxes, Insurance, And Tenant Improvement Deposit Liability" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r153", "r154", "r155" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r768" ] }, "sbra_FinancingReceivablePrincipalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "FinancingReceivablePrincipalAmount", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails": { "parentTag": "us-gaap_InvestmentOwnedBalancePrincipalAmount", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFaceValuesCarryingAmountsandFairValuesofFinancialInstrumentsDetails", "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails", "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSScheduleofAdditionalInformationRegardingtheCompanysLoansReceivableDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Principal balance", "terseLabel": "Loans receivable", "label": "Financing Receivable, Principal Amount", "documentation": "Financing Receivable, Principal Amount" } } }, "auth_ref": [] }, "sbra_DebtInstrumentInterestRateAtPeriodEnd": { "xbrltype": "percentItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "DebtInstrumentInterestRateAtPeriodEnd", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate", "label": "Debt Instrument, Interest Rate At Period End", "documentation": "Debt Instrument, Interest Rate At Period End" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSDerivativeandFinancialInstrumentsDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative liability, statement of financial position", "label": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes derivative liability." } } }, "auth_ref": [ "r458" ] }, "sbra_SeniorHousingFacilitiesManagedPortfolioMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "SeniorHousingFacilitiesManagedPortfolioMember", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFLOSSINCOME", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESOperatingLeasesNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails", "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Senior housing - managed", "terseLabel": "Senior Housing - Managed", "label": "Senior Housing Facilities - Managed Portfolio [Member]", "documentation": "Senior Housing Facilities - Managed Portfolio [Member]" } } }, "auth_ref": [] }, "sbra_A5.88SeniorUnsecuredNotesDue2027Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "A5.88SeniorUnsecuredNotesDue2027Member", "presentation": [ "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesDetails", "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "5.88% senior unsecured notes due 2027 (\u201c2027 Notes\u201d)", "label": "5.88% Senior Unsecured Notes Due 2027 [Member]", "documentation": "5.88% Senior Unsecured Notes Due 2027" } } }, "auth_ref": [] }, "us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsFiscalYearMaturityAbstract", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESFutureMinimumRentalPaymentsReceivableforPropertiesHeldforInvestmentUnderNonCancelableOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Future minimum rental payments from the Company\u2019s properties held for investment under non-cancelable operating leases:", "label": "Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "sbra_InterestRateSwapOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "InterestRateSwapOneMember", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNotionalAmountofDerivativesInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap One", "label": "Interest Rate Swap One [Member]", "documentation": "Interest Rate Swap One" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r721" ] }, "sbra_MortgageLoansReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "MortgageLoansReceivableMember", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Mortgage", "label": "Mortgage Loans Receivable [Member]", "documentation": "Mortgage Loans Receivable [Member]" } } }, "auth_ref": [] }, "us-gaap_RealEstateInvestmentPropertyAtCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstateInvestmentPropertyAtCost", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails": { "parentTag": "us-gaap_RealEstateInvestmentPropertyNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total Real Estate at\u00a0Cost", "label": "Real Estate Investment Property, at Cost", "documentation": "Amount of real estate investment property which may include the following: (1) land available-for-sale; (2) land available-for-development; (3) investments in building and building improvements; (4) tenant allowances; (5) developments in-process; (6) rental properties; and (7) other real estate investments." } } }, "auth_ref": [ "r524" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r728", "r739", "r749", "r774" ] }, "sbra_RepaymentsOfPreferredEquityInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "RepaymentsOfPreferredEquityInvestments", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repayments of preferred equity investments", "label": "Repayments Of Preferred Equity Investments", "documentation": "Repayments Of Preferred Equity Investments" } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESInvestmentinUnconsolidatedJointVentureNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESScheduleofInvestmentinJointVenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Entity [Domain]", "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "us-gaap_RealEstateInvestmentPropertyNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstateInvestmentPropertyNet", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 }, "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Real estate investments, net of accumulated depreciation of $1,002,484 and $913,345 as of September\u00a030, 2023 and December\u00a031, 2022, respectively", "totalLabel": "Total Real Estate Investments, Net", "label": "Real Estate Investment Property, Net", "documentation": "Amount of real estate investment property, net of accumulated depreciation, which may include the following: (1) land available-for-sale; (2) land available-for-development; (3) investments in building and building improvements; (4) tenant allowances; (5) developments in-process; (6) rental properties; and (7) other real estate investments." } } }, "auth_ref": [ "r861" ] }, "sbra_OperatingAndInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "OperatingAndInterestExpense", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFLOSSINCOME": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFLOSSINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "Total expenses", "label": "Operating And Interest Expense", "documentation": "Operating And Interest Expense" } } }, "auth_ref": [] }, "us-gaap_DebtWeightedAverageInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtWeightedAverageInterestRate", "presentation": [ "http://www.sabrahealth.com/role/DEBTSecuredIndebtednessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Interest Rate (percent)", "label": "Debt, Weighted Average Interest Rate", "documentation": "Weighted average interest rate of debt outstanding." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Items Measured at Fair Value on a Recurring Basis", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r477", "r478" ] }, "sbra_FinancingReceivableMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "FinancingReceivableMeasurementInput", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loans receivable, measurement input", "label": "Financing Receivable, Measurement Input", "documentation": "Financing Receivable, Measurement Input" } } }, "auth_ref": [] }, "sbra_SeniorHousingFacilitiesLeasedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "SeniorHousingFacilitiesLeasedMember", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails", "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Housing - Leased", "label": "Senior Housing Facilities - Leased [Member]", "documentation": "Senior Housing Facilities - Leased [Member]" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentMeasurementInput", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt, measurement input", "label": "Debt Instrument, Measurement Input", "documentation": "Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt." } } }, "auth_ref": [ "r481" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDNarrativeDetails", "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDPurchasePriceAllocationforRecentRealEstateAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r72", "r74", "r451", "r698", "r699" ] }, "us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentSummarizedFinancialInformationAbstract", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESSummarizedFinancialDataofUnconsolidatedJointVentureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Summarized financial information", "label": "Equity Method Investment, Summarized Financial Information [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_SeniorNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeniorNotes", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Principal balance", "label": "Senior Notes", "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer). Senior note holders are paid off in full before any payments are made to junior note holders." } } }, "auth_ref": [ "r117", "r863" ] }, "us-gaap_Land": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Land", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails": { "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Land", "label": "Land", "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale." } } }, "auth_ref": [ "r800" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basis spread on variable rate", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock, $0.01 par value; 500,000,000 shares authorized, 231,219,523 and 231,009,295 shares issued and outstanding as of September\u00a030, 2023 and December\u00a031, 2022, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r135", "r529", "r704" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.sabrahealth.com/role/COMMITMENTSANDCONTINGENCIES" ], "lang": { "en-us": { "role": { "terseLabel": "COMMITMENTS AND CONTINGENCIES", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r164", "r343", "r344", "r653", "r828" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.sabrahealth.com/role/EARNINGSPERCOMMONSHARENarrativeDetails", "http://www.sabrahealth.com/role/EQUITYCommonStockDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock units", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Non-cash interest income", "label": "Other Noncash Income (Expense)", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": [ "r155" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r758" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive (loss) income", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r43", "r225", "r227", "r233", "r520", "r536" ] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDNarrativeDetails", "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDPurchasePriceAllocationforRecentRealEstateAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r451", "r698", "r699" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock issuance, net", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r18", "r134", "r135", "r169", "r567", "r626", "r650", "r718" ] }, "us-gaap_DividendsCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendsCommonStock", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Common dividends", "label": "Dividends, Common Stock", "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK)." } } }, "auth_ref": [ "r6", "r169" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r795" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFaceValuesCarryingAmountsandFairValuesofFinancialInstrumentsDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFairValueofFinancialInstrumentsDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESItemsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r477", "r478", "r482" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFLOSSINCOME": { "parentTag": "sbra_OperatingAndInterestExpense", "weight": 1.0, "order": 5.0 }, "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFLOSSINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "verboseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r10", "r286" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDNarrativeDetails", "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDPurchasePriceAllocationforRecentRealEstateAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities." } } }, "auth_ref": [ "r72", "r74", "r451" ] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDNarrativeDetails", "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDPurchasePriceAllocationforRecentRealEstateAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Line Items]", "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r451" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r20" ] }, "us-gaap_ConsolidationVariableInterestEntityPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationVariableInterestEntityPolicy", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Interest Entities", "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined)." } } }, "auth_ref": [ "r78", "r80", "r81" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Derivative and Financial Instruments Designated as Hedging Instruments", "label": "Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]", "documentation": "Tabular disclosure of derivative instruments (including nonderivative instruments that are designated and qualify as hedging instruments) of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position." } } }, "auth_ref": [ "r89" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r720" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value of Financial Instruments", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": [ "r13", "r31" ] }, "us-gaap_PaymentsToAcquireBuildings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireBuildings", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESInvestmentinUnconsolidatedJointVentureNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments to acquire buildings", "label": "Payments to Acquire Buildings", "documentation": "The cash outflow for acquisition of buildings (properties) whether for investment or use." } } }, "auth_ref": [ "r152" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r721" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock issuance, net (in shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r18", "r134", "r135", "r169", "r566", "r626", "r650" ] }, "us-gaap_AccountsNotesAndLoansReceivableLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsNotesAndLoansReceivableLineItems", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails", "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSScheduleofAdditionalInformationRegardingtheCompanysLoansReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]", "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r721" ] }, "us-gaap_InterestAndFeeIncomeLoansAndLeases": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestAndFeeIncomeLoansAndLeases", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFLOSSINCOME": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFLOSSINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Interest and other income", "label": "Interest and Fee Income, Loans and Leases", "documentation": "The aggregate interest and fee income generated by: (1) loans the Entity has positive intent and ability to hold for the foreseeable future, or until maturity or payoff, including commercial and consumer loans, whether domestic or foreign, which may consist of: (a) industrial and agricultural; (b) real estate; and (c) real estate construction loans; (d) trade financing; (e) lease financing; (f) home equity lines-of-credit; (g) automobile and other vehicle loans; and (h) credit card and other revolving-type loans and (2) loans and leases held-for-sale which may include mortgage loans, direct financing, and sales-type leases." } } }, "auth_ref": [ "r183" ] }, "us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Notional Amount of Derivatives Instruments", "label": "Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]", "documentation": "Tabular disclosure of the notional amounts of outstanding derivative positions." } } }, "auth_ref": [ "r84" ] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NotesReceivableNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesReceivableNetAbstract", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loans Receivable:", "label": "Financing Receivable, after Allowance for Credit Loss [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": [ "http://www.sabrahealth.com/role/EQUITYCommonStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued upon vesting (in shares)", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r18", "r134", "r135", "r169" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_SecurityDepositLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecurityDepositLiability", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESOperatingLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Security deposit liability", "label": "Security Deposit Liability", "documentation": "This element represents money paid in advance to protect the provider of a product or service, such as a lessor, against damage or nonpayment by the buyer or tenant (lessee) during the term of the agreement. Such damages may include physical damage to the property, theft of property, and other contractual breaches. Security deposits held may be interest or noninterest bearing." } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r721" ] }, "us-gaap_BelowMarketLeaseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BelowMarketLeaseNet", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Lease intangible liabilities, net", "label": "Below Market Lease, Net", "documentation": "Amount after amortization of leases acquired as part of a real property acquisition at below market lease rate with a finite life." } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireFurnitureAndFixtures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireFurnitureAndFixtures", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Additions to real estate", "label": "Payments to Acquire Furniture and Fixtures", "documentation": "The cash outflow for acquisition of furniture and fixtures." } } }, "auth_ref": [ "r152" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r722" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r721" ] }, "srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis", "presentation": [ "http://www.sabrahealth.com/role/IMPAIRMENTOFREALESTATEANDDISPOSITIONSNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESInvestmentinUnconsolidatedJointVentureNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESNetInvestmentinSalesTypeLeaseNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESScheduleofInvestmentinJointVenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Real Estate, Type of Property [Axis]", "label": "Real Estate, Type of Property [Axis]" } } }, "auth_ref": [ "r652", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662" ] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "srt_MortgageLoansOnRealEstateNamePropertyTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MortgageLoansOnRealEstateNamePropertyTypeDomain", "presentation": [ "http://www.sabrahealth.com/role/IMPAIRMENTOFREALESTATEANDDISPOSITIONSNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESInvestmentinUnconsolidatedJointVentureNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESNetInvestmentinSalesTypeLeaseNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESScheduleofInvestmentinJointVenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Real Estate [Domain]", "label": "Real Estate [Domain]" } } }, "auth_ref": [ "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "verboseLabel": "Shares issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r135" ] }, "us-gaap_OtherIncomeAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherIncomeAndExpensesAbstract", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFLOSSINCOME" ], "lang": { "en-us": { "role": { "verboseLabel": "Other (expense) income:", "label": "Other Income and Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails", "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSScheduleofAdditionalInformationRegardingtheCompanysLoansReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]", "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables." } } }, "auth_ref": [ "r40" ] }, "us-gaap_SecuredDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecuredDebtMember", "presentation": [ "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails", "http://www.sabrahealth.com/role/DEBTSecuredIndebtednessDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFaceValuesCarryingAmountsandFairValuesofFinancialInstrumentsDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFairValueofFinancialInstrumentsDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Secured Debt", "verboseLabel": "Secured Indebtedness", "label": "Secured Debt [Member]", "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets." } } }, "auth_ref": [] }, "sbra_EnlivantJointVentureMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "EnlivantJointVentureMember", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESInvestmentinUnconsolidatedJointVentureNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESSummarizedFinancialDataofUnconsolidatedJointVentureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Enlivant Joint Venture", "label": "Enlivant Joint Venture [Member]", "documentation": "Enlivant Joint Venture [Member]" } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSDerivativeandFinancialInstrumentsDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Domain]", "label": "Balance Sheet Location [Domain]", "documentation": "Location in the balance sheet (statement of financial position)." } } }, "auth_ref": [ "r90", "r95" ] }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Loans Receivable and Other Investments", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables." } } }, "auth_ref": [ "r40" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESInvestmentinUnconsolidatedJointVentureNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESScheduleofInvestmentinJointVenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Axis]", "label": "Investment, Name [Axis]" } } }, "auth_ref": [ "r309", "r310", "r311" ] }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Discontinued Operations and Disposal Groups [Abstract]", "label": "Discontinued Operations and Disposal Groups [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativesFairValueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativesFairValueLineItems", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSDerivativeandFinancialInstrumentsDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives, Fair Value [Line Items]", "label": "Derivatives, Fair Value [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFaceValuesCarryingAmountsandFairValuesofFinancialInstrumentsDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFairValueofFinancialInstrumentsDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESItemsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r477", "r478", "r482" ] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSDerivativeandFinancialInstrumentsDesignatedasHedgingInstrumentsDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSEffectofDerivativeFinancialInstrumentsontheCondensedConsolidatedStatementsofLossIncomeandCondensedConsolidatedStatementsofEquityDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNarrativeDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNotionalAmountofDerivativesInstrumentsDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESItemsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instrument [Axis]", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r91", "r94", "r96", "r98", "r576", "r579", "r592", "r593", "r594", "r596", "r597", "r598", "r599", "r601", "r602", "r603", "r604", "r614", "r615", "r616", "r617", "r620", "r621", "r622", "r623", "r637", "r639", "r643", "r646", "r672", "r707", "r709" ] }, "us-gaap_SecuredDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecuredDebt", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Secured debt, net", "label": "Secured Debt", "documentation": "Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower." } } }, "auth_ref": [ "r32", "r179", "r863" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "verboseLabel": "Shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r135", "r588" ] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Shares outstanding (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r18", "r135", "r588", "r606", "r870", "r871" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r789" ] }, "us-gaap_SalesTypeLeaseNetInvestmentInLease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesTypeLeaseNetInvestmentInLease", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESNetInvestmentinSalesTypeLeaseNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net investment in sales type lease", "label": "Sales-Type Lease, Net Investment in Lease, before Allowance for Credit Loss", "documentation": "Amount, before allowance for credit loss, of net investment in sales-type lease." } } }, "auth_ref": [ "r199", "r320", "r503", "r822" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r790" ] }, "sbra_ScheduleOfDividendsDeclaredAndPaidTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "ScheduleOfDividendsDeclaredAndPaidTableTextBlock", "presentation": [ "http://www.sabrahealth.com/role/EQUITYTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Cash Dividends on Common Stock Declared and Paid", "label": "Schedule of Dividends Declared and Paid [Table Text Block]", "documentation": "Schedule of Dividends Declared and Paid [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "sbra_CanadianDollarTermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "CanadianDollarTermLoanMember", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Canadian dollar Term Loan", "label": "Canadian Dollar Term Loan [Member]", "documentation": "Canadian Dollar Term Loan [Member]" } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityAxis", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails", "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSEffectofDerivativeFinancialInstrumentsontheCondensedConsolidatedStatementsofLossIncomeandCondensedConsolidatedStatementsofEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r781" ] }, "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Decrease in loans receivable and other investments due to acquisition of real estate", "label": "Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed)", "documentation": "The net book value of a nonmonetary asset transferred or exchanged in connection with the acquisition of a business or asset in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Nonmonetary assets and liabilities are assets and liabilities that will not result in cash receipts or cash payments in the future." } } }, "auth_ref": [ "r53", "r54", "r55" ] }, "sbra_PreferredEquityNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "PreferredEquityNetAbstract", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Investments:", "label": "Preferred Equity, Net [Abstract]", "documentation": "Preferred Equity, Net [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.sabrahealth.com/role/EARNINGSPERCOMMONSHARENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r56" ] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails", "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSEffectofDerivativeFinancialInstrumentsontheCondensedConsolidatedStatementsofLossIncomeandCondensedConsolidatedStatementsofEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving Credit Facility", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "us-gaap_HedgingDesignationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingDesignationAxis", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSDerivativeandFinancialInstrumentsDesignatedasHedgingInstrumentsDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNarrativeDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNotionalAmountofDerivativesInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Axis]", "label": "Hedging Designation [Axis]", "documentation": "Information by designation of purpose of derivative instrument." } } }, "auth_ref": [ "r19", "r462" ] }, "sbra_LessorSalesTypeLeaseNumberOfProperties": { "xbrltype": "integerItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "LessorSalesTypeLeaseNumberOfProperties", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESNetInvestmentinSalesTypeLeaseNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Properties in sales-type", "label": "Lessor, Sales-Type Lease, Number of Properties", "documentation": "Lessor, Sales-Type Lease, Number of Properties" } } }, "auth_ref": [] }, "sbra_FinancingReceivableNumberOfLoansNonaccrualStatus": { "xbrltype": "integerItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "FinancingReceivableNumberOfLoansNonaccrualStatus", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSScheduleofAdditionalInformationRegardingtheCompanysLoansReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of loans receivable investments", "label": "Financing Receivable, Number Of Loans, Nonaccrual Status", "documentation": "Financing Receivable, Number Of Loans, Nonaccrual Status" } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": [ "http://www.sabrahealth.com/role/EQUITYAccumulatedOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r228", "r229", "r488", "r490", "r491", "r492", "r493", "r494" ] }, "sbra_SaleOfStockMaximumProceedsFromCommonStockIssuances": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "SaleOfStockMaximumProceedsFromCommonStockIssuances", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/EQUITYCommonStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate gross proceeds possible from sales of common stock under equity offering program", "label": "Sale Of Stock, Maximum Proceeds From Common Stock Issuances", "documentation": "Sale Of Stock, Maximum Proceeds From Common Stock Issuances" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireRealEstate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireRealEstate", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Acquisition of real estate", "label": "Payments to Acquire Real Estate", "documentation": "The cash outflow from the acquisition of a piece of land, anything permanently fixed to it, including buildings, structures on it and so forth; includes real estate intended to generate income for the owner; excludes real estate acquired for use by the owner." } } }, "auth_ref": [ "r152" ] }, "us-gaap_PaymentsToAcquireInterestInJointVenture": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireInterestInJointVenture", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Investment in unconsolidated joint ventures", "label": "Payments to Acquire Interest in Joint Venture", "documentation": "The cash outflow associated with the investment in or advances to an entity in which the reporting entity shares control of the entity with another party or group." } } }, "auth_ref": [ "r47" ] }, "us-gaap_SeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeniorNotesMember", "presentation": [ "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails", "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesDetails", "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesNarrativeDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFaceValuesCarryingAmountsandFairValuesofFinancialInstrumentsDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFairValueofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Notes", "verboseLabel": "Senior Notes", "label": "Senior Notes [Member]", "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityDomain", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails", "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSEffectofDerivativeFinancialInstrumentsontheCondensedConsolidatedStatementsofLossIncomeandCondensedConsolidatedStatementsofEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSGrossPresentationEffectsofOffsettingandNetPresentationofDerivativesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSGrossPresentationEffectsofOffsettingandNetPresentationofDerivativesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net Amount", "label": "Derivative Asset, Including Not Subject to Master Netting Arrangement, after Offset and Deduction", "documentation": "Fair value, after effect of master netting arrangement and deduction of obligation to return financial collateral not offset and financial instrument subject to master netting arrangement not offset, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset. Includes derivative not subject to master netting arrangement or similar agreement." } } }, "auth_ref": [ "r28", "r101" ] }, "sbra_SaleOfStockAgreementTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "SaleOfStockAgreementTerm", "presentation": [ "http://www.sabrahealth.com/role/EQUITYCommonStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forward sale agreements term", "label": "Sale Of Stock, Agreement Term", "documentation": "Sale Of Stock, Agreement Term" } } }, "auth_ref": [] }, "us-gaap_OffsettingDerivativeLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OffsettingDerivativeLiabilitiesAbstract", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSGrossPresentationEffectsofOffsettingandNetPresentationofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Offsetting Liabilities:", "label": "Offsetting Derivative Liabilities [Abstract]" } } }, "auth_ref": [] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r782" ] }, "us-gaap_ProceedsFromRepaymentsOfLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromRepaymentsOfLinesOfCredit", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Net (repayments of) borrowings from revolving credit facility", "label": "Proceeds from (Repayments of) Lines of Credit", "documentation": "The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets)." } } }, "auth_ref": [] }, "sbra_OtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "OtherMember", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other [Member]", "documentation": "Other [Member]" } } }, "auth_ref": [] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Revenues", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFLOSSINCOME": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFLOSSINCOME", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESSummarizedFinancialDataofUnconsolidatedJointVentureDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total revenues", "verboseLabel": "Total revenues", "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r231", "r246", "r282", "r283", "r293", "r298", "r299", "r303", "r304", "r305", "r312", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r486", "r522", "r832" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSGrossPresentationEffectsofOffsettingandNetPresentationofDerivativesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSGrossPresentationEffectsofOffsettingandNetPresentationofDerivativesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net Amount", "label": "Derivative Liability, Including Not Subject to Master Netting Arrangement, after Offset and Deduction", "documentation": "Fair value, after effect of master netting arrangement and deduction of obligation to return financial collateral not offset and financial instrument subject to master netting arrangement not offset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset. Includes derivative not subject to master netting arrangement or similar agreement." } } }, "auth_ref": [ "r28", "r101" ] }, "srt_ConsolidatedEntitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidatedEntitiesDomain", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESOperatingLeasesNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails", "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidated Entities [Domain]", "label": "Consolidated Entities [Domain]" } } }, "auth_ref": [ "r249", "r453", "r454", "r456", "r457", "r506", "r663", "r831", "r834", "r835" ] }, "us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Distributions in excess of earnings from unconsolidated joint ventures", "label": "Proceeds from Equity Method Investment, Distribution, Return of Capital", "documentation": "Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities." } } }, "auth_ref": [ "r238", "r806" ] }, "srt_ConsolidatedEntitiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidatedEntitiesAxis", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESOperatingLeasesNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails", "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidated Entities [Axis]", "label": "Consolidated Entities [Axis]" } } }, "auth_ref": [ "r249", "r453", "r454", "r456", "r457", "r506", "r663", "r831", "r834", "r835" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.sabrahealth.com/role/EARNINGSPERCOMMONSHARE" ], "lang": { "en-us": { "role": { "terseLabel": "EARNINGS PER COMMON SHARE", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r263", "r274", "r275", "r276" ] }, "us-gaap_LineOfCreditFacilityCapacityAvailableForTradePurchases": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityCapacityAvailableForTradePurchases", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Available borrowing capacity", "label": "Line of Credit Facility, Capacity Available for Trade Purchases", "documentation": "The maximum amount of borrowing capacity under a line of credit that is available as of the balance sheet date for financing purchases of goods acquired for inventory or imminent delivery to a customer." } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r788" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r781" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFLOSSINCOME", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESSeniorHousingManagedCommunitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r303", "r515", "r551", "r552", "r553", "r554", "r555", "r556", "r667", "r688", "r705", "r797", "r829", "r830", "r838", "r864" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r721" ] }, "us-gaap_EquityMethodInvestmentDividendsOrDistributions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentDividendsOrDistributions", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Distributions of earnings from unconsolidated joint ventures", "label": "Proceeds from Equity Method Investment, Distribution", "documentation": "Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities." } } }, "auth_ref": [ "r8", "r10", "r143", "r532" ] }, "us-gaap_EquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestments", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESInvestmentinUnconsolidatedJointVentureNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESScheduleofInvestmentinJointVenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in unconsolidated joint ventures", "verboseLabel": "Book Value", "label": "Equity Method Investments", "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized." } } }, "auth_ref": [ "r291", "r307", "r799", "r819" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r35", "r246", "r312", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r454", "r456", "r457", "r486", "r586", "r676", "r719", "r832", "r851", "r852" ] }, "us-gaap_PaymentsToAcquireNotesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireNotesReceivable", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Origination and fundings of loans receivable", "label": "Payments to Acquire Notes Receivable", "documentation": "The cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics." } } }, "auth_ref": [ "r46" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accounts receivable, prepaid expenses and other assets, net", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r9" ] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenuesAbstract", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFLOSSINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues:", "label": "Revenues [Abstract]" } } }, "auth_ref": [] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFLOSSINCOME", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESSeniorHousingManagedCommunitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r303", "r515", "r551", "r552", "r553", "r554", "r555", "r556", "r667", "r688", "r705", "r797", "r829", "r830", "r838", "r864" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "sbra_A320SeniorUnsecuredNotesDue2031Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "A320SeniorUnsecuredNotesDue2031Member", "presentation": [ "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesDetails", "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "3.20% senior unsecured notes due 2031 (\u201c2031 Notes\u201d)", "label": "3.20% Senior Unsecured Notes Due 2031 [Member]", "documentation": "3.20% Senior Unsecured Notes Due 2031" } } }, "auth_ref": [] }, "sbra_PreferredEquityInvestmentFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "PreferredEquityInvestmentFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFaceValuesCarryingAmountsandFairValuesofFinancialInstrumentsDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFairValueofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred equity investments", "label": "Preferred Equity Investment, Fair Value Disclosure", "documentation": "Preferred Equity Investment, Fair Value Disclosure" } } }, "auth_ref": [] }, "sbra_DisposalGroupIncludingDiscontinuedOperationAssetsAndLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20230930", "localname": "DisposalGroupIncludingDiscontinuedOperationAssetsAndLiabilitiesNet", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/IMPAIRMENTOFREALESTATEANDDISPOSITIONSDispositionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net carrying value", "label": "Disposal Group, Including Discontinued Operation, Assets And Liabilities, Net", "documentation": "Disposal Group, Including Discontinued Operation, Assets And Liabilities, Net" } } }, "auth_ref": [] }, "us-gaap_FairValueByMeasurementBasisAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementBasisAxis", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFaceValuesCarryingAmountsandFairValuesofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Basis [Axis]", "label": "Measurement Basis [Axis]", "documentation": "Information by measurement basis." } } }, "auth_ref": [ "r27", "r106", "r372", "r683", "r684" ] }, "us-gaap_LiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAbstract", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities", "label": "Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued liabilities", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r9" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESFutureMinimumRentalPaymentsReceivableforPropertiesHeldforInvestmentUnderNonCancelableOperatingLeasesDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESFutureMinimumRentalPaymentsReceivableforPropertiesHeldforInvestmentUnderNonCancelableOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Lessor, Operating Lease, Payment to be Received, Year One", "documentation": "Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r500" ] }, "us-gaap_DeferredFinanceCostsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFinanceCostsGross", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred finance costs", "label": "Debt Issuance Costs, Gross", "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r112" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails", "http://www.sabrahealth.com/role/DEBTSecuredIndebtednessDetails", "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesDetails", "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r37", "r249", "r359", "r360", "r361", "r362", "r363", "r365", "r370", "r371", "r372", "r373", "r375", "r376", "r377", "r378", "r379", "r380", "r497", "r682", "r683", "r684", "r685", "r686", "r808" ] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFLOSSINCOME": { "parentTag": "sbra_OperatingAndInterestExpense", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFLOSSINCOME" ], "lang": { "en-us": { "role": { "verboseLabel": "Provision for (recovery of) loan losses and other reserves", "terseLabel": "Provision for (recovery of) loan losses and other reserves", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": [ "r235", "r317" ] }, "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payment of contingent consideration", "terseLabel": "Payment of contingent consideration", "label": "Payment for Contingent Consideration Liability, Financing Activities", "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date." } } }, "auth_ref": [ "r5" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceived", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESFutureMinimumRentalPaymentsReceivableforPropertiesHeldforInvestmentUnderNonCancelableOperatingLeasesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESFutureMinimumRentalPaymentsReceivableforPropertiesHeldforInvestmentUnderNonCancelableOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Lessor, Operating Lease, Payment to be Received", "documentation": "Amount of lease payments to be received by lessor for operating lease." } } }, "auth_ref": [ "r500" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceivedFourYears", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESFutureMinimumRentalPaymentsReceivableforPropertiesHeldforInvestmentUnderNonCancelableOperatingLeasesDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESFutureMinimumRentalPaymentsReceivableforPropertiesHeldforInvestmentUnderNonCancelableOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessor, Operating Lease, Payment to be Received, Year Four", "documentation": "Amount of lease payment to be received by lessor for operating lease in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r500" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://www.sabrahealth.com/role/EQUITYCommonStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Axis]", "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_AccumulatedDistributionsInExcessOfNetIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDistributionsInExcessOfNetIncome", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cumulative distributions in excess of net income", "label": "Accumulated Distributions in Excess of Net Income", "documentation": "The amount as of the balance sheet date by which cumulative distributions to shareholders (or partners) exceed retained earnings (or accumulated earnings)." } } }, "auth_ref": [ "r865" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFairValueofFinancialInstrumentsDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESItemsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r476", "r483" ] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued liabilities", "label": "Accounts Payable and Accrued Liabilities", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations." } } }, "auth_ref": [ "r115" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceivedThreeYears", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESFutureMinimumRentalPaymentsReceivableforPropertiesHeldforInvestmentUnderNonCancelableOperatingLeasesDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESFutureMinimumRentalPaymentsReceivableforPropertiesHeldforInvestmentUnderNonCancelableOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessor, Operating Lease, Payment to be Received, Year Three", "documentation": "Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r500" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceivedTwoYears", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESFutureMinimumRentalPaymentsReceivableforPropertiesHeldforInvestmentUnderNonCancelableOperatingLeasesDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESFutureMinimumRentalPaymentsReceivableforPropertiesHeldforInvestmentUnderNonCancelableOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessor, Operating Lease, Payment to be Received, Year Two", "documentation": "Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r500" ] }, "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Receivable Type [Axis]", "label": "Receivable Type [Axis]", "documentation": "Information by type of receivable." } } }, "auth_ref": [ "r40" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESFutureMinimumRentalPaymentsReceivableforPropertiesHeldforInvestmentUnderNonCancelableOperatingLeasesDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESFutureMinimumRentalPaymentsReceivableforPropertiesHeldforInvestmentUnderNonCancelableOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "October 1 through December 31, 2023", "label": "Lessor, Operating Lease, Payment to be Received, Remainder of Fiscal Year", "documentation": "Amount of lease payment to be received by lessor for operating lease in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r849" ] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESCapitalandOtherExpendituresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Future capital expenditures", "label": "Capital Expenditures Incurred but Not yet Paid", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": [ "r53", "r54", "r55" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Future Minimum Rental Payments from Non-Cancelable Operating Leases", "label": "Lessor, Operating Lease, Payment to be Received, Maturity [Table Text Block]", "documentation": "Tabular disclosure of maturity of undiscounted cash flows to be received by lessor on annual basis for operating lease." } } }, "auth_ref": [ "r849" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events [Abstract]", "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESOperatingLeasesNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Axis]", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r206", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r305", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r339", "r341", "r342", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r681", "r797", "r864" ] }, "us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancingReceivableAllowanceForCreditLossesRollForward", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSScheduleofAdditionalInformationRegardingtheCompanysLoansReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financing Receivable, Allowance for Credit Loss [Roll Forward]", "label": "Financing Receivable, Allowance for Credit Loss [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "presentation": [ "http://www.sabrahealth.com/role/EARNINGSPERCOMMONSHAREComputationofBasicandDilutedEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Denominator", "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r789" ] }, "us-gaap_FinancingReceivableAllowanceForCreditLossesWriteOffs": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancingReceivableAllowanceForCreditLossesWriteOffs", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSScheduleofAdditionalInformationRegardingtheCompanysLoansReceivableDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Write-off of uncollectible balances", "label": "Financing Receivable, Allowance for Credit Loss, Writeoff", "documentation": "Amount of writeoff of financing receivable, charged against allowance for credit loss." } } }, "auth_ref": [ "r16", "r318", "r323", "r679" ] }, "us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember", "presentation": [ "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDNarrativeDetails", "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDPurchasePriceAllocationforRecentRealEstateAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Recent Real Estate Acquisitions", "label": "Series of Individually Immaterial Business Acquisitions [Member]", "documentation": "Represents the aggregation and reporting of combined amounts of individually immaterial business combinations that were completed during the period." } } }, "auth_ref": [ "r74" ] }, "us-gaap_RealEstateAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstateAbstract", "lang": { "en-us": { "role": { "terseLabel": "Real Estate [Abstract]", "label": "Real Estate [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FinancingReceivableAllowanceForCreditLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancingReceivableAllowanceForCreditLosses", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails": { "parentTag": "us-gaap_NotesReceivableNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails", "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSScheduleofAdditionalInformationRegardingtheCompanysLoansReceivableDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Allowance for loan losses", "periodStartLabel": "Balance at beginning of the period", "periodEndLabel": "Balance at end of the period", "label": "Financing Receivable, Allowance for Credit Loss", "documentation": "Amount of allowance for credit loss on financing receivable. Excludes allowance for financing receivable covered under loss sharing agreement." } } }, "auth_ref": [ "r15", "r201", "r203", "r204", "r213", "r315", "r316", "r319", "r859" ] }, "us-gaap_ProvisionForLoanLossesExpensed": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProvisionForLoanLossesExpensed", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSScheduleofAdditionalInformationRegardingtheCompanysLoansReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provision for loan losses", "label": "Financing Receivable, Credit Loss, Expense (Reversal)", "documentation": "Amount of credit loss expense (reversal of expense) for financing receivable." } } }, "auth_ref": [ "r317", "r518" ] }, "us-gaap_CurrencySwapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrencySwapMember", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSDerivativeandFinancialInstrumentsDesignatedasHedgingInstrumentsDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSEffectofDerivativeFinancialInstrumentsontheCondensedConsolidatedStatementsofLossIncomeandCondensedConsolidatedStatementsofEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Currency Swap", "label": "Currency Swap [Member]", "documentation": "Swap involving the exchange of principal and interest in one currency for another currency." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails", "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails", "http://www.sabrahealth.com/role/DEBTSecuredIndebtednessDetails", "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesDetails", "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r249", "r359", "r360", "r361", "r362", "r363", "r365", "r370", "r371", "r372", "r373", "r375", "r376", "r377", "r378", "r379", "r380", "r383", "r497", "r682", "r683", "r684", "r685", "r686", "r808" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails", "http://www.sabrahealth.com/role/DEBTSecuredIndebtednessDetails", "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesDetails", "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r32", "r132", "r133", "r178", "r179", "r249", "r359", "r360", "r361", "r362", "r363", "r365", "r370", "r371", "r372", "r373", "r375", "r376", "r377", "r378", "r379", "r380", "r497", "r682", "r683", "r684", "r685", "r686", "r808" ] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFLOSSINCOME", "http://www.sabrahealth.com/role/EARNINGSPERCOMMONSHAREComputationofBasicandDilutedEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic common share (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r234", "r255", "r256", "r257", "r258", "r259", "r264", "r266", "r271", "r272", "r273", "r277", "r474", "r475", "r521", "r537", "r675" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails", "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails", "http://www.sabrahealth.com/role/DEBTSecuredIndebtednessDetails", "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesDetails", "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r37", "r68", "r69", "r110", "r111", "r114", "r119", "r167", "r168", "r249", "r359", "r360", "r361", "r362", "r363", "r365", "r370", "r371", "r372", "r373", "r375", "r376", "r377", "r378", "r379", "r380", "r383", "r497", "r682", "r683", "r684", "r685", "r686", "r808" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFLOSSINCOME": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFLOSSINCOME", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESSeniorHousingManagedCommunitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Resident fees and services", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r282", "r283", "r293", "r298", "r299", "r303", "r304", "r305", "r404", "r405", "r515" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/IMPAIRMENTOFREALESTATEANDDISPOSITIONSDispositionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consideration, net of closing costs", "label": "Disposal Group, Including Discontinued Operation, Consideration", "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation." } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 }, "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFLOSSINCOME": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME", "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY", "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFLOSSINCOME", "http://www.sabrahealth.com/role/EARNINGSPERCOMMONSHAREComputationofBasicandDilutedEarningsPerShareDetails", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net (loss) income", "terseLabel": "Net (loss) income", "verboseLabel": "Net (loss) income", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r144", "r155", "r182", "r208", "r223", "r226", "r230", "r246", "r253", "r255", "r256", "r257", "r258", "r261", "r262", "r270", "r281", "r294", "r300", "r302", "r312", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r475", "r486", "r534", "r608", "r624", "r625", "r677", "r717", "r832" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "verboseLabel": "Par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r135" ] }, "us-gaap_HedgingRelationshipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingRelationshipDomain", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSDerivativeandFinancialInstrumentsDesignatedasHedgingInstrumentsDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNarrativeDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNotionalAmountofDerivativesInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Domain]", "label": "Hedging Relationship [Domain]", "documentation": "Nature or intent of a hedge." } } }, "auth_ref": [ "r19" ] }, "us-gaap_NonperformingFinancingReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonperformingFinancingReceivableMember", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSScheduleofAdditionalInformationRegardingtheCompanysLoansReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nonaccrual status", "label": "Nonperforming Financial Instruments [Member]", "documentation": "Category status of financial instruments in which payments are past due in accordance with the terms of the contract. Financial instruments include, but are not limited to, financing receivables, loans, debt, and investments." } } }, "auth_ref": [ "r61", "r823" ] }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": [ "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATED" ], "lang": { "en-us": { "role": { "terseLabel": "RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED)", "label": "Business Combination Disclosure [Text Block]", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": [ "r170", "r452" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosure of cash flow information:", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPayableCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/DEBTInterestExpenseNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued interest", "label": "Interest Payable", "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables." } } }, "auth_ref": [ "r116", "r862" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Long-Term Debt, Maturity, Year Four", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r12", "r249", "r376" ] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSEffectofDerivativeFinancialInstrumentsontheCondensedConsolidatedStatementsofLossIncomeandCondensedConsolidatedStatementsofEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) [Table]", "label": "Derivative Instruments, Gain (Loss) [Table]", "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": [ "r19", "r91", "r96", "r98", "r103", "r104", "r462" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Long-Term Debt, Maturity, Year Three", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r12", "r249", "r376" ] }, "us-gaap_NetInvestmentHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetInvestmentHedgingMember", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSDerivativeandFinancialInstrumentsDesignatedasHedgingInstrumentsDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNotionalAmountofDerivativesInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Investment Hedges", "verboseLabel": "Net investment", "label": "Net Investment Hedging [Member]", "documentation": "Hedges of a net investment in a foreign operation." } } }, "auth_ref": [ "r87" ] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESSeniorHousingManagedCommunitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r405", "r688", "r689", "r690", "r691", "r692", "r693", "r694" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r758" ] }, "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableInterestEntityPrimaryBeneficiaryMember", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Primary beneficiary", "label": "Variable Interest Entity, Primary Beneficiary [Member]", "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity." } } }, "auth_ref": [ "r79", "r453", "r454", "r456", "r457" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive income", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r41", "r42", "r142", "r212", "r530", "r561", "r562" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Interest paid", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r237", "r240", "r241" ] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/EQUITYCommonStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax withholding obligations incurred on behalf of employees", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [ "r236" ] }, "us-gaap_NondesignatedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NondesignatedMember", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNarrativeDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNotionalAmountofDerivativesInstrumentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Not Designated as Hedging Instrument", "terseLabel": "Not designated as hedging instrument", "label": "Not Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r19" ] }, "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SOFR", "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]", "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg." } } }, "auth_ref": [ "r843" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r136", "r704", "r868" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Par value (in dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r134", "r390" ] }, "us-gaap_DerivativeCollateralRightToReclaimCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeCollateralRightToReclaimCash", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSGrossPresentationEffectsofOffsettingandNetPresentationofDerivativesDetails": { "parentTag": "us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSGrossPresentationEffectsofOffsettingandNetPresentationofDerivativesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash Collateral Received", "label": "Derivative Liability, Subject to Master Netting Arrangement, Collateral, Right to Reclaim Cash Not Offset", "documentation": "Amount of right to receive cash collateral under master netting arrangements that have not been offset against derivative liabilities." } } }, "auth_ref": [ "r28", "r102", "r216", "r670" ] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSEffectofDerivativeFinancialInstrumentsontheCondensedConsolidatedStatementsofLossIncomeandCondensedConsolidatedStatementsofEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r338", "r340", "r611" ] }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of Derivative Financial Instruments on the Condensed Consolidated Statements of (Loss) Income and Condensed Consolidated Statements of Equity", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": [ "r91", "r96", "r462" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFLOSSINCOME": { "parentTag": "sbra_OperatingAndInterestExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFLOSSINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r145", "r610" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Long-Term Debt, Maturity, Year Two", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r12", "r249", "r376" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESOperatingLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r247", "r248", "r362", "r392", "r505", "r669", "r672" ] }, "us-gaap_AccumulatedDistributionsInExcessOfNetIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDistributionsInExcessOfNetIncomeMember", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative Distributions in Excess of Net Income", "label": "Accumulated Distributions in Excess of Net Income [Member]", "documentation": "Cumulative distributions to shareholders (or partners) in excess of retained earnings (or accumulated earnings)." } } }, "auth_ref": [] }, "us-gaap_RealEstateInvestmentPropertyAccumulatedDepreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstateInvestmentPropertyAccumulatedDepreciation", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails": { "parentTag": "us-gaap_RealEstateInvestmentPropertyNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated depreciation", "negatedLabel": "Accumulated Depreciation", "label": "Real Estate Investment Property, Accumulated Depreciation", "documentation": "The cumulative amount of depreciation for real estate property held for investment purposes." } } }, "auth_ref": [ "r523" ] }, "us-gaap_DerivativeCollateralObligationToReturnCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeCollateralObligationToReturnCash", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSGrossPresentationEffectsofOffsettingandNetPresentationofDerivativesDetails": { "parentTag": "us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSGrossPresentationEffectsofOffsettingandNetPresentationofDerivativesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash Collateral Received", "label": "Derivative Asset, Subject to Master Netting Arrangement, Collateral, Obligation to Return Cash Not Offset", "documentation": "Amount of obligation to return cash collateral under master netting arrangements that have not been offset against derivative assets." } } }, "auth_ref": [ "r28", "r102", "r216", "r670" ] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSDerivativeandFinancialInstrumentsDesignatedasHedgingInstrumentsDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNarrativeDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNotionalAmountofDerivativesInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Axis]", "label": "Hedging Relationship [Axis]", "documentation": "Information by type of hedging relationship." } } }, "auth_ref": [ "r19", "r91", "r96" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSEffectofDerivativeFinancialInstrumentsontheCondensedConsolidatedStatementsofLossIncomeandCondensedConsolidatedStatementsofEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r340", "r611" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r762" ] }, "us-gaap_LoansReceivableFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LoansReceivableFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFaceValuesCarryingAmountsandFairValuesofFinancialInstrumentsDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFairValueofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loans receivable", "label": "Loans Receivable, Fair Value Disclosure", "documentation": "Fair value portion of loan receivable, including, but not limited to, mortgage loans held for investment, finance receivables held for investment, policy loans on insurance contracts." } } }, "auth_ref": [ "r60" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r761" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r791" ] }, "us-gaap_CrossCurrencyInterestRateContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CrossCurrencyInterestRateContractMember", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSDerivativeandFinancialInstrumentsDesignatedasHedgingInstrumentsDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNarrativeDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNotionalAmountofDerivativesInstrumentsDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESItemsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cross currency interest rate swaps", "verboseLabel": "Cross currency interest rate swaps", "label": "Cross Currency Interest Rate Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to interest rates and foreign exchange rates." } } }, "auth_ref": [ "r839", "r842" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://www.sabrahealth.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r495", "r508" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r789" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r760" ] }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherOperatingActivitiesCashFlowStatement", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-cash items", "label": "Other Operating Activities, Cash Flow Statement", "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities)." } } }, "auth_ref": [] }, "us-gaap_FinancialAssetAcquiredWithCreditDeteriorationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialAssetAcquiredWithCreditDeteriorationMember", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSScheduleofAdditionalInformationRegardingtheCompanysLoansReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Receivables with deteriorated credit quality", "label": "Financial Asset Acquired with Credit Deterioration [Member]", "documentation": "Financial asset acquired with deteriorated credit quality." } } }, "auth_ref": [ "r817" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r790" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r792" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r759" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "October 1 through December 31, 2023", "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year." } } }, "auth_ref": [ "r810" ] }, "us-gaap_OffsettingAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OffsettingAssetsTableTextBlock", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Presentation, Effects of Offsetting, and Net Presentation of Derivatives - Assets", "label": "Offsetting Assets [Table Text Block]", "documentation": "Tabular disclosure of derivative and other financial assets that are subject to offsetting, including master netting arrangements." } } }, "auth_ref": [ "r140", "r217" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r791" ] }, "us-gaap_RepaymentsOfMediumTermNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfMediumTermNotes", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Principal payments on term loans", "label": "Repayments of Medium-term Notes", "documentation": "The cash outflow to pay off borrowing used to receive debt funding on a regular basis with maturities ranging from 5-10 years." } } }, "auth_ref": [ "r51" ] }, "us-gaap_OffsettingDerivativeAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OffsettingDerivativeAssetsAbstract", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSGrossPresentationEffectsofOffsettingandNetPresentationofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Offsetting Assets:", "label": "Offsetting Derivative Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract", "presentation": [ "http://www.sabrahealth.com/role/EARNINGSPERCOMMONSHAREComputationofBasicandDilutedEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Numerator", "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Principles of Consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r77", "r674" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r759" ] }, "us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialLiabilitiesFairValueDisclosureAbstract", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFaceValuesCarryingAmountsandFairValuesofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial liabilities:", "label": "Financial Liabilities Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "presentation": [ "http://www.sabrahealth.com/role/IMPAIRMENTOFREALESTATEANDDISPOSITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r758" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r760" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net decrease in cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r0", "r153" ] }, "us-gaap_GainOnBusinessInterruptionInsuranceRecovery": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainOnBusinessInterruptionInsuranceRecovery", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain of unusual amount", "label": "Gain on Business Interruption Insurance Recovery", "documentation": "The net amount (to the extent disclosed within this portion of the income statement) by which an insurance settlement exceeds incremental costs incurred from the event causing an interruption of business, plus the insurance award for earnings lost from the event, such as a natural catastrophe, explosion or fire." } } }, "auth_ref": [ "r150" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_MeasurementInputDiscountRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputDiscountRateMember", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discount Rate", "label": "Measurement Input, Discount Rate [Member]", "documentation": "Measurement input using interest rate to determine present value of future cash flows." } } }, "auth_ref": [ "r845" ] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total Debt, Net", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r32", "r179", "r371", "r386", "r683", "r684", "r863" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r793" ] }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DesignatedAsHedgingInstrumentMember", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSDerivativeandFinancialInstrumentsDesignatedasHedgingInstrumentsDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNarrativeDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNotionalAmountofDerivativesInstrumentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Designated as Hedging Instrument", "terseLabel": "Designated as hedging instrument", "label": "Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r19" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r724", "r794" ] }, "us-gaap_FinancingReceivableRecordedInvestmentNonaccrualStatus": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancingReceivableRecordedInvestmentNonaccrualStatus", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSScheduleofAdditionalInformationRegardingtheCompanysLoansReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Book value", "label": "Financing Receivable, Nonaccrual", "documentation": "Amortized cost of financing receivable on nonaccrual status. Excludes net investment in lease." } } }, "auth_ref": [ "r62", "r202", "r203", "r321" ] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r761" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of foreign currency translation on cash, cash equivalents and restricted cash", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r487" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r724", "r794" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r785" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Equity [Abstract]", "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEquityMethodInvestmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEquityMethodInvestmentsTable", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESInvestmentinUnconsolidatedJointVentureNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESScheduleofInvestmentinJointVenturesDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESSummarizedFinancialDataofUnconsolidatedJointVentureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Equity Method Investments [Table]", "label": "Schedule of Equity Method Investments [Table]", "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available." } } }, "auth_ref": [ "r208", "r246", "r309", "r310", "r311", "r312", "r486" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r761" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period", "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r52", "r153", "r242" ] }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentUnamortizedDiscountPremiumNet", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails", "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Discount, net", "negatedTerseLabel": "Discount, net", "label": "Debt Instrument, Unamortized Discount (Premium), Net", "documentation": "Amount, after accumulated amortization, of debt discount (premium)." } } }, "auth_ref": [ "r110", "r111", "r112", "r113", "r114", "r837" ] }, "us-gaap_ProceedsFromCollectionOfNotesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromCollectionOfNotesReceivable", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Repayments of loans receivable", "label": "Proceeds from Collection of Notes Receivable", "documentation": "The cash inflow associated with principal collections from a borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [ "r45" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFLOSSINCOME": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFLOSSINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "(Loss) income before loss from unconsolidated joint ventures and income tax expense", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments." } } }, "auth_ref": [ "r281", "r294", "r300", "r302", "r538", "r677" ] }, "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSDerivativeandFinancialInstrumentsDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position." } } }, "auth_ref": [ "r90", "r92", "r103" ] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": [ "http://www.sabrahealth.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Line Items]", "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r495", "r508" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r724", "r794" ] }, "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEquityMethodInvestmentsLineItems", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESInvestmentinUnconsolidatedJointVentureNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESScheduleofInvestmentinJointVenturesDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESSummarizedFinancialDataofUnconsolidatedJointVentureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unconsolidated Joint Venture", "label": "Schedule of Equity Method Investments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r246", "r309", "r310", "r311", "r312", "r486" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r761" ] }, "us-gaap_DerivativeAmountOfHedgedItem": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAmountOfHedgedItem", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNotionalAmountofDerivativesInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notional amount", "label": "Derivative, Amount of Hedged Item", "documentation": "Amount of hedged item in hedging relationship. Excludes hedged asset or liability." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleOfProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfProductiveAssets", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Net proceeds from the sales of real estate", "label": "Proceeds from Sale of Productive Assets", "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets." } } }, "auth_ref": [ "r151" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTable", "presentation": [ "http://www.sabrahealth.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Table]", "label": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued." } } }, "auth_ref": [ "r495", "r508" ] }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "presentation": [ "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average amortization period of intangible assets", "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life", "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r158" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.sabrahealth.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r495", "r508" ] }, "us-gaap_CorporateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateMember", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate Level", "label": "Corporate Segment [Member]", "documentation": "Component of an entity that usually provides financial, operational and administrative support and is considered an operating segment. Excludes intersegment elimination and reconciling items." } } }, "auth_ref": [ "r815" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r762" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeDomain", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type [Domain]", "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFLOSSINCOME": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFLOSSINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "Total other (expense) income", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r147" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails", "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails", "http://www.sabrahealth.com/role/DEBTSecuredIndebtednessDetails", "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesDetails", "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesNarrativeDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFaceValuesCarryingAmountsandFairValuesofFinancialInstrumentsDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFairValueofFinancialInstrumentsDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r37", "r65" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.sabrahealth.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r495", "r508" ] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r762" ] }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfFinancingCostsAndDiscounts", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.sabrahealth.com/role/DEBTInterestExpenseNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash interest expense", "label": "Amortization of Debt Issuance Costs and Discounts", "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r380", "r496", "r685", "r686", "r807" ] }, "us-gaap_RealEstatePropertiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstatePropertiesLineItems", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESNetInvestmentinSalesTypeLeaseNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESOperatingLeasesNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Real Estate Properties [Line Items]", "label": "Real Estate Properties [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "presentation": [ "http://www.sabrahealth.com/role/IMPAIRMENTOFREALESTATEANDDISPOSITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]", "label": "Disposal Groups, Including Discontinued Operations [Table]", "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r14", "r23", "r33", "r122", "r123", "r124", "r125", "r126", "r127", "r129", "r130", "r131", "r163" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a),(b),(c)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-14" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(f)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21B", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-21B" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21D", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-21D" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-5" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(c)(1)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)(1)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2C", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2C" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "SubTopic": "20", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(c)(2)", "SubTopic": "20", "Topic": "860", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4D" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13", "SubTopic": "20", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-13" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "SubTopic": "20", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-8" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "60", "Paragraph": "1", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.3,4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "310", "SubTopic": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//310-10/tableOfContent" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "310", "SubTopic": "10", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-29" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "310", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-7" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "55", "Paragraph": "37", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "2AA", "Subparagraph": "a", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-2AA" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-4" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-5A" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a),(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-8" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-8" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-8" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "55", "Paragraph": "182", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480401/815-10-55-182" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "25", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480238/815-25-50-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480870/815-30-50-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-4" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15(1),(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.16)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205-20/tableOfContent" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-11" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3A" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4A" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4B" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5A" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5D" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-7" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483613/220-20-50-1" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483605/220-30-50-1" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483605/220-30-50-1" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//360/tableOfContent" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3A" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r170": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//805/tableOfContent" }, "r171": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r172": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r173": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r174": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//815/tableOfContent" }, "r175": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r176": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r177": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r178": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r179": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r180": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r181": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r182": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r183": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r184": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "970", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//970/tableOfContent" }, "r185": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "972", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//972/tableOfContent" }, "r186": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "974", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//974/tableOfContent" }, "r187": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "976", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//976/tableOfContent" }, "r188": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "978", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//978/tableOfContent" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "SubTopic": "360", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479638/944-360-45-3" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "SubTopic": "230", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481160/942-230-45-4" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "SubTopic": "360", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479638/944-360-45-4" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "360", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479607/944-360-50-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-7A" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1405", "Paragraph": "(a)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1405", "Paragraph": "(a)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1405", "Paragraph": "(a)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1405", "Paragraph": "(c)", "Publisher": "SEC" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-4" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-10" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-15" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-21D" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482964/270-10-50-6A" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-6" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4CCC" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4E" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5C" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480627/815-20-45-3" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-2" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479016/842-30-45-3" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-12" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-5" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-5" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-6" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-14" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-12" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(5)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(1)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r667": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r668": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r670": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-20" }, "r671": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r672": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r673": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r674": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r675": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r676": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r677": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r678": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r679": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "79", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479294/326-20-55-79" }, "r680": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "80", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479294/326-20-55-80" }, "r681": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r682": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r683": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r684": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r685": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r686": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r687": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r688": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r689": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r690": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r691": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r692": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r693": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r694": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r695": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r697": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r698": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r699": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r700": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r701": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r702": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r703": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r704": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r705": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r706": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r707": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r708": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r709": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r710": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r712": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r713": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r714": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r715": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column B)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r716": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r717": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r718": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r719": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r720": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r721": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r722": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r723": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r724": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r725": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r726": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r727": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r728": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r729": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r730": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r731": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r732": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r733": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r734": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r735": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r736": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r737": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r738": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r739": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r740": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r741": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r742": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r743": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r744": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r745": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r746": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r747": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r748": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r749": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r750": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r751": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r752": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r753": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r754": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r755": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r756": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r757": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r758": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r759": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r760": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r761": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r762": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r763": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r764": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r765": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r766": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r767": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r768": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r769": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r770": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r771": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r772": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r773": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r774": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r775": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r776": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r777": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r778": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r779": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r780": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r781": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r782": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r783": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r784": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r785": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r786": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r787": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r788": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r789": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r790": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r791": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r792": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r793": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r794": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r795": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CC", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4CC" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1404", "Paragraph": "(a)", "Publisher": "SEC" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(b)(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(b)(9)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//310-10/tableOfContent" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//310-30/tableOfContent" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//326-20/tableOfContent" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//326-30/tableOfContent" }, "r825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-5" }, "r826": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480682/815-20-25-6A" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-12" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-3" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(7)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(14)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } ZIP 87 0001492298-23-000025-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001492298-23-000025-xbrl.zip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

Y6K;N,2_O('SQE4*+9;?[V7P](WZLEX#$(C,4'FQM@Y@IF]<:7-$N MRJ@=66;LW#/@N<^&/[U]TF%__FK)S.GGBWHF\9;2C%E:T7VS&8GQ+E"*J"!K M),C<&$H>O:JWU%DO78FA- \,Q\-\-JR;RI5WV:?VOC-Y983%NWQ*^6;Z,/N M?_WKY/SSY]EIH@'0>[(%-[TP+*)CD#BEH:J0B= I#:QH3LFHMZ;YI0:[8GUV M/)S$J7?)J/>>"N/GG"Z6D_=#!EQLL^#J,%>@MMD6K!( 7_M/90@B6^".<\8U ME]FV5F U S]5F>&A)\N#./M8:@O?7X3%23K!^;?K^=/RKDD64ZP=MRA%(IMZ M*^JE$A*$BQQ3DDJSYOS+5AKXX#&LXE]P+)R!%GBM22H62DQ#0,XPF1G%[:^S1LN4! MM()!O[+#9!-;NH&5?+:CKOFX!HU7, M*<"H9&WO2&\ _4PSL$DZ6K19MFX.

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�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Û!,.UL$I'$TSK1ZOG\2@^2+G[/(H/D72' M:-F$%TYE;CP%C+$D5>L>Z0R5&*$8)XWT4LF'L?E?YU%\D(;W>Q0?(NZI@_1_ M_>WSWWY9G)_C\@LQ4I?/7;_8%FN-KHLP(VHZ2KPR(0O4T7BE1(SONL+ M?6'A$-4M6LMQ:C"\PCFF&!9JGMY%% )Y)#KF0SW&+GUU_>$@D/5MF@J MPZE1\&96+GY]\6V=1<)Y^I17%[=[X!\R5CMUK'8*Z"]UKITEGD(D[0?I7>$. M==IW&?7^7^WIMFF!F=$DWL%-=,7$&XRS\]G%C[6=M73Y1C*GD'@=UV(=@Q"" M@1AER8SE))KON/J9BOX>CX[Q6(Z40)+&6 M9> VM$XW;Z-CVCOJ6-T^"I4#!-T!6#[EWQ;GO\WF7^\SL[&0*5H5'%VV/F>R MD);".:>E@\P#5UHR)7SKU;^/$M03? [1]V(LX7> I/JT^J%<<;+A (66&CF" M1:QE8:@H#$ '1F>9BS%!-V_@_IF*:5V"_F* EW8$SNTK\Y-(+^ M+2=4!!G+>D.EJ>& J4/B4[$^9?5PD%]3C/3@OQRGU4<@AVATT4Z\':#C):[N M4D_VDCD;"NAU(983"8(2"$FLIU3*+&QK7^0^!=/Z(8VQ<81PIT[*O5O,TV*^ M+MH+./^O#X5(N-I@_.[MRP^?KFN,C4)6C$S N>-U$JZ"D$+MA?&9JZR5>^B2 M[$C'[?>]:9,HC= QEGP[L":?KXK1/Y ;/*\[/J]&<5'HMJ[Z7)3ES3]Y.T_Y MC\^_X_<[YR.@82DI 3I%?7+AT_7*6^2%?-<0@FUZMD)#1B#!69L"%XI04;\@**'+9^: MMC.EI4%K*]4I,;*\./N$\Z]7L0-JYW1V'I@7I4YOB^"C$1 X^F"T,.CWLDGT M6^_8(_K3K2VZ]\&>6I4.#[ /EV$/BK]NU[2JT'\36%UM&C()H>X5L4Y(&Y#8 M+WL]!NRC^BD#HR.4]5#=!TAN8H7_8ED6@6=MF04Q4X\%262#[YU2G8[);U Z%A-+YJ+O8OG MXETMW,8RAH[,,W.F#F'4B7@H @S=S]9'K@-OG54[9GZ"?3XWV?'R[L#JO+M3 M*7%36G/EV[U<+)>+WVOA#7ZG?W+QXXS%H-&2=QBXM-59+. SN8W%!(-<%Z]Y MZPD*0^B;VD(U ,0C=2Q-M=,!\N[+B[C++[[5O2]G-B)F1\%$C,2"TD6!CQ14 M)L]0*>M9:E[GLHN6GBJ_VR"JB=2G3N$/.19O%LL\^SI_=4E$SN./LRQ*UDEZ MD+*ZFR%1J.JR@>R#D+A.<>W7XGH$$3T5@Q\'JY.JHP.C]7=R-U?O%JM57GV8 MO_[C@CB[G*U^K8+\4*I@S[*O+H4ID&)0H H98*>]@)PBTRIK)WWK._))HGHJ MVVMCQMKJ83BP_!6PYOEK[9P9X3Y\B:O9ZC-1@^G#_.Y#'3\+0<3 -*LO9W1D MDG04FK@(D:'4H:#,S1&V+VT]/5^-<5\VTDH'AFR;S?[7_'*5T[6E?K7X]FUV ML?82\MV%5JXPBHP+ ZWK)&_R+L$SJ:!PP[QBW 7;NJ7W8&)[2IZ.%Q&TUUL' M -VVSN_O2[+X9\F*P()$,$IH4 8%6?9D@0']9,WL?RNLZLFY%*OKPO2IJ=6:+\YD+!CG*.I0#$[A"X@HY.J5#U#\- M8AL0$NSZZE[(<<\!.>,*O$,D9F=+=*9EHJL:>$08LZU>HJ!4UR M+&@B!3-*JL-CRQT?W0M'_EGCJ(6X.[C1[K)VYA"9JOZA"Z6ZBZ$*"#UP+G7T M]%- ,:(7M5^JE#T'V!PMWBZ>;[;A_MJC>_$;SLYKI/%FL?RRQ)0_7B[CKTBQ M[YE%+J.D6*-$F4 Y7L!Q:R"8;(3FVNC8?,C?093N![AGGYQOK++.K-8UEW?? M3%]<7%GCU_-TED*,NO (/(DZ@7,J0PA.)FU<"CGLY6[M];G]X/-\LO;M M9=R!M;HM$WDS^R.GNUR=61]XC%F#\.0SJCIYS9N$$#/31B2IV@]0?H2<_>#T MK)+RK83?!8YV'8[7A0Y$Y?%.:DU$S RE@.Q(5"H3FUZ' E&;P$L. >7I-DML M(7 _K#WCO'Q+!34,!\99,7'-[.L_OE,XG%NMF'CJU[9<,3&(A7%73' CBY2, M0:C-:"J33^Z]B* -2EZ1&&/K0'R<%1,/9+I^!(TL1>2&@S,A@F*UBA%= >-% M*D(8S53K\' +&=/791VI]UTUHX>*NHN,PXMOB^7%['_6>OA0;OI]UPG_%_-4 M158+@RA@S2$7*Q)DYDO=4V9K95 &GDF Q)I2KG4I^[ZT35^?U1A9HRBE W_J M^L1\Q!\U*W)5_G-!'+U?S./5'\YLTJB+IK"4*58; 3(X2SZ!LUPPHX0H>2QC M]0A9T]=JC62\6JFB\X5YT7Y)UY<+F<7L[PJB^6'RXO5![Y$2A"(#%(ID5(I,J8RC!GS]KNX:HO=]5G<-$74'%]W6=4-^WNFN(N#L S6944V7B>K*<+RRIB&1D M50+E2Z%CQ 6(P+5 2:%G&6ERUBT1?4'E$,UNGXAUH)B["/'O/@]>S\OF,=/_ M$DA6Y[M(7B6B)3#),&#Q0<8Q6_AZF/(X E:.%'0'1J7N*%MM0L(-!TXC*THI M"@(%>7*L./!&1V!)HK:&#H)IW8?W,Q73AM]C0.4X07< E<]Y/ELLWR\N\NK: M,!+]I2[LYFZ]'X)@'HQDP (*SS$I)5KOS?B)B&E[G$:Y?XX1> Q8="14NX.)]/IW3ZY?,K? M\4?E:_6A?%S.YG'V'<\_Y7KB4FV!>C-;13S_/QGK9*GLN:)CDH7WH$+F$%@4 M8$+@L9 7YW/K=6''TMQ3XOA X&S)!)Y,B\\+M6_G[_,?%U]^S^>_Y7\NYA>_ MKLX,%H5,$WS/!/?DX9\8649W!E>*E>SM*.^^PRGM%#E^=^5WWMGBCL,1DM.7-V_0.(;3/:4(G1>5@?4W=N;>%PQ\O M"OWR&VY\B,Q(XL'J8&H6NR8,B@;CG3 V627]@]JIW3O#'O]4G]-_#L'/"*+M MP'K=E] K7"Y_S.9?-_,HBRO!!,8@U9W.RBL+0?-"'H*QC@N,7+4?H+Z;GCX' M_1QCBYI)_W D+2[P? 0D_6N.5V7T^:9@_N,R?YM=?GN?+\[J 3$I<3 F"5"2 M(:")$7)M"]-:1N'''2_[*'E]C@5JA[-VNCEV:..744>556Y<--G+NK),L\+T7HV#K3MX.4/H<$'8>JXV7>#X+N7NUG03@=(L4@6.N%5'1$ M/3-U9!\33&HA$Q\S:NQT-% KMWN0>">\VH9/5>.YL")=AL 5Q:X\T74=*(I% MZV)FPF-^V,EZJC%VIY_K<[B3/9;$)P_,A@Q68SS[&!AP7K> !AX!LY$@HRS! MB>R\3P?SM,42"WDW76[W:>W_W[QY>V_7[]X_\L_7O_R][?OZ7^? MOWSZUS]?O__RNMK*E-DK8.'4%B$F'2Q]!>RWZW]\^V4] *J Y2[:"[I+O&RJ;E++#L3 MR3&TAM= PQ?PZ"@\3<2@$XX"DM;%K+MHF18S+?3\)'0.$'H'X+EF(*<7JPU/ MM\;ZIL)2DA$6M9FZU GLA8%SK@Y1\UF;9'2*[4L3GR2K-T@=HO^?+JZVRNBB M&_#]@IS0:[XV3(1@?8G2@[',UN$VSG0)U 4QWG'+QT/"=A?L2+5T@*]7N/KUS?GB]PU#&[-MC'>Z: 6VZ,V: M">]8 #0^VZ"4<,V?\;82TH6?=:R2'[:D'2WQ#F#SZ'K[X!-W-F8P&-;K[>N0 MVYPA"\-YB<8YV[[<8#<]4]]':;UG7 Z4@4=P.GN..S/O^/WC5G-*7)T=-KTNCR0 M! )>8P+A)+'%;>:\=?I@.R6]0.A83>^8K'F$V+L(^U[5=7_7&YKO,G4MKPUC MAW MI1M96/H/!U$[RY2N+;JR<' L:HHNI(F\]:+B+61,W5HUAL-]F(P[@,G=<#-? M)T6^+%[F3SF>XVHU*[.<_C.[^'4VO]= ZXLC7A*2)VD]'3%=P$LLD$,.-@67 M)6^=)C^0U%YIR;39Q74NMEC"O>7T[S]=K;.9Y=9._(V$R M[5V)(&VMQD"RR(Z'N@! B*Q3CB4]J./9N?)LWV_VXDL=AZ@Q!=V!8=N:]7V_ MN'CT(?.&VUHX'U*1PED#/'"*G7/4X()B8'2A6T&3;Z''NRT/)+H7IZR-L3NM M#OMI?K@K1PRU4':65V=:BV(TF7"OZL*XJ!U),@70+'I6>"YWMLV/X+W=$-*+ M_]8:8X?*^AG7'R^NJJ^O6AP7Y7+8"A*C3N:/$[-KOX>BFK%D;[A4=,&"R;C4TFFR UQ:,U"DA'5TE M6H^\^=.4-0]!SE-ES4/TT*NO^'2%@(PDLEAW0L5,SH5TAB3F-5CAD6MNF6/M M%R6.5M5SLK+H0>!H4]4S1%,=X'%W98%/+J>@%*!VL<[0MT!'-D"6(3+GO58/ M1X7\;U7/X4C8NZIGB%HZP->.&A-E T\4'-E<9^(5H6K;IB6?M\B$O'#7?!'& MLZKJ&:3D_:IZ!DB\ ]A00/UV3F[P13UK]SD)"HW,.@,328%RS B0PA9JOH_ M:YKOV]E-31?%TXT!U$CV':!H1\>+SCID9B(PHS6H9!,XQ0H$$QDG$^VE:]V1 M>$0/V]^TA&R+T#L"S5]L25]KK[,$(.E@*Z0+VP0F01O/M\>LD'Z M/Z2';( R.L#7MJ8F(X41##TX)FL;''EUWC,+W,J4'%EPZ5O;I>?3078,?HX5 M=@=X>;18US ?5@( MD,$K+\BP1ZS-EA$#U!6.(+-B7$?',+?VP8]HQ)BF3OX8-#40^]3C^AZR\&%^ MO2VV:"$<2G+Z4#%R#11Y@^@C*.&CURRA2@]:G7>4 .[\1"^N4"-4-)1G;ZCX M\OOB.C)P27'2+^AUO2(W!0*S"HHL#-$7D1Z62^V)BIM/]%((-28J#I-G!Q?- MMCJQNHXQLUK5E9%B"!4,D"1J26!6.GE-_QVO;_1=G_T/;>*JPV3<%4SNUWV= M>>*_@]E M73Z?JH3.,+$4T'&HO:QU\ZL&]"Z ,)++'+SDS=]#'Z.G%Z^V-8*.E'Q7*+J> MJ7VGG.4?^3R=I>QY$'6Y+*Z?<4HD;ZPXD&B=REPXWGP@V9-$]>(/-[=(#73P M?,O!;^6 \\T:B5E=NW6GZ/DZ^XY;^B[&JQ-O1-B)"LC'$&,'E>7<1Y&<]>!3 MIEB0UY'LMFX#S,QJ+THTS7?D35A9_@9GRW_C^27][MOZ_Y=X7E>K?/XUYXMW M]5<0>E[^V!Z(W90@WGD#N_*X>2B%K9_ UBM]7&W%C+G0-<4L!6>!1=LZ"AF/ MFUY\TW'Q_/#&Z 0='?@O.VI/C"HI)8/@8B%?G@ORY8N)).L@Y1U>2TJ+>F?Q=9=0,^J,&R0 MGO<>+CY Z!V 9Y]:I,0"9B\5"(YU!H%AY$<92.!DT1&-B7=>'1IVB27-0H<]HV:%.[\AF"NP* MC%N>BJP+T1O4D)@*=:8[@C=>@,C9(EJALOS?FJ'A6A]2,S1$!1W :4E^)=/Y.2ZO"[^S M)[/,/!@M;=W4GL$)NN3I>H]6.!>$>A Q[O%WWV8KS8L6+G#1VM%I6<(Z32'1 M,1?6&(KI8QSTAJ<[MW"1DDNTF2RLIZ WL0RH98# O9)<(6)J#JZ?J-@+1_KY MX>@X<7=@H@X<5F&B3"@Y@DRB-DLIXK)N58M1VLB%5%*V3T"--F!FM,OR&640 M&BN] VCO'G? (K?DA4I@16@*3'!=,&K 1B&DE#8%W;H&ZL\UJV80$O:>53-$ M+1W@:_ODE&*T\(I;$"G4_:C>@1,F3Z#SF<+H#/G &Y)I'13TG8UK6]SV]:S3$0:B3[+G"TS9&X MFJ^1"C.*S@'!/]89L;GN%"%KG3,REJ/TV31&T2Y:I@T@._6_FBBN@QMP&Q^; M,VJR+BH%.I0^\CHM@SR$K PHQIW(O)1L6E'F>A57X*G8Q$#;2GQF$I .%V"P1G+ME7\X4')'5G7W M-_K#Q2$J7+27Y_2PP/GJ(_ZHEO;+XB7._^NZ+9@Y+ZLDG!*6Q*$1D(E,5[]W M7$IFDXQ[@F+[%Z;U><:!1 -9=G#9W+G!;Z[U=S==%IAL7?H>0?LZ:#_'.F6P MSL;W]%=A"Z.08+2$U!:"IDUX=NKWM%-A5WA\L5KEB]5-^7;,TB<>R+(J[NE< M9?K)H@?.DA*).!0XWG:6^[3TDEPZ6MV[^^P.EWU_&-K5Y&5L$(FC!,VL)*[J M4#'BA;B2(9NH74BM:];WHZP7?!V#@L>AU4(E_0%M=2:S#$$%A,AB "6% ,=K MRXGQUI(W43"/5^AY14,O92_C@6>8F+N"R9V50[=[.)S,FI.':*PDB^V3KD^; M$2Q+Q?F,*?GQ?*PM!/4"H/%NMV.UT"6D?NRRJ3(RZP1Q5E)TFRGDUF2(13"R ML%*CS*/C:Q=UO5QU1T/B2; UT4^7R*O[TZ))&HWD$"73E0F252D*I-4Y"I71 M8.M:X*V$]&*\QL?34*D?L>WP8BR3]9E4D^M)^%!N^N8_+E:SJJ_7M0-^-:/@ M^/6<3LMRK<0SY!012Q&!Q^H@^BP!HZ.;WRD6C;/.!CF^,1M,=R_%I>/?J2/K MM"L#N/9&A_/K?/))10W)^;J]LN8UBM^@**R8YJ6#Q]+<2\'JR!F/<77Y M? ?%O%XOB+Z[&G/;F).Z>+RF.Q/)*2?Z8;4XGZ7:Y7DCU]6BU!*HMW/ZF1B#M$#N02U:L"0D MK&,]HDP\1>8MCG?_/:N9 (.T/F0FP! 5= "GQS94.,:<3!%$8)QBHJSIFG$, M4E8UH^DUP];Q[;/<%C)(XX_,!CA"_!T ZM7U6W$M(E@ Y1] YO_7"I=P"=J[:7-QC7S[R;I9IH M;)82T-2I4UD+"#$9*%$*F5D4 IMW9?]$12]N5==WXI'*ZPY^UWZK+ M;_3]7VOI4N6NBK8R=7?F2[Y12"Z+9?Z4XSFN5K,RVP10\_0%_SACQ?C"R3TU MH>Y90R[ %T>2+B:KDAB)N'7_75,&>GD(:(>P12_J[F)LRV/L_S2>9C\9( K% M6&2 S-20KP1 G05(%9R*3N@D6H_G:4=^Q7S^1.]-&T<^W M2/_O=?KVQSN?NRKV7BW*AU)6^:).@,>UF;C[+]VM!1]QHVM#XDY4*C^6.#NH M=@]:QZ)R!)?K_'7+R=')PD+Q0B:M'%=BO&7E)Z]VOU77SN$$O#@1>0K -:O# MRH,";TH&7D?(A>R=\:T?^9^FJL. =01\_63VVVJK@S3,G5Z;Z^:U#^4!W3.2D?(^2L#UTW,L'GQA&E(T/##GK(LCMZ#NH&S:;,7) -=,.4=T M]7^M+7I?QIN%9)F1T?AD:5U>'70+*31\@*G1=,P M@7<0R=\M2#T_)S N\?Q#.)]]72OHR^)3OKA+F\FG9A=4D>F01IB2ME MI 8G3>V_X#YI[IGWK8%FO4F&U3CU,W[:S4+K X6$D]HG"W<_KBV^*RSJJHDG[Q%6<4 MJ-U*XRRY[#,:#<0AUG>[!,$E!,-C<8YE%,TKUX\F>B_,FF>/V5.HM(,;?IL\ MMPW&TMHF5JP%AMR"\B;2"56)_%^78C'6E=BZ'FM/TCI\/)TH!W.LWKJ*C;>> MO]L S!47T1$WMHX54L%R.F;DP4@1A;')AIS'*^9ZG+;^$C)' V.8E3Q,2UVA M[X:%^PF JWR3\"&:Q T8)BCX)]F!7^_Y%CP:M-K+XD?#WF.4]9>9&0]YS334 MHS]Y=X D)Y_!>CHT/"")"Y,#S\E+#FA2*;)(Q/%\Q*%C.T^:J!D?7$/EWX%# MMRWJ^C3[^NM%#;CB.1(SD?L017)V5P\+6Q.$MFC&61)7^*X'@7 M??VE:L:#7&-M]6C5=K&X3@&(8(Q(6@)CG%P%1];:2U5SI%$A\PEC'F]J[&.4 M]9>C.3T(!VNH1_@][JL^'M4SD[VP,D/)=?=//81.>P0LBG-;%V_FUN%O$\+[ M2]9,%8NTTV^S2[Y]^=F;%V\__?O%NW^]_N7MYU?O/GS^UZ?7G]_C;IS,/^9L7XL?9A_JM['LB:RYNG]8KZ\_N-+7,U6]?__ M52X_QU_GL_^^S*NK/J^2,_DC0H'D=*B59A1^!:$A6F1"&VUX;!VRC,G/M F= M9JC\::!4+Q#H(/.S8;=F;]_.OU^NYRZMN[0%2E4,!7Z2'D:%F,H+I.(7B] 37DG$NM-LJV>MX"P47#H$B=R/5V,HG6 M]G0W-=/"L(VV]X#0 :+O$$3USJA^;YU!N6GN#Y(55[*'6)@'Q>M;>XJ:KHQ: MF50P_TT5?V!ZA#]/P&K(Y4Q91?C\N+L4YTZN3YJ)7'E6$E07$A$- O@ M:EZ@U*&FA2F?REZ3&NFWWD$/_>D6.?<^..VS1G<7W^'*Z %!&^"+)+Q"Z<'; M4HCQ.JTYH >1Z(Q)&73P>X53^V!H2A-SA+(>JOL R4VL\'_.YK-OE]\VA"NM MI'%1D"E%00&+,X#"6-1[/38\H?)['YU8Z8>H;-%"?E,K'O^X0WAM M,Q4%/Z7XNQ^=YLYHIOB#Y3>QXO^3Z[M! M3B]^RTN\$4,TVBL;!!1K75T9;<'YZ"!DP[13F@O6PMAO_?@TS]:M@'"\/#L( M2MXMYE_IMWW[)8?;>(T\7U4B.A#&95 E!PA:FQ<+W:0Q0:*0#E14"0*R!.@LRSQI$9I7;VVG9-J8]W@-/P&9 M \3= 6C6Y18Y52:N1P![GYW3!G1T2 QX&+5DF'*'WS'KF?B.@+*H=H M=M%2S%T,,QO)=K^[FMEU!:>IA:9MMIW7D:,RSWZIP'R92SS!I8Z069"QJ',1YA! U0@R)LQ*Y M(YOQ5$W#OA_[4SZ['0B-Q8AZFAIW'Z\_>K4&]W9.V^HGMF(,Y"EI!SHX 4H* M!CZK#)&E(F4D#RK$O>"W_S?_E#GP!B@<26L=>*+5-[KM*?N9&T^^EC4<*/HW M=?AK >3DN6/A'DMT)LKV];*/4?2GC*2/0^@(JNQX]MVVNKTW&/-:+:M7N%S^ MJ()?UV&N<)YN5+9:E&TKSAO7*[8@90F'"@R1JD3&$R9S(6DN#AE UP$6YP7 EWK]&8SXCOQ M>(_%VQA1UG#E=N!)W##^\L>=NV?-SSKKATJED*,&[Z,"Q72!((0$:;P,+CMG M0_,%KH^3U D"3PN477!MH+6>0'A[K*MCM;GC-BE%7K+ NA9$2%^?R;P'%[T& M&Y/1@E#D9>NN_GWHZ@2.+8"P"V2MM-(!TCXNEFO5W [OV\+E]4MJ8%EK68"E M[$")P(@UX4#ZP$RL:3O3.HH:0%XGN&N&C<5I%-4!!J]=^$_Y.S&9TY70=K.' MD>1GE0.F- =E@@3Z8P&GBPPQJMH@UQB' TF<%HNC0>7A8KT1]=8!+%^O+F;? M\")_*'O($7D=5X46Z >2HZMC=5F1P+V(,;J@VX_8&4+?M!G14P%R-(UU@,:M M)0A,L\AU*I 31A(60PB1_&9KDV.AA$24]%(7U'6^_?@(Y&C]=(BQZ[8.RZU3 M.8,QAL0B:JNWE1&LL1)Y%H6KUAU5SZ8(:)"&]RL"&B+N#D#S.<]GB^7[Q44] M;%2L/KQ(LZU9%9!8PI<@"BU2JW[O[^B8B^H'*(9G\J CI&S%W@ MY&$54['&!\6(?Y0U%K<<4#,-*.DL*8K'/6M=7'A8L=AH5]"+T!!\8[RHZ^$'.LFFG5[?6ZJVCA)^ M)P"Z6WGVD6049]^)K77"YBRA-\93),Q=34MR'NANB*+Z%9J.IM,6^1 L/?*M MB5H,FRGSB9J^8R3;@8OV;H'SU2TW6W(G9Y$JUKH@ *"4 )*48'Y M& )_6!DSM$;TYEL3M3B.8H$:2W92Y_\IAGX^ R[9+ PA/XB@015EP2N2G0Y< M2B,4^N".!1GT*S'0#W?OES->0;7Y(7+E%P!VD]T4+: M"($@5>N@HTB1.^'V&B1T< W[+2T3!X=C N#18O0#M=%%4NTA)QMYG5ER#HJ7 M%IPSH0[%%!2B\ PEQ2R-E:(&AKV^ M-FZ/PG"&3]*&4$+06B+DY,B38XE" ETGU0L3#%V]7MF_VG#FJPRUU,:*E"(4 MGQ.HZ!R0 \V 6Y5\5C&5.%I_QI^Y#6$ WL9K0QBBW [^!RMDXY#R>1 5Q8@&&9!:Q8U2N4<.TTKPCVR.D'B:0&S5SO"X=KK"9#; M&-J\6^ML?(C*$$M9DE.,%GPR"J3EG&&)7,K6&Y+V(*L30+:"PBZH-=)+IU!; MW9S8354#UXP+)108K\E71H7@='1U,ZC,2HD4>.LE,_O0U0G86H%A#[ =I9F> MT/;R=COB/V9Y243]^N-=_BV?K\^HL<:89!%8JN4+V6OPH4X5904]IU!$-U]J MM!]ESS\OV/2^;:7#GI!Y][3]S-_F7$=3C$M:D.@"@A+(P6%P=(D$);TDR>)) M#.(N CNQC T1LH]Q;**NGK"XGL*Q6DN,7Q>B,AUYK(N+&5,DM)@! PO@>796 M\Q)<\SK.1\CI!&?M0; +;D=JI%-PB0TK20@=@HOP?]N[LJ:X=9H6I H!, ;0 M.1B[<@H@?-B">4\M\Q0*S$^6\=M6IY!*WRS&U861 HQKYYT@*PFEMG*@BD_, M$6@D$$(YP*4T+FAAO4I]%_3'[-;=?V/0FY\";6PY P7DVL;85',?9TK 1J#* M ZHJ9!%16K/_VM;",<"TB6^^"0>$LQCXX+RI M<4Y!F+I^Y&W6U@+J(P9/O"F&-(,$=9T-X&A\N@ 5)9#Z!55#J- M R*I2T+>QKV\?I;2!^8B+"5M#:#G2DMI%6#S3DS,$J!I\-:*&0\IY0SK$M\] M_O3CM&=/F'=]=8LH8(EM<$T#5U (8<(2@)E<]!@1\<"%6T2%K20VR=]!3W1; MIN@#^HXFT_Z:31O^"KYFLSTP3Y5B M& FZ/Q 08'PF JP W&S&)(.6QV?33Y MW8FB3ZKZ&=YI:2K (^ZK:Q65"!,(!IQ@?*[&AK'(V"[%5EA+Q"6E,G6A4I\: MXZ)S(FE\7PJFWEAW]3EH*Y#5\YCKD;I:0SAQ)7+K[YZR)KD?"*]1G* M*&A*?.&J].KD-O9VNNKD-N06L- W*6K$RGKAG0-57)D($BYV6M3 !%B)1@1* M[TYEKS]^=7(K@^E0G=R&O9(,\D#AH^6ZDEQ;X,(@XF8. F$#;H97AC*"N& G M,\BW7)WWX:504]NJ@:620*0Q */UYUW M8:2L@^\=U; F/AEDPB1T@L84O8Y](* !/.!CO!8X3-J?]#R9_SD (AQ*%7#%")0DCA*@]TI3GPQ$H3_+20(GW[G_WZ%&)@6;<+R?@J M(#!['LN[>C1/N+\HIZLM[S:DG!068T\=1D.4FTRLU===_JZ^KFMN*$%89!!CF8;;Q*N9T_/R% \Q5 M921-?HUGMR:EF%!?INODL.?O+?MR$._JX5"-5^]C4"ZH@QH0JUF87-P!950( M'WD8 G<">K]QL+JG%FK?%_(&Y!K6[TTS7Y7T M(TO"3M5:$")'"(BD'JB(E$=(NHH*[#;=R[[^^(V^ES<&.HVYG #I I:C=^-Z M,GD7@K]X@+$^(Q;0K3JB&"@Q(QQ8&OLR"V^#CR0F)N^(4H0J:E.7 3=4+6\1 M^\D6K%,04\1>+FT%(<*XTLP%7TVD"L-'",@*A]-];<.SL;NL_^^CY, MOS [G U0?G6CR7)&C]7H;I&(_N7Q^?]*0H=]RKF'Z6L6F* M QJY^# 4A!6D,$2VJ4\ADRF?UZ/UL*FM.[A9Z"Q@G;R>Z+]XLI8$_NX8&4#G)+'YLP. R0,5-9B0JOD;_7N4R:OG64RCDT33<)4"2;W MK/Z%>@B_W@3X)F$&!RB7.SP(,0QQ! +60!='Y("P(0K62E8JA H&B>2V=U2K MS$:8AOY-HTK+1>ZTW6)%>#\(*\) S^;4W(W=?&:>W?Q^.:[OQNIAU63!6JIT M%:(NIV/QL@S+10AJ@?>88(,T1YN%N'MR=RT^FMF$$I-=OP+R!?BKA?]>-1#2 MRG!2"0*4B6^JF8"5#G\&UC%+#5?D '/J#MSSL$?V MYC5YK*: MF^,"[/S*Q;7 3)V=KSA?1H/IY.KZRU-^W7F,C0;:A!\$:@ND(1XPA#PTA!&8 M/!UW4*',*W-V>ZE/15X!EG@4W7W@/J<[E=7"224!K4R(L9'V0%:< \2,H!)" M87'J%NK]M +T(\7]7WPAOG[.1#(.A%KO?C9#)3 M(^/B$S-6*LQC"TP40GX?.QE5I +QK4H.A9*(ZD;[H/;?+MSI)C:-^O5X*L@, MG[:!-V[\<$NU],@%_8V*[>U2&277' MO(35^D668A;#C>4",HE3P=F/HQ=9BULID5$&>:"]\0$MHT*X'H)T#!WS2 EL MJ]1U"FWTR[P"Y['&DQ-9D'>[?S[ZIP7#>,K >KSSW+;;*&!^" M%@\UCV^X.2 4I4!X*@PV5 0DV_J\!M_-6P)3B"=,S4\)_G$5%CC[?A8K,R[= M>%#;Q=3:#7N874)3$5L;4!6W@HP!124!3%DNL?!&^^3;E_9J-K)8^H-9[&O1 M6H#E+D&;7+FAFCI[4]^H[_\<3._OZZ$- PYS0J*4Y"QYE\BNNC:R8?:#VO"K$%QP<\EE196:W+\??!M8-[*3>K168&6& M*K97' 7P![9_<5C;+R4N'>LUT-,4EGG--3%. :]",$E<;%.JI09>>$1]])8Z M]:-@:0O+7J*XPC8L!?.)LX+UMF):& ,)\(S%-Y8X 8)6' @4L[K:.I^\/J*) M7D65@[6QA*U; JE)*-YIG1DS>YC-W?;GZ;T;1_<\=O?!0\_OG8;_[7J[JQ;? M2.NHN@[N-"Z*(XR1PK':&<7+<(8#;7P5[,8*9ROJD4E=\)G6136 \U,]6=Y@ MH*IBN/(:2 8E(-QCH,G\_1LC+ H+O#&I7WYOHU]1+JN-96S51)R*E (V#M>! MD7GXNL K#JT>Q4!ST?O*J0I7% &D+0R[($3"L+0- 2RUD%36,I<\!WA(HS@ZT-:RI2"K"PC3&LJN&,1XYX#UAZA] S%E>R,!QB= @8<8@:,9):&\-\&.7K+X4E MU+\D,(3VRV$'5HJXZ?MB:/,3E.&")OOOV>*YF.6X<'SHF\96N42$B>F@"Q/3 M.F"HL11"K0E-W;^IF6;%KX]=#&._^:7BJ"Q7]VN8H#&.N'#3F ;Z,*S__LW9 M.W/T (D9]9;Q)?K&MK8[%FV6:+<1)J2O M-.<)Q'CX$20N0IQ;K126E0S.GL5^;1"'R25C[Q+HC!<"$L/3;U8WM2A^!>[! M^JYCU>X4E-UMX.SJXN/%K]>7YU?O/O_^^^>+Z]_.KLXCG+.%_-K'K@U&C>S[ MP7 6\#Y7XU@,\2*7W3VEF^SCR7*]IX$C51)XXUM/23]+,6.:*0"5".:H=.Q& MJUA8>)D)/I5#D;R$;9\N??U=""N>Y^]3K(X93D5EP0\@6 (IH1B"I1R M8>C6.Z"X$B#L^3RTVA(D4Q_;=58V\U8YA1UM>LG7(:Z %7EMH+>&Q]Q5 JI MV$C,6 MTO$,M8'Q^73EA9>HN)&L*Y+6D5R+]D*FU8J \_FG&]S=1R3"\J[N MW'I9Z^?9=#(-BTN8G4O GE\5G "(8YD#[$R_&^ MOC:I+VNV4C"O'\UA01V-N#V=162\PX*Q>--!#9>+TWQ@9]-%LXG%LK5=V/CB M@N$MKQC#VE# JGB;NV)ATZ<,!\0AY"FUW-K4JU# ,4T$#J^]UYQ:(5"SJ+4S_NU5#'O':@"C/B4E':WV#K, MJ00-ES9"LOD"<_:<8+F\?H:0.\%DA8##)*:'N0#"DW@740C%N VAV\9F:U^_ MI<;?S&MZ2EAP>R*E/0A27PC%G 9=6 M H*Q 9H+$B)WJ9B2$A+Y5DY"GIO?G(VF QLG04#U.C93G_=;/_]NAK, Y;+; MQ^J$ZK/?5&CY#(#TE%GO@2,V7O2L')!45U:]OI9O5/H683+&SYT7O/A8;G%$2XFU-4 C!JT MSC&=,A<-E6(\C8RZ(Y,%6.;AQH\*"N@9<\!8%)_P\R:,HX+ (TTI%1P'7Y#8 M+ ONVIF6^U8=.-L048!5]9R]GYY* 67E"*=,!D1I6'\PD4 190 VWO%*0DU( M\MK=1+J7TKC[K<KV_CT)61AE!1+%I_6K>*5$0THJL^M"L]-HY;C5.G<3> MITN*-Z=>R%VL*$1@I2MN@5,4Q50,"N/S&' L.46(T"IYDGZ7'OD?^>G-_JZ' MHWK!7<#:N3F&U2,-B!@A3 B!@]+!'0L=W#'R&GB./5?2"8'-B:VFS;LLKV4X M'3@^8C1= "_3;I9[,RKCI(5JQOD M!9A.H]Z#EFN#M?5 *"T B>] *.@-X(%]C2J".7:)S:C\!I!I+*!+*\@V=)1P MI7@N?>+,_][5W_[/&;OXP.+)G<'#O!QV50=[?$.^9EDOA2Z,RMAG6]K]A9;[ M],[*I]JBG^+AN\0N_^1O\R4^62KNT"C?PP@]K*?5&5)O?S3LL]J%>;M\;_%A M/E^?HY*NOF6_Q 0J_C[Z.HA";X(/^27\XY])U-R6FF7]/,K%RJX:(9(QA%K3 MSTWO:YN8KPV960+H;FSM1J,0KB[#9Z?CAY'],%1W29A:EYCE&D@GGG8B40A+ M<<:_&TWL.!U-&R*S+,R=O=\V%H40]5O]][-^:3W@'M%9'N[I1-QA;#(3^+2F M#AZ<_5#/.V/]H8:]I]LAN5G>JVE%70-42IAXDW=AS^ENZB=UY[>3T\V^(_*; M\,CS3\%F*!7+YXEH;,2>*)2]0DC[.+(Q/S=3P_EQ;!^B-D3EW90=QKP^!D#N MJ30S.MF !1PVO"<5#H\:3K5#:[)SKM9;C2+#H*2 MG*Q7KX'<.:K-4[13IB?SF_OYP]=A_>CA M+L <%J^E?PV?-X,Y%%>Q57/E[F/;G;:?41JM[E9^U0Y"4 M0-GY][&Y' ],@OGU+*H1.04G<_NKLT_=S>$=&-J,M[QM8,G/Q7IG;7-YV/ MYXGO$Q5F;4M/4I1U1.F>!5F1U"MGZF]N_/C9;WUKRQ@ZV7VC#_28LDNIJ\_T MSS+O%)@M0=:&GY>3]1 LF9ULK*I:OH@9UX#>V>9=\K+Q=1#WNA$(_]7G ">) M3IJ2\O,$X.<)0"MN+NK1A:M3D+(N*=^)V2&LZR,#+VA=<4'DPV TQRSZUV0+ MS);@;$ZM:V30!*;<+N_N;KH<5.]LT[JH;)6,7=G:#45F?E8*C=3P<3*8I"G2 MV2LT6U5CS]A[+SR9V;N>_GDY-I_'-Y/Q^60Z>%"+HZ5TY=Z-/I"MY+$KJVU@ MR\SPB]<0$KK2_5*SU4!VY?(H0.4L@!?U]%_N::5VJ>J1FWP@6TED@L7R*&R9 M&?X0A-8CMQIIB@/1/2*SE49V9?$P-&7Q]G[F;NKS[_&LWX5QCGP]-O/0NJ^S M;?.=;(?=B1AN F*!M/\QJ(?+5G._U0_N7>PN-W[\I/X^!?<'/Y;OX#RE!33! MLT S""/^:Z:& S\P2^UOU/=?W,CYP;1WL42G#^8[JD]I#DUQ+N;]F@_&37TGCE%M\IA')1:6^VF-8 M:A70Y;=350"M2TY2_7- V025/Y?J\8_8B2OLMA[4R+C4A3]-Y/>8UP&<_K4^ M3T*R';BV8.'EC-PX#H>_.S-NROPMNXJX>/_8N'=DM,1]-FWC7#0>?.Y$\ M'&ZJ-W")BDCV"\Y7?760BKH=+IFINW1U IZ>I>2L*3F.=7U@X/F+?()*%TGH MV)25[U)O2U+V@/"S5O$U5YJ?]8D_ZQ/;<6/_?5//]^-]I\>ZI&QE5(=FQ\[! MYB9@.'Q2*\W4V!27;UG?"7?=9.RYVX0Y%3=8O>?$2SG9BM0.S8@= \T=U"ZU M39-TVY:6;]GNMX\O[?SB77WMABYV/E[:4.^CB]T2\RTDW?@ZB$ON?4I0Q3X% M]9^]'Y@@]\,HS5P[+CV?"^S&96.\I' MCV.4VZ/>QR8P]DG15"P>DINM+K>K=SV.4?:Y6-_44S5,<0Z\*2M;N6WG.;<3 MB_P,G9EIV(D/'R_5P"8B:I?(;(6UW?DZ@$SNC7+<*08-HU:I7.,^F=GJ93L2 M=P2;W&'G*C-\]NTNF6_<*S1?J6O7*/,(/ 6Q-]?LA8=(2>(NV?GJ5!-P>0"L M$ESIDZK)'>I>R?DJ3/OXU6- Y:ZL^&LVF#[&'ED+*,/VYF'>"_3]P =E7!AM M*G9;?BI?P6E'NKM!F7O;N.%F_IC,%Y%Y%]'[>AA0OIJFVDFV^U2^6M7.N;LN M4!;'_X6;?AR9^B%1#KW1!_*5K";C>C]LQ3&\E60^%=,'/M2(\:)R1QU@S,S\ M#O<31[Y,?J4AO>DW&O%=4O:I)7C%3?+/TWLW/O'\WOV-1E27E+AJ"5[N6:WT M;*C&GP:3:<*C[OU2&]%94CKK*$"Y"=SV+'TS(7M$-JI6*"F9=1B:[)G_E?-/ M3^ QV8V8+"F5U1"L MX8>0K?>FHVV]*BHI35)@F6H]^C4$+DO%WKN)&0_F MQS")ZE2/BV]$8DD)D.:095^7["#JI8:D0M^>1Y?J^/F8]$;,EI0+:0Q8J0TU M/HXF@P#KS5C-FZF^>.IP7?.>W34.?"9)JXVFPTC0=V/K4UL&TO'^ZEZQ?7)A M3^)^B;0S\8"/QL+M-M;3\?#&S=^F'SV-V,; M["M-A'] ;+8YU"Y&. Y,]D@A:I6B&>FZI&PW>=O&<#N&7PHE-X-I[_!Z352V M*[D=25D#('?CT-G0P4I3&*,:6W^=.OMAJ.YZT;-/9K;KMNUX.@))_L3B*3@[ M(#;;_=IVM!T'I@@'.-_G!XFA;;1C2O5RZ6V*^.[1=O.$>/(K@ZOUL/%Q?P'I";[]YK%\(.8O,V M3ADOZ^' A %OA2= M:DMW7'HA)Y('>5M/X#?$*_L9RRX]+^KI4M4T:>3F7RDDJ]R3YP/XG=ZC+_\A M_M!JXO[_?_X#4$L#!!0 ( .B 9E=U-@7;Z0< 'PG 3 U::W/;-A;]WE^!.K-I,D/)DBSY(3F>\3K>J6=GFZV= MF7[L@"0H80P2+ !*UO[Z/1>@'K:DA)XFC=PV'Q23>-V+>W#N 8CSBRIUT2EPL^CD_#,_GAWZ0\UBG\XOS5$Z93-\=R$&<=KIQQ@>][*0_ MZ)Z=]N-^K],7 WX\B ?)R:_= S1%]=#&NKD2[PYR6;0F@L8?]GOMDT'I1C.9 MNLFPV^G\X\!7O3C/=.$PGD'[\&?H9J,S)QYI8/0=%&<:*7-\%7' M_QM122OCN53SX0\?92XL^TG,V*W.>?%#9'EA6U88F86*5OY/P":8YQ]GP>03 M]*-D(18N='MD]/7#1,;2L:-NN\L>F[SN.3=C..]T.3Q#MVNV)YAL8;Z1\5?" M.)G)A#NI"Z8S=C61(F/7#R*IG)P*]B%#J3"LK(RM. QT>K>3^^+5G4C(G]>O MNL>=T5&G1XZYB6!WW,2\$+;UX4&).;M,')7T.JC1,'!?W:'^5H=N(G8KDPDW M*?MWF_V'.Z-MQ!(?O#E;%ED:TU*GJ9@D)82&*&ZP!-'8\-9S\*KMR$77$CV.WUS<>(W11)&_$\&S6+S='Q MBX]H;^\B^D]N$4=$+)^S^T+/E$C'(@J!K<.9:IA0:&1(,V1H5"),):;N94)>?WPK/7LD^+=RF, MP9#*Y_*:WA)ID+M1K4!S6)*"MV<3\ :S%?VLVL\$P!8Z(0=R:162/.F%F006 MC; E*)1&IWY+F*93N#E%LY3%\_5I^&L!]>CE %6P3!: J%J%?H(*$5U%)NU MX?*CX]"^/K5::][,K(U[FK=0G2C:WE)P;UAE ()1H"%C)6@<#,![,9*V@E5 MIVHYJ);HEIY3:1.E;85V1,)&JX"GTNA$I'AMV1O )Q7 8\#(]0-D5#$67OS= M5@HUND>\U1V\$6]]T^X@#4_A49*,+0*.J7]&)+@&[P WLJ7Q0-FC@3(,1'X^ M!3UJD*;PNFX#DE\XT/U&* MRNHG$[!,('@.C?]+N#;[9 N%O]V:!'+?/O )_ M+RSV2<"*S\V?!W)$LB'AE6W>A/)W+ #*>J2@"'1ET $(="JMIV74$H7OAS82 M*T)?3PI&*.Y17DN"%5*C.F%0H02YPQ:KE4S]&82M8BM3R8TD!V00+CY-%=13 M94E,>%*P7GEX$M=6P""'I$&-2HAHF52*4^Z!6]Z(E2A!BR!QUI49_HH%541Z M0'N1^G30:'>T=]"-]PFZ_=XF=!LSY :"FW-K8R #_%.9$CZYU06G),(ML$V2 MF$"+'?0"0("TY+%4TLU)=&P;EI:3QYJ'T?*,9)NN"KGJH7:HK$P)&%LODI)$ MF]0;X,7U6!30/@IH1HDH:9E0%6P< F*QG&2)=/%I";//D$WV";*!;:^G7%6> MDBB>(LOHA&B*2-@MBG,I5QI0;'C<+D(]0M$0]&B#U(UUY79;T"0)\&5M03H^ M^_P&C<6+'8)?="+,A#\>(U*D 5XDRM)]0EE-C"& FT"@DX%:#OJ2K6A[!AU2 MGM9)4AD*]UI2W-)KKJW#>SJ/15\V04?UP11[LZ-)!MR"J)[4K@W'5DWX0PTZ M[RBJI5UO@U43;I<*@BC.XURDGOO]?-2\/&=*W@M5GW \J1_][BEJ@.U/0/FE M[@,'?Y)]H#],31>+*5HQ&!'J.J!79$:0?(82V9"Q2],XI*S3QBZ3OW^!+O-< M.B?$)])%K.F 'N6IA'V^DS> /=C9$OOC?Q+4B[4J?JLDS/?KLBK\!PO[]N_M MWI]TNW>IH!:A7OW'-MA$)P6)% !F+2*6VZZ9X/>D"H)Z]+K ZUY_;+PX-GL6 MW.L=4CA=V<*_/$5#*Y;TNW-IU&H938!OB-HH2!,+76*K'(C +'EGZK2W]8#Q MAAY2LKP9XM12*Z]L?QST@^9@N@#@$VJ6+@>N[(6U_-^30I9ME9Z?ML\[N MXDZ[NRP[]'V'_N&!+7GQ[N#HX(FJ&_;*!];==D/CJ1O!@S\>;YT0S_[)Z,[_ MAM!N_M[>7/UX>?O>7QBX_'C[X6X9_0:S48>< (')8/Y$CRW#,Q,C(P,C-Q,RYH=&WE6FUO&S<2_GZ_@N>@:0*L9+W+EAP#KN.B!J[- M71RT'PONR[M??#+EZL24E,JYIY+M\4+S+MQG.PV<>FZPJ0'N66> >!*N=5J= M+OO-V'LYX['<2Z_@G<@TS5K=G@ Q[)SU M!OV,=X=YO]43@ZPS; T$_-X^P:98/;9Q?J'@W4DA=6,*-/ZHUVD.^Z4?SZ7P MTU&[U?KN)%2]O,B-]CB>Q?;QS]C-5F<>'GR#*SG1H^#226RZ+,Z,,G;TJA7^ MC:FDD?-"JL7H^T^R ,=^@3G[: JNOT\:<^,8R4\A HZ'>5@4-&3C'[8*J%/P> G.M^G3X3J Q.*0*>;RFMDQ: MS-M836-SM$0@9\^GR!G,5?2S;C\'!%OLA!PHI%.8X$DKS"5BT8(KD3YI=.JW M1-.,0#=GV$RP=+$Y#?]?0.V^'* "RU<9?!WZ!%&*U;'8;I1+G2,Q10$@=:8J M%'4$KXTX)PA-2616(CH(V 1XI=;(K4'CG@R-BT-(ZCBA&I7""@A7@Y@*P[E@ M3\;=E.7*S-T2RQ8FTGE+:H/3RV@W6IEL0-(MC=FR]FN@LLZAJ?'>%$'!'2]. M>T>'TT^/@OKZU5FG/1R[&HFUDB$",K78I'#?,DJ*!"P$BDP5$ 8()I3)=V4 MJE.U LF7")B>A729,J["=D3+UJB(L-*:# 2^=NP- DH (C2BYN8!196>0)"" M'RN%-=I=WFCWW\#;T+3=%_$I/DH2M3HBF_IG1(L;@(\ )%L.'BA_-%". Y&? M3YE+6'R+T>3?_CD/2&S4[_FT&3OST:: Z:YT$-OP>'^Q6,4LB3 M7X900BD\XY4[O GETA00#O5(,3N;RF('2&8SZ0)%8BW0H1\2]6MRW21H"XH' M?-7I>8V1I"9O*I1(M&B+,TJ*UB.+JB M0*C& 1KDD<"I48F"5F:5XI0'T*U@Q%H@8(LH-S95$OZ5 E5$JL;V( (U'[13 M.3KHIL<$W5YG&[H'<],6@@]GM8.!C."?24'XY,YH3O3-'6*;Y"F!EENQ!!!" M6O)4*ND7) !V#4O+*6 MP&AU5K%+X\0L\5 [5%:V1!B[(%BRS%@1# A"=P(: M=8A"-&,)E+1,J J*^(A87$ZR1*+^O)PX9LAFQP39R+8W,ZZJ0$D43\AS.JF9 M823<#O6W$@H'4&Q\W"T( T*Q(=*CB[(S-97?;\$A28"O:@-IZOS+FR66+M5Z M6'009R(<4Q$IT@ O$F7BF%!6$V,,X#80:)=>"[%0LA-MSZ!#RM,FRRI+X=Y( MBCMZ+8SS^)[.1;$OEV%']2$1>[.G28ZX1:)Z4KLV'+=-$ X8Z.Q!5RN[WD:K MIMRM% 117, YB,#]83YJ7EXP)>]!U:<-3^HG__44?0;;+_LPH/\_LLD*9Y=B MN5Z2-4D19VYB=LU7A+IGB(TMI;HRC:-:]<:Z57X/+[#+HI#> WPF(Z0&%025 M"XGVA4[>(+*1@!T1//Y/FGFY'.&/2J+Y8>E5.GP;<&_#7NK0[S5'Q+='N(>Z M4BC!4!*&+TEH$VU\,PD(A3HSK_8R<^#WE&JC) O)-HC)<"ZZ/!=Z%L#J;4<\ M+-A!:EQ@0P507B 6018C]*9J@>7C@GW/P^&T_/[['F8X?&7]!OXL471\DX0;!GJS^IQEX M?I!]AY^(Q6GW84-:EZ:XUL$VT%3%2P>CY1]CS(JEXHN1U&'$T&C\^""8EN^, M4BL*M/K#=Q HL;B^VS#H()0'=+W!8Z"]6 YO^P5,WH@=_/=Y:,9Z]X?@N_,;0 M;O_^?'O]T]7-/]CUA[M/5ZO('S 3=;@)##@1+)R1L:5+1S)-PR_=<@BS].A& MP'.FX-E>XF1]-1=#AR/I<:3L &CLN9^2L#O(+'CZ;DK9]^8!LHKV]>Q7+&;_ MQ#V[%.%6T]-I.@WK^IG[DB=WF$KCPF>N43R>G<'6K:8U^@)OM-9->(H0K/S^ M)OLNU>R](E7_Q@M;I^&BV'\ 4$L#!!0 ( .B 9E<[ '>>?00 %(1 3 M H+J/U=H>QRMLKV]W Z2_OK.[22 $6B+="T7(2CP[+\_,,[.[&9>Z MKD[&);+\Y*?QSYX'9R*;U]AHR"0RC3G,%6]F\#E'=0V>MUPU$>U"\EFI(0JB M&#X+>I>>.5:/R/>I%_?-3JY);GNAR% M0?!+QRX]&1>BT>1/DK[[Z,QL&=-XISU6\5DSLI Z3G4ESD0EY&@OL'^)D7@% MJWFU&+VYXC4J^(BW,!4U:]YT%6N4IU#RPBU4_&^DF"@\^_76A7Q,=BK>X I" M&)F@W]^5/.4:XL@/83/DA\B9G!%X+=K1D,P^B#VC9*/\0<%/4&I>\(QI+AIH MYU+-&46A!80#^-._]"<^7&)FI/M[83](PO@HZ#X/\[7@8@I.<]&:/G@(:@/* M,.B#*$"7^/KQ7#*9L@:5=W%7X0).,VU"CX(@VHURO,D)QBCJV>;[YF!Z3X(Y M;R 33>-J ;=6"-3F\O\M*ULR0QFI=MXW0!F>MN)*-/M[9!?)P\[&QRSIYH'+<0 M'K3,\XSLDIQ1$*1F%J:HK*CD"JX;<4L)G>'^WM$@^0K4?6*?>&"F97E.FZ!7 M84'<&SRRY)DW/Z@%0G\5]/?WGFRF)?!M.J\LA6S?%?.*FC 3=5L9IJ_9+_'+ MG$LTIP-E^W%S8WC+#H"Z+#QZFQ^L67+?,.MF65(E',8]HL$P,53>*N'_N[S1 MJRPO;V@*UFZKIP&L&6GF]'8Y/ESM::)0\5N:,Z;,72-F506D1L&PBDB@6JJ[ MZEJM@C>LR>/]=T9LSHT?5/PS2I6; M;Q_%C=U8H.^VE&=8_M4"'+XH/M>O+\FAF[.:I16NI*F0.4J/0JU8JW"T^I#D M7+456XQX8SU:I61I*Q5:B]J82V[,EI2Q:EE;6V8G7MX$^I'?B_KF,J"IT#I? M.5[>$WQ[3SC4^;9L./"'P?/BP _7LD-KV]DG!*IES;M.W'DT6$91>P?A4Z?U MQS <@N_/M\#5LW><7-JG*^WVP%%=CE/;N?DT#;S MCIOSHVM^*Y3='482*V9BV+KXW]/-#HO@7H6EQ+FY?EYEA\UBX^E^TSBTOZ7\ M U!+ P04 " #H@&97N:EI<8<$ #C$0 $P '-B#,R,C(P,C-Q M,RYH=&W56&UOVS80_KY?<7.P- 4L19+?8LL)$+@I&F!MUR1;/PZT=+*(4*)& MTDF\7[\C:3LOCK<&?4D6.(*MX]T]=_?I+"(+EJHEL%HK/2@-)E'3@LU27_(IYN>%&X-'*SGC? M_Q[O.R?CJG7!*]3P :_A3%:L?M76 MK-:!1L4+OU#SOY$P$3SW\]I#'I =P6M,<-E#\ZFBL$[9((T)DPAG)V<7K3AM,Y"V+,F=G<.DB1* MSW#&M5%4='TNDV 8/T;J,3'O9('_F%<*>#MA.T37)&($C- M+IRB=J*2:[BLY37E=X:[.[V#]!LP^9%MXXZ9AN4Y[8F!P(*H>/# 4F#O/%-' MQ.$*](_WGMY/2Q2Z=%XX"KDV+.:">C*352,L\=?-H/"O.5=H#PO:M>?]?6*/ MO09JNKBWE[]>L^2V?]:]LZ1*/.QTB0;#U+)[HX3_[_(F+[*\O*:A6/F=G^:Q M8:29T]WE^/"U9]P.Y(:FBRUSVXJ9$$!J!(:F$PD:JKMN.ZUB/;7(8,Z=:3NL M:-5<>);(!I7SJ3D-5\*/S@[QR6QCT_>;U MO0$.OR:1CXQU/\(-FPI<2:=2Y:@"@BI8HW&T^I+F7#>"+4:\=AZ=4KJT-97& MR,J:2Z_L;IPP5%&3KQPOGTA"]T2R;_)-V? @ M'$;;Q5$8KV7[SK:W3Q'HAM6'K4[KPPRJD%Y*FP7^=U5V6 M[AWIGI*")T=)R?IN(3J#(V[(4_8%U/C*4^MFFO9=7S]I_/[[\>#!>X=&:K<_ MC10*9A%MO(FX9::;*=&M"IL2/>=FN\JVQ\:MKS665_^29=^]W/D'4$L! A0# M% @ Z(!F5R2M G>]BP$ FT(8 !$ ( ! '-B'-D4$L! A0#% @ Z(!F M5\+OFAP))0 .5\! !4 ( !7Z(! '-B91:8$;78 *=,!0 5 M " 9O' 0!S8G)A+3(P,C,P.3,P7V1E9BYX;6Q02P$"% ,4 " #H@&97 M)+]\Y)&UL4$L! A0#% @ Z(!F5S%<&SN\MP EG8( !4 M ( !!6@# '-BR[J!P +R8 !, ( ! M#B@$ '-B#,Q,C(P,C-Q,RYH=&U02P$"% ,4 " #H@&97.P!WGGT$ M !2$0 $P @ $I, 0 YJ6EQAP0 .,1 3 " =